'' | '' | | '' | |

''

|
2005
 0 / )
,4
- 616.94+616.9-022.369
-31
|| | 3 - } a nt %
a nt % dc
t
} % %
c { fa

| | ' © *
,
-. ))
( ))( ® ))
( ®± ))
- ® ©
5 ±
(++
0)-/1
1)
ISBN 966-8224-21-3

| || | | | || |
|| || | '
| | || |
3
|| | | | -
|
|
| ' || | |
| | | || '
| | | | | |
| | | |
| | ' |
| |
| | | | | |
| | ' | | |
'

0/)
,4

JSBN 966-8224-21-3 y )) ( )) (
)) ®( )) ®± ( ++0

y ± ®5 ±( ++0©
)
 ]^ ]
......................................................................................8
]] ]..................................................................................................................... 11

• • ........................................................ 15

[ ] ] ] ]
] ] ] .................................................. 23
° •........................................................ 25
°
£ •................................................................. 28
° £ ° ° •............................... 32
° ° £
•................................................................................ 37
° • ..................................... 41
[] ] ] [
] ................................................................................................ 45
NUCLEAR FACTOR KAPPA c • ) )00
°
............................................................................................................................................ 56
v ..............................................................................................................57
y ................................................................................................................ 62
............................................................................. 62
c .......................................................................................................... 66
........................................................................................................................ 67
y % { ........................................69
n ( "........................................................................................................................71
u } ................................................................................................... 72
° ........................................................................ 74
i SIRS................................................................................................ 76
......................................................................................................................... 77
- - °
...................................................................................... 79
£ ° ° ....................................................... 86
y } - ..................................................88
y } .......................................................................90
• • •................................................ 90
° •............................................................................ 100
3
 °
2
£ ................................................................. ,u

[ ] ...................................... ....................................................... 106

° ............ .................................................... 107
p } ........................ ..................................................................107
i } ..................................................................................110
y } } .........................................................113
r ................................ ...........................................................123
r ................................ ........................................................... /26
.................................................... ..................................................................128
{ ............................................................................................................129
p ....................................................................... ..................................................................130

[ ] ............................................................ 133
SIRS........................................................ ..................................................... 133
° )) \ )
SIRS MODS ................... ..................................................... 141
° ................ ..................................................... 143
........................... 152
- • .................................. 155
• .................................. 157
............................... ..................................................... 161
• ° • .......................................................... 166
.................................................... 169
• • ...................................................... 172
•£ •................................................................... 174
° ............................................... 180
• ............................................................. 182
(° ° PS. AERUGINOSA ............................................................ 186
o { } .......................................................................................186
r { Pseudomoncis aeruginosa
...............................................................................................192
y % Pseudomonas aeruginosa
...................................................................................................................................... 201
SIRS ............................... 203
° ............................................................................................ 223
................................................................ 228

] ] ................................................................................................ 233
 ..................................................................... 237
} ..................................................................................239
{ ...............................................................................241
] ] - ........................................244
.................................................................................................... 248
..................................................................... 257
° ................................................................................. 264
n } .............................................................................................266
i ...........................................................................269
o } ........................................................................................................................272
] ____________________________ ________275

................................................................................................................ 275
• • ................................................ 276

- • • •
..................................................................................................................................... 298
• •
..................................................................................................................................... 302

• • •................................................ 303
° ...................................................................... 305
- ° °
° ...................................................................... 307
[ ] ...............................................................311
5 | } •:..................................... 311
• •
.............................................................................................. 313
• °
............................................................................................. 315
............................. 318
o .............................................................................................................319
o ...................................................................................321
u ..............................................................................................321
o .............................................................................................................323
u .............................................................................................................................323
u .......................................... ................................................324
o g s.............................................................................325
o ...............................................................................................326
 o ..................................................................327
o ................................................................................328
r } }} } (PACK)................................................329
p } {
} ..............................................................................................................332
r - { ................................................................................................333
u } ............................................................................................................................334
u .............................................................................................................................335
u ............................................................................................................................336
u - } ................................................................................336
•
:..........................................................337
] ] ] ] .....................................................................................................340
° •.......................................................342
) ).0+
p { ........................................................350
• • ...................................................352
a} { ...........................................................353
a { { } ......................................................373
a { ...........................................................................380

..................................................................................................................385
] ] SURVIVING SEPSIS CAMPAIGN ] ]
] ..........................................................................................................................396
°......................................................................................................................396
A. • •............................................................................399
B. ...............................................................................................................400
C. •.................................................................................402
D. ......................................................................405
E. • •................................................................................407
F. ° ..................................................................................................408
G. • •..................................................................................411
H. °............................................................................................................412
I. ° °
$ % ................................................................................................415
J. ...............................................................416
)
$ , %* (ARDS) ..............................................419
L. •( • ° •
...................................................................................................................... 422
) ....................................................................................... 423
H) ....................................................................... 425
) • •.............................................................................. 425
) $ % )
......................................................................................................................................... 426
Q. ° • ............................................................... 426
R. • °
• ........................................................................................................... 427
S. ........................................................................... 427
° ° • .............................. 433
] ] ] ] ] ]
] ..................................................................................................................... 435
] ]........................................................................................................... 439
] _____________________________________________ 441
 ±
± ®
±
±
± ® ®
® ® ® ®
®
®
± ± ® ®±© ±
±
± ® ±
®
- (+) ± $± ± %
± -
©
(± ® ® ± ±©
±
± ±
- ®
±
©

± ®
± ®
± ® ±©

®
± ®

-
± ®
® ± ± ®
± ® ®
± ±
± ± ± ®
 ± ©
£ ± ± ±
®
± ®
CJI ±©
± ©
± ® ® ± ®
± ® ®
±
± ®

£ £ ©
£ £ ± ± -± © ® ± -
±
£ £ ©
£ £
APACHE © ± ±©
II ± $
Acute Physiology, Age,
Chronic Health Evaluation)
DO2 ® ±
CARS © ®® ± ± ©
® $
compensatory antiinfammatory response syn-
drome)
CSF ± ± {colonystimulating
factor)
ELAM £ ± ± ± © ®
± ±
Fi02 ± ®®
®
GALT ® ±
(Gut Associated Lymphatic Tissue)
ICAM ±±± © ® ± ±
IL ±
INF
LPS ± $ %
MARS ®® ± ± $
mixed
antagonist response syndrom)
MODS ± ©
NF&B • $
Nuclear factor kappa c"
NK ± - ±
± (natural killer)
NO
NOS NO
PAF ® ®
PG ©
±
Sa02 $ % ± ® ±-

SIRS © ® ± ± © ® (Sys-
temic Inflammatory Response Syndrome)
SSC ® ± $Surviv-
ing Sepsis Campaign)
TGF - (teansforming
growth factor-beta)
TNF ±
VIP ® ±
VO2 ± ±
 ]] ]

± © ® ® ®
± ( ® ± ±
± ) ® © ® -
± ®
( ®± ® ® © ±-
® ® ± ±©
®± ± ® ± ® -
± )
® ®(® -
® © © © ± -
( ± ® © ± )
© -
) ± ® ± ® ±© ®
®2 0+ ) © ( ,
0 )
± , ± © ®± ,+ +T,4.
U)
® ± ® ± ® ( -
± ®± ± ,
! ®( ®-
® T4/U) © (® ® © © -
± ± ± ± ® ( ©-
© © ± ® )
© 2
0 ) ±
$ ± ± © %
T0+(4 1(4 2
U) © ± ± (® + +.© )® ®
® © ±, /
++ ± )
® ±® ± ( ± )
® ( Fenton ))
Parker ) )$+ +.%
( ±® ± ± 5
± ® ® ±
±® ( ® $ -
%6
± ® ® ® ®± ©
± ± ® 6
® ® ®® ± ( ®± -
® ± ± ±® ( -
T,40
U
 ® ± ® -
± 5 ® ± -
( ®± ) ± -
± ,© ( ± - ®©
, ,4± ) ± ± (
® ± - , +!( ± ® -
® ® ± T ,
40U)
±® NI[ ©
© ( ± ± ) -
± ± ®®© ± (
± ± ( ® (| -
®± } ® ± © ± ® ) ± ± ® ©
®± ©± ± ±
)Schottmuller (1914): o } % } -
} } % }
{ % }
{ % {
{ [ £ ± ( © © ±
± ® ® ( ± ±
( ± ® ± (® ± (
± ( ® © -
® ± © ) ( ±
® ± © -
± (® ® ±© ®
- © © ©)
® ± ® ± © -
± ® ® © ( © ±© ±
® 0 - © ®( ® ±
( ® ± ( ® ® , 4
33
+++© )
( © $ ,44
, %
( © ± © -
® $ ± %( ® ® -
©± ± $ ( + +.6 -
±(+ + /%)
® ® ± ± -
® {- { 5 ± -
® ( ± ±± ( © )) ± ® -
± ® ± ± ( ± -
12
 ± ( ®
® ± ± ± -
) ® ( ± ®® ± ® -
±® ± ) ® ® ® © ®
® ® ( ® ± ®±
) ± ± ±
® ® ± © | }
( ® ± -
© (
© ®
(® ® © ® -
©®
( ® ±® (® -
± )
® } } ±
© ( © ( -© ±©( ±-
© ( © © ® ) ± -
© ± ±® ± ( -
® ± ± ±
® © ©( ® ® ® -
± ®® ® ± ± ± ©)
| © } ®± -
( ®® ® ± ©
© ±® $ ±( ±( (
±© ( ± ( )% ©
© © ® ® © ® © ± )
± © ® ( ®®
± (©±® ± © ±
® ) ± ± -
( ®® © ± © ( -
© (®
± ))£ ® ± ± ® -
± $ ® ± © %)
±® ± ®± -
± © ) ®® © -
$ % © ± ®± ± -
® ± ± ®± ®
)
 ® © ± ± ®
© | ± }( ±
®, ) ± ® ± ® -
± ) ± ± ® ©(
® )
® ± ® © ®
± ® ( )
± ± ± ®
( ® ± ± ®
± ) ± ®
± ( © | ±
}
) ± ± © -
® ± )
 ] ] ] [ ]
® ® ±±± -
± ± ±© )
® ±© ® ± -
®± ( ®± ± ©± ± © © -
© T.,
(/1(0,(
1 .(
,40(,4 3(.2, U
)
± ± -
( ® ® ( ±
© ® ®-
± ± ) ® (
± © ®
© ® © ( ®± ± ® -
® ® ( ® ®-
® ® " |-
| " -
' © ( ( ® ± ® -
® ©( ) ® © )
| | - ( ±
®® ± ± ± © ) -
± /+-0+± ± ® -
±) ® ® ± © © -
± ± $ ± ( ± - ± ©
© ( ± ±±( %
)o
} { } -
{ % { ±-
( ® ( -
® ± ® ± -
© ®( ®± ® © ± ® -
®( ® ± ®
® ® ± ®
)
± ©± ® ±© ® -
® ® ® ®± ® ± ©
±-
± © ±± ±
® ± ± ( ® -
(American Colledge of Chest Physicians / So-
ciety of Critical Care Medicine Consensus Conferens, ,44 ©)%
( -
± ® ±© ( ± ®
® ± ± © ± -
( T,4(4 0(4 4U) -
± ® ®
± ®± ® ± ± ± -
© ± ® ± © ± ©
± ( ® ± ® ®± (
© ® ® ± ± )
± ©± ± ( ±
© ® ± ( ±® ± (
± ® ( © ( ® -
© ® ( ®-
® © ® $ % ® ±-
- Systemic Inflammatory Ri sponse Syndrome - SIRS. -
{ { } -
{ {
± | © ® }
| ® ± } ( )) © ® ±©
) ± ®± ( ( ±
© ® -
® T
40(4 4(, ,1U
) ® ± ® -
® ± © ®
± ( ( ®
© ® ) ± ( SIRS
®± ® ®( © ( © ±-
± ®± ® © -
± ( ± ±®
± ® ± ± ©± )
± % ® -
$ ± )
,%( ® ± ®® ( -
® ® © © ) -
- ± -
©( ® © ( ±
± ® T3U
5
± 9. 3u ± 7. 1u6
' 94+®, )
6
' ± ± ® 9 +® )(± +
2 7.
))
± 9,+++
*± ± 7/
+++
*±( ± ,
+! ±
±®)

± ,
±© ( ® ©
± ±
(
,44,f95]

± ± ®( ® ® ®
± -
© ® ® ®
©
± ® ®
- ± ± ± ( -
© ® ± ± © ± ± ± 5
® ± 9.3u ± 7.1u ( 94+* (
9 +* ± 7. ))(
± 9 ,+++*± ± 7 /+++*± ± ±
9,+!
® ( -
± ± SIRS
± © ® ( ©-
± © )
± ( ±© ( -

± © ( ®® (
® (
© ( ± ( ±© ( -
)
± ® ( © )
± © - ± 74+ )) ± 9/+
)) © ® ©
±©
± - ± © © ® -
© - ( ©
± ® © )
± ± -
® © ® © ) -
± ® ® $
±© %
 (. - (/ - -
± ) . / © ® ® -
± © ® ± ( ® © -
( ± ± © ® T,/+U)
® ( ±
® ( ®
® ±® ± ( ( ± ( -
® ®± ® ® ® ( ©
®® ®± ± ) -
± © ®
$ ± © ( ± ±© ( ±-
© ( ® ± %( -
± ± ±® ± SOFA (Sepsis related Organ Failure
Assesment) T ,3 1U ® ® ®
®, 44 /© ) ± © (® -
± ± ± APACHE-I1, ®
± ±© (
® ( ± © ±®-
) ± ® ± ± -
± ± ©( ± © ® ® -
± ± ) © ±
SIRS ± ± -
)£ ® ® -
± ® ± ® )
© ® ® © (
144 /©)T, 34U
)
© ±( SIRS,
© ± ± CARS (compensatory antiin-
fammatory response syndrome).
®® ± ± ® ®
® ® SIRS © © ®-
® ®® ± ± ®5 IL-10, IL-
13, INFy, TGFp.
± ® ± ® ® ® -
( ®± ®® ± )
® ± ± ©( ® ± ± ©
 ® ®( ± ± ©
± )

MODS (2/3)

Nosocomi
al
infection

),) SIRS CARS (R.C. Bone ®)

(,441%

S. Wade ®)$ ,4
43%T,3
3U( SIRS
® ± ® ® ©
± © 0 ,),
!5..0 101 ± ( ± ®
± © ® ® ± - -
6 1 0$, 4(/!% ..0 ® ® ® ± -
± © ® 6 / 2 1 0 ®
®± ± ± 0.(!)
A. Bossink ®)$ ,443%T ,
+0U(® ± ®
-
® ® ± SIRS
± ± 40 ! ± ) / /
! ± ±© -
® ± ± 4!) ®
± ® ( ® ® ± ®®
( ±( © ± ± SIRS ±
1! ®± /
! - ) ±
® ± ® ® ®)
SIRS ® ±± 2 !( - ,1!(
- 41!) ± ® ®( -
SIRS, ± ± ± ± -
® ® -
± © ) © ± ® ®
 ± ® ©
± ± ® © ± ±-
® ± © )
© ± ® ® ± ± ±
$©
± ± % -
© © ± © © T+U
± ± )SIRS $))® ± ( © © ±
®± ± ±® - ± ® ®
% ± © -
® ®/ /! ± ) $© ± ®-
± SIRS ± ±® ± -
% ±® ® ± ®. +! ± ) ± ©
± ± © ® ®, 3! ± (®
® ®± ® 3 ! ± ) -
± ± © ± ® ± ® -
± ,-1,5! ± ) ± ® © ± -
® ± ®± ± © -
± ®± 3 ,!( - 30!)
® ± © ± ±
®± / 1 !( SIRS - 15%.
±© ± ® ® $ ® -
± % ± ® ± ® ± ( -
± ® ) ± ± ± -
®® ± ± ® ,! ± ® ) ® ±
® ( { -
% {} ® -
± © ± ® ® ± ± ± 5
Staph.epidermidis - 50% ± ( Staph.au/eus - 13%,
Prot.mirabilis - 17%, Klebsiella - 8%, Str.faecalis - 1! ± -
T+ U) ®±( ® ® ®±±
± ( ® ® ® ±-
±© ± ® ± ± ® -
® © ± ® )
)) )) ± ® $+ ++% ±®-
± ± ® ± ± ® ®® ±-
© ± © ± T+U
)
 ® (
© -
®
± ± ® ® SIRS -
® ® © ® . )
± ± ± © ± ®
± © )
© ®
(® ® ©
®( ® ± ® ± ® ®
®( ® )A.M. )) $
,44
0%
± ® ® ® ® ± ( ±-
® © © ® ® © ± 3),
!
± ± ( ® ±
T4U) ©(® ± ±-
® ® ® ® ® ± (® -
® ®( ® T/1
U) ±(
® ± ® ® © -
® ® ± ®
®
® ® ® ± © -
± ) £ (
)) ® ®)$ ,444 %T / 1U( ± ®
± ( ®® ± )
± ©± ( -. ® ® ® ±
© ± ( ® ± ® ± ( -
±© ± ® ® ®± © ®
® ® ± 6
± © ® ® ©
® T/1U)
± ® ® © -
) ± ® ±©-
$ ± ® ® ® ( -
± ± © ± % ± ± ®
® ± ± $ ±)% ) ± ±-
- ± ® -
(Nystrom, 1998) [54].
± ± ±© © ± ®-
® ® ® $ ± © -
± %( ± SIRS, ±-
21
 ( ± SIRS $ (
® %
(± - ± ± © ® )

±
© (Nystrom, 1998) [54]

® ® - ±
$± ± ©- ® ± ±-
± %
(SIRS)
® ® SIRS -
) ± ± -
© ® )
® ®
® ®
 [ ] ] ] ]
] ] ]

±© ©
® ± ®± ± ® ± -
® © © ® ± ± -
±© ) ) )
± - -
± ®© ©( © ®
±© ±® ® ® 5
® ± 6
© ± ± 6
® © ® -
± 6
© ± ®® ± ®6
© ± ± ± ±®( ®
± ® ® ® ® -
6
© ( © ± © ® -
© ®
6
( ®6
© © ±
± ®T 2U )
p }-
% %
{
®© ± ± ® ® ©-
± (® ® ©
± ® ® (® ± ©
-
± ) ±-
± ±®-
±® ® ± -
® ± ® ® ® -
 ± )c
[72].
± ®
±
© - ®
6
® © ® ± © ®
( -
© ®® ® 6
±© ® ± © 6
±© ±
© ® © © )
© } { } % -
} }% ±
® ± ± © -
± ± © ® ± ( ®± -
© ± © ±
)l } % {
±
± ® ®
± ® )
®
± } -
% ® © ± ± -
© ) ± ® ±
±© ± )
1) ± ® © ® ±
$ ± ( ± -
-, )
%( ( ® ±
®( © ±® ±©
® ± ± )r
} } -
® ±
± ± ® ± ± © ± -
} % ©
® ® ± © -
® ± ®® ± ®)
2) ( ± ® © ® ± (® ® -
± ® © ®
( ® -
 © ± © -
® © © ) ± ®
)
.
% ©® ± ± ± (
®( ©© ® ® ± -
®
( ®± ® ®± ® ±-
© (
± ®
)
c % { } % -
{
} ±-
®
± ® ± ±-
± ® ± ®© -
©) ® ® -
± ® © ® ± ® ® ® ® -
± ®( ® -
± ( ©±
® ± ± ® ±-
T
2U)

] ]
± ® - ± % -
% ®
[45, 72]. p $
± )alteratio - %-
® ® ®( -
®( ± ®
±
±© © ® ± ) ® ±
± ® ® ±© © © -
± ® ± ± -
© ® ® ) © ± -
®± ® ±© (
® ® ® ± ± ® ® ©
)
c -
} 2,
%
- ± ® ©® ±
 ± ( ±® ±® ± -
± ® © ® ± 6 % ©-
® © © ± ± ® ±-
± ® © ® ± 6. % -
© ± © ®
© ® ± ± ± ± ( ±-
± ®± ® -
® ® ± ® ± 6/ %
± ® ® ± ± ±
® ± ( ® ® -
± ± ® ©( ± ® ® ® -
± ± (® ® ® -
© ® ± ® ® © )0% ± ±
® © ® ± ®
© ® ± ± ( © © ® ®
®$± ± %
)
±± - ®± ® ©
® ± ® 5 ± ® ± ® ± 6® -
± ± ® ± ±
® ± ® ± 6 ® ± ± -
®
( ® ®® ± ©
® ± ) }} "
} -
% n {
} %
% -

y $
± )exsudatio - ® ® %- ®
±
® ® © ®® -
± ® ± ® ± ®
® ± ) ± ®
± ± -
± ® © ® ±
® ± © ®
± ® ©
® ± ® ± ® ±
(± -
®( ± ±± -
®
) ® © ® ± ®
®® ± ) ± ±
® ® )
± ± -
}
±®
±® ± ± ±©© ®( ®-
®® © ® ±-
® ® © ± ®
)
-
±®
±® ® © (± ©( (
) ® ® -
©® ® ± ±( ,+
+ ) -
±
± ® )
® ± ± -
± ® ± ( ® ®
®( ®-
± ® © ± ®®
)
® ® ® ® ® ± -
± ® ® © ±© -
® $ ® ( %
( ± -
)
± ® ±© ©
± ± ± ® ± ±-
© ( ±
± ® ® ±
( ®
® )
o -
®® ® © ® ± ± -
© ±) ± ® ± (® ® -
© © ( ® ± ®( ± -
± ® ± ±± © -
© $ ± ©% ) ® -
® ®
± } -
{ r" % ±
± ± ( -
® ± ® -
®
) ® © ® ± ® ®
± ) ®®
 ©® ± ±®
±® ( ® ® ±
± ®T
2U)
b } ®
±-
± ® ©
© ± ® ® ©-
± ®( ® © ©
® ± ) ± ®
± ® -
± ® ®± ® ±-
© ( ® ® ±©© ® ® ±-
® © ® ± ± ® ® -
± )
p $
± ) proliferatio - %- -
± ± ® ® -
± $± ±© ® %® © ® ±
± ®
(® ± ® ® -
± ) ± ± ®±
± ±±© ® )

] ]
] ] [ ]
±® ± ± ± ® ®
-
± ( ©
± ® ®
( © ®
)
± ± ©
©
± ®© -
± ®® ± ( © -
( ± ± ® (
® )
® ±© -
®$ ( ± ® ( ± ©-
( )
% © ± (
® ( ® ® -
®
- ±©© ® ® ® © -
± ( ® ± ® -
© © ±( ± © ®
® ® ® © opi ® ± ® -
% { } ® -
 ± ( ± - ± © (
® ±® %
® ® -
± © ®
)
± ( ±
© ® ± ± ( ®
± -
± © ®( © ® -
® ± ®® ± T2U)
® ±® ± -
® © ® ± ± ® ® ® ®
$ ±)
.%)
± .
® ±® ± ® ©
® ± T ) ),443U

| | | |
|
© ®
© ±® - © (
±
©© ( ± © ± ® ± -
® © © ±
® © ® - ® ® ® -
® ® © - ® ± -
® © -
± © -

£
£ ® ® ± ± ® ® -
® ®
± ± ± ± ®
) ± ® -
± ± ®® © ® ± ± ®
±-
} adhaesio - "± ® -
± ± ± ) © ® ®±
® ± ± ± ±® -
± ± -± © ® ± ±$ £ %
)
± ± ± -± © ® ± -
± ® ± ®
± }
 ± ®® ±-
£ ( )
£ ± ®
® ± ®
( L- - ± ( ®
± ±® © ®
)
± ® ± ®- ® ®-
® ©
±® $©± © ®
% ® -
±® ) ® £ ® -
±® - ©± ±-
± ± $ ± ± ± © ® -
± ± , %) ® ± ® © ± ± ® ®-
® ® ±( ® ®
© ® ® ®- }
® ® ± ®
®± ® © ® ± ®
± SIRS ® ® -
£ ® ± ± ± -
±® ®
)
± ± SIRS, ±
® ® ± ( © -
® ® © © ±© ©
®© ( £ ® © ± -
® ± ® ± ± ± ) ©-
® ± ± ® -
± ( ® ® ±©© -
® ® ® ± ®-
± ± ® © ( ± ® -
© ± ® ± ) | | | |
| | | | | | -
| | | | -
'
± ® ® ± ® -
®
± ± ® ®® -
± ( ® -
( ® ® ±®±® ® ±-
- ± ®( ± -
® © ±® ± ( ±® -
® ® ® ©© ± ± ® ®
® ®) ® ± ® ±
® ©
± ± ® © ® ± ± )
± - ® ® -
± ®) £ ® © ± -
± ® ± ( ® -
±
± ® ( )) ± ± ± (® -
± ® ® ± ( ± ® ± ®
± © ® ) ®
± ®© © } -
}} -
} { }
} "
± (® ® ± -
( ±® ® ® ®-
®( ± ® ® ©

± (® ± ® ® -
® ® ± ± ( ® ®
® ® © ® ( ® -
® ® }
£ © ®
± -
± © ) ® ® ® ±-
® ® © $ %
) ® -
( ® ± ® ± ®
© ® ® ® ± ±-
± ) ± ®± ® ± -
® © © ® ( ©
® ± ± ® ) -
( ® ± ®± ® ® ± -
® ® -
®® ® )
£ - ® ± © -
®(® ®© ® ©
 ± ® ® ±
± ® ±
( ® ± ®© ®
± )£ ® (
® - © ) ±® © - -
© ( ± © ®
± ± ©)
© -
® ® ® ® ® )
® ® ®± -
± ± ± ® ®
± ±® $ ± -
© ®
± % ± ® ± ® ± (
®
± ) ±
± ® © ±) ± ± -
© ® ® ± © ± ®-
®® © ® ± ) -
® ® ± ±®
® ® ® ® ± © © ± -
® ± (® ± ® -
± - ) © ® ®
® © ± T2U)

] ] ] ]
]
| | | | - ± ( ±-
® ® ® ® ® -
® ± ± ®© ©-
± ( ® ® ( ®± -
® ± ± )
| | " | - ® ®( -
± ± ( ( -
®
± © - ©± ±
± ® ® ( ® ® ®
® ± ± )
© ±©© ® ® ® ®-
± ± ( ® ® ± -
 ( ± ± ± ) ± ±®
± ®© ± © © ® ±
® ® ± ± (® ® ®-
® ± ® ©- ±) -
± ® ± ±( -
® ±-
± ± ± © ± ± ®
(Fc- © % ) ® ® ® ®
® ±® Fc- © ® -
± ± ) ® ® ± ® ±
±©© ® (® ± ® ® ® ®
®
) ® ® ®-
± ® -
® ± ± ± ®® -
© ®)
±® ® ± ®± 5 % ±-
© © 6 % © © -
® © 6®% ® ± -
© ) -
© © ®® ® ±-
® ® ® }-
® ±® ( © ® ® -
{ % ®-
© ) ± -
± ± ® ® (
® ± ® % ®
± ±®
® ± )
± ® ± ® ± (
+ ®
( ® ® ± -
® ® $ ± %) ±
®© ® ® ® ±-
$
,) ©*±%
) ® ± - ±© -
® ( ± ® ±
( ± ± -
± © ® $± %
) i{ -
%% } } % -
 } -
% -
T
2U) -
® ( ® ® © -
®
( ®
± ±©© ®
( -
±®±® © © ® ®
® ± © ) © -
® ® ® ®
® ± ± ® -
©®
)
± ± ®
© © ® ®
® ± ) ® ± ® ®
® ± ± ® -
® ® ±
± ®© © ® -
® ® © ® ® )
± ® ® ± ±©©-
®
)
® ± © -
± ± ® © ® ± ®
± -
5
® ± ® © -
$ © © ® ® -
± © %6
© ®
® ± ®
® 6
® © ® ± ®6
© ± ®± ® ± 6
® ± ± ® ±
± ® ®6
®
± ® ® ®
6
® ± ± -
®© © ± ® ® ® ® ©
 © ® ± © 6
'® ® ± ® ® ± ± -
© ± ® ® ±©© ® )
0 - ± ( ± ®-
± ® ± ±- ® ( ®-
±©© ( ± ® -
© ® ± ) ® ®
®± © ® ®( ± ±
© ® ) 0 -
® © ±( ® -
± ± ± ± ( ® -
± ® ® ± ±®)
©( 0 ± ® ® ® ®
± ±( ® ® ±
±©© ®)a -
{
{,"
2
® ® ® ®
© ± ± 6
® ® ± ± ® -
®® ± ® ® ® ®
±©© ®® ® ± ®)

± /
© ® ± (® ® ®© ©
± T ) ),443U

| | | | |

±
® ±
®± © © ®
± ® ±±
® ® ® ±
® ± ± ® -
® ®
±
 ± ±
)/
® ® (
© © ± -
± ®
( ± ® ± © -
© ® © ®
( ± ( © ± -
± ± ® ©® ±
±® ±®
-
±® -
±®
( ®- ® ®
- ±® ± ® $ ± ±-
%
©© ® ±© ±
© © ® ± ( -
±®± ®
± ® ®
©© ® ® ® ®
)

( ®
® ±® ± ®
± ©- ® ®
© © ®
± ®® ±±

®± ®± ±-
® ±
® ® ® ®
)
©
± ® ± ± -
$ - ® ® ± ( ® ® -
± ©- ® ±®
(
% ® ® ©
± ® © ® ± (® ± -
© © ( ® ® ®± ®
® ± ± $® ® -
©
± 2).

® ±© ±
$ - ± ©® ± ® )

± © %
 | | " - ± ± ®-
± ±( ® ® ± -
© ( © ± ® ®
© ± ± ® ± )
± ® ± )
p } { -
{ } {
% }
% { } £
5 - ( ±
± ©-
( ± ( ® ( -
± ±© © )
- ® ® ®
( -
± © )
® ® ® ©
© ® ± ® ® ® ±
®) ® ®
®± ©© ®® ® ®
® ± ©
± ± ®
®
) ±© ± -
± ® ±
®- © ®
® ± ( © ± ®© -
© © ± ® © ± © T
2U)

] ]
] ] ]
® ± ± ©
® ± ®± ±
) © - ®
© ® ± ® - ±
± ® ® ® ® ( -
® ® ® ± ± -
® ® ± ±®( ®
© ±® ±® ® ± ) ® -
± ± ® ®± ® ©
® ± .
-1 © ±) ± -
 ± ± © ® ± ± -
-. ® ± ± ) -
-
%
( -. ©
® ± ® © © ± ®
± ± ®( ® ± ®
( -
® ® ® ® ±©-
© ®$ ± ± ®® ± %
)
® ® ± ® © ® ± ® ® -
± - (® ±©© -
± ± ®) ® ® ±
( © ®( -
® ® ® ® © ® ± ) -
® ± ® ® ( ®
( ® © ® ® ® ±- ®
© ® ® ©) -. ® ®
® ® © ( ®
© ® ± ) © ® ® ® -
® © ® ± ± ® -
© ± © ®- ±©© ®5 ©-
± 2( ± ®
( ± ( (
©± ® ( ± ®( ® ±( ±-
± ® ® ± ±®)
® ©± 2 ± ® ±©©-
®
- © ® ± ±® ±
© ® ± © ± ) ®
©± f2 ( ® ( ± -
© ® ± ( ±® ±-
® ©® ± ±©© ® ± ®® -
± ± ®)
® ± ±( ® ® -
(® ® © ® -
® © ® ©± ) ± ®
® ± ±® ® ®
® ® ±©© 5 ©
± (
± (± )
38
 ± ® ± ® © ±
® ± ® ± ® © ® -
± ® ® ± -
± ® ® ± (
± ± ® $ -
)£ ± ®
® ± ®± © ® ±-

® ± ©± -± ©
± © ± ® ® ® -
©± ® $ ( ® (
)
%® ® ®®
© ® ± © ) ®
© ® ± ® ® -
± © ® ® ©®) -
± ± ± ® ® © -
® © © ± ® ( ® © ® -
± ® ® )
® ® ± ± ®
(® ± ® -
® ® © ( -1 -{ %
® ® 5
£ ® ± ® ± -
®
( ±® ® © ® ± © ±-
® ± ®) ® -
® ± ± 6
© ± ± ® ® -
± ±®( ®© -
±
± ( ±© © 6
© ± ± ® ® ®
® ± 6
® ± ®( ® ® ±-
) ±© ± -
± ® ® ® ± ® ®-
± ® ® ±
± ± © ± ±
 ± ± ®® ± ®© © ±-
® )
c } -
® ® ©-
± ® ® © ± ± ±
± ® ± ®) c
% ® ± ® © ©
- ( ± ®± ® ® ±-
(® ® © ® ± ± -
( -

® ® ® ± ®®
® ® ® ® ® ®
( -
± ® ® ® ® $ ± -3
)%( ® ® ®
£ ) ® ± ® ± ®
± ® ± ® ® -
® ± ® © $ %) ±-
® ® ® ± © ±
-
± ) ® ± ± ®
±± ±± T
2U )
| - ( ± ® -
± ± © © © )
©( ® ® ( ® ± -
® ® © ± (
® © ® ® ®)
® ® ± ± -
® ® ® ) ( -
± ®
± ± -
®® ± )
- ±©© ® - ®
)
( ±
± ±-± ±
-
) ® ± ® ®
® ® ® ®- © ®(
® (±© ( ( ( -
© ± ® ) ® ® -
© ® ® -
40
 ®
( ® ® ® ±
± ) ±
± ® ® ® -
±± ) ® ® ©( -
±± ®® ± ± ® -
®® ® ( $® )) ± -
± %
( ± ± )
| | | © -
± ® ±© © ®±-
© ± ( ( ± ± (
®© ® ± (
® ®® ± ® -
) | | - | | |
| | | -
| | ± © ± (
® ® ± ®± ® ® -
± ±± © ® ( ®
±© ± ) ® ® -
® ± © -
© ® © ® ± ±-
)£ ® ±©©-
® ® ±( -
®( ® ® ® © ® ± ) ©(
® ® ±® ±® ® ® -
±® ® ± T2U)

] ] ] ][ [
® ± ®©
±© ©
©±© ® -
© ® ( ® ®
® ® ±©© ® ® ® ©
® ± T
2U ) © ±
±® (® ® ® ± -
® ± ) © ©
® ± ® ® ® ( -
©± ©
(± / ® ® )£ ±©© ®-
® ±® ® ® ® ®
 ® ®
5, % ® -
®
6 % ® ® ®± ® ®
®(® ® )
±© ( ® ® ® ® ±
® ® ® ® ® ® -
± ± ( ± ® ® } } -
® ®® © ®-
± ® ® ®
® ±© - ±©© ( ® -
± $ %( ® ® -
®$ ® ©± ®% ± -
© )£ © ® -
®± ± © ( (
© ® © ® ± ® -
® T2U)
±©© ( © ® ±
® ® ±® © ® -
± ( )
o ( ® ®
± ® © ® ± $ -
( ± )
%(® ® ® -
® ®® ± ® -
( ± ® © ® -
± ) ® ±( ® © -
®® ± ± ©( ± ® ® ® © -
± -, ± - ± © - -
® ( ± -
± -
©± 6
® ®±
® ® ©± © (
® ® ± ( -
® ± ® © )£
® ® ± ®
± ( ® ( ®±
© ® ® ©±
 ® ± © ) -
®
± ® ± -
® ® ± ® ± -
©±® © ©5 © ± (±
) ® ( ® ±
± ± -
®© ©
± ® (® ± © -
© ® ) | |
| | - || | |-
| - | | -
| | | -
| | | | T2U ) (
® ®
± ® © ® ± ( ®± -
® ®© ® ( ® ® -
± © ± ® -
± ) ± ±
© ® © ® ± ® ±
® ®© © ± ®
± ) ± ®
( © -
® ® ® © © ©± )
® ®± ® ± ± © ® -
± ± ®® © ±-
® ± © ® ±© -
±(® ® ® ©
© )
± ® ® ®©
©± ( ®± ®
® ± ± ® ±© ) (
© ± ( ® ® ® ± (
® ® © ± ®
© ® © ® ± ® ± -
® )£ (® ( ®± ® -
® ©
± 2
± 2) ® ± 2
®
± ® ® - ® ± -
® ±©© ®( ±
® ®) ± 2 ® ®
± ® ± ® ± (
®
± ± ®T
2U )
 [] ] ] [
]

® ® ® ± ( ©
® - ± © ®
±± ® © ®
( -
± ® ) ± -
± (® ® ® ) ±
®
± ± ® ®
± ( -
® ®®± )
± ®± ® ®
® ± ® -
±® ® ± ( ® ) -
® ® ± ( ® ®( ® ®
( © © ® ®± ± ± © (
®± -± -
)
© ® ± ® ±
®± ± ± (®
( ( ® ))
( ± ® ± -
® ® ±© ( ±© ( (
© ± ( ® ±® (
© ± ®
± ® © ± -
® ± ® ±
® © T
,40U
)
® ± ® ® ©
± ± ± ±® ®±±
® © ( ©±® ®
®± )
4+- ©©
) +® ± ( ®-
± ± © © ©
® -± ± ( - ® ( -
± )± © ® ±
 ® SIRS. ® © ©
± ®± ®± ( -
| } ® -
) ® ± © ® ± ± -
| © ±} (± ®( © ® ±©-
) ( ( ±
± ® ± ±± ± )
® ®± -
± ) ® -
®® ± ± ® ®± © -
± ± © ± )
© ( ± ® -
±© © ± ® ® © ® -
® © © ± ® ®± ±® )
± $ % -
® $ ± ( ©± ( ® (
± %( ± $ ± ± (± ®( -
®( ©® ))% ® ® ®$ -
± ±® (© ( ®( ® -
©± ( ®%) ® ® -
® ©± ® ± © ©T ,
41U)
® © ± ® ± ± ®±
® ± ® © ® ( ® -
® - ® -
± ) ® ( ±±±
® ± ± ± ( ± -
± - ©)
® © | } ® ®±
® 5
± 5
® ±
® ±
® ±
± ®( ® ®
± ®
© ® ± ± ( ®( ®
® ± ± ® ®
 | ® ®
} ©
©± 5
® ©±
© ® ±
±
® ± ± ®5
±
± ®
± ± ± ®® ©
® ± - -± ®
(® ® -
±)
± ®5
® ±
® ®
® © ® ® ±
5
® ± ± ±
© ± $ ® %
© ©
± ± ( ± ®T ,4
1 U
)
® © ® ± ±
± ® ±( © -
(® ® ± ± ® -
± $ %( ® ® ®
® $ © ® ± % -
$ ± %$ ) % ) © ®±-
® ® © ( -
® © ( ± © ® ( -
0'
±® ® SIRS ®± -
( ®± ± ±
(LPS), ±® ± ® ®
®± T2.(3.(,,U) ± ±-
® © ± ± (® ± -
® ± ) © -
® ( ® ±®
± ® ® ®
(
® ®( ±
 L P P P JP P J

P P

1 1
- ^

-
R R

t
I 1

}
R 6 K
PJ P P P ] R

S J P :
R R K
[ ^ R
R R
S P :
R K ^ K [ ^ R R

J L P LP J
:
^ R R R
R
[
R C R K

SP S J P

L J PS L J

SP SP P P:
J L P J
P P

PJ J P J L P S /
J L JS P P PP

P SP L :
:C __ _ _ _ -
K [ [ K :C [ [R -
^ ^ C

) ) ± © $ ® ))
(
1999).
 ± ± T,//(,
11U
)£
( ± ® ®® ®
® ® ± (® ® ©
-. -
±® ± ± ®
± ® - ± ®) ± ® ©
®± )
± © ± ® ± (
® ± ( -
® ® ® ± LPS.
±® ® ® ±©-
5 ® ( ©± ( ± (
± ® - ±( ±( -
( ©( ± T,
.+(, 3,U -
® ® ® ®( -
® ± T,
0+U) ± -
® ®± ® ®
± ( ± ®( ± ® ( ®-
± © ( ©± ( ® -
± ±( ®±
® - ©± ® T 43U( -
± ®± ® SIRS
± ±© )
®
± LPS ®± ± ±
( ±® ± ® ®
± ± ® ® ( ± ®T 3+U)
® ± ± ± -
® ® ( ® ± ®
®©± ® ± ( ® ( ®
© ® ± ® ©± ± ® ± -
± * ± ± -
T
2( 4
2U$ ) . %
)
® ± ± © ® -
± ® ® ± ( -
® SIRS [41, 73, 74].
® ® ®® ±
± ® ± -
®- © © ( ( ± ( NADF- © © (
49
NADH- © ± ® -
± © ± ± ®
) ± ®
± ® ± ®
(
® ® ± ± ® ±-
© ±± ) ± ±® -
® ± ® ®( ® ® -
± ± ± ( ®( (
( ®
( ® ® -
± ) ® ± © ± ± ®
± ± ± © ®® ±
± © ± ( ® ® -
$ % ± ± © ( -
( ( ± -
)£ ±®± ± © ® ( -
® - © ± ©
© © ® ± © ± PGJ2,
® © ®® ® (
® ± © NO, ® © -
T,. U
)

^ m c c

c -
cm

LPS r

c
cm

m
cm cf

| i
c m
cc

c }c m m
c

fc cf c\\
m
c}

i
c

m c cm c
( cm c |' c j c
|c ) c fj mm m
c

P | _ c V f j m c f
m m
\r cm cjc} c0

) .) ®
Bone R.C., 1994).
 ® ( NO - $ % $Endothelium-
Derivated Relaxin Factor - EDRF) P. © T2.U
)
NO ± ( ±
® ±® ( ® ® -
± ® © © ( ® ® ®
( ® ®± ®( -
6 ±© © © ®
©6® ® ® ® ± ®-
± 6® ® ± ±-
® ©± ) ©( NO ® ®® ± -
± ® ® ©± ® ± -
T
,. U
)
H+ © ± ± ® ® ± ±-
± ( ® ® ® )
© ( H+ ® -
- )
®± ± -
®( ±® ( ±® ( -
©® ± ± ® T 2( 3 1U
(
© ® ± ® ® ® ±© ®
® ®- ®( ( TNF-a TNF-P, ± ®
(IL) 1-1 )T 2
2(, 2
1U)TNF - ± - -
® ± ) H+(
© ® © C
C( ® ®
± ± ±®© ± (
© ± ±-
© T,. (,.4U)
® ©±
® ® ± ® ® ( ±
± ± ® ® ® ± ( (
± (LTC4, LTD4, LTE4), ( ± -
( ( ( ® ®
± T,1U( ® ®
®± © © ±± © ®±
® ® ± ) ® -
® ± © ± ± ± ® ±
 ( ±® ©± ( ( ®-
® ®T
,10
U)
± ® ®- © © ( -
® ® ® © ± SIRS © -
© ) ( ® ®® ®-
IL-1, ( © ± -
± © ± (
± ± ® -
T2(
42U
)
© ® -
± ± ®
± ® ® ( -
®± ( TNF ® IL-6 ® © -
® T 2(2 .U
) ® ® -
± ± ® ® ± TNF, ± -
® LPS ® ± ± ±-
® ( ® ± ±
® ± ( ®± ± ± (
± T
2( 2.U
)
© ±® ± TNF
®± ± ± ± ( ® ® -
® ± (PGS2), ® ± ± ( -
± ® ± ( ® ® -
® ± ® ® ± © ® (
( /( 0( ± © ± ± ( -
± ® ® -
±± ® ) ® ±-
± © ±±© ® ® ® ©
© ® ® ±
±
® ) £ ® ® ®
©( ±® © ±±
®± ( ®± ® ® ® ± -
®(LTC4, LTD4, LTE4) T
2U )
( ±
® ® © ®
SIRS ® © ® ® -
® ® © T2(42U)
 ©± ® -
( ®
± ® © © (
{ - ± ®© ± © ® ( -
® ± ® -
± ®6 ® ® ® ± ®-
©± ® ( ® ® ® ® © ± )
±±5 © - ® -
©± ®± ® ±± - ® -
( ± ±®(® ±
± ( ± ® ± ( -
± )£ ® ± ® ®
( ± ± ± ® -
±© ® ©± ® ( -
± )
±± ® ± © ) ® -
± ® ® ® -
®- ± ± ©© ( 2( -
( T2( 2 .U
) ® ± (
© ® ® ® ± (
± ® ©±
± ® ±± ± - ®
T
,0+U)
- ® ±
® ® ) ®
± © © ® ( ® © ®±
® ± ± ®T 44U
)£ ®± -
± - ± ±
±( ®± © ± © ® ®
® ® - IL-2 - (®± ® -
® ) © -
® ©® ® ® (
± ± ± ® ®
® ± ( ( (IL-8 )
® ± ®± -
® ( 0 ®
± ®( ± ®( ©± ® ( -
® ®(PAF), TNF, 2( -
® ± ± ® ® ® ±-
± ®( ±® ± ( ® -
® ± T
2U)
£ © ( ± -
± ( ±® ± ( ± ±-
± ® ®
)
± ± ± ® (® ± ®± -
® ® © ® ® ± C
C(
© ® ± (
® ± - ± ± © ® -
® )
± ® ± ±® ® -
®®
(± ± ® ± ( © ® -
® ® ± ( ®
® ± ® ® ® ± (
® ±® SIRS ® ± ® ® ®® -
® ® ± ± ( ® ± -
© ) © ®
) ( ±®±® ® -
® © ®
±
:T2( 2.
U)
± ( ® ® -
(®± ® © ©
©± © ) ± ± -
® © © ®( © ®
® ©( ® ® ®± T.0
(
95].
± || | | | |
3
1) ( (
©± © ± ®© ®
© ® ® ® ± ( ® ( ± -
® © 6
2) ® (
( ( © ( ® ± -
 ( ©
± ± ( © ( (
©
± ® ) 6
.
% ® ± ( ± $ -
%( ® ± ® ±© -
± ± ±© ± ± © )

Nuclear factor kappa ]

± ® ®± ( ©
±®
® ± ® ® ± ± ®
® © © ± ®)
± ± ® ® ± ©
® ± ® ®( © (
® NF&B $ - Nuclear factor kappa

Hv <- ( ® ® ® ±
-
®(® ® 0+ (NF&B1) 10(RelA). ®
® ® © I&BA. £
± ® ± ± ®(© -
± ®( ® ( ± ± ± ©± -
± ) ± ( ®-
® ± $©±)0 %
( ® ® -
± ( ± I&BA ®-
® © © T ,4
1U)
± © (® ( -
± ±® ( ® ±
$ (® ® ® ® ±-
±®® ± - %
)
® ± © ± ®® )
® ® ± i ± ® ®
© ± ® ) ±
® ( ± ®
± ±© ± ( ® ©
))
 ( ® © NF&B

|NFfcB __________________________________________
v
TNF-a, IL-1, IL-2,
4
b
£ (LPS)
£
, ©
c
® ® ®$
®± ® herpes simplex)
®
o
± ± ±
®
u
______________________________________________________________
|NFfcB __________________________________________
v
IL-10
{ }
£ (LPS)
± C
© _____________________________________________________________
a

±
±

e }
±
± ±®© $
heat shock proteins) ______________________________________

] ] [ [ ]
] ]
© -
® ± © ® -
T
.0(
40(,4
2U5
1) ± 0)
2) ± 5 TNF-a, IL-la IL-ip, IL-8,
IL-12 heterodimer, IL-18, IL-6, MIF $ (
© ©® %
)
3) ± $ ±® % 5 IL-3, INFy,
GM-CSF, ® ©)
4) © 5 IL-4, IL-10 $ ® ± Th2
± %
*
5) ® ® ® $ Vila, 6
6 ® ® % )
6) £ $ ©± ( © ( ± (
PAF * ® *
%)
7) ® ± (CV, NO, 0N00).
8) © ®5 IL-lra, 1 3 (sIL-lRII), 0 0 (sTNFR
I), 20(sTNFR II).
9) $ ( VIP).
® ® ( ©(
± ± (± ( ± ± ( -
± ) ( ± ( ®
± $ % ( ( ( -
± ( © - ± ® ± ± -
- ± ®)

|
± ® 0 ± ® (
® © ± 5
1) ± 5 % (IL-1, -6, -8, -12, -18);
% . )
(IL-4, -10, -11, -, %6
2) TNF $ ±% )
3) ® ± ®6
4) ( ± ± ©® ©-
± ®6
5) (
® ® ± ± .
® ® ± + ®
(
± ® ± $ ±)
1%)
 ® ®T
,43
U

5 ( - - - ± ( - ® ®± ( -
± ± ± (± ± - ® ±® ® (
IFN-a, IFN-(3
©( - ±± ) ® - ( ®± -
± ( i ® ± ® ± C C
C
± ± ± - NK- ± ± ®
( ± -
±
® ® - ±
NK- ® )
® - LAK- ± )
IFN-y ® ® - - - ± )NK- ® ®± ( -
± - (NK- ± ± ± ® ±® ® (
± ( ©( ( ®± -
± ® ± C C
C
± ®
( ± -
±
® ® - ±
NK- LAK- ® (
® ©®
± ± ± (
± IgG2a

TNF-a, (tumor ® ® - $
® ® ®± ( -
necrosis factors - ± ( LAK- ± (
GO) - - ± (® ±® ® (
©( - ® ® - ( ®± -
±- % ± - ± ( ± ( ® ± C C
C
©
( - ± ®
( ® -
± ( ±(
©®© ± ®
)
± ( -
©

±® ± ± ±-
± (
© © ®

IL-1 (intcilcukin - - B- ® ®± ( -
± % ± ( ® ® - ® ±® ® (
- - ± ) ( -
± ( ±
©
( ± ( ± ® ® -
±( - - ± ( ®
± ) © ± ± -
± ( ® © ±-
® ± ±
± ( ± © -
IL-2 ® ® T- - - ± NK-, ® ©® -,
- (LAK- LAK-, © NK- LAK- ± ( ±-
-
® ® B- ± ( -
± ± -
® ® B- ± ( -
± ± -
® ® - - ± (

IL-3 ® ® T- ©
( - ± © ( -
± ( ± - ± ® - ± B-
( ± ± ( ± (± ( ® -
±® ®
IL-4 ® ® - ® ® - ® ©®) -
± ( ± - ± ( B- ± ( ± -
- - ± ( ± - ® ® -
( LAK- ± ( B- ± ( ±
©( - ± ® -
± ± ± (
® - B- ± ( ® -
± IgE- ®
- ± ( ± IgE
IgGl
IL-5 ± ( - ® ® ± ±
® ® - - ± - IgA, ®
± ( ± ( ± ( - ±
± ±®
IL-6 T- - ± ( - ® ® - ® - ± ( -
± ± ± ( - ± -± -
± ( - ( © ® ® B- ± ( -
©( ± - ± ® ®
© © - - ±
IL-7 ± - -) - ± ( - ± -
© ©( ®± - (NK- ® ® - - ± )
® ± ± ® - ±
±
IL-8 ( - ± ± ®
® © ± ®( -
± ©© ® ( ±
© © © $ -
® ® ®
%
IL-9 ® si*- - ± ( ± ± -
± ® ± ( - ± ( ±
® © © ± ®
IL-10 po- 22r- Thl - ± ( - -
+/- ® ©( NK- ± ( ® Till - ± (
- ± ( ® ©® NK-
- ± ( ± ± ( ± -
± ( ©( ®( B- ± ± -
±
 1L-11 ± ( ± ® ± © -
© © ( - ± -
© ± ®
® ® © -
® ©®
(
± ± -
®( ©

IL-12 ©) - ± - Thl-, NK- ± IFN-y

(B- - NK- ± ADCC
± ± (antibody-dependent cellular
± - cytotoxicity)
IL-13 ® ® - B- ± ±®
± - $ %
( B- ® nitric oxide (NO)
± ( © ® ® -
© ( ± -
B- ± ( ±
IgE- IgG- ±

IL-14 - ± - - ± ± ±
±® B- ® ® - ±
±
IL-15 ( - ± LAK- ± ± -
± ± ± ± ±-
± © ® - LAK- ±
© ±
IL-18 ® ® -± - -
® ± -
( ©( - $ ® IL-2, IL-12,
( ± ( IL-ip, IL-8, Fas-
®
( - ±© %
©

G-CSF (granulo- £ ± ± ± ± -
cyte colonystimu- ± ( ±- ® ±® ± ®-
lating factor) ( ©( (©
± - ± ±
± - © ©
±

M-CSF (macro- © © ® ©®
phage colonys-
timulating factor)
( -
±
©®
GM-CSF (granu- £ ± ± ®± ©(© - ® ©®
( -
locytemacrophage ± ( ±- ± ( ©( ± © ±
colonystimulating ( ® ® ± ± ± ® (
factor) ( - ± ( © ± ©
±
© -
® ©®

TGF- (trans- ± ± (
forming growth ± ± ®
factor-beta)
-

R-

NK
(natural killer) - ® ± - ±
± 6 LAK
phokirie-acavated killer) - ® ® ± ± -
ADCC (antibody-dependent cellular cytotoxicity) - ± ®
- ® )

®
± ® ± -
± ± ± ± ± ,
+ /
0 ) -
± © ©( ( ®
± ( ± ± ® ) ®
± ® ± ® ® ± -
® ® © ( ® ± ®
® ± ( ® $ -
%
( ® ( ± ( ±© ©
© ) ±
± ( ) )® ( -
± ± ± ± ®-
± ) ® ± ± ©®)
± ( ® ± ®
± -
± 2 +! ® ©® © ) ± ©
±®
± ® ± © ®( ( ® -
± ®( © ® ®T,34U
)
® ® © )
±( ± -
® ® ±
© ® ± ) ®
± ® ® ® ± ( ® ® )
® ± ( (
®
± ®( © ®
(© -
( ± ® ( ± -
(
® )

y [93] - ± ® ®
( ®
±
± ± ±
± ( ® ® ®
± ® ± ( ± ± -
®) ® ® } % -
{ % %} -
£ ® ® ® ± ( de
novo, ® ® ( ® -
± ) ® ± ® -
® ©± ©(±© © © © ®-
( ± (
© ± ±© )
± ® ® -
® ±® ®± ±
± - ® ± ) ® ® ± ®
© ® ± ( ®-
± )
® ± ® ± ± -
®® {
(PAF) - ± )

| |
£ - ® (® ®
( ® ® © ± ®
±© ® ® ®
® ± ) ©
± -
± ® ® ®
2+
® ® ( ± - ® ) -
® ® © (® ± -
( ) © -
± ® ®
( ©® ©±
 ® ±
2+
± ± ® ± ®
± ± ® ® ®-
± ®) - ® ( ± ( ±-
± ® ±© % 2 ( ®
® ± s ® ±
± ® © ® ) ©
(® ± ±© ± ( -
± ± © ® ) -
® ( © © -
® ± ±© -
®( ® ± ®
) - ( -
® ± ® ®±
® ®® ± ±
®( ®
± ± © ± ®-
© -
)
s { £ ® ® ® ®
® ( 2 ±® ©© ®(
,
2 ®± ) © ± © -
® ® ® ® ® -
®) ± ® © ® -
( ± ± ® ® ® ® ±-
±® ± ©
®
( ®® -
® ± ® ® ® ) ± -
® ± © ® ®± ® © ©-
®(® ® (
±±© ± ± )
®
± ± -
® ± ( © ±® ©
©© ±®)
e ® ± -
2 ®± ± ± ) ± (
±® ±( ± ±©( ±
± ® ( ± ) -
± nrF2(X 2 ® ±
 ® ) ± -
® (J1TC4, JITD4, JITE4), ± © -
®( ®± ® © -
) ® ±
±® ) ©( © ®® ®
® © © - ) ©
±© ± ® ® (
© ®® ® ® © ®
± ®
)
i - © - -
® ©±® ± ( ©
® ® ) - -± ®± -
± © ®±( © ± ©( ®
± ) -
® ± ± © -
® ® ® ® ® ± ± -
± ®
) ® ± ±
© ± ®) ±-
( ± ® ® ® ®
± ®( ®( ± ±-
± )£ ± -
( ® ± ©
© ® ) © ± ± -
± ( ® IL-1 IL-2 © ® ±
C
C © ± © © ± )
( © ± ± ± -
-± ®)£ ® ® ± ® -
± ®-, - ( ® ± -
- ) ±® ® ® t
© ® IL-2.
p ±-
® ® ® (® ( -
± ± © ± ® ( -
® ± ) ®® ± -
± ® $ ( ( % ± -
® ©
± ®
( ( ©
® ± © ) ( ®± ±-
 ± © ± © -
® ( ® ® ( 2 (
) ± © -
® ®
± ( -
) © ± ® -
©® ©± ± ( -
2+
® ± ± -
± ® ± ® ±® )
y } { ®
©± ® ® -
® © ± ± ® ) © ®
- ( ®© ® ©© ± ®
±( ® ® ± ® (
© ® )
r ± ± ±® ± -
± 2 ,2)£ © ©± ® ® ® -
± ( ® ± ± ) ®( 2
© ® ± ® ( ®
® ) ± ( ® ® ® -
± ( ® ± ± ± © ) -
® ,2 ± ) ±-
© ® ± © ± ± ©
- 2) 2 ,2 ± ®-
® ± ± ± ±
$
£ % (
- ± )
g s ® 2 2 ®
±
e ± ± ± -
± ± 2( ,2( ® ± -
2 2 )
s { ©© ®® ± -
©± ( r ,2 -
± ®
± ©© ( 2 ±® )
v r
2 ® ® ® ± ± ) -
© ® ® ± -, ( ®®
 ® ® ® 2)£ ± -
© )

||
± ® ®
± ® -
± ) ® ® -
® ©± ® ©
±
± ) $© -
C
C(® ( ± Y), -
$ © ( -
(® ® ± ( -
( ( ® © ± -
%
)
- © © $ ® %( -
® ± ( ® ® ® ®
© C
) ®± © ® © -
$ % © C ® ® © CC( -
©( ® ±-
± )
i }{ apu $ ± ± ± % ± ±-
® © C® © CC
( }-
{ © ® ®( ®± ( -
( ® (
e } :
: © C
C ® -
® ® ® © ®(®± ©± ±-
®( ®( ©) ±©
- © ® © ± ® ±
® ©± ± ± ± ®
)
c ae © CC ®± ®
® ® 5 ± -
®/ + ® ( ± )
® ® ®
®® © C
C ®
©± ± ®
( ±)
c ±-
 ® ©©± ( ® ® ® -
± ± ©®© ® ® ®
( ± ® ( ±©
®± © ® )
c © II -
® ± ® ®( ±
± ) ±
±® ©± ®
)
c © II ® ®
±
® ® ®
( ®
± ± ® ®±-
)

£ © ® ®
)
± ® ® © ® ®
®
( ® % } ±
-
± ® ® ± (®±
( ± ± ( ( ® ±
± ) ± ±± ± ® ® ®®
® ( ±
± ( ® -
) ± ± ± ® ® ( -
© (® ( ±± ) ®-
® ® ® ± ® ±-
(® ± ® ( ( ( ± -
± ) ®, +
® ( © ) ± ®
© ® ® ©± ±-
±( ®± ® ® ±-
± © ± ± © (EDRF), ®± -
(NO), ± ©± (
2 ,2) ® ± ( ±-
©± ® ® - ® (
® ± ©
± ±
® ± ® ® ® ©± ®
(
nrF2o. ® ® ±
® ± ©± ± )
67
 ±
(® ® ( ®
®± ®± ® ±± ±(
® ® ® )£
±© ® ±± ®
(
® ± ± ± -
± ®
( ® ®± -
® © ®
± ® ® ® ) ±
® ® ® ® ® ®
® ® ® ± ( ®± ® ± (
® )
® ®
± ©± ±-
( © ± ® ®® ® -
± ± ± ®® ® ©± -
) ±± ® ® ® -
® ± ) ® ® ® -
± ± ® (® ® ± )
p -
® ®
fANP). ® ® ® ® ANP (
± ® ®± .
©( ® ® ANP ® ®±
( ± ± ® ± © ®
© ± © )
y £ ± ®± ® ®
® ® )
- ® ( ® ± )
£ ± ® ® ® ® ® ® -
± ® ) ®, +
+ ± -
® ( ± ® ± )
® © - 5® ± ®
( ± ± ® ) ©( -
± ® ® ©
± ± (
® ± © ( ) © -
± ®± ± ± ® ( ±-
® ± © © ©
± ©± © ± ) ®± (
® ± ®® ® ±
68
 ± ® ( ® ©
( © ) -
® ± ®®
± ® )
i ® ±
(VIP) ® ± ® ± ±© ,-
©( ± ® -
® ) VIP ® ® ® ® ± -
® ± ® ± (® ± (
( ©® ®) ±-
© ® ®
® ) ®( VIP ± ± ©
±
± ®( ( ± ®-
± ± ®® ( ® ©± © ± ®
(® ® ® ® ± ® ±-
± © ®)
r{ ®± ® ® ±-
® © ® ® ) -
± ® © ®
©
± ± ±
) ± ± ± ©
®
± © ± ± ± -
± ©± ± ® (
®)

| || | | |
± ± ® ® ® ± ®
© )£ ± ®± ±
® ® ® ( ® ± ( ®
© ©$ ) / 0
%)
2
£ ± $2++ ,
)0 ©*
2+ ©% ®
± | ® }
® ± © ±) -
© ± ( ©± ® ® ± -
® )£ ± ® ± /©±®
5,% ©± © 6 % ± © -
6. % ± ®6/% ©± ©
© ± ®[196J.
± ± © ± ®
 ± ± ± ± (
® ©© ) ® ®© -
® ® © ) -
± ® ® ± ®
± ®
± ®®
(
® ® ±© ® © T
,41
U)

) /
) © ® © ® ±
- )
p | |
| | |
| |' | "| |
' | 3 [ - |
| | | ' - | - | | | -1
| I, A-II - | << - || | |
- " Rubanyi G.M. et al., 1991).

mcf f

) 0) ± ®
( ± -, $ -,
%
± $ % ®
)
o{ 2 - | [- [-] -
]2, 2 - 2. - " D
'*212'
 ® ® ± ( ± ©±
®® ± iNOS, ® NOS
(NO %
( ± ± ® NO.
± © NOS © ± ± -
L- © ± ) ( ©
® ® ® ±
( ® ® ± ®)
® ± ( ± ± ±
NO, ± ( ® ®( ®±
® ± © ®
± ® ® ± ( -
© ( ± ( ( ® -
(NO , ® ± )£ ± -
:
± © ± ©
® ®(
® © ±)£ ± ± ± -
® ( ®® ® ± )
± ± ±
®± ± ® T
.0U
) ®(
® ® ± ( -
± ( ))® ® ® ) ®
-
± ® ®
( -
± ( ® -
±) ® ® ( ©± (
® ®)

(NO)
® ® ± ± ©
(® ± © ± ) ® NO ®
® L- © ® © ± (
± ®) ±© ( ® ± -
® NO ®± ®® © -
± ®) ± ± ( -
± ®) ± ( ® ± -
© ± ± ®± ±© -
( ® © (
± ® ® ± ® ±-
 ±
) ± ® NO ® ® ± -
± © ® © -
( ® ±
® )NO ± ®$® ± -
% ® © ® ® TNF, -
® ® ©® ( ± ±
± ® ®
( ® ® ©± ©
( ± -
®( T
,3U )
NO ®± ® -
® ® ® ( ®
® © © ®± (
® © ( ® ®( ® (
(® ® ± © (
® ± © -
) ® ® NO ® -
( )
( ® NO ®±
® © ® ® ±® -
® ( ® ® ± ( -
® ® ± © ® -
± ) NO ± ±® -
®
( ® ®® ± ±
® ) © ® NO-
NO ® ®( ® -
® ( ® ® ®( ®±
± ®± ) NO, ® -
©± ± ±( ® ©±-
- ® ©
( ®, 4
43© ) ±
±® )£ ± -
} f% ® ® ±-
©© ®)

©± - ® ®
± )
 CC$ © % © ± ± ® ©
© ) © ® ©
©± ® ® ± © $ '%
® ( LPS. ® ®
C
( CC ± ®© -
® © ® © ® -
® $ % ( ® ± -
® ± )£ ± -
® ±± ® ± ± ( ®
( ± © ® © © ) -
® ® $ ( PAF), ® ± ® -
± ( ® ® ® ®-
© © ± -
® ®)£ ± ® ± ( -
® ± ® ® ® -
®) ® ® ± © ® -
( ® ® ± ® (®
(® ± ± ) ® ® (
± ® ® (® ®
LPS- ® ® ±© )
© ®( ± ® ( ±
® ® ± ® © -
© )
£ ± © ± ± ® ®
©± ® ± )
®®± ® © © -
®( ± ± ® ± ) ± -
© ( -
® ± ® ± ± ± (
® ® ® ® -
® ®® ® ®) ®
® ® ± ® ® -
± ± ( ® (® ±
© ® ±) ® ® ± $ % -
©± ( ± ® - Vila,
© ® ® ® ®
± ± ( ± ® ± -
 ©± ®± ® ± -
® ®
) ® ® ( ® ®
± ± (® ® ± NF&B, -
® ® © ®
®© ± ± ) ® -
® ® ± ® ® ®± ©±®
± © ± ©
± T
32(
40(
44(
,43
(.0
4(.
2,U
)

] ] ]
± ® © © -
± $ ® % ± - ± ± $Natural Killer - NK-
± % ) © © ®± -
± ± © ± ± ® ( -
® ± - ± ± ®± ® ± -
® ± ± )£ ± -
© ® ± -
) ± -
® ± ® ± ®
© ®® ± ( ® ® -
© ® ± ) ® ® ± ® ±-
® ®
± - ® ± ± )
±® ® ±
® ® ( ± ±© ® ± ±-
© ( © ©® ± $® %)
® ± ( (
® ® ± © -
®® ± ) ® $® % ©
® ± (® SIRS.
£ ©± ® ± (
( ± -
® © ® ± )
± ® ± ® ® ® -
© © - ±-
® ± ± ® ) ®
© ® ± ® -
 © ® ® © )SIRS ® -
© ® ( ± © -
® ® ®
± © )
± ( ® ®
® ± ± ®
± ± © © 6®
± ( © ® ®± $ ®
%
(® T
.4(
0.(
,44
U)
± © ±© -
® ® ® ± ± ® -
® ) ® ©
® ± ( ® ( -
® ( © ®
) ®
± © ( ± ® $
® ± ©-
%
( ± ©® ( (
© ® ©®(
±® © ± ) ® ®
®® ® ® ± ( -
( ± - ® ±-
± © ± )
© ® ) ±-
® ® © ® ® ± )
® ® ® ® ± -
®± ® ) ©
( ± ® ©
,v ®® ± ® ( - ® -
± ± © ® ± (NO, 02,
PGE2) ® © ® ± ± ©
© ® ® ( ®
® ± ® © ( ® © -
© T
.0U)
(® ® ± -
©® ® © ( ® ± )
25
 ± 2
)
( ± ±© © © -
® © ® © T,4
4U)

CD4/CD8 < 1
± ± J.
- ± J,
® ® ±
± ®(NK) J,
± ®(IL-2, IL-3, IFNy) J,
£ IL-2 ®J,
IL-4 IL-10 |
£ HLA-DR J,
© ®® ± (DTH) I

± ® IL-6 $ TNFa ?) |
± ® f
+IL-1 J,
* ± ® + PGE2 IL-1 |
© ± ® $ ( © % j
± ® r

SIRS
± ®
± ± ® -
SIRS ® ) ® ±®-
®± (® ( ©
$ ±
)3%
)
$± ± -
± * *% ©± © ± -
® ®
) © ® © -
±© ± - ® ®
( G-CSF ®-
® ± ± ( ® -
© ± T
,44
U) ± ± ® G-CSF
± ± ± ±
® © ± )
® ® ®
± ®± 1)

± 3
± ± T
,44
U

d i }
± ± ± - ® © 6
± ® ® ±
± ± ± - ® © 6
± ® ® ±

- ® ± © ± ®

± ® ® ® -
® ± 5 ) -
© ± ± ® -
© ) ± ® (±
± ® ® ± ®( ©
± ± ® (® ± ) ® ± -
( ± ± ®± © ®
± ) ± (
± ± ( -
( ± ± )
© (
± © © ) -
± ®± ± ± ( ©
±( © -
© T++U) ±© ±
®
± ® ® ± T+,U
) ©
® ±® ± ±© ® ( -
® ) ® ©± ®
© ® ± ® © ± © ( -
®( © ® ±® (
)

) 1) ® © ± © ± ± ©
(G-CSF), ©± © (M-CSF), ©
©± © (GM-CSF) IL-3 $ ± %
± T,44 U
)

( ® ®
- ( ± -
) ( ® ® -
® ) [ ® ±-
± ± (® ® -
® TNF- ®
) ± ®± 5 Fas/CD95 -
$ ® ® Fas-±© ± FasL), C C CTNF -
(± ± / 0) 5 -
 $ ® ® ®
- %
( ®±
± ® ©± T+U
)
± ± ±-
© ® (NF&B ® © ± ® (®-
( ©± © ®( ® ® ®
T+
.U) ( ® ® NF&B ® -
® ± ± ± -
± )£ NF&B ± -
) ( ±© ®
® ± ® ® ® ± ± ® (
± ® T+/
(
+0U) © ® ® NFAB
® ± ± ® ® ±© ( ± ®
® ® ± ± ®T+1U
)

] ] - -
] ] ]
TNF-a IL-1 ±
© ®® ® ® -
©
± ± ®± ) ± ± (
® ± ± © ( -
® TNF-a IL-1, ± ± -
( ®® ®± ® © -
± ± © ® ® ® ± ± ( -
®® ± ± © )
± ±© ®
± - ®® ± ± -
$ ±)
4%)
± ® ± ± ® SIRS
) ® ±
® ®
± CARs ±
®® ± ± ® © ®(®
) ® ( ©
± TNF-a $
®± FasL) ©±
© ® ±® ± -
 ) ® ® © -
© ® © ± ± ± ® -
® SIRS, ® ± © -
© ® T ,4
2U)

± 4
® ± ± ® ± ±

p
TNF-a
IL-1
IL-6
IL-8 ____________________________________________________
a

IL-4
IL-1
0
IL-1
1
IL-1
3
TGFfl___________________________________________________

© ± ± ® ± -
® ( ± ± ® -
® ® © ® ± ± © -
© ® ( ± CARS )
± ® ® ±
 ± ± ® ®
± -
± ® CARS, ®
± ®-
± ±© © ® -
± (SIRS). ® ® ± © IL-
± ± ® ± (
( ± ±© ±®-
) ® ± ® ( ±
© ® ® ® (
® ± TNF-a IL1-P, ®-
± ± ® ) ® ®®
± ©- ® TNF-a IL1-P ® ® ,-3
® /-3 ®6® ®
IL-lra, 0 0
(2 0 ® ® ® / ®
± T , 42U
)
± ® ± ® ®-
IL-lp, ± ± | ± ± } -
® ®® ± ®
® ) ( TNF-a, ®
© IL-1 $® ± ± ® -
± ®± ® ± ® ® ®%
) -
© IL-1 ± ©
© ® ( ®± ® TNF-
( ©® ® ® T ,1
2U)
IL-10 ± ® ± ® ® ( -
© ± ® ® ©
± ) ® ®® ± ± ® (
IL-10 ± ± ® ® ) -
± © ® ® ± ± ( -
©± ®± ±® )IL-10
© - ± ® ® © ± ±(
®± ) ®± IL-10 ® ® ®
® ± TNF-a IL1 ± )IL-10 ± -
®® ± ± ® ®
± 5 ©( ± ( ® -
± ) ® ®® IL-10 ± ® ®
TNF-a IL1 /3 ®)
® ®( IL-10, ® ® ± )
 ± ,
+
®® ± ± ® ® ® IL-10

®® ± ± ® ®
® ± TNF-a IL-1, IL-8, IL-12, GM-CSF, MIP-1,
IFN-y
®± ® ® ® IL-lra, ® ± 0 0 2 0
© © ® © -
± )
® ± ©® ( NK- ±
± ± ® , _______________________________________
® ® ®
® ± ± - ± ® ( ®±-

®
± ® °- ± ( ± -
® ®
± ® - ± ±
® IFN-y ® ± CC±
± ® ± ®________________________________
in vivo
£ © ®
® ® ® -
® © ± ±

£ © ® ± ± ® ±
±® ® $
±© ® ±
( %
£ © ± ±© ® ±
±® ± ®( ± ± ©
®
® ®±© Sreptococcus Pseudomonas
£ © ± ©® ® ©± ©-
± - ±
± IL-10 - ® ______________________________
| | TNF. TNF-a - ± ®±-
® ± © ±-
© ± ®
)
± ® ® ± ®
) ± ® ± 5Fas-±© ( -I ±© (TRAIL
- © ( ( ± ® ± ® ±
® ® ® © )£ ± ©± -
± ® ± (® NF&B ®-
± ± ± ± ±
 ) ® ± ± ® ® TNF-a -
± ® ± © ± ® -
® ® SIRS. ® -
( ® ± ® ± ®
( ± ®± ® ® ® ±-
± ®( )
± ® ± TNF-a ±© ®
® ) ® © ± ®
(®± Fas-± ©
TRAIL, ® ( ± ± - ® )
± TNF ®
± ± ( -
® ± ® )£ -
±®±® ± ® ±
-
®® ±)

± ,
,
® ± TNF-a.

TNF-a
Fas-±© (FasL)
± C±© (Apo-I)
® TNF - ±© (TNF-related -
tosis-inducing ligand - TRAIL), ± Apo-II ±©
- (
± -
®®(NGF)
CD40-±© ( +2-±© ( -±© (
+±© (
-/ /-, ±©
± (ODF)
® TNF ® (TNF-related activation-
induced cytokine -TRANCE)
© ( ® NF-kappa
LIGHT
TWEAK
APRIL (a proliferation-inducing ligand). _____________________________________
£ ® TNF-a ® ± ©-
± ± ® ®
± ,)
 ± ,
£ ®® ± © ± ± -
T
,42
U

© ±
TNF-a ++++ ++++ + /- _
FasL ++++ ++++ + /- _
TRAIL + + /- + /- + /- + /-
CD40-L + /- + /- + /- + /-
CD30-L * + /- * + /-
p 2 - ±© ® ± 6 *
± ® ±

|
' ± ®
© © ± ©® ® ±
$
±© ® ±
% ± ® ® ±
± ) ±± ® (
± -. ®
( ±
±( TNF-a, ®FasL ®
® ± ( ©) ± ©( -
( ® ®-
® ® © ® © ± ® -3.
® ± ( ®® ® -
® ±®± ® ± -
) © (®® © ® -3
®
® ® ± ± -
) ± ± ® ©±
® ± ® ® ± , .)
TNF-a | - | '
® ( TNF-a ® ® 5 ± -
® $1 kDa TNF-a) $,
2 kDa TNF-a),
± ® © ® ) (
± ® © ® ® ( -
,2 kDa TNF-a, © ® ± ® ® ± ±-
® ) ± ®
±( ® ®±
 © ( ± -
® ® $1 kDa) TNF-a, $
,2
kDa TNF-a) © ± ®© ±
±± -
© (® ® ± ± )
± 1 kDa TNF-a ® ±±±
T
,42
U)
± ,.
± ± © ± ® ± ©± ®
± ± ©® ± T
,42
U

* ±

TWF-a ® © ® ®
± - ® © ® 5 © -
± ( ® © ± -
©
- ® © ® ® -
® © ® )
( © ± ± ® ± -
® ± ® )
FasL ( © ± ± ® ± ±
± © ® ®
± - ® © ± ©± © -
® .
( © ± ± ® ± -
® ± ( ± ® -
-± ®
)
- ± ® ® ± -
* ® )
TRAIL ( © ± ± ® ©
± ©® ± )
( ± ® ® ± -
CD40-L / CD30- ® )
L, © ±
TNF
± - ± ± ® ± ® -
± )
® ± - - ±-
)
® -3.
- ±© ® ±
 | | ' ± ®® ® ©
± ± TNF-a IL-1. -
( ®± ©±®
® © SIRS, -
± ® ) ± © ± ®© -
±( ® ± ± ®
® ® )£ ® ± ± TNF-a
IL-1, IFN-y, IL-12; ®® ± ± IL-10 © © -
® IL-lra, 0 0( 2 0 ( 13)£ ±
® ®( $ IL-
10) ® ® ® ( -
® ® Th2 ® ® ± -
)
® © ® ± -
± ®
( ± ®
® ( ± ® ® ®-
© ® ± )
" SIRS - " -
-
-
-
-
- -
" -

[] ]
© -
,
42,© ( © ± -
®® - ® $ %® -
® T
,.,
(,1.
U) ± ± ©-
® ®( ® ± ®
± ® ® - ® © -
$£ %
)
£ ® ± ± ± ±
® ( ±( ® ® ( ©
£ 5 % % ,,+U
)£
© ® ® © ± ± )
© (® ± ± ® ® ®
£ ( ± ±( ® ± -
® ( £ ® ®
±© ( ® © (
® £ ® ® ±©
T/U)£ ± ±© ® ®
® ® ® © -
±® ® ® © ©
® © ® © ©)
± © ± ( ®® ± -
$ © - - % © ± ® -
® ® -
±© © T,,
4(,/ U) ( ± -
± ± ® © ( ®® ® ®
®® © T,/ U
) ® © ®
® ± ® ± ( ®-
± ® ( ® ±-
MDF, ®± ® ( ®
± ± ( ± ® ©-
© )
®± ( £ ® -
® ©± ± ±-
( © ® ® ® ©
± ( © ( (
® ® ( - T,
/2U) ®
£ ® (® ( © ®
®© ® © ( ± ®
-
® © -
® ®® ± ± ® - ± ±
± T,,
U)
( ± ± -
± ® ± ±
® ± ®
© © ) ®
 © ® ® ®)£ ®±±
® ± ® © ®
® ± T,,.
U)
( -
± ± ®( ® -
© ® £ (
± ± £ ( -
© ® ® ® ) -
® (£ ® ® ©-
© ( ®
® £ ® ©( ® ± ®) ± -
± ± ® ® - T24U
)
± ®± ( © ±
® ±© (® ± ± -
©( ® ± ±® ± ®
£ ) ®± ( ± ®( ±-
® ± © ± (
®® ± ) ±
® ) ® ©
T
,/U
)

| | | - |
®
± ( ®® © ® ®
± -
± © ®
± $ % )
± ® ® ® (
© ® © ® ) ®
® ® ± ® ®-
© ± T
,/ (,
1+U) ® -
( ® ©± ± -
® ® ±
® £ $® ® - ® ± © ®%(
® ® ® ®
( -£ - ® ) ±
± © ± ®
± ± (©
£ ® ® ® © ® ©
) ©( £ ± -
® ® ® T,U) -
®
± ( ± © ® ® £ ®
88
 a-2- ®
( © ® ®
± ± ± ± T0U)
® £ ± ®
± ® ±
± © ( -
± ® © ® )
( ± ± ± -
© ® £ ) ®
± ® ®± ® ( £ ±
± ® ® ± 5® ± -
± ® ® (® ± - -
® ( ® ± ± ®
± ®± )
±© ( ® ± ±® ± V ® -
® ® ± ( ±©
® T
,U ) ® ± ® (
® ®® © ® ®± ( -
(® ( ® £ ©© ± -
®± ± © ®T ,2.U
)
© -
± ) ± © ®± -
® ® © -
®± ( ® ± ©) ©
©
®
± ± © ±) © ®-
® ® ± ± )
± ® ® ® -
± ± ® ® -
± ® ® ® ® £ © -
®( ± ®T,2.
U)
(£ ( ± ®± ® -
® ( ® ±
± ® ® ®
( ± -
®) ® ± © ® -
± ( © ® ® ©±-
± - ® ® )
® £ ® ® ®-
 ±® )

| |
± © ± ® ±
± £ ® ©± ) ® ® -
® ± ®
± ± ®5 ± ( -
± )
® ® ± -( t( -
) ( - $£ %
®
± ± ® ® ©
± ( -£ ±® ± ® ©
± ± ± ) ® -
± ± ® ± ® ( -
± © ® ®
- ® ( ± -
® IL-2 T0
3U)
( -£ ®
± ± © -
± ® ±® ( ® © ©©± (
± ± ) -
®® ± © ®
) ® ( ® ± ®® -
± ± © ±± © ± ± ®
$® ( © ±®% ®± ® ±-
T,3(, 0.U) - (
® ® ± ±® ( ( -
® ® ©
± ®
± T
,2/U
) ± ® ± -
© ® )
± ® ®
±
® ® T
,,0U
)

] ]
,
41/©
) ± (
© ® ® ® -
 ® ± )£ -
± ® { ® ®
® ± ± ± ®± (
© ® ® ® ® ±± © ±
( ± ± © - ± -
) 3+ - © ©) ® ±
± ± ® T+ 2U)
± ± ® ± ®-
© ® ± ® ©
) ® ± & ( ®-
± © ® ® ±
( (® ® ) ± ( ±-
® ® ® ±-
(® ® © -
®( ® ®± )£
± ® -
®® ©
) ± ( ©
"gut associated lymphoid tissue" $ ®
± % ®± ©
® © )
± - ( ® ®
- ± ® ®( ® ± -
± ±© (® ± ± -
® © ® ® ®
) ± ± ± -
± ® ± ) ±© -
± ® ±-
T 4+
(, 01(, 3.U) ® ± ®
® ± ® ±
± )
± © © ®-
± ± ± ® ( -
± © ®
) ±
± ± ± ± ® ±
± ® ) Mandel (1987),
|± ± ® ® ±
® ( ® ® © }) ®±
91
 ± ±® ± ) ® ± -
±® ± ®
5 ±
± ® ® -
± ® ( ® -
) ( ®| ± } -
± ( ® ® ® ® ± NO,
± ± ® ® ± ( -
® ± (® ® ® -
® ) NO ® ± -
± © ± ) -
® ® ± ® Candida albicans
E.coli, ® ©±±( ± ±±( Helicobacter pylori,
®T4,(,, (, (,0/U
)
® ± ± ± -
© ® ® (
® ± ® ® © (
® ® © ± (
® ®± ®± ® (® ±
- ± ® ± ( -
± ® ® ±©
® ® ®)
± ® ± ) ( -
± ® © ± ( ±-
± ± © ( ± ± © -
9
± ± ± - ,+ © ®®,
± ± © ®± ± ® © -
± ± © ( ®
T
.+U) © ® ® ± ± -
( ± ) -
©( ® ( ® ±
± ± ) ± © ± ® ± ©
® ± ) -
© ( ± ® © ± ± ® -
©±® ± ± -
® ± ± ) ± ±®
® ± -
© ± ± ( ® ® © -
 ± ® © ® T
.+U
) ± -
®± ®© ( -
± ±± ( © )
4
® ,
+ , ± © -
® ± ± ± -
© ® ® ± -
®
± © ) ±
± ® © ®± ® -
± T
.+U$ ±
),/
%)

± ,
/
± © ®® ± -
$ A.JI. )
(,4
41%

| | -
|
± 0-102 ® 1 ±
6 © ( 109 ® 1 ±
6 -
( ± - ® © -
- ± ±

® 102 ® 1 ±
6 © ( 109 ® 1 ±
6 ±-
( ± - ±
- ±
104 ® 1 ±
6 - 109 ® 1 ±
6 ±-
( ( ±

± 105 ® 1 ±
6 - 109 ® 1 ±
6 ±-
® ( ( ±

± 105 - 106 ® 1 ±
6 -
® ± ±
1012 ® 1 ±
6 ±

± ®
® ± ® © ±
® ® ( ±
( ( - ± -
 ) ± ® © ± © ®
® © ± ± ® ® ®)
± ± ± ± ± ) ®
± ±® ± © ®®, ± -
9
© ± © &,+( ± ®± /+
+
± ® ) ± ± -
( ± ±®
( ®± ® -
® ( ®
© ± T
.+U
)
( ® ± - ©
®© ±® ®
± ®( ® ( ® ® ©
) ® ® ( ±
® © © ) -
® ± T
.+U5
©± ± ® 6
® ® ® ® ± ( © -
® ® ® ± © IgA, -
® 6
( ( IgA -
® ± ± 6
± © ± © ±
6
± © ® © ©
± ± ± ® (® -
® ©± © ® ®
± -
± ( ® ® ± 6
©® -
® © ®( ®®
® ( -
® 6
± ®± ± ® -
± © © (
©±® 6
± $
± (
± )%
6
 ± ± (
® © ±®±® -
®® ® 6
® ® ®
-
± ( ® © ®® ©
± ± ® )
( ± ±® ®±
® ® ® ® )
® © -
± ±®± ±© -
- © ® ) ±© -
® ± ± -
± ) ®® { -
i "% ® ± ± ® -
® )
i T
.+, ®± ±©-
© ± ± ± ±
± ± ( -
± ® ® ® ±
± ) ( -
® ® ® ( ®®
,
++! ± ®± ® ® -
± ®(
®
)
®
± ( ®® ±
( © ( ® ± ® ± ®
±© ®
± ® ±-
® ) © ® © -
® ± ± T
.+U5
± © - ± © ( ®® -
± ± ( ®© ±© 6
± ± ©± ± ® ©
± ± ® 6
©( ±
® 6
® ± ® ©
± ( ® ±® ® © -
 © 6
± ( -
® ±© ( ®-
® ®® ± ® ® ± )
£ ± ® ± © ±
( ± © © ® (
® ® ( ® ® ® ©
± ±
) ( ©( -
± ® ± ±-
) ® ®© © (
±® ± ® ® ® ®
± © ® -
®± ® ± ® ±
© ± T
.+U
)

±
,0
© © ® ±
$ A.JI. )
(,4
41%

| |
® ( ( ( ±
® ±®
± ( ±- ± -
± ® ® ±
± © ± ± ±-
® © ± ©( - © ± -
®
( ® ®
( -
(
©± ± ©
± © ® ± ±

® ± ± ± ± -
® ®
± ±- ® ( ®-
® ® ± ±
± ® ± - © - © -
± ( ±
±
 ± ®
± ® -
( ® ® ®
$£ %
( ± -
® ) ± ® ± ©
£ ®® ) -
® ® ± ( -
± © ®
( ® ± (
© )
± ® ( ± -
± - ® ® ( ± ®
± ® £ ® -
( ± ) ± ±-
® ± ® ( ± ®
±-
® ® ® ( -
± ®
)± ( (
®± ®
±® ± ® ± © )
± ± ® ±
®± ® ® - ©
®( ) ± -
± ± -
( ( ( ©-
© ( (
± ® ± ± ±® )£ ® -
±© ® ±
® *±
® ® ± ±
® ) ± ± © -
®
±
± ® ± ± ) ®
( ©
® ± ± ®( ® ( ® ®
± © )
( ± ® ±
® © ® ± ± ©
( ®± ® ® © -
® )
 ± ± KFUIOK -
® ® ) ± ® ®
± ® ± ® ® ± -
± ® ± © © -
) -
®± ± ) ® © ® ®± E.coli,
± ®± ®± )
± ®
®34
! ® ± ®( -
® ®
± ( ± ®
± ® T1
4(4+U
)
® ®± ) ® ±-
± ( ® ( ©® ® -
® ± ®± ) ± ®
± ± ® )
( ( $ ® ©
± © % ± ® ®
± 0
.!® ± 1,!
[208].
± -
± ® ± ) ±
® ± ( ± ®
-
® ± ± ®® ± ® )
± ® ® ± ( ± ± -
® © © © ( -
® ± ® ®± .+ ( ®-
® ± ± ± ® 4
+
( ® ± ® ± ® ® TNF -
±±± ® ± ® )
± ± © -
±® $ APACHE-II, SSS) ± ®± ® -
®® ± ±
®)
± ® -
® ( ± ± ®
© ® ±
) ±© ®± ® ® ®
 ® 5 (® © ± ®
± ® ® ± © -
( ® ®® ± ± ® ±
® $ ± -
® ® ® ± ±-
®%)
±® ® © ©® $ (
))%
( ©
® 41 ® ± ® )
± (® ® ( ® ®
*± ® ® ® ± ± -
± *± ) (
® © ® ± ± ®
± ±© ) ( © © (
® ® ® ® ± ± ®
® )£ ®±± ± ( -
- ® -
- ® ± ± T+ 2 U
)
± ( ®-
© ®± ® ® ®
± )
±© ± ® -
± ( ©± ® (
± ® ) -
© ±® Fas-
±© )
£ ± ± ©
± ®
( ©
± ®
( ® ( ( ©( ® ± ® -
±© © ) ± ©( ( ±
± ©( ® -
© ® ® ± ± PGE2.
£ © ©
± -15-
©
s © © ( PGE2, -
® | } ± ) © ®
®± ® ± ( ® ®± ©-
± ® ± T+
2U)

]^ ]
® ® ±® © ± ®
© ± ± ® $ % ®± ±-
® ± ± ® T
4+U
) ® ® ±-
± $• % © © -
® ( ® -
© ± ± ± ± -
( © ± ±
( ®( ± ®( -
± ® ±
)
® ± ± ®
©
± ® ± ® ® -
± ) ® ® ® © (
© ± ±
( ® © ®
± ( (® ® ( -
® © ± ± ®® ® -
± ) ( -
± ® ± ± ± ( ® ®
® ±® (® ® -
± © ® ± £)
± © © ® ± -
± ® ® ® ®-
® ® ® ®( ® -
± ( © ± ± ± ( ® ± -
® ® ± ® ± ®( -
± © ® ® ± © -
± ± ® ± ± © ) ± ® -
© © © ± ±
± ) ®
± ±
© © ®® ±-
® ® ( ±® ± ±-
± ®) -
® ® 0-7- ± )
10-14- ±
$ % ® ± ± ® ® ± ±
® ± ®± 2
.(4! ± ) -
® ± ® ± ® -
® ±
© © [74J.
± ® ®
± ± ± ( -
± ± ®
± ± -
± ®± ( ± ® ®
±-
( ® ± ® ± /
(,! ± )
® ±®±®
± ® ® -
± ®
) © ± -
® ® ©± ® -
±®
± ®
± © ® -
± ®
) (
© ® ® ( ® ®-
± ±® ® © © -
± ) ® © ( ® (
± ® ®± -
± ® ® ( ®± ® ®
±
) ® ® © ©-
± ® ® ®
-
± T
2/U
)
(® ® ± © -
± ±
-® © ® -
® ± © ± ± ®
( ®±
©± ® ± ± ) ±
© ® ®± ® ®
® ( ® ± ®®± ®
± ® ± ®
( ©
© ±® ) -
± © © ® ± ® ±
® - ( ®±
®
± ® -
® ± T
2/U
)
 [] ] ] ] ] ]
[ ] ]
® © d-
± ® ® ± ± (LPS)
± T
3.(,
,U ) ± ®± © ±-
$
-% ) ± ® ± ® ±
®
± ® ± ® -
± ± ±
© ® ( ( ©
® ± ± ±® )
± ± ® ©
± ® ± ® ± ± © ® )
( ® ± ( ±
± © $ )
2%)
cm
= cm r c|
r m | c m
c| i^L i
j c }| | mcr
m
m
V |
r
i
LPS
cm c }| L- |^ ^ m |
fj m
m |
6
c m
t r | c f c }|
j

| mc cm
- JNH1
®
- fc-j C
Cj -------- c |c
\ j

j L Pcj c
c m
P P
(
)

)
2) © ± ® ®® ©
© $ Cohen J., 1995).

± LPS ® ®-
± ©®(
± ® ± ± -
( © ® ± ± ± ® (
± ±( ± ®
 )
©( LPS ® ® ©±-
± ) ® ± -
® ®± ± ± -
( ( ( ± ( -
) ® ® ® ± -
® ± ± ®
( ®
± ®) (
± ®® ± ( ( ®± -
© ® © ©
®
± ( ± ®± ± ± -
( ® ® ®
) ©(
® ® ± ® TNF, ± ® (IL-1, IL-6).
® IL-6 ± ®± ® ±
± ± ( ± ( ® LPS [83].
® ® )
® T © $ '% © $ -%
± T
4+U) $
'% ® ®
(
± © $-% ) © © $ '% -
± ±( ± -
± ( ± ©± ®)
® ® ± ± ©
® ± ®) ©( ©
© ( ± ®
( ® ( ±©
® ± ) © ©
®®
± ( © $'% ±-
) ® ®± ©
± ± ( -
) ® ©±
© ± ±-
® ®
) ©± ® -
± ® ± ® ±© ±-
) ± © $
'% -
® ©® ± ® ® ®
± ) ® © ®
© $'% © ® ® -
 ® ± ) ®
® ± -
® ® ± ± ± -
± ® ± ± T
4+U) ± ®
® © $
'% ± ®± © ±
± ( ® ®® )
® ® ± ± ® ®( -
® ® ® ® ® ®(
® ± ® ± -
® ± ® ©± ®( ®
± ( © ©±-
( ®± ® ± )
®® ® © ( ®
( ® SIRS. -
® ®( © © $'% -
® ( ± ( ±
± ( © ± ( ® ± ®±
± ( ® -
® ± ± ® ® -
®( ± ® © ® ± ±
± .
© ± ® -
± ( ± ® ± -
± ( ® ® ± ± -
T,/
(, 02U) © ®® ± -
± ± © ± ® / ® ±
© ®® © ® ± ® ± -
© ) ® ©
®± ® © ® (
® ® © ©( ± ® -
±® ( © ® -
© ( © ® ± ®
)Naef ) ®)$ ,44/% ± ® 2/
+
®( ± ± ® ± ( ± , , ±-
® © $
1 0 ( ®-
0.)© %T ,0
2U)
© ± ±©
± ± ± ® ®
J 04
 © ® Candida. ®
® ± ± ±-
± 5,44.
-94 - 11-13%; 1995 - 26%; 1996 - 36%;
,442W0 +
!) ® ± ± ± 5
! ± ®®,
6-2 44/©) +! ®, 442©) ® ± ©
® ± ®2 (
0! ± ®®, 443© )T,/U
) ®
± -
±5 © ® - 100%,
® ® ©- , +
+!( ± -
1/!( © ± - 0/!( ± -
/0!(± - .1!) ± -
®± 2 ! $ .*
,,%
6 ®
±) ± ®® ( ± ± ©
®± ® ± ® ®
) ® ± © ®±-
® ® ®
® T
,02U
) -
® ± ® ± -
© ® ®® ± -
)
 [ ]

© ®
® ( ± -
( ® - © (
± ±® ® ®
©( ± © ± ) ®®
© ® ± ( ©
®
± ® ) © -
© ®® ± ± )
± ± ±®± ( ±
± ®± ( ± ® , -/3
! ± ®
T+ (0+U) ± ( ±-
® ®® ( ® $ (
± ® ( ©( © ®± )
% -
© ® ® ®© -
® ± ± © ) ©( ±
© ± ® ±
® ® ( © ( ®
® ±( ® ® ®
± ® ± T4U) ± - ± -
® ® ± ®
© © ® ± © © ± ©
) ® (
©
± ±( ® ® ®-
± ) ± ®
®
) | ± } ©-
) ± ® ( ® ))
)) $,4
40% ,4U( ±( ® ® ±®
(® ( ®
± ± © ± ± $ -
%( ® ± ®( ± ± © -
® ® ± ± ( ® -
® ® ± )
 ] ] ]
± ®
± © -
© ( ®
±
))( - 52% [1, 62] - ) ® ( -
± ® © © © ± ±®-
± (25%) ± -
) ± ± ± ± ® ( -
® (
( ®® © ± © © © (
± ± ©
± -
®
)
®± ®
± © ( ± © -
® ± ± ®® ± ) ± -
® © ®©
® ± $ ®© -
± ± © ± % ®± ® -
±© ® ® © ± © )
± © ®± ±
± ± ) ±
± ( ® ® ± -
®® ± ® © © )

|| |
1) ®± © ®
© ©® ± ®)
2) ®± ® ® -
± ( )
3) ± ® ® -
© )
4) ± ± ® ±© $ -
(± )
%)
-
® © ®
)
1
% ±© ® ± ©
 © )
± ® $ -
± ®
% © ®± -
±© ( )) ® -
® ®© ® ® ± (® ® ® ®
® ® ® ± ®) -
® ( ± ® ® ®-
± © ± ( -
® ®± ® ± ( ® -
± ± T/0(1U)
( ®© ± ®± -
®( ® ( ±®± ® -
® ® ® ( -
® ±© -
± ± ± ® ® ® ® -
±) ( ( ® (© ©
± ® ±± ± ± -
( ® ± ®
T
1U ) ± ( ±
® ® )
)) ( )) $,44
+%T /0
U( ) )$ ,
440%
T
1U © © ® ® ( ® ± ® -
© ®
© ) ® -
( ©) ®-
± ± ® ®± ® ®
( ± ®
® ® ± ®
$ ®%( ®
± ± ® ( -
® )
± ± © ±
© © ® ® ± 1 +- ©-
®( ® - ®0 +- © ( ® ® ±
© ± ± ± -
( ® ® ® ±® -
© © ) ± -
 ® ± ®© ©-
± ( ® -
®( ± - ± © ©
± ( ± ±±) ± © ® ±
± © © -
- ± ® Pseudomonas, Acineto-
bacter, Alcaligens, Flavobacterium, ® ±
5- 3!( -
© ®( ®
) ®± ( © -
± ± © ± ±
® ± ± 1)0! 4/!( ©
® ±© ±® - 2/)
1! 4+!) © -
± ± ®±
42.9-1+! T /0( 1U ) ± ® ± ± T 1U ±(
®© ± ® ± ®©-
( - -
© ©® ® ®/ 1
)-,++!) ± -
± ± © ± ± ® ®
- ( ©
®± ® © ® -
)S ± ±
± ® ® ±© ©-
® ® ± ® ±(
® ®© ±
® ± ) ±
- ± ±® ±
± ® ® ) ± (® ® -
® ( ® ® ®± ® -
( ± ) ±
® ® ±©
± ® ±
® ® ® © ©
® ® -
© $ ± )
, 1
%)
 ± ,
1
® ± © ©
$ ))
(,4
40%

| || ! | |
Finland {1973) b e
(1995)
)
1.,} )
1./} )
1/(} )
1/} )
10} )
11)}
Staphylococcus aureus 47,8 21,7 21,4 69,7 63,4 57.2
Streptococcus pyo- 3.5 2,2 1.0 1.8 1,2 2,0
genes
Diplococcus pneumo- 9.6 5.8 4,2 5,3 4,1 5,1
niae
Enterococcus 9.6 13,8 11.1 21,2 21,7 20,3
Escherichia coli 16.5 18,1 16,5 28.3 36,5 30.4
-
Klebsiella- Enterobac- 18.3 21,7 34.7 28,3 29,1
ter
Proteus 20.9 10,1 17.4 23.1 27.4 31.3
Pseudomonas aerugi- 8.7 9.4 22,4 11,8 19.7 31.9
nosa
- - -
Serratia marcescens 0.9 4.1 5,1
© 6,1 22,:3 20,4 23.4 19,4 17.1
| |
3& ± ± ® ± ®

|
± ± $© ± % ±
© ) -
± ® ( ± ® ± ® -
© ® ®± 1 -3! ± ® ®
® © ® ± ®) ® -
± ® ± © ®3 +
- ©
± ± , ,/! $
,1 %
6/! ± ± ® ± -
± ±®± © - ±
[170].
® ® ± (
® ( ± ± ® © -
110
± ® $ %
) -
® ®
± 0! ®
± ± ® ± ® ± T,
+U)
)) ± ®) $, 4
42%T ,
+U(
± ± ± 5
1- ® - 79% ® ± (
± - 15- +!( ® - 13%
© © - 9%.
± ® ® ± © -
® © © ± © T ,+U- © -
© ) ® $
® ( (® ( -
± ± ( ® ® ± -
© % © ® ± -
© ± © ± ® ©
)
£ © ®
® ® ) ® ± -
( ± ®
- ±© ® (
® ® -
) ® ± ± ®® -
± ±
± ( ® ± ©
( ® ® -
± ± ± )
® ± ®± (
: ® ± - -
® © © ) -
© © ® ®
± ® ±), 2) ©
± ® ® ± - ®-
© ±® ( ®( ®) ±
® ( ® ®-
( ± ±-
- © ) ± ©(
± ® ± -
( ® ± ( ± ± -
 © ± T
,2+
U)

± ,
2
© © ® $± )) ®)
(,4
42%

| |

® ( ( ® - )
±® ) ® ± ±
± © ) )
± ) ® ® ± -
± ± ® ® - ± )
( ± - ± -
) ( ± © ±-
± © ± ± )
± ® © ) ±-
® ± - © ± ®
± ) $ ± © %
)
± ® - ± -
®) © ® ®)
® (
® ± ± ( ±
® ± ±
( ©)

®
± © © ( ( ±
-
®© ( ® ±
±© © ®
±® ± ± ®
( ® ± ® -
± ( ® )
® © ± ®
© © ® ©-
®
) ± ± ( ©® (
( ® )
± - ( ®±( ® -
® © )
( ± -
®± © © © ©(
± ± ® © T
,04
U)
 ® © ®± -
± ±® ® ® ® © ®
)£ -
± ± ® Deitch $
,44
3( +
+,% ±( -
± ± ± © ® ± ® ® -
® ± ± © ® ( ®± ® ®
® © ® © ® )
© ( ± ®
( ®
± ± ± ±® (
© ± ® ±© ) -
® -
® ± $
gut associated
lymphatic tissue - GALT). ( ® ®
± ( © ±( ® ±© (
® ±
± © -
® (® ± ® ± )
® © ± ± ® (
® ® ± ± © ©
© ® T
,+U
( ± ±
- ± ±
© -® ± ± ±® © ® -
± ) -3- ± © © ® ±-
® ® ± ( ® ®
± ® ± ±© -
± ® ® ® ± ® ± -
± ®) 20! ± ® ±
± ( 0 +! - ®
® ® ® © ± $
± ( ± ±±( ( ® %
) ±
® ± ± ® ® ®± ®
± ® ± T,+
U)

| | |
± /
++® ® ( ® © -
±® (± ± ,
0 © ® ± ® ±©
± ) ± -
 ( © ( ± ( ± ( -
- ® ® ±© ® -
± ± ® ± ( - ©
® ± © ) ± ®
± )) ®)$,
442%T,+
U( ±© -
± ® © © ( ± -
± ® ( ± ® -
$ ± ),3
%)
± ,
3
±( ± ® ± © © ±-
( ± ® $± )) ®)
(,4
42%

| |- |- |-

± £ £
$ ± ( ± ±
± ± ±
±
± %
®
± ±
±
£ ± ±
£ ± $ ±- © ±
±
% ± ±
® ® ®

®
± ®® ( -
® ± ±© -
± ) ± ® ± ±
© ®( ® © © -
± ±© ± © -
( ©±® ® ® ®±
© © ® ± ©T ,
+U)
± ® ± ® ® ®® ® -
± ± ® ± ±© ©
± ®
( ® ±
© ® ± ® ) ± -
±© ± ± ® ± ) ® -
© ,
++! © ® ± ® ±® ®
© ± ( ± ( -
 ±© ± ® © -
®
) ± ( © -
± ©
± ® ® © -
®
( ± ( ® © -
± )
±© ±
( ® © ± ±
6± © © ®± ®
® © ( ® ®
± ± ® ©® ± ®)
±© -
± ® ® ±)
,4 +
)
± ,
4

±© ® ± ® ±
$
0+0
3± ® )
M.Pfalier, 1998), [54]

Staphylococcus aureus 22.8%

Escherichia coli 18.8%
Staphylococcus spp. 13.3%
Enterococcus spp. 9.4%
Klebsiella spp. 7.2%
Streptococcus pneumoniae 5.3%
Pseudomonas aeruginosa 4.6%
Enterobacter spp. 3.7%
b -} 3.6%
Proteus mirabilis 1.5%
Streptococcus "viridans" 1.4%
Acinetobacter spp. 1.3%
Serratia spp. 1.2%
Citrobacter spp. 0.8%
Stenotrophomonas maltophilia 0.8%
P. agglomeratus 0.6%
Salmonella spp. 0.5%
Jlaemophilus spp. 0.4%
_Morganella morgani 0.3%
S^orynebacterium spp. 0.3%
 ± +
± ® ±© , 44-, 4
42© ©)5,.12 3± ® -
± )
(Roveaux )et al, 1998) [54]

| | | "
® ± ± 40.3%
- ® 23.5%
) 36.2%
© ( ®
$ ® - ® ± © (© ± -
® - ( ± ±
± - ± ±% (
± ± ® $ ® -0 !( -
± !%
- 0.4-, ( ® ± -
± ( (© ± © )
® ± $± ± -
% © ® ®± ®± )
± ±© ± ±
0
)1! ® ®
( ® ± ) -
®± , .(
1 ± ® ,++
+© ± ® -
®(® ® © ®±
/
)1 ,
+ ++) ± ± ® -
± ± © ) .3
! ± -
± ± ± © ± ) ±
±® ± ® $02!% ® ®± © -
± ± ± $ ® ® ®-
® %( ±-
® ® ± © - ± ± ) ± -
® © ®± 3 !( ®
® ® - 55% [141].
,+± $ ,43
4-,443%® ©
± ±© ® ± © -
® ® ± © - ©
® T
,/U) ® ±
± ± ® ® ® ® © © -
) ( ± ± ±© ± ±
® ± ( ® ( -
± ±© ® ± ) -
 1989-, 440© ©) ± ® ® ± -
® ± © - ± ± -
© ® ± ® © ® ± -
,/),! ®, 434© ) .) 4 ! ®, 440© ) ±©
± ®® © ± )
® ± ® ± ® ± ®
2+! ± ® (© - ± ± - ®, 3!)
$ ( ( %® -
±± © ©® ± ± ±©
®± 5 0+! 2+- 3+!
© ± © )
± ±( ( -
± ® ® © ®
Candida ® ) ( ± ®
1993-, 44/© ©)® ± ± ® ± ,,-13%
± ( ®, 440© )- . 1!(®, 442© )- 0 +! ± ) ±-
± ± 5 1 ! ± ® ®,
-2 44
/© )
+! ®, 442© ) , 4
4 3©) ® ± © ±
® ± 2 )0!) ± ®1 +! ± ®® ±©
± © ± ® -
-4- ® ® ( ± ® -
®±± )
± © ® -
± )| }- ®± ® ±
® © ) ®±
± ©±
± ± ® (® -. ( ® © -
( ® © ® © ® -
)
® ® © ® ® ± -
© - Candida, ± - Aspergillus ©
Coccidiomycosis. © ® Candida ± -
®± C.albicans - 10%, C.parapsilosis - 7%,
C.glabrata - 6%, C.crusei - / !) ± ±
© ® ± ± ® ± . +-60%.
® ®® ®
 $± %
( © (©± $© ( -
® % ± ) ± ®© (
( ± ± ( ( ( ± ( (
© ) ± ± $ ±%( ®
)
® ®
± ( Candida
±( ® ) ±
/
+! ± ® ± ©
® ®± ± Candida.
±© ± ± ®
± ®( ± ± ® -
®© ® ® ®± ® (
± ® ± ®± ® ± -
±) ± ± ± ®
± r albicans, ® © ®-
± ® © ®$ C.crusei, C.glabrata )%
) ± ©(
± ± ®± ®©®
© ® ® C.crusei, C.glabrata. (®
® ralbicans ± ( a C.crusei ®±-
± ®. ) ± ®® ± ® -
© ®© ± ( ±-
± ® ® ± ® ±
® ® ± ± © ± ® )
® ± ± .0 / ± (
® ± ® ± © ( ® -
±© ) ± 1 +.$ 3 +!%(® ±
1
0, $+ !%) ®© ± ® ® ± ® (®
/
3! ± ± ( ® 0! ® ± -
± ) ± ± ®
± ± ®2 4)
3 ! ± ® ( ® ± -
0
4)2!) £ ±© © ± ± 5 ± -
± - 0. )
0!6 ± - . )
3!6 -
- ,+)
0!6 ±® - © ± - 3 )
0!6 © -
© - 3.7%6 © ®- , ,)
0!) -
± ± (® ))® ( ®
.
1)! ± ® ) ± © ±® © -
{ ± ± $2,)
.!% (
® ± ®/
1),
!) ® ±
© ±
® © ± ®
± © ± - /
2±
),
!) ®
± © ± ± -
® 4! ± ® ( ® ± - 3 +)
2!( -
± ® ® ®± ® ± ®3 +
!) © ±
±® © ( ® -
± ± ® 0)
2! ,
.)4! ® ±
$ ±),%5
± ,
± ©

± ±
Staphylococcus aureus 70.6% 45.2%
Staphylococcus epidermidis 12.5% 6.5%
Streptococcus 13.3% 14.5%
E.coli 9.7% 6.5%
- ± ( ® )) ® 10.9% 48.4%
© ®$ ±% 8.8% 14.5%
® ® ± ± ± ±
± - 3
.)/
! ®®) ® ± ±
± ± ± ± ± ®
14).! ± ® ( ± ® ®
± ®. +)
.!) ± ±-
® ®®/ 2)
3! E.coli, ® 1! - Klebsiella
pneumonia.
®± - ±® - ©
± ± ® ±© -
® © ± )
±© ± ® ©
® ± ®) )
±® : ± (
( ®© © ± ) ± ® -
® ± ®± © -
© ® ± ± - © )
® ± © ®± -
( © ® ® ®
(± ± ®
± 9 ± - © ± -
 ) ± ® ® ® © ± -
® ® ® © ®(® ( ®± ® ®®
- ®
( ®± )
±
± - ± ±®
$ ))4
44%T
0/U

| | 3
Acinetobacter spp.
Corynebacterium spp.
Staphylococcus spp. + Escherichia coli = Fusobacterium spp.
50% + Haemophilus spp.

Enterococcus spp.+ Pseudomonas aerugi- Streptococcus "viridans"

nosa + Enterobacter spp. ' - Staphylococcus spp.
Neisseria spp.

© ± 8.
+! ^

Bifidobacterium spp.
31) Lactobacillus spp.
Bacteroides spp.
©
Enterobacter spp.
© ® ± ® -
Escherichia coli
± ( ® ( (® -
® ® ® -
- IL-1,1L-6, ±( SIRS.
±) . ®
± ± (± ±
® ± ± ® )
® ©( ± ± ) ± ® (
® © ± ® ± ±-
® ® (
® ©( ± 5 ©
*± -
© ® ± ,+
+ ©*± - © ) -
® ± ( ± ± ® ® ± ©-
± ( ± ® ± -
 | |
" '
1'
± .
± ® ± ± ®
IL-1, IL-6, TNF (Henderson 'Et al., 1996) $ ''*
222 .

| - [ - -
| | |
LPS $
± ± - - +)
+, ,
++
% ©
*±
- ,
+©*±
± ® - ,
+©*±
-*©' +
)0©
*±
± -* ©' +
)+0©*±
-* ©' +
),©*±
©
± - ,
++©*±
® ± + +
)+,©*±
® ± ,
+++©*±

) 3) ± ± © ±
$ Brooks G.F. ®)
(, 44
/%) ( ®±
± ± ( © ± ( © ± -
± ) - ± ± ( -
® ® © ± ® ® ± -
) ©
± ® ± ±
®
± ± © ± ± © ®
( © -
 ± ) ® ©
± ® ± -
®± ± ) ±
± ® ® $ %
®
± ± ® ± ® ± -
® ® ® -
©
± ®© ± 6 -± ( ± ® (
± ± ® ® ± ® ± ® -
® ± ( © © +
-
± (
( ©
± ( ± ( ©
±
© ± ( © ± ±
- ± ) -
® ± ® ± © ± ±
®
)
® ( ± ® ± ±
® © ± ± ± - ±
) ( ® ±( ±
± ( ®± ,
+++ © *±
) -
® ® ( ® ± ® -
® ± ± ® © ± ± ±-
: ® ©( ® T0
/U$ ± )/ %
)

± /
( ® ® ®® ± ± ®
' ± (Staphylococcus spp., Streptococcus spp., Enterococcus spp.) [54]

| | 3 ± ( ® ® ©
± -
± 6
® ©-
®
( ® ±

®
3 ® ®

± ±
® ®® ±
©© ± )

© ® ( ®® -
±© ® © ±® ( © -
±® ±©
) ( -
 ±© (® ® ( ® -
- £ ± ( ® ® ©
± ± ( ±-
© ± ®( ® ± ( ))(
± ( ®± © ±
® ± ( ± ® ® ©-
±® ) ®
® ®) ± ®
© ± ©( ® -
( ±-
± ® ®® ± ( ± (® ®
©© ± )
©±® ±® © ± © -
± ®± ® ®± ®
© ® ±( ® ± ± ± © -
)) ± ® ± ® -
± ® ± ®
± ©
± ® $ ® ( ±-
©( © )
%( ± ®® ±
±© © ± ® )
® ± © ® ± -
- ±© ® ® -
± © © T
1U)

|
± $Staphylococcus) -
© ± ± ( ± ®
® 5 Staphylococcus aureus, epidermidis, saprophyticus. ± -
± ® ® ® © -
® ± ± ± -
® ®6® ®
® 1 ®T
1U)
© ± ® ±® ± ®-
® ® ) ± ® -
® ® - ± (± ( ©-
( ( ( ©± (
± ©± )® ® ®
 ( © ± ®
± ®® © ) ® ±-
® ® ©± ( ±-
© ® ® ® ± ) ±©
® ©± ® ± ± -
® ® ® ® ® (
®4
0! ± ® ® ® ©® T/
0U)
± ®± ± ©
® ± ( -
( -
® T/U)
± ® ® ± © ±
± ± ) ® ®
± ® ± | } (
® © T 1U)
± ± ® ®±-
®® ± ± ® ( © ® ± ± -
©® ± © ±® © ® © ± (
$ ±
® %) ®±
® ± © -
® ) £ ±®± ®
©± ( © ® ® -
( ± ( © ± ±-
) ± ©± ® ±-
® ± ®©± )
© ® ± ®$ ®-
± © ± % ®±
5
± - ® ® ® ©
± ± -
® 6 © ± )
® ® ® ± - -
® ±® ± ± 6 ® -
® ± 5
S ± ±© - ® ® ± 6
wL - ® ® ± 6
 w
* ©- ® ® ± $ ± -
® % )
' ® ® ± ± ±® - ±
)
© ® ± ( -
® © ± ( ± ) -
® ® ® ©
± ± ® ±® (
® ) ± ® ®-
± ©
± ± ±© ± ©
±) ® ( ® ® ® ® -
± ±® ± ±-
) ©® ( © ± ±® ® ®(® -
±( ± ±® ( (
± ± ® ® -
® ( ® © ±
® ± ) £ ±
±© - ® ® ( -
- ® ® ( ©- ® ® ± ) (
® ( ®±
- © ® © ±® )
® ® ± ± ±® ±
T
0/U
)
± ® ± ® )
±©±( - ± © © ( -
® ± ® ) ± ( ®-
® ± ) ( ® ®
® ® ®
) ± ®-
± ± ± ®
5
® St.aureus ± ® -
® ± ± ®)
St.aureus ®® ® ±
® ± ± ®
5
V 6
V © 6
wL ± ® )
± ® - © - -
± -± ®)
 ± ® $ ( -
© ( ± ® %
± ® ± ® ± ± -
®
) ± ± ® ®
±
© ) ± -± (
© ( ©
© ) ® ± ±® ® SIRS.

| |
{Streptococcus) - © ± ±-
( ®± ® ® 5 Streptococcus pyo-
genes Streptococcus pneumoniae. ® © ® ±-
± © © ® ©
) ±® © ®
®± © ± ® ( ® -
± Streptococcus haemolyticus, viridans ahaemolyticus. -
© ± ( © -
- ± (± ± ( ©
)T
1U .
± ® ® ©
± © ± ® ® © ® ±5
®± ® ®
±±± ± ± © ±® ©
$ ® ©% ® © ® © (
± $©
± © % ) ® ®©
| } © © ® ± - -
® ± (® © © ±
±
± © © ) | ® }
® $-. !% ( ®±(®
® ) © -
±® ( ® ® ( ® ± ®
± ® ® T 1U )
± © ® ± ± ® ®
® (® ® Str. pyogenes. ®
© ®© ± © -
® ± ± ± ®
( ® ±
-
® ® ( © ®
)
|| || 3
© ® 5
- ® ® ± 6
- ® )
| ® ± ± ® 5
- ® ® © (± © ( © 6
- ® ® ® ± 6
- ® © ± ( ® ± ± ®)
- ± ® ± ® ± 6 ±-
© ± © ® )
.- | 3
0- © ± ®
±® ©® ± )
| | 3
IL-1, IL-6, IL-8, TNF.
( ± ± ® -
© ® ) ® ® -
± ( ® ) ©
( ± ® ® ± ± ® )
± ® ( ® ® © ( ±-
© ( © ( ® ± ( -
® ® ®© ± -
® ± ± ®) ± ® ® -
± ® ± ® ® © -
© ±) ® ± -
®± ( ® ( 0- $)® % )
0- © ± ® -
) ± ®© ® (© ± ± ®-
® ) ® -
) ® ( © -
® ® ± ± ®)
 |
± $
Escherichia coli) © -
±® - ©© © ± (
)£ ® ( ®±
± ±® $ ® ®® -
® ®© %
( ( -
) ±® ( ® -
± ± ) ± ®
± ®
® ± ( ® (
± ® ( ±
-
)
(® ® ± ( ± ®
± ® © ±
® ® ® ® © ± ) ©
± ® ± (
® ® ® © ± -
( ± ± ± (
® © ) ±
®® ± ± ® ® © ® ®
± ± ® ® -
( ®© ± $ ®./)
2! ± ®%
T1U
)
© (® ® (
± © © (
± ± ® )
© ® ± ± ±-
® ® | ®
}) ® ©
® ( ® ± -
( ® ± ± ® ) - -
( ± ® ( ±
® ©® B.frugilis. ®
± © ® ®
® ± (© ( - 6© ± -
®± )
® © ® ± -
® ± )
®± 5
' ® ± ® ©
® ® $
Shigella, Sal-
monella, Yersinia)',
'± 6
©6
)
® ( ®® ( -
± ® (® ® (® ±
® © ± - ) -
® ± ® ( ± ± -
® ± © (
® ( ® © -
- ©±± ( ± (±
± ) ®
± -
± ( ©® ( ®)
± ® ± ± ®
© ± ® ®© ± -
± ) ± ®
® ® ® ) ±
®± ® ® ± ± ( ®-
® ) ® © -
® ©® ± ® ±-
± ®Escherichia coli:
± ± 6
© ( ® ® 6
® 6
± ±®© )

| |
±® - © © ± ± (
®± ® Klebsiella, Enterobacter, Serratia-, ®-
±© ±
± E.coli. ®± ± -
± ( ®± © ® ±®-
® ® ± © ±) ± -
Klebsiella © ® ± ±®
 ±© ®± ® ® ® -
± ) ±
® ± ®
( ± ® -
® ( ± ±
) ± ±
± -
© ± ® ®
$ ®© ± © ± -
± %® ® ± -
( ®© © ± ± )
( ® ® ± ® ± ( ® -
± © ® ± ® ® -
® ®© ± ±
± (® ®-
± ±
± T
1U)

|
$Proteus) - © ± ±-
(®± ® ± ® ®) ®
® ± ® Proteus vul-
garis, mirabilis, morganii, rettgeri.
± ® ± ±±-
± ( ® ± © ® ± -
®) ± ® ® ± ® -
® ( ® -
® ( ±® ( ( -
± ®, ).-, )/ T1U ) ( ®±( ® ® -
( ® ± |® } ® ± $ -
%( )) ± © ( ® ®
± ± 5® ±
± ( ®® ± (
® ( ® ® ® ± -
)
)) ( )) $
,44+%(
)) $,440 % )T / 0
(1U ( ® ©-
® ®± ± ± © ®
50-, ++ ! ± ® ) ± © ± © -
© ± ©® ( ® $
®
± %
( ®± ® ® -
© ( © © ± ®©
± ) ® ±
© ± © ( -
± © ± $
) ®* ,4 2 2
* © © ± -
© ®%6 ®® ® ®
® ( © ® ± © ®±
13.8-29.1% [45, 62].
© ± © ©
± ®® ®(
® © )o } -
} % %
% £ -
®± ± ® ± ±® ( ±
± ±® ( ®( ) -
% } -
® ± ® © (
±© © © ©
$ ) 4%)
 S SS
£ ,
£•
p| pu p d-c1 1 )

pu
f p |u
| pp
ap p
( P . 1/) | ry y
) (
9
u p|p u p
|u
| pp p|u p |u
| pp
gp u u
s pp t u
QP
e-p s
u
$ %

r
p
u|
©± (
| u
|u p

/
J
kr
PJPP r vt u u
r
p cup |
|u y p P IL-2 i
- u p|
p t ry
psusp J , V- u u p
S -
tusp sp p
sus
p
| i
: R r vt pr i __________ | pp 3 |
LP SJ I s
pspt r
t
p y r S S P J
s
up

®
tu

® ± ±
®

ruvu u hu
pyuy|uu
©
© *
|
J L P, hu
L PSP S u y
S /

P P hu u y
u
'
u
SP

)4
) ®
± ± - ± ® ±©
$ Bone R.C., 1994).
 T] V

± -
± ® ® ® ±
©
® ( SIRS -
) SIRS, ®® ®± ®
± ) ( ± (® © -
® © ® ( ® -
±© ® ® -
® ± ) ® ±
® ( ® ± ©-
( ® ( ® -
± ±
© ® ®) ® ±
® ± ( © -
® © ®® ± ±
- ® ± ± ®
± ) ±®
SIRS ± ® ( © (
± © T
.0(
4/(44U
)
SIRS
± SIRS ® ® / (® -
± ® T+
4U)
r a% ®
± ® ±
± ± ®( - ±® (
© ©
®
± ®± ) © ®
© ®±-
5
® ± 4
++ +
-,++ - - .)
0-4.0
±
* ) ® ± ® -
± ±© ±© ®± ® -
®± ® -
± ± ) ®± ® ±
± ®
± © ± ®
( ± ® ± )
£ ®± ± ( ±
133
 © ± ± © ® ± ®
®) ( ® ± -
® ( SIRS, -
© ± ® ® ± ± (
®® ± © ® ± ±©
)
r c ®± ® -
®) © © ®± ®
5
$73++ - - % ® ± ± -
5
7/++ - - ) ® ®
© ®± ® ©
± ±© ® ±®© ± -
® ®± ® ± ± ®±® -
( ± © -
- ® ± ) ® ±
® ± ±±-
± © ®± ® © -
® ± ± ± © ±
± ® ) ± ® ©
$ ± ± ± ® % (
® © ±
SIRS.
± -
® ± ) ±
® ± ® ±
± ®± ® ±
® : £®± ®-
± ±© ( -
± ® ® ) ®© ®
® ± ® -
± 5 ± ® ±
( ± - ± © -
± ± ± )
® ® ®± ®
± © (MODS). ®±
± ® ® ®± -
± ® ± ) ® ® ©
134
 ® ) ® -
® ® ± ( ®±
± ) ® ® © -
® ® 4
+ *
±) ± © ±® ®
SIRS ( ± ®±
® ® ± © ± ±-
) ( ® ® (
® ®© ± ® ® ( © -
® ® ®® )
r r SIRS ®± ®
® ) © © ®±
® ) ±© ® ±®© ±
® - ® ©
© ) ® ® ±
± ±© ® ( ± | ± }
±© ± ©6 ® ± -
© ©
® ) ® ±® ®-
© )£ © -
® ± (®
| ® } ® ) ± ±
± © ±
®® )
® ± © -
± ® ® ® ± ± © -
© ± ® ® © )
± ± ± ± ±
© ± (® ® ±
± ( ( -
± ® ©± © ) $±
% ® ± ® ® ® ±-
® ®® ± ( ± )
® ± ( ® -
± ± © ® -
± ± - )
$ SIRS) © ® © © ±
$ ± )0%5
 ± 0
± ± SIRS

± - ± ( ± (
© ± ® ± ©-
®6 (
® ± ® ± -
±® 6 © ® ±-
© ® ± ±© 6
® ± ® ® 6
® ± -
®
)
( © ® (
® ± © ®
® ®
± ±
® ± ± © © -
© ® ± ®( © ® -
®±
)

®
e - , *± ©
® ± ± © -
( ± ® ±©-
)
® © $ -
± ±± % ±
® © -
© ® ) ®± ± ® ±©
±± ® ± ® ®
3 ) ))
15-,
d ± $ %
®± © ® ®± ® -
® © © -
®
± ) D, ®
± ®± ( ® ± -
® ® ± ®
- ® © ®± ©
®± ® ®
)
p © ©
®© ± *± © ± )
 - -© ± ±
± ± ± )
® ® © ± (
®±( ® )
± ± ± -
± ± ® ( ± ® ±
® ® ± )

r D ®
± ±
SIRS. © ± -
® (
( ± ® (
® ®
® -
) ®±-
® ® ) D, ® ( ®-
± ± ® -
SIRS. ± ± ® ±
± ( ® © ©
® ® ) ±-
± ® ) ± ® ®-
± ® ± )
® ( ± -
© ® (± ©( ± ©® -
® ( ± © ®
© ® ± ® ± -
© ® )

] [ ] [
]
®
± ( ®
®± ( ± -
® ®± (SIRS), ( -
® ± © © ® ± ± ± -
® ± ) ©± © -
± ± ® ± ± © SIRS: ©
± ® ® ± ® -
©± - ± (® ± ± -
®± )
 | |' ® -
± ® ® ± ® ® ± ±
± ®® ± ± ®) ± ®
®® ± ± ® ® ®
( ® ± ± ±
® )IL-4, -10, -, .( ® IL-1
® © ® © ± © ®® -
± ± ® ® ± ±
± UT) ® ±(® (® ® -
® ® ± © ± ©( © ± -
± © ± © ) © ( -
®® ± ± ® ® ® ( ®-
© © ±
)
± ® ± ± ®® ± ±-
® ( ±
± ( ®± ©
( ®® ±
SIRS )
± ( ± ® (
± ± ± ) ± ® -
® © ® ± ± © ®± ©
® ( ± ®-
® ®
( -
± ± ® ± ± ®)
® ® © ± (
± ® ± ® ® ® $±
® ® ( ( ± %
) CARS ®±± -
± ( ® ± ± ( ®® -
± ± ± ® SIRS. © ±
± ® ( - ®® ±-
± ± ® ®® ± ±-
- MARS (mixed antagonist response syndrom).
| - | -
|' ® ®± ( ±© -
± © ± ® - ®-
® ± ± ± ) ± ©-± ®
138
 © ® © ±® ) ± -
® ± ± ® ®
® © 5 ± -
® ( SIRS- ± CARS- -
® ( SIRS-CARS (MARS) ®) -
®± )

± ® ®

) ,
+) ® ® - ®-
® ± ± © ® ® ± ® ® © -
T, ,U)
p 2 - SIRS $ ® ( ® ®-
© ( ® ® %
6 -
® ± ± © ® 6 - ®® ± ±-
© ® )
 riRS - ®

u
| r-mfc

) ,
,) ® ® - ®-
® ± ± © ® SJRS- ® ©-
T,
,U)
p 2 ® ± ± ± $% © ± (
®® ± ± $%)

CARS - ®

) ,) ® ® -
® ± ± © ® CARS- ®
T,,U
)
p 2 ®® ± ± ± $% ±
® ® ± ± $%)
 MARS - ®

) ,.) ® ® -
® ± ± © ® MARS- ® ©
T,
,U)
p 2 ± ® - $%
®® ± ± $% ± | ±©
}( ± ±®
± ± ® )

SIRS MODS
£± SIRS © ± ©
± ± ® ® ± ®
( ± ®
-
© )
©
( ± © ® SIRS
® ± ©( ® ®
© ®
- ) ± ± ® ( ©
( ®
SIRS )
® ®
± ± -® ± ( -
® ± ± ©) ® -
± ® ± -
® ± ) ± ± ®
x ± ( © ±( -
 © ( ®
)
± -® ±-
® ® ®± ± ± ) -
® ± ± ( -
® ± ± )
® ± ® - ©
± ( -® ( SIRS.
± ± ® ® ®± ± ®
© ) ®
®* ± ± ® ± ® ± -
± © (MODS).
® SIRS
® © ) © ©
± © ± ± ®( -
® ® ® ® ) ± ©-
+
©± ± ± ± ± ©
± ® ± ( -
® ®± )£® ± -
® ® ± ( ® ®±± ±-
( ® ± ® ® © ©
® ® ± ± -
± ® ® © ± ® ± ) ±-
® ±© (
® ® (®
® © ® ±® ± -
® ± ± ) ® -
± ® © ± ± ± ®± -
) ®
± - ± ® ± -
® ± © ± - ± © © -
) ® ± * ®
± ® ± ® -
® ± ® ® ® ) -
( ± ® ± ± ( ±
®± ® ± ® ® ® -
± ± ± (® ( ® ± ± ®
® SIRS MODS ±( ® T, +
U)
 S ®
± ©
®
± ± ® ±
® ®
± ±© (
± -
) ± ® -
® ( ® © ®) ± -
® ± ®
± ± ®
± ®® ± © © ® -
© ) ± ® ±© ( (
± ®® ± )
© ( .
+ +
-/! © ®
®± ± - ± © ±© © -
® ) ( ± ® ±© -
± ® ® ±-
© ®( ± ® -
® © (® ( ®) ( ±
® ± ® ± ®± © -
® ±© © ® -
© © ) ® ± ® ±-
©
[210].
® ± ± ®® ®
0
+! © ± ® ® © ® ) -
© ® ± © ® ( -
± ± ± © ( -
© ® ®
± ® ® ( ®
± ( ± ±© $ ® ( %
± ® ® ) ® ± ( ®
® ® ± ± MODS
± )

] ] ]
©( ®± (
®± ± ± ® ® -
® ® ) © ± ®-
± ± ® ® © ®
(
®± TNF, IL-6, -8, -, + ( ® ®-
±© ) ± ® ® -
± IL-6. ®
®® ( ©( ± -
© ( ® ® ® ± ± ®)
© ±© ® ® -
± - ® ± )£ ± ® -
± ( ( © ® -
±±± ®) ® ® ®
± ± ®® ©± ( ±
± ®± )
± ( ® ± (
±© ® ® )
© ( ® ® ® -
± ± ± © ±
± ® © ® ±-
( ) ±
(± ( ± -2.
± ®© ±-
±© ± ( -
®® ® ± ± ± © ® ) ©
±( ® ± ®
± ® ® -
®± ) ± $
.-/ ±% -
® © ® ® ±
±© ± ® ®-
± ) - ® ± ± © ±-
® © ©( ® ±© -
) ± -
®® ® © ± )
©
± ± ® ±
± SIRS ® ± -
© © ) )Blackwell ®)$ ,441%T 4 /
U -
± ± ® -
®( ®± ®± ® ® ±-
± © ® )
 +
20-.! ± ® ® -
± ) ( ® ®
± ® ®
± ® ® ® © ±) ± © -
± SIRS ® ± ®
. ® ( ® ± ± - .
-7
) ®
± )
± ® ® ± -
® ®) ± ® -
( ®
) ± ® ® -
± ® ®
± ® ® ©
( ( ©
) ±® ®
© ± ) A. Pollock
$
,44
1%T ,11U( © ®
± ± ± ® © ©)
)) $+ +
+ % ± ± ®(
®± © © © (
$ ®
%T.0
U)
± ± ±© © -
±® ® ± )
- ± ±
®± ± ® ± ©
) ± ±®± ® ± -
© ®(® ± -,($ -
® (® ± ® ® ©( ©-
± % © ± ( © © ± -
± © ® ® © ) ±-
±© ( ±
± 5 ± ® ± ±
® ± ± )
®± ± ®±
®( T
42U
)
145
 ( ( SIRS, ± -
®
( ® ©± ( ±
© )
® ® ®
± -
© ® ± ( ® ± ± ±-
± ± )
® - ©
) ±
© © ®
± -
± © ®± © ® )
± ( ®
± (
(
® )
± -
±© (® ± -
® © ± ( ®®
® © ® © ® ® )
-
$ (® ( %
) ±
® ± ® © © -
( ® ± ± ® ©
±) © ® ±© © -
®± © ®
(
5© ± (© ( ±© ( -
) ± ± ® ® ± -
± ± ( ©
®© ® ®)
©
± ® ± -
® ± (
® ®
± ( ® ® ( © ®
® ± ± ± ± ® ) -
( ± ± ®
(
± .© T.
U5
( ® ® ±
± (APS; APACHE I, II, III; SAPS; SOFA);
/ ( ® ± ® ( -
6
( ® ± ±-
® ± ® ± ® ± ( -
± ©® (- TISS.
® ± ® ± -
® ±
( ®® ± (
) ® ±
± ± ® © -
APACHE; SAPS, ® )

± 1
© APACHE II (Acute Physiology, Age, Chronic
Health Evaluation)

± ±
±
4 3 2 / 0 1 2 3 4
(
r >41 39- 38,5- 36- 34- 32- 30- <29.9
40,9 36.9 38,4 35.9 33.9 31,9
± >160 130- 110- 70- 50- <49
( 159 129 109 69
®, >180 140- 110- 70- 55- 40-54 <39
179 139 109 69
®>50 35- 25- 12-24 lO- 6-9 <5
, 48 34 ll
+
2,
>500 350- 200- <200, 61- 55-60 <55
499 349 >70 70
%2,
± >7.7 7,6- 7,5- 7,33- 7,25- 7.15- <7,15
® 7.69 7,59 7,49 7,32 7.24
>52 41- 32- 23- 18- 15- <15
® ® ®( 51.9 40.9 31.9 21,9 17.9
W ±*±
1
Na+ ®>180 160- 155- 150- 130- 120- 111- <110
® ®( 179 159 154 149 129 119
±*
±
 ' ®>7 6.0- 5.5- 3,5- 3- 2.5- <2.5
® ®, 6.9 5.9 5,4 3.4 2.9
'
- >3,5 2-3.4 1.5- 0.6- <0.6
® ® - 1.9 1.4
®( }
± © - >60 50- 46- 30- 20- <20
(
! 59.9 49.9 45.9 29,9
± ± - 20- 15- 3.0- 1-2.9 <1
9
®(10 ' 39.9 19.9 14.6
± Glasgow 13-15 10- 7-9 4-6 3
12
±
±®£ 5
bo
± ±
±
1 2 3 5 6
<44 45- 55- 65- >75
54 64 74
cc }
±
± ®
± ®± ± 5
1) ( ® 6
2) ± ) (C
O -
± ± 6
3) ± ® ±® ±© 6
4) ± 6
5) )

± ©-± ±® ®
± ±± ® -
± ± ® © ± (
1 ±
±® ®
± ®
± © © ©® ± ®)
± ± ® APACHE C
C -
± ±
±® ® 5 '' 8
2,® ® ± ©) -
$ W.A. Knaus, ,
430
% ® ±
T
,/U
5
 APACHE-II

±
±® ± © ±±® ±
APACHE-II APACHE-II
0-9 __________________ 20! 25-29 0
,!
10-14 ,
,! 30-34 2
,!
15-19 /! .
0 ± 30!
®
20-24 .
+!

SAPS ®± ,/ ± -± -
± ® ±© © ± ± ©) -
SAPS ® ®± ± -
®± ® ® ±-
© ® ® $ ±)3%
5
± 3
SAPS

± ± ±
±®
4 3 2 1 0 1 2 3 4
(
© <45 46-55 56- 66-75 >75
65
® >180 140- 110- 70- 55-69 40-54 <40
179 139 109
± >190 150- 80- 55-79 <55
© ± 189 149
®± (
©
))
© >41 39,0- 38,5- 36,0- 34,0- 32,0- 30,0- <30
±( 40,9 38,9 38.4 35,9 33,9 31,9
- >50 35-49 25-34 12-24 10-11 6-9 <6
± ®-
® -

® +
® ±
±©
 ± ® >5,00 3,50- 0,70- 0,50- 0.20- <0,2
(±
* 4,99 3,49 0,69 0,49
® >55,0 36,0- 29,0- 7,5- 3,5- <3,5
®( 54,9 35,9 28,9 7,4
±*±
(
! >60,0 50,0- 46,0- 30,0- 20,0- <20,0
59.9 49,9 45,9 29,9
± ® >40 20,0- 15,0- 3,0- 1,0- <1
± ® 39,9 19,9 14,9 2,9
106* 3

± - >44,5 27,8- 14,0- 3,9- 2,8- 1,6- <1,6

®( ±*
± 44,4 27,7 13,9 3,8 2,7
± ®( >7,0 6,0- 5,5- 3,5- 3,0- 2,5- <2,5
®*± 6,9 5,9 5,4 3,4 2,9
®( >180 161- 156- 151- 130- 120- 110- <11,
0
®*
± 179 160 155 150 129 119
+
3( ®
*± >40 30,0- 20,0- 10,0- 5,0- <5,0
39,9 29,9 19,9 9,9
± ±© 13-15 10-12 7-9 4-6 3
± ® ± SAPS
SAPS SAPS
4 0% 13-14 30.0%
5-6 10.7 % 15-19 44.2%
7-8 13.3% 19-20 50%
9-10 19.4% >20 ,
++!
± © ( -
® ( ®± ± ±
® © ®
± T.
U) ± ± ® -
® ( $
®,© %(
$ ( ( ® ± ± )
%( -
® © ± ± ( ®
± ± ® ®( ±) )) ®©
)) ± ® $ ,4
44% T.U ®± ± ± -
± ± 2/+ ± ® ±
® ©
150
 ) )) ® ©) ±© ±
0
,2( © - ,
2 ®
) 30!
± 1+ ±) © ±©
®
± ® ± )4
)
± 4
± -± ±© T.
U

| | | |- |
|
(
"
$ ± - 55 75 35
%
(! ±
(
! 61 68 27
±
© ©
± (
©*± 86,8+5,3 88,8+3,1 4
.(,{/
(,
®
( .
(,{+
(1 .
(.{+
(, .
(0{+
(.
12
10 *±
± ®
( ,
.(1{(
. ,(
/{,
(2 ,
+(1{,
(0
9
10 (
± ®± ( 54,0+0,21 0
4(+{+
(3 1
+(+{+
(0
©
*±
£ © ( 35-45 40-50 20-30
±
*©*
± ® ® ® ± ± ©
( ± ± ® ® ®( ± (
(® ± ( ± (
( ® ± ®- © ® -
± ± ( -
® © ® ) -
® © ®$ ( (±© ( ( ( %
® ± © ) © -
± ( )) ®©
)) ± ® $ ,4
44%
( ± 5 - 00(
3! ± 6
® ( ±© ( ±® - / 3(.!6 © - 78,1%;
- 30(
/!6 © ± - 0 0(
+!6 -
- 2
0(.
! ± ) ± ±
± ( ( ±© ) © -
®± 0! ± ± T.U)
 ] ] ] ]
] ]
± ®
® ± ®
-
® © ® ± © © -
± © ( )e
[
% {
[ [1, 45].
© ( ®±( ®
) ± ®
± ®®
( © ®© ± ( © © (
© ±
®± ± ) © -
® ® ® ® ±® ±-
±( ± ± © ± )
© ± ± ©
© ® ± ® ®
® ®( ± ® ®(
± ( © ± © T,(/0U
) ±-
© ± $
± ® ® ® © ± ®
%) ±
© ± ® ± ( ®±
± (© ± ± )
© ± ®© © ©±
- ©± ( ® ® ®
± ® ± © )£
©± ± © ® ® -
® ®®® © )
± ® ( ©
± ( ® © © ± -
7 ® ( © ± ® ®± ®-
)£ ® ®© ± ® ±®±-
© © ) ± ®±
±© © ( ® -
® © © © ©
®± ® ©® ®± ® -
© ± © © ± )
 )) ®® ±± 2
© © - ± -
© ©± ®( ± ± ® -
± ® © 6© ± -
- ±®± © ©) -
± ± )
± ± ± -
® © ®± ± -
± ®© ( | ± } ± -
± ± ®) ®± (
® ± ( ± ® ± ±
© ) ± ± ® ®
®( ± ® ( ©
9 9
1
+, + - 2 +, +* ±) (® ® © ± ±-
( ® ±
) © ® ® ± -
) ± © ±
± ± ® ± ® ® -
®( ( (® ± ± © ±-
±® ) ± ± © ± -
$
9
,+* ± %)
© ± ® ±
± ± ®
) ®± -
®© ® ± ® ®± ) -
( ± ® ± ® ± ® -
( ®± - ±© ( (
®± ± ± ®
± © ( ©
© ) ± ±
± ® ® ± © -
± ± ± $£ %)
® ®( -
( © -
} } $ %
( ±
- ) ® ®
® - )
153
 ® © ± (® ± -
± ( © © ( -
® © ( )
® ® - -
®± © $ ± % ©-
$ ® ± ( ®© ))
%
) ± ± ® © ® ® ®-
® ± )
© ± -
® © ® ®© ±© ©(
± © ± © ® )
® - ®± (® ® © -
± ± )
- ± ® (
± -± )
® ©© ±
± ®
) ± © ©± ®(
® ± ± -
± © ±) ± ± ©
® ©±
®
) ± ± ± ® ® -
® ® ® ( ®± ® ± ±-
© ® (® -
© ( ® © ®
-
® ± ± © )
® ® ®-
® ®( © ® ® ® -
) ® ® ± ± ©® -
® ® ± )
± } ( ± -
®® ® ®
( ®
± -
©± ® T ,(/0U) ± ® ±® ©-
©± ®± ± ® ® ®( -
± ® © ®± ®©
) ® ® -
® ®
)
 ± -
)S ® ± ®
±-
© ±-
±© ® - ± -
®± ±© ( - ( -
( ± -
± )
®± - ( -
®® © © ) ± ® -
© © © ( ®
® ± © ® )) -
© © © © ® (
® ® ® ± © ± -
( ( ± ± ®
® ® )

]- [ V V V V V

- ®© ® © -
± ± ®
®) ( - © ®© ©
® ® ± - )
® ® ® ® ®
± ® ± ( ) -
® ®© ® © ±® ±® -
) ± ® ® ± ± -
© T,
(/ 0U
)
±© ©
± ® ) ( ± ®
± ± $
2 !%
-4 ±
® ® © ± -
© ®©®) © (® -
± ±®± ( ® ± -
® ± ©± ®© ( ± ± -
® ± ± ) ± ® ©±
®± ± ® $20 +
-3! %
) ±-
© ± ® © -
 ® ± ± ( ®
® ® ®)
® ® ©
® ± ® ® -
®
(® ( ± © ± ©±® ®
(
® ± ± ®® © ® ±-
) ® ± ± ±
© (® ® ± (
® ®( ± ± -® ® ± ®
(
± ± ® ® ®(©±®
± ® © ±) ®
± -
© ±± ®± ± ® -
© ± ® ® ® ® ±
)
± ® ±
® ® ± ® ) -
± ® ± ®© ± ± ®
® © ) ± © -
© © ,3
.-0,0 ©* ) ±
®± ® © T
,(/0U
)
± ®© - -
± ( ®
± -
® © ±® ® ®- © -
® ®)
3
+! ± ± -
± ) ®-
® ( -
®±
® ® )£ ® © ± ®
®) ® © ±® © ®
-
± ®® © © ± ( © ±
®± $,1(
10 ±*± ±%( ©
± -
© ® ®, (
3 T,
(/0U)
® ± ®
± ± ® ® -
© ( ® © ±-
 ® ©± © )
± ® ®© ) -
± ± -
$± % $ %
)
± ®-
© ® ± ± ) ±
®± ( ®±-
©
± ® -
) ± © ©® ( ®-
® ) ± ®
®
)
± ± ® ©± © ± -
) ± ± ± ± -
± ± ® ± ( -
® ± ( ® ®± ®
+
) ± ®® ® ) -
+
± ± )
® ® ®® ,)£ ® ® ® -
© © ± - ©
© ( ©± ©-
T
,(/
0U)

[] ] ] ] ] ]
©
± ) ® ± ® -
± - )
® ® ± -
± (©
± -
± ®
( © ®± (
± © )
| | - | | | '
± ® ®± -
© - ( -
®± © ® -
© ®± T
4+U
) ± ±
® ®
± ( -
157
 ®
® ® ®
) -
© )
® ( ® ®± ©
® (® ® © ®
® ( ®
) ( ±®±® ® -
® ( ® ) ±© -
® ± ® ± ±
± ( ®( •( ±®( ® ®
(NO), © ® © (
5 ± (© ( ( ® ®
± ® ®® ± -
® © © )
± ± NO ® © ®
± ® NO © -
± ® ± ± © ® (
® © -
( ®± © ©± ®
® ® ® ®) ± ± (
© ±® ± © ( ®±
( ± ® - ®® -
®
( ® ± ® ± ©± -
) ± ± ± ® ® -
® ± ± ( ®
® ± ®) ®-
® ± ® ® © ® ±-
± ± © ± -
)
| | - | | | '
± ( ± -
® } -
{ % -
© ® © ® ® © ( ±
± ( ± ®®(
) ±© ® ( -
)•) ® $ ,44 /%T
/2U
(® ± ±
 ( ©
)
® ©
© ®® ± ( ± ® -
® ® ) -
® ± ±©-
© © (
®® ( -
± © ( ® ® © ±-
© T /2U
)
± © - ®
® ± ® ± | ±-
}(| }(| } )) © -
± ± ± ± ± ®/ +! ±-
® ( © ± ± - ®0! ± ® )£ ®-
® ® ® ( 1+
-
2
+!(± ± T
/U)
± ©
± © ® ®-
± ± ® ® © ( -
® ® ) ± ©
® - -
®® ( ( -
± © ) ± ®
® ( ± © ± 2+ +
-1
) )$ (
9,33-3+ %
) ± ® ± ®
± ± ± ( ®®
©) ®®
± ( ® ± ± ) -
± © ± ± ®
® ) ® ±
±© ( ® )s { %
%
} [47].
p ® (© -
( © ( ( - -
± ( (®-
© ( ± ± -
( ± ®
)
® ± © ± © © -
© © © -
( ± ®
± ®-
® © ± ( ® -
( ± (
± ± © ® ®-
)
®
± ® ® ®© -
©± ®
© ± © ± ®
±
® ) ±® ® ® -
® ® $© ( ( %
( ®
± )
© ®
±
© ® ®
) -
® © ®® ® ±-
±T/2
(21
U)
i } ® ® -
® ® ® ± ®±
®± ~ } }
© ®
( ®
± ® ) ±
-
± ® © ® ± ± ®
± ( ®± ® ® ± (
)
® -
®
± ®) ®
± ( ® ± ®-
( © ® )
± ®
± ± ±± -
®
( ®
® © ® -
 © ® ( ± -
)
( ©
( ±®
± © ±
® © -
) © ®
® ® ± ® ( } -
{ % } -
- { [47, 76].
± © ® ± (
© ® -
± ( ±
®
± ®® © ) -
® ± ±
± ± ± ( © )

- -
±®±® ® ® -
± (DO2), © ± (VO2) T
,0,
U) ®±
VO2 ® ( DO2, -
± $± ( -
± V02 ©
± ± ® ±
±-
®( © ® ± %
) ±
± ® ± -
5 ® DO2 ® VO2 -
± ) ®
(± ® ® -
± ( ©
( ® ® ® ® ®
-
± ) ©( ®® ® ±
± ® ® ±
±© ® ± ±® ±
T
21U$ )
,/%
)
 ®
® ±

i ±

± ®± ®

±
±© ®

) ,
/) ±© ± ®
± © ± © $ )
(,4
3,%
)

® DO2- V02. ® VO2 DO2

®
± ± $
± ® -
%
) © ±® ( V02 ®
® $)) © ® % ( ®-
© ® ® ®± VO2, ®
VO2 DO2 ® ( -
± ® ±± ® ®
® ± ® ) ®
VO2 DO2 ® ± ® -
® ± ®
) ® -
± ® ± ® (
® ± ®± V02 ©
 ®
±® ) £ ® © -
± ± ± ® ± -
T,0,U
)
| | VO2. VO2 ® ± ± ®
© ± © ) ©± -
VO2 ® ( ± ±
± © ) ®
VO2 3
-, (
© ®
( ®
© ) ± VO2 ® ±
® ±® ® © ® ± ) -
® ®± ± VO2 ® ® -
® ± ± © ) ±-
® ©± ± -
® ( ±
©± ® $® ± ® %)
± ±
± ) ± ® ± ( ® VO2
© -
© ( ®
±
® VO2 ± ± ® ±
®± )
± ± ) ® ® ± ® -
® ± ) ±© (
® ± © ©± © -
® © ® ®® ® © T
..U
$ ) ,0%
)
© ± ± ® ® ± ±(
® DO2 © ® ®
© ± ( ®± ® ®
± ( ® ® -
± ( ® ± ) -
© ® ± ( ± ® -
± ® ® ® ± ® © ) ®©
®® ® ± ± ±
© © ® ± ( ®
163
 ± ± ® ® )
© © ® DO2, ®-
±
® ± ® ® ± ±-
( ± ± ® ± ©± ®T.
.U)
® ± ( © ® -
± ± © ®± ± ±
® ± © ® ( ±
®± ® © -
® ® © ® ® ± ± )
( ® ± ® ® -
® © © )£ ® ® -
± © ® -
© )
± ® ®± ® ±
®± © ± ® ©± )
® ± ± ± -
± ® ) ® ® -
® © ± ® ± ®-
® © ( ( ±
®± ® ± ©-
) ® ( ® ®
±®± © ® ± -
(NO), © ® ® ±-
®
) ±
® © ± ±© © ± ®
®± ± ® ®
® ) ± ± ®
± ( -
© ® ± ) ± ®
± © )
 - -
. C

-C
^ -
- --
Cv

- -
. C

- -
. C
\ * - -

-
- --
v

- -
. C

- -
. C

*
-
- --
Cv

- -
. C

) ,
0) ±© ( ®® ®
© © ± ( ®±
® ± ® ® -
®)
$ ))(,
442%
- ® ©± (® ® ± ± ± -
H+
(® ® ® ® ®
® ± 6- © (
© ®± ± © ) ± ® © -
® ® » ®± ® ®
± ® ® -
® ± ® ± ± ® ® ± -
( ± ® ® ) ± © -
® ( ± ® -
® ± ® ± 6 ® -
± ± ® » ® -
® ® ± $
± ± %
( ® ® ®
® ) ± ± ® ®
® ± ® ± -
® © ± ( ®±
) £ ± ® ® ®±
± ® ® ®( ± © ±
)

± ± ® ± ® -
® ® ® VO2 ®
± ® ) ± ® ®
® ± ± ® ± ® -
© © ® ®
± © -
± ® ® )
± ® ± ® ®±
±*
±) ® © ® ± ®±-
± ± T
..U
)

] ] ]
± ± | -
| | | | | |
| - * 0 2 0' ® -
±© ±® ± ® ±
TNF, PAF, ± ( ©( ® ®
® ® ®
)£ ® -
® ® ® ±®( © -
( ® ±® ® ®
® ± ± ® ® ( ®± ® ±-
± ± ® ® ) ®
 ± ® © © ® ® )
© ± -
± ® )n { -
% % -
±®
± ®© ®
)
®± ® ±©
± ) ®
© ® ® ® ±© -
± ® ± ® ± ±
® -
±® ( ± ® ®
) ±-
® ® ± © ®± ® ±
® ( ® ® © ± ± ( ®
® © ± )
®
± ® ® ® ±-
± ± ® ± ®
® ± ± ® ± )
± ± ® ± ±-
± ±© )
® ©
± ± -
( ±
© © ± ® ) ± ©(
® ® ±
±® ® )
®± ® ® ©© -
± ® ® ± ©® -
± ) ± ® (
® ® ® ± © ±© ( ±®
-
± ® ® -
± ® ® ±® ± - ±
±
)£ ®
( ± © ±© -
±® ±
( ® ±
® ± ® )
® ® ±© © -
 ® )£ ®
± ® -
© ® ) ± -
±® ± ® ± -
© ± ( ®± ® ±
± )£ ±® ® -
® ± © ®( -
± © ± ± ©
± )
± ± -
® ± (
( ± ® ( -
® ® © ± ± ( (
( ) ± ®
±
® ( ± ± ®
- )
± ± -
® )£ ±
± ® ±© -
© - ® ) ®
±
± ® © ) -
±© ©± ®®
± ®
±© © ® )
( ® ®
±
±
® ±© ) -
® ± ± -
( ® ® (
± © ±© ±© ©
® ® ® ±)
® ± ± ± ±
®® ± ±© ©) ® ® -
± ( ® ® © ± © ®
( -
± ±© ©) ®
± ± ® -
® ± ±© © ± ® -
± ® ) © ®
±±- ± ±© © -
 ± ± ® ± ® (
©
± ± ®± ( ± )
© ® (® ± ± ® (
© ±© ®± ± ©® (
® ® ± ±© ©) ± © ±© -

± ®( ± ®®± ® ®©
±© ©( ± ® ±® ± ± )
±© © ±© -
± ®® ® ± ( © ±-
® ©®
( ® ® ±) -
® ® ® ± )
± ® (® ® ± -
± ( ± ® © ( © ±-
© ® ® ® ®
± ©® ®® ± ) © ®
-
®© )

± ± ( (
± -
$ © % ® ± ±
$
03(
1!%
( ± ® ( ®-
®® © T
,.2
U)
£ ± ±
± ) ® ®
® ± ( ( ®± ® ® (®
®
) ®
± ® ± ( ± © - ®
® ( ® ®
± ®) ± ®
± ®± ® ®
± ®
± ) NO ® ± ®±
± ® ( ®± ( -® (
® ® ±® ® ±
± ( © NO © ± ±®
169
 ± ± )
® ® © ®
± ®
± ) ±®
®± ® ® ®
® ®® ) ±
© ± © ® ® ®
© ) ±® ®± © ®
± ®±
® ® ® © ( ®
® ®( ® ±®
® ® ® © ®± )
±
®± ® (
® ® © ± ® ±
© ± © © ® )
( ® ±
® ±® ® © ©
± (
)
® © ®
® ® © (
± ® ± ) ± ©
± ® © ®( ® ± ± ©
® ) ± ® (
± ® ®
± ® ® ® ® ® ±
® ( ® ® © ( ©
® ± ± ®
5 ± ®( TNF-a,
± /( 0 ± )£ © ( ®
( ® ® ® © ®
® ±® CDlip/CD18 ©
± ± ) ® (
® ® ±±± © ® ± ±
(ICAM)-l ± ± ± © ® ± ±
(ELAM)-l. ± © ®
®± © ±® ® )
® ( ® ® ±
® ± ® ® ±
170
 ± ± ± ®
) ±
± © )
® ® ® ®
±® ® ±
± © )
©
±® ± ® 5
± ± ( ©
± ©
® /
0+( ® ± © )
® ± -
( ±© ) ® ±
( © ( ± - (
® ® ® AJIT ACT. ± ® (
® © ® ± ± (
© ©± ( ± ( ® ©± ( -
± ± © ± ® ® ®
±® ± (
±( © ± © ®T4(,
.0U)
© ±© ± ® ®
© ( ® ±
) ± ®
± (® ± ± © ± ® -
± ± ± ±-
®T
,/0U)
® ® ®
± © -
$® ® ®± (
® © ±±± (
( ± %( ® ® -
© ± © ) ± © ± -
® © ® ®
± ± ®® ± ( ( ® -
± ®© T
,13U)
® ©± ® -
( ® ®± ® ± © ± ® ®-
±® ± T,4
+U) © ± ± ®
± ± ® ± ± -
 ) ( -
® ®
(NO) ® ® ® © ®)
± ± ®®
-
® ®± ®©
® ) ±© -
± ± ± ) ( ± ± -
± / ®( ®® ,
++! ±-
) ® ± ) -
± ®
± ± ® . ( -
± )£ ± ® -
± © ® © ( ®-
) ± ® ® ® © ®®-
® ® ( ® ( ±® ±
© ® © C
CT,+4U
) ® -
± ) ± ( ® ® -
±® ( ±
® ± )

] ]
® $ %±
®
(® ± ® ± © -
( ® (® ® -
) ± ®-
© ± ( ± ®
50%, ®± ® ±-
© ( )
±© ® -
± ® ) ±
±© ( -
± ® ± ( ® -
® ± ± ®© ± ® ± -
© ® ± © ® ±-
± ® ± ® - ± © -
) ± ® ± © ± ®-
© ® ±© ® ± ©)
 0
++ ± ) ± ±-
® ± ( ®
) ® © ± ®©
® ± ® ® ® ± -
( ®© ® ± ±-
® ±© © T
2U)
® ± ( ± -
( ± ® ®® ,!)
© ± ®© © ±-
( ± ® (
± ± © ®±® ( ± ± -
® ® ® ± ® ® ± ® ®
-
) © ® ( -
± -
( ® ± ® 0 +!
± ± ®
) 0! ± ± ® ©
®
± ±®± © ® -
© ®( ® +! ± ®- © )
© ± ® ®± ± ±© -
±© ( © © -
® ± T
2U 5
® ± © -
®± 6
®± © ®(® ® ®
± ® ® -
® ±© ® ±-
® ± ®® -
( ® ® ® ®
± ® 6 ® © ® ± -
® ® ± ® ®± ®
® ® ®6
±© ® ± ±-
®
( ® © ® ± -
© ±6
© ©± ® ©±
® ® ®± ® -
 ( ±® ® ± - -
® ®
± )
®
± © ± ® ± ±-
® ± ® (
±®
±® ® ® - ±®©
) ®
( -
© (® ±
®± ® © ± © -
±© ) ± ± -
®© ® ± ® ®® -
( ± ± © ± © ± (
® ± -
© ©©± ± T
2U )
± ±
® -®
± © ( ± ® ® -
© ±© ±© ® -
© ) ± © ( ±© -
® ± © ( © ® ±
$ ® ® ± ( ®-
%
( ±®± ® ±
5® ® ® -
± ± ® ± ©
± © )
± ± ®
± © ± -
) ± ± © ® ®
± ®
± ( ± ( ®-
® ® ±® ( -
( ® T
72].

] ] ]
£ ± ± ® 2
+! -
± ) ± )
®® ( © ± (
© ± ) £± -
±© - ®® ± ± -
 ± T,+( , +.U
) ±
( ± © (
| | ± )
® ± ®± ±
® ± © ±
) ± ® ± ± © -
( ®© ± ®± ) ±
© ) -
( ± ® (
® - ± ( -
± ® ±© ± )
±© ®
®± © ( © -
© © ± ©
± ) -
± ± -
®( ± )
± ( ® ®© ± ®
( ±® (® ® -
® ® © ± (® ®® ±
® $± ( ± ®± % ( ( -
± ± © )
± ® ® -
± © ± ( (
® ® ®± -
± © ±® ) -
± ± ® © ± -
( ® ® ±
± T,0,U
)
®® ± -
® ± -± ® ± ( -
® ( ±® ± ± ©®
® ) ®
± -± ® ± © ® ±
©® -
® © ® ® -
)£ ®©
® ( ( ± ©)
 )) ®)$+ ++ %T,1U ± ©± -
± ® ( ( © © ± -
© ®± SIRS 1
3 ± ®® -
,3 03± ( ® ® -
® ±© ± ( ) . 3
± ± ± ± -
(® ± © ® (± -
©(® ± )
± ® ®± ® © -
© ± ( ± ® ± ± -
® ® ± ( © ( ®-
± ± ( ) )
± ± ® ®
± ® -
± ( ® © ± -
± ( ® © -
© ® )
± ( ® ® ±
® © ± $® ® ± ± ©
-
© ® ®( ® ( %( ®±-
© ©®© ® $
© v. a.opticus).
© ® ®±
® ®( © )
®± ® $®/ % ©
± ® -
®( © (v.jugularis). ®(
©( ± ± ± ®
± ± ) © -
© ® ± -
®± ®
® ± ± ©) SIRS
± ± ® ±-
©® ® T
,1 U)
® ® ©-
± © ( ®± ) ® -
®± - © -
® ) ( ® -
( ® ± ± ®-
176
 ©(® © ® ® ®
(
® ® ® ±-
®± ± ± ) © ± ©-
® ®±
± ± (v.hepatica) ® -
®
± © $ ® -
± %
( ®® ®± ®-
® © (® ( ®± ® -
± ± ± © ® -
± ) ® ± -
® ± ± ®® -
® ± ( ® ± ®-
± ® ) ® ® -
® (® ®( ± ©-
®
( ® ® ® )
± ( ® ±© © )
® ® ®±
© ) ®
± ® -
© ( ® ® -
± (© ®± © ©
) ® © ® ® -
± ® ® $ © (© © ± %
)
® © ± ® © -
© © ± ® ®( ® -
® © ±
± )£ ® -
® ® © ± ® ® ®
± ± ® ) ( ® ± ©-
± -
® ® ® -
© ® ±-
© )
® ®® © ®
± ) ± SIRS, )) -
) $+++% ±® ± ® ©
± 5, % ® ± ( ® ®
® ±6% ± © -
® - ( ®
©± ( ® ®© ± T ,1U )
± ® ® ®
® - ± © ®
±
©± ) ± ® ®
± ®© ± ® © ®
±) ® ® ® -
© © ®± ® ±-
® ( ®± 20
! ± ©
® ) ®(® ® ® ± ( ®± -
) ®( ©
©( © ) ® -
® ± ® ®(
® © ) ( ( -
® © © ± ® ® -
© © © ®
) ® ±
± ( ® -
® ± ( © ® -
± $ 9Na3p).
© ® ®(
( ± ©± ±
® © ® ± ) -
© ®± ® ® ®
® ) ® ® ±© ®
± ® ± ®( © ®± -
± ( ± ®
± ) © ± ®
© ( ± ± ®± ®
© ® )c
} % % -
} } " -
} }
SIRS T,1U$ ) ,1%)
® © -
± ±) ® -
± ® ® 9-
178
 ± ®®
-
± ( ± ± ±
©)

) ,
1) ® ± $
2000).

® ( ® ®( -
® ±© ±® -
± ( ® © ® -
)£ ± ±
© ® ± $ % -
© ± -
± ® ( -
)
® ± © -
± ®
± 5 ± ® ®
6
© ©
± ± 6 ®± -
6 ± ®
 ®( ©±® ©( ± ® ( 6 ±
± ©
± )
± ® -
± © ( © © ± -
®® ± $ ± ( ± ( ®± %
(
® ©
± $ ± N-Hepa 5%
3! ® %
)£ ® ± ® ± $
,+©® % ± ®)

] ] ]
® ± - ®
® ® © ( ® -
® ± ® © ± ® © )
± ©( ® ® ©
±®
± © ( ® ±
± ) ® ±
® ® ( ± ± ®-
( ® © T,(.0
(
62].
® ®
± }
nui{e } ® -
© ± ® ± ± -
® ® ±® ± (
® ± ) ± (
® ® © ©(
( (©± ±
® ®± ® ®)
± © ® ) ®
± ±
©® ® ®
)
®
± }
V
[1, 35, 62]. ±
® ©( -
) ®
± © © ( ®-
± ®
180
 ©© ±® ( ±
P © ©®
(® ± ©
±© ) © ©©
© © © ® ± ± © ©( -
© ± ±( -
( ( ± (
.-/ ® ® ± ± © ±
( ®±( ( (
L M ®( ®± ® (
©
± ) ® -
( ® © ) •® ®± ±
) - ( ±
(© © ± -
®® ( ©® ) © ®-
± ®© ® ( © © -
© ® ± ® ± ( -
± ± ( © ® -
± )
® ± ® ±-
± ) ± -
© ± ©± ( ± ®
±© ) ± ® ± ± ® (
® ® ± -
± ± ±® ® ± ® -
± ®® © ±
® ± ± ( ©±
© ® )
± ± ®
-
± © ± $± % ±© ) -
© ± ±© © -
± ) ± © ±
®± ® ® ) -
( ® ( ®-
±( ( © ®
±
-±±®© ® ( ® -
) ± ® ± ® ®
© ® ± ® ® )
 ± ( ± ® © -
©® ® ±® ±
® ®© ( -
± ± ®± ® © -
± ) ± ®©
® ©® ® -
± )) ©® )
® ®
® 6 ± ®± ® (
( ®± ® ® (
® © - ± ±© ± ©
® ( ± © ) ±
± © ± ( ® ©
©® ± ± ± ) (
© © ± ± Clostridium sporo-
genes, - ± E.coli communis, Proteus vul-
garis, ± © ± - ±
© ® ± © ± ) ± ±
® © ± ± ® ( ± -
± ± © (© - - ± -
± ®±© © ( ± - ® © ( -
® - ± ©
± )) ± ( © © ± ®
± © ± ( ± ± - ®(
±© ® ( ± ± ± ® -
© ® ± ©) ± ©
±® ± ® ) ± ®-
± ± ) ® ± -
± © © ®-
± ®® ® T
,(.
0(1U )

] ]
± ! ® ® ± ®
± ® ® ±-
( ± ± 0+
! ® -
± ® ® ±
T,U
) ® - ± (
®± © )
± © ® ± ® ®
± ® ®
] ( ®
® ® ® ® -
®
± ±
)
( ± ® ®
(± ® -
± ( ) ± ©(
± ® ± -
( ® ± ® ± -
|± }
) ± ±
® (® ® © -
± ± ®
® ± © ± ± -
T,.U
)
± ©
± ® ± ( (
®® ± ( -
( ® ± ® ® ®
( © -
© ) © ® (
( ® ± (
® © ® ± ® © ® -
± ± -
® © © ©± )
± ®® ± ® ®
±
± ± ± ± ® ±
± ± ® ) ± (
± ®© ±® ® -
± ( ®
± ©) -
± ± ± ® © ±© -
± ± ® (® ± © ± (
© ( )
® ® . ±
) ® (©
 0 ± ± ( ® -
® © ® ±
$ )
,2%
)

%
1
0 ©
0 V± ©
-

0
\
" O
6
\
-V
V,
( --- - U$
- ~ )
©-'tzS ^iti^::
UL. 92
),2) ± ± © ® ®
( © (!)

®± ± ±
( ±
® ® ± © ± © -
© $ ) ,
3%)
® ®© ± ® ± (
® ®± ® ® ® . 1 ) ± ± -
) © ±© © ® ( ± -
® ® ® ± ® )
® - ® ® -
® )£ ® -
© - ® ± (
© ) ® -
( ± ± ® ® ®
-
± ± ± ± ® )
± - ® ®
© ( ® ± (® ® -
© ± ± ± ± -
± ( ® © Clostridium perfringens. ®-
®± ( ®
 ± ©(
® ® © ± -
± ± ± )

),
3) ±
© © ®

® ® -
® ± ( ® ± -
± ) ® ® ®
® /
3 ) ± ®
) ®® -
S.aureus.
,! ® ± ® © ( © -
® ± ± ±® ( -
± ® ® ) ±® ± ®
® ± ® ® / 3 ) ± ) ±-
®± © ®
± ± (
( ® ( © ) ±
® ) ® -
® ® ± ® © ® ± ® ±
® ± ± ®®±) -
® ®
( ®
® ± © ± ®© -
© )

] PS. AERUGINOSA
® ®® ±© ® ®
±® ® ® ± ©
( ® ) ®
® © ®
®( ® ( ® -
® ® ® ± ) ( ±-
® EPIC (European prevalence of infection in intensive care)
© ± ® ± ® -
© ± +! ®T ,30U
) ±
® ± ®±
® ± ( ® ± -
® ® ± ) ® ± ®
Enterobacteriaceae ® ® ± ® . /(/!
± ® ( Pseudomonas aeruginosa - 28,7%, Staphylococcus aureus
-.+(,! $ 1+
! ±± %( Staphylococcus
spp. $ ©± © ® %- ® , 4(,
!(Enterococcus spp. - 11,7%,
© - ®, 2(
,! $ ® ,
+ +! ® ® ±
%T,3
0U) Ps. aeruginosa, ® -
± ± ( ± ± -
® (
® ® ±® ± (
® )

| | ||
± - ± © © $
Pseudomonas aeruginosa) -
®© ( -
® (Enterobacteriaceae) -
© © ± © ®)
± ® ± ® ® -
± ®
(® ±-
® ( ® ®
±
© ± (® ® ± ® ±
± ) ± - ± © © - © -
( ® ® -
® (® ) © ® ±® (
® ±®±® ® ® ± -
( © $ ®% -
± ) © ® ® ±
- ± © © ® ® ± ) -
® © ® ® ±
®5 ± ± © ± ® ±© ®
® ±( ± ® © -
( ± -
±±± ( ±
± © ) ±© ( ±
- ± © © ± ® ® ® ® ± ±
(± ® ®( ± ® -
± ) ± © ® ± ®-
± (® ® ® -
® ©® ( ®® -
® ®- T/0
(1U)
© | ± ® } ®
$ )u ± ® %
(® ®
± ( ® -
( ± ±® ®© ®® )
± - ± © © ± ± -
®© ( © © ( -
® ) ® ®-
± ® ± ® ®
®± ± ± - ± © ©
|± }
( ±®±®
®© ) ± (
± - ± © © ( ® ±
© ® ® - ± ®
© © ( © ® ± )
± ® © ± -
® © -© ©® ± ±
 ® © ± (® © ®-
® ® ( ® © ± -
) ± ( ® ± - ± ©
© ( ® ®( ± ®-
- ± ± ( ®± © ±-
) ® © ® ± -
( ®© © ® ±
®)
® ( ±® ± ± - ± ©
© ( ® ® (± -
© ®± ± ®© ®
) ± ©
® © ®® ± ( ®® (
© ± ( 6 © 0+-
90 % [45, 62].
© ± ± ± ® ± Pseudomonas aeruginosa
$% ® ® ± $ % ®
)) ®)$ ,44
4%T 00
U) ® ± ® ® ±
( ± $ !% ( ± -
± $ . !% © ± $ 2 !% ® ± -
$.- /
!% ) © ®
± © © ®® ± -
( ® ± ® -
© ±® ) ® ±
( ® © ( ® ( )
± ® ® ± ® -
® ( ® ® -
± ) ( © ± ± ®
© ( ® ± ® ± ±
± ) ® ® ® ± -
® % ®-
± ® ® ) ± ®
± © ± ® ® ± ©
± ±© $ ± © ® ®%) -
± ® ® -
±® ® ±( -
±© ® © (
188
 ® ®
© ® ® -
) ® ± ± ± ©
© ® ) - ® © ±
® ® © ®
± ± (© © ® )
- © ( ±®±® - ±
® ® © ® ± ± © -
© ± © ® ( ± -
® ® )
® ± ® © (® ®
% © - ( ® ± -
) ± ® ± -
® © ± ±© ) © ® ±
± (® ® ± ®-
® ± © T
00U
5
£ ®± ± (® ®
( ©± ©
± - ± © ® ®
$± % ®
® $ ± % (® ± -
(® ®
± $ ± % ± -
± ( ® -
(© ±
£ S © ± ( ®
± -
® ±©
© ± ± ±
( ® © ® ±-
®( ±© © )
± ®
(© -
± ± ± ( ® ± -
) © ± % © © ± (
® ® (
®± © ± ± © ±
® © )£ ®
±
® ( ® -
®© ( ® © ® © ® ± (
SIRS [55].
± ® -
® ©± ®® ± ) ®
® ©± ®
± -
© ±®
± © )
® © ® ® ®-
± ) ® ®
© ± ® -
± ®( ® ® © -
) ©± ± © ® ® -
© ( (
± )| ® } ©
-
±® ®
± (± ± ®
® ± © ) ± ©-
± ± ®
± ® -
± ( ® ® -
) ± ® ®
®± ® © ® ®® ± -
± © )
©( ©± ® ® ±
® ± ) | -
® ®® ± } ± | ®® ® } (quorum
sensing), ± ® ± ® ±
± ± ( ®± -
± ±-
® ® ® ± ) (
© ®® ± ® ® ± -
± ) ±© ± (® (
® ® ± ® ® -
± ± ± ± -
± © ® ± ) ± -
® quorum sensing signaling system ® ®±
±® ® {- ±® [214].
 ± ® ® ± ( ± ®
± (© ( ® ± -
.
+! ( © ±6 ®( ( ® ±
± (® ±) ± ± ± (
® © ® ±® ® ®
® ± in vivo. ± ± ®± ®± ( -
± ® ® ± ( ® a-1
Lectin /Adhesin. ± ( ±© © -
± ± ® ® ± ®® -
± ± ( -
© ©
±® ® % ) a-1
Lectin / Adhesin ® ® ® -
® ±® $ ( -
© ® ® © ® ±% ) -
® ± ( ® -
±
± ± -
V ® ± © ® ®
© ® ± ) ± -
©( © ®® ± ±-
® ® quorum sensing signaling system, (
© | ®® } ± ® ® ±
® ± ( ®±
® T,/U)
® ® ®± ± -
® ± ® ®
)
®( ® -
± ®® ® ® -
± ± ( ± ® -
± ( )) ®® ± ) ©
( ® ±-
®( ® ± -
© ± ® ® ®)
±® ± (®-
® ® ® ± ( ®
® )
191
 ± ® ± ± ®® -
± ( (® ® © ( -
± ± ( ® ® © ±® -
© © ) ®® ®
© ( ± ( ® (
± ) ± ± -
® ± 5® ( -
± ±© ( ®© (
) © ® ± ® ® ® -
± © © © )
®© ± $ %
(® ®
%± ± ® ± ± -
®® ( ± ±
® ± - ® ® $ %
)
® (® ® % ®
± C
CC ± ( ± ± © ±
± ® ±® ±© ® ) -
± ±© ® -
© 2 .! T
00U
) ® ± ® ©
± ±( ± ©
±® ± ± ( -
®® ± ( -
± I03 *±
)
± (
© (® ® % ± -
± ® ®
© ±© ) p { } } -
% { % { %
} {

| | Pseudomottas
aeruginosa | |
|| |
® © ®
( ± ± -
® ® ( -
± ( ©
± ± )
 ® ®
( ± -
®® ± ( ®
±
® ) ® ® -
% © © ± © -
®
( ® ± ± ± ± ( -
± © © ± ® ®$ - -
®( ± ( ®%
(
± ± ®± ®
±) ® ± ®
± ® -
± ® $ ® ± %(® ®± -
± ± )
± ® © ±
® ® ± ± ( ®
®± ±± ® ® ± $ %( ± ± ® -
® ± ) ± ® ± ( ± ®-
± ® ± ® (
±® ® ( ® ±
®)
± ® ® ® ® -
± ± ®® ± -
± ® ® ®
± ® ®±
$ ± ®
%
( ± ± ® ± ±
± ± ( ©( ®
±© ± ® ± ± ® ® ±
± ®
) ± ® ® ® -
® ± 5 ± C
O ±
$ %
( ( ± CCC ±
$ ( %( - ±±
$ ®© ±± %( ±± ±± )
® ® ± -
®® ® ® ±
© © ±
-± ( ® ± ( -
® ± ®C O ± ( ®
®
± © ( ± (±®±-
193
 ( ) ® ±
±
± ( ± I-II ± ( -
) ±± ( ±
± ( -
± III ± ®± ± (
®® ± © ± )
( ® ® ± -
® :® ± © ® ® 5 -
® © (
® -± 6
® © ± )
$
± ± % ± -
( ± ( ± ± ±(
® © ±-
© ®$ ® ® ±%( -
® ±) ±
± ® ± (
© ± ± ® $
%
) (
® % ± -
± ± ± ®
® ± ®® ± ) ( © ®
® ® (® ± ± $ -
© ® % ® © ®® ± ±
® ± (efflux pump).
© © ® ± ± -
® ± ( -
± ( ± ± ® -
® ) ± ®® ( ±-
®
± $ % ®
± ± ®,+ ® ( ® f coli. [55].
± ® ± ® ±
® ( © )
® ® ©
± -
® ®
® ® ± ® ± ) ±-
©
± ®® ± ®
± © © ± ) ©
±-
® ± © ®
®± © ® ) ± ®
® ®
± (© ( ± -
( )| } ©
± $ -
( ( % ® -
± )
p { { -
± ® ( -±
®
± ® ® ®
)
© © -
® ®
± ® ®
± -
® ®± } -
-± ± ) ®
®
± ® © ( ©±
®) (® -
-± (® ® ® -
® ®
) ( ©
± ®® ± © ®( -
© ®) ±
± - ® ±
-
± (® ± ( ±
± (ha ±
± ( ( ± ® © -
± -± ( ®
-
± ® ) -
® ® ± ± C
O ± ) -
® ®± ® ®
± ( ®
± ® C
O ± ) ®
± ®)
-± ( © ±
± -± )
® ®
®± ® ± ©
® ± ®)£ ® ±
( ( ± ©
 ®
± © ® ± )
± ® ± ± -
® ®® ±
( © © ± )
± ± (
© ® ± ®
± © ) ( -
-± © -
± ®
) ± ® ®® ± -
( ©±® © ® ® ± -
(® ® ( ® ±
)
® } { -
( ± ® ®-
± 5 -
® ® (
® ± ± $ ® -
± ® %( ® ®
®) ® ©
± ®
®± . © ®(© ± -
®± ± ® ± )
© ® ® ± ®
)
± ® ©( ® ®® ± -
©
± ( © ® ® ® ®-
± © ®± ® )
©± ® ®
® ® ® ( ±
® ®® ± % ®±( ®
©
± ®® © ± ± )
± ® (
®® ± 5 ® ® )
® ® ® -
( ®± ® ® ® -
± ) ® ®
± ®± ®
®) ® ± ®® ±
196
± ®
± ) ± © ®
®( ® ® ± ± ±(
± ® ) ® ® -
® ± ± ®© ( © ( -
| ± ( ® ±-
}( ® ® ( ®±
® © ® ( ))
®
± ) ® -
± ® ( ±
±® ( ® © ® )
® ± ± -
( ® ® ® ® )
± ± ®± ± -
® ( ( ®® ±
± ® )
® © © ± ±
®± (® ® " -
© ® ® ±-
® © $ ® -
® - ® ® ®%
) ® ± ® -
® ± ) ± ®® ± -
± ± ® ± -
® ® © ®)
)) ®)$ ,444
%T 00U ± ®± -
® ± -
® ® ) ± ®-
± ®± ± ® ± $
®© , /,%
(
® ± ± ( © -
® ± ® ®± ± ± , )
® ± ® ®± ± ® ± ® ± -
± 6 ®(± ® ®± ±
± ® ®
) ± © ± -
± ±© © (± ± -
± ) ® ± ®
® ® ® ® ®-
± ® ®
± ® ± )
.+)
 ± .+)
® ®® Ps.aeruginosa [55]

R, 1, S, . 5 | || |
% % % ( ( (
(
| || 9 9 82 2 8 1,14 0,031-64
||| 15 4 8J 2 16 2,32 0,031-256

| 37 18 45 16 64 8,4 0,031-256
|| 16 31 53 8 32 7,54 0,5-256
| ( 45 15 40 64 256 37,82 0,1-256

45 1 54 0,5 64 1,38 0,031-256

[| 60 1 39 256 256 25,78 0,25-256

10 1 89 4 32 5,56 0,5-256
| |
3 R - ® ( I - ( S - ®
)
® ( ± ® -
± ± ® © -
® ®© ® ® ( -
® ® ) ® ®
® ® ® -
± CC
C ± - )
® ± .
2! ®( -
,
3!) ± ± ® ± ± ±
C
O ± 5, 1
! ® ± ® -
(.,
! - ± ) ® -
±
± 5 -
±
± * 5/
0! ® ± ® (,0!
- )
± ® -
± ( )) ®) $
,44
4% -
( ± ®
± $
©-
% -± ) ± ©
± ® ± ® ± -
±
± * -
()) ( -
 -± ± $© -±
®
± ®
%) ± -
® ± ®-
± ( ® 4 ® ® -
, ® ± ( ± -
) ± ® ® -
± ® ® -
± ( ± ®-
® ± ® © ) -
± $ ± ® %
( ® © ® T
00U)
±© ± ® -
® ± ( ©
/
0!) ± ©
± ® ± -
± ± ® -
) ( ± © ® ±
1
+! ®$ ± ± ® ± ®
± ® ± 0 1 © *±%( -
± ® ®
± ± ,
+! ®T00U
) ± ( , /
, -
© ,++$ 2,!% ® ± ± -
) ® ±
) ) ®)$,444%T00U® ® -
± ( ® ± ± ® ±
± ®© $0 ®% ® ± -
III-IV ± ± ± ±
$ ® ©( ® © -
± ± %® ® ©
± ) ± ® © $ ,
1 ®% -
± ± ® ) ® ©
± ®® ± ± )
,
1 ® ® ± ® ®-
,. ± ® ± ®( ± ®
)
® ®
± -
® (® ® % -
® ) ± ( ±-
© ± $
® ± ± C
CC-
C
O ± % ® ®
®± ) ± ® ( -
± CC
C ± ±
© ® -± ( ®
( ®® ± )
® ® ®T 00
U® ® ® ± ®( -
® ® ) -
® (® ® (®
® ® ± ± ) ®±
± ® T 00U
± ( ± -
® © © (® ± ® ± ® -
± ) ( ,
0+ ® ( ± ® ±
® ® ±© ( ® -
±± * ( ± +-
.+! ( - +!® ( ® ± -
® ) ± ® ± (
±± * T,1/U)
± ± 1,0 -
®(® ± ® ± ® ® ® -
) ± ®± ( ®® ± 24)
1!
®
( ±± - 12)+!( - 2.
)/!( -
± - 00)
3!( - 1/)
,!( ±± -
33)
,!( ±± ( - - 4) /!) ® ®-
± ± ± * -
± © ( ® ® (
® ± )
® %® ± ® ® (
® ± ± ®±
/)! ± ,) 0! ± T
,03U
)
®
± ( ± ± ( -
® ± ® ( ±© © -
±© ( ± ® ® -
( ®© ( ± ® ® ± ®
± ) ( / 1 ® ± ± -
© ± ®® ± ± 3 3! -
®( -2.!( ±
± * -2+!( -
 - 30
!( ± - 3
4! © -
81% [127].
® ± ® -
± ± ± -
® ± ®
) ® -
® ± ® ®
® ± -
(® ® % ® ± ± © -
© )

| | Pseudomonas
aeruginosa
± ® ±© -
© ( ® © ® -

± ± -
(® ® ± ® ®
± ®
® ± 1+- )
© ® (® ® % ®-®©
± ± ± ( ® © ± ® ± ±
± ± ® ® ±
© ± ±
± ) -
± ± ± ® ± ( © ® ±
± ®® ± ) ®
± ® -
in vitro © ® ©± -
± ® © -
± ± ± ® ± -
© ® ±
± ® ©
±-
)
± ®
± ± ® ® -
®( ± III-IV ± (
± (® ® ± ®±
® ± ® ® -
© (® ® ± ± -
± ® ( -
® ©± -
 $ ®© %
) {
}
( -
± ® ®
' (
® ) ® ± ®
® ® ® ± ±
' ±
± * ' )
± ± ± ± -
± ® ® ( ®
® -
® T
3U)
® -
( ± ( ± C
CC ± (
® ® ±±-
©
± ®® ± ® s ±
® ) ± ( ( ±
± ® ± ® ± -
±© © ± ® ± ® ® ® -4
( ± ± ®± 1 - 2!( ® -
® - ,2!) ± 9 ®
± ± ®± ® ® /3 / 0!T 3U)
® ± ® ,/ ± ®
± ®± ( ® ±
©
± ®± ®® ® -
± ( ± ± ±
(® ® [146].
( ± ( % -
% { -
% ± © ® -
$® ® ( ( ± -
± ® %
) { -
{ {
} £ ± -
® ® ± ±
± ( ± ®-
±© ± ± ± ®® ± ©-
202
 ® © © ) ±
®® ( ± ± ± ± Pa- -
© ® ®
® © ( ® ® ® -
® ) ± ( ± -
© ® ± ± © ± -
(® ® ( ® ( ® -
) ± ® ® ± ( ® ®
±
© ±© ® - ® -
(® ( © ±
® ± (
© ± T
3U)

SIRS ] ] ] ]
® -
® ® ± © T/4
(0+
U)
® | }
| } © ®
± ® -
± ± ± ± © ±-
® ± © © ® ) -
± ® ±©
±© ( ® ©
± -
® ± )£ ® ®
± ( | -
© } | ±© }(| © }
| ® *
© }
( | ®
® }
( | }( |
© © -
} ))( ® ® ® ± -
( ®± ® © ® ± -
)
® ®
± ± ©
( ± ®
± $ (
,44%T,
+2U
5
I. o 2" } %
{"
II. o -
"- -
III. p 2" %
{"
IV. p
V. p {
( ® ± ® ±
© ± ( ±
© © ±®
± ® ±
® ± ± (® ® -
± © ® ± ± -
®
) ® ® ± ±-
® ) ®( ± ( ±®± ® -
® ± ± ( © -
± ) ± ® ±® ® 2
®® © ± © -
$ %* - ±® ± ( -
© © ® - Marshall * )
® ® ± -
® ±® ± ® ±-
© ® ® ± ± ) -
© ±© ® ± -
® ® ® ® ± ± -
®® © -
) ® ± SIRS
± ±
® ± ± ( ( ±© (
© )
± ® ±
± ® ± ± -
± © (B.C. ®± ® ®)$ ,444
%T /
4U
®± © ± ± ±-
®± ,
++ ± ®
± © -
) ® ± ±
± ±
± ( © ® ± ( ±
± ±
© ® ± © -
 ® ipb ± ® ±± -
® ) ± ©
®
± ® © ± ± -
} } sur"
% SIRS,
® © ®
) -
SIRS ± ± ± ® ® ± -
© $ % ® © -
8 T
$® ±
) )
% ,
++* ± $ ®
*
±%U
)
± ® SIRS ®-
±± ® ( ± -
® ® ®
± ± ±
© ® -
®
( ® ± ®®± ± ®
® © )£ -
® ®®± ® ® ( ® ®-
® ± © ( ® © -
© -
± ® ± -
© © )
SIRS ± .
® (SIRS-3) ® ® ±
® 21-28% ± ® ±
) /- © SIRS (SIRS-
/
%( )) ® ( ± ®
® ® ®
± ) SIRS-4 -
© ± ± ® ® ±
® )£ ® ® -
® ± -
® © © ( -
± © ® ± ± ± ® -
$± © ( © % © -
± T
/4U)
® © ® ±® -
± ± ± ® ) ±
±© -
 0 ,! ± ( ® ® ( ©® ®
SIRS ± ® ® ® -
©) ± ®® ± ± ®
© ® ± ± ±
® ) -
± ® © $
®
± ± ®
%( ® ± ± -
±
(® ± ± ®
® ( ® ± ±© -
© )
® ( ©
® ± ± © .
.! ± -
© ®® (
® ®® © ( ®
± © © )
® ® ® SIRS ® © ® -
® ± ± -
( ® ± ®±
® ± © ® -
SIRS ± )
( B.C. ®± ® ®)$
,44
4%
T
/4U
( SIRS-4, ±© ®
±
® ( ®
± ® ® ®
)£ ® SIRS ® ± -
©± ± ±
± © © ±® ® ® -
)
®
± ( SIRS-3 SIRS-4 ®± ±
± © ® -
( © ± -
( © ® ±© © -
© ® ± ±
)
® ±© © -
± ± ® (± -
206
 ( ± ® ®-
) (® ® . ± ±®-
( ® ± -
) ® ±® © ± ©
R ( © -
®± ,
. ±
±® ®
SIRS, © © ( ®
®± ± ± ® -
) ±® ®
±
) -
( 7 ± ±® ® -
±
®± © ) ®
±© © .2! ± © ®±
± )
®± ( © © -
® ± ® 1{ / ( ® -
® ± .{ ) ±
® © -
® © ± © ® -
®± 0 { . ® ± © ± )
± ± © ± ® ® ® ±-
©± )
( ® ® ® -
®±± .
+ ) © ± ®± ±-
± ( ( ®
± ® ± -
) ,- ± ±® © ± 0 ! ±-
( ® ± . - .
2! ® ®
) ® ®®± -
) ® ®
±® ®± ®± ® -
± )
4 ±±® ® ± © -
± ±© ( ±® ® -
® (± ± ®± ® 2{ 1 )
± ®± ( ± ± © -
® ® ® ± -
 *± ± ©® ( -3- ±
±® ( ± ® © -
± $ ® % ± ® $ % -
® ) ® © ©
®± , 4{ 3 ( © ± ± ± ®
± © ± 5 . )
[49].
( 0 ± ®
© ± , 1$1/!% ®( © ± -
02 ± 3$ /4!%( ® ± ® -
( ±© ® -
© ) ©
® ® ( ©
± ® ( ® ©
® ± ± ± ± ±-
5 ,3 ± © ± 3$ /
/(/!%) ® ±®
®± © ( -
® ±© © © ±® )
± ± ® -
± ( ® ±-
® T
/4U) ± ±
® ® ±® ±
± ±
( ± -
® © ± © ® , . ± ± (
© ± ± ©
®± , + ± ±® )
®± ® ± -
® ± ® ® © -
( ® ® ± ±
® ®-
( SIRS. ±®
® ® ± ±®
®® ®
SIRS-4, ±© ( ( ® ©-
® ±© © ±® ) -
© ( ©® ± © (
® ® ± ± ® -
 ± ( ± ± -3-
± ±® ® ® -
® ( © ±
© © ( © -
)
® ± ®±±
B.C. ®± ® ®)$
,444 %T /4U® ± ± -
© ± -
± ±© ± ® © © -
® ®5 © ® -
± ( ±© © ± ©( -
± SIRS, ± © $ ±).
,%)
® ® ± ± © ©
± ® ( ® -
® -
± ± ± ± ±
±® ) ± ® ± ± -
± ©( ® © -
© © ® © ( © -
)
® ± ± ®± -
± ®± © ( -
± ® ± -
± ( ±© ©
( ± ± -
-± © ± © © )c -
SIRS {
{ } {} ["
%
{ }
}
{ } [49].
 ± .,
© ± ®± ®
± $ B.C. ®± ® ®)
(,4
44%

- - ® ±
© ® ® ± -
® ®
- ®

I - ± ( ® 8 ® ®
0(
1{0,6 ®
8$
2'1 %
3(
4{,(
+

4 ®± - 5 ' 8 (3 + 3
±± ® ± © , ({+(
4 % ' -
*± © 8 $
1'0 %
± - 11,4+0,8

10-12 - 5 ' 8 $,4 '

±± ® ± © 4)
.{+(
1 3 ' -
*± © 8 ® $
,.
± - 7,1+0,6 ', %

HIA 10-12 ®± - © *± - 8 $
1 ' /
±± ® ( © - 14,0+0,7 '
( 8® $
,3 ' ,
® ± - 11(
4{+(
2 %
±

± - © *± - 8 $
1 { /
, ±- ( © - ,/)
+{+(
2 '
±® ) 8® $
,3',
® ± - 11,9+0,7 %
±

IV ± ®± - ± ± - ±
, ±- '
±® } ,.| }
},+
} ,.
},+
± ®± ± ± ,3 ±
® ® ± © ,4
4/
,
443©©
)$± © ( ® ±©
® © ® -
%
( ± ® ® -
® © $ %
) ®± ± ® -
® ± ®® + 0
4± $2
2(.!%
) -
 © ± ®± ,(0 ® .
+ )
® ±© ± 0+(
3! ± ( -
20(
/! ®± - ±® ) S -
± ± © ± ±
± ( © ± ® ® ® , ®
± ±® $
,3(!%
(® ® ®© -
® ® , - 2 ( ± ® ®
±
29,3%.
± ® ± ,
24 ® ® -
± ®$ 0, ® %
( ® ®± , (/
© ± ©) ± ® © -
® © ® ± ® ± ± ( ± -
( ± ® -
± ® ± -
1
4 $
0.(
4 !%) ± ±®±
± ® ± ® © -
± )
± ® ± ® ± ± ± -
® ® ± ) ±
± ®± SAPS.
® ®± ± ± ® ®(
® ® ( ± (
BosschaK. ®) $,443 %T ,+
/ U -
± ± ± ® ±
± ± ® © ) -
±© $
,+ ± ±® ® ± SAPS)
± © ± ®± ® )
± ± ± ©
± ± ® ± © 5C- ±-
( ® ®± ± 6C C- ± (
± ® ± © ) ±
± ® ® © ± ±
$ ® C© - /2)
. © (C C- / .
)1± % ) C©
± ± ± ® - 0,)4!( ®
© © /
2 )
,!) C C© ± ®, (
4 ±
± © )
 ± ±® ® ± ±
® ± © ) ® ± ,
© ± ± ±(® ® ®CC©
0+
)+! ± ) -
®
±± ® ©±± -
( ® (
( ± ® ©± ± ® -
® -
®
) ,
2® ®® ± C
C© $ . /
%
® 4)
/!( ,
2 - ®
82.3%.
± ± $ -
±( ( ( ± $ %
± - ± % ®® ± -
®±± ® ± © ± ®®
® © ®
SIRS ( ± ® ( ® © ® ± ®)£
±® 2
® ± ( .
± © ( ± - 2
( ® ± ® ±© ±-
© $7+ (
+0%
6
®± ® ± ± ®
® ± ®
± ±©
5®C©) ® (
0! ± ®( ® C C
© -/,
(!$7+ (
+0%6
± ®® ± -
®
± ±© © ± -
© 5® , ,© ® ± ®
. 1
(! ± ® ( ®,© - ±)
± ±© ± ®C C
C©
® ± ® ( ± -
® ± © $ ± ® (
® ( *% © ± ©
® $ IgA).
® ± © ± (
 ®± ± ® ± © ® -
±® )
±© ±® ® C© ® -
® ± $©
8+(4, % ± ± -
± (± ±© )
® ® II © ±
® ± ® ± -
$
©8+(
4% ( ® ± ® ±©
±® ) ± ± ± -
± ± © ® ±
± ® ± ± ©)
® ± ( ±
( ( - ( ( -
- ± ©( ± ® ± ® ®( -
® ± ® ( ® ± ( ± -
® ®I II © ©
± ® ± - © ± )
± ± ®
© ± ± T
./(3 4U( ® -
± © )p } ± ±
®
± © ) ± (
± ( ®± ® ± -
± © ®± ® -
± ± © ) ± ± ®
© ® ± ® -
© c } ®± © -
± ± ® ) -
± ± ± ® ±
± ± ) ± ± ±±
© © (© - -
± ®
± © ±® © T. 1 U)
± ® ± ± -
± ( ± ®± ±
)) ®)$ ,443%T.3 U) ± ± ± -
± T
.3U ± ± /© 5C -
® ®± ± 6II - ±
 ® ± © ®
®±6CC
C- ± ( -
± ± 6C
O - ± (
± ± ® ± ) ® -
± ± ± ® ®

C© ® ± 2 4$1, )
2!% ± ) ± -
®± . 4( )£ © ±
± ± ® ± (® +(3 ± -
, ± ©) , 3$ 3,)
3 !% ± © ® -
- ± -±© ( ® / -
$
,3 )!%± - - )
C
C© ®± ,2$ ,.(.
!% , ( ±
® ± , ® ®±) ± ±-
® ± ± ± ± ( ® C©
®± ® ,(
/) ± 02(
1 ) C C
© ± ® ® ± -
® ± ±©
5 © © © - -
® ± 20! ® ± ) ± CC©
® ® ® ®1 /(
2! $ ,, ± ® % ©
± ® - ±-
( 1$ .0).!%- © - ) ± © -
- ± ±-
® ± ® 1)0! ®
© ®)
C
CC© ® ± , 0 ± ( ± , -
) ± ® - 4$1+ !% , 0 ± ( ± ® 4-
± © - ® ©
) ± ± © -
®± , 2)4 ) III © ± ®
®
± © ® ± ± (
® © ( ± ± ® ± ®±
® 0) $% , ± ©) © ® ® ± 23 ± (
/ $ 0
.)3!% ± 4 ± ± ® -
$ ©
® %
( . 1 $/1 )!% 1 ± © -
± )
214
 ± C
CC© ( ©
±®
± ± © ± (
) ® ® © ® ®
$ ® ® ±
% ® )
pon $
± ±
® ® ®± 3
2)0
!% ( ®±
±0 +! ± )
CO© ®± ,2$ ,.)
.!% ± ( -
± ± ® ± ) © ±-
± ± © ®± ® / ) ±-
® ± ® © ® /)
2 , ± ©)
-±© ± ± ® , 2$ ,++
!% ±-
) ® CCC© (© -±© -
±® ® ± © ® -
© ®(® CO© ®®± ±±±
®± ® ©® )£
± ® ® ®±
© T2
.(, 0,U) ±
± ± 2+)
1! ± ( ® -
± ± ± ± ) - ®
CO © ± $03)
3!% ( ®
© ®
± ± ±
-
)
± © ® /,
$.!% ± © ®± ® -
®± ©
T1/U) ± ± ®± ® ±
± ® ± (SIRS, ( %
)
®± - ± ©
© ® ® ±-
® ) ®± ± ®
± ± ©) ® ± ±
± © ± 5 111
ipynna - 4.(
.!(C O © - 2+)1! ± ) ® ®®-
± $ ± ± ± %(
® ± ± 5® C© - 12.7% ®C
C© -
29 4%.
± ±
( ® ® ©
® © ± -
© ® T .1(. 3U) ± ® -
®± T
.3( , 3
2U) ± ± ® © -
± ® ® © ± (
± ± ® - .)3 , ± ©(
)) ± © - ± ®®-
®0 )
3 ) ± ® ± ®©
® © ® ± ® ® ±-
© - ± ( ± -
® ( ± ® ® ) ± -
± ® ® ± ®
± © ± ®
- 0 )3! ± ® ( © -
,,)! ± ® ) ®® ® ® ©
® © ® ± ® ® ® ® (
± ® ± 2)
.! ± ) ± ® ± ®
® ®
± ®± -
© ± © $ 0 3 ± ±% ) ®
® ® ±® ®± ±
± ©® ®± )
± ± ® ® ®
±
®© © ± /
. ± ) 2$ ,1)
.!% ±
± ± ( .1$ 3.)
2!%- ® ±
® ) , , $0 )
1!% ± -
© ®
) ®± ± ® ®® ®±
© - ± ± - 3 1, !( ®. .)
.!
© ± ) ± ± ® ±
® © ± ® T1/
(3 /(
,+3U)
® ® ± ±
SIRS, ,.0(/ 4
U) ±
± ® SIRS ®
® ),4)
 100%

80%

60% -4
-
40%
.-2
20% -1
-
0%
C© III © II © C
O
©

),
4)SIRS ± $ ,
- %

, © ®± ± ® ± ±
SIRS-0 -1 - 0 3
(2) * *
% ±± SiRS-2. ± SIRS
3-/ ± , 4(
+ ! ± ) V± SIRS ® © -
®±, (
/ /)
CC© ± ± ® ± $
/.(
3!%
± SIRS-2. ± SIRS 3-/ ± 0 (,! ± ) -
±±® C C© , (
4/) ®± ± ® ©
®C O © - 1 3
(3!( ± ® ®±
SIRS-?-/) ±±CO© ® - 2,69.
CC
C© ± ®© ± ± ± SiRS
3-4 - 60,0%, a SIRS-2 © ® 1(2! ± )
±± ®C CC© ®± ( 0
.) ( 3 1(
2! ±
© ® ® ± SIRS ± )
( ,3 ± SIRS © ® 2.
$01(.
!% ± ) ® ®
(SIRS-0 SIRS-1) /
.(2! $00% ± ) ±
± SIRS-3 SIRS-4 $ % ®± . , (
+! $ .4 ± ® %
± ® ® ± ® V SIRS ® ® -
± ± ± ( ± ® ± ®
® ® ± ® $ C
C C O © %) ± -
®± )+ 5
 10(
1%
80% -4
60% CCBP
3
40
j
%
IIr p -1 © IV r p -1 IV rp
on. ® on. on. " "

)+) SIRS ® 5
5)

± CC© ® ® ± ® ®
/.(3
! ± ® © SIRS-2. ® ® -
± ® ® rpvnnt ± ® ±
® SIRS-G SIRS-1 $ . ,( .
! 0(1!% ( ± ® SIRS-3
SIRS-4 ® ®® $ 0 (
,! 0+ (
+!%) C O©
± ± ± ® ® ± ®
± SIRS -. SJRS-4 ®± 1 3(3
!) ®
± 5 ± ® ± ®
± SIRS-4 ®± ® ,3(3! .+(.!( ® SIRS
3-/ ®± 3 ,(
3! ± ®
( SIRS © CC C O © ®
® ( ± ® SIRS-3
SIRS-4 ® © 3 ,(
3!)
± ( ® ±± ± -
± SIRS-2. ± SIRS-2
( ± ®±
© ± © ® ® T3
/4U) ± ® ±
) ± ®± ± ©
T40U
) ,3 ± ± © ® ®0 0
$/.+ !% ± ) ® ± ± ®
®© ± ® ® ± $ ), %
5
 I r p III © © IV

),) ± ® ± )

C© ± ® ± -
®± - ,4! $8, 0% ± ) ±
III © ± ®± © ± ® ± -
86.7% 4 , .%( ® © ± ,. ±
± © ® ® © -
± ) ± ,, ± C
CC©
± ® ± -
± ± ± ) © ±-
( ± ® ® $CC C O%(
± © ± ® ±-
51
/)2 ! 8, ,%4 /)
,!$8, 1%( ® ® )
± ± ® ± ® ® C C C O ©
® ® © -
± ($( ± ® ( % ± ® ® -
® T
1/U
) ± CO© (
± ©±® ©© ( © ® 4/(,!
$, 1
% ± )
,4 ± C
C C O© ± ® ±©-
± ® ®) © ® ± ± ±
®
,/$2.(2!% ± ( ® - ® 0 $1 (.!% ± ) ®-
± Ps.aeroguinosa ® Kl.pneumomiae E.cloacae.
± ± ® ± T
1/(
3/U
) ± ® ® ® ± & ± ( ±
± ( ® ® ± ±
® 1 )
.! ± © ( )) ± -
±© © | } V ® ± . 5
,)£ -
® ® ® (
®± ± ® (
© T+ U)
© ± © ± -
®± ± ® ± © ®
© ± © T3 (0 1(1 3U) © ± ±
® ® ® © © -
© ±© T/4 )1 /U) ® ± ®-
® ® ® ® -
± © ±©
) ± © ± © ® .
$0!% ± ( 3$ 32)
0!% ±) ± ® -
© ® , ± ®± ®
.)
.2) ± ± ® ± ® ± ±
© © - . 2)
1! ± (
- ® . /)/
! ± ® © -
- ,)3! ± ) ± ®
± © ® ± ® -
- 1)!( ± ± ® ±©
® ® ± ) .)
®± ( ± -
±© - 1 (
4! ± ® ) © ®± ®
© - ( - -
± ±© ® ± ®
± ® -
® ® ® T1.(2U © -
± ®± - ± © - 0! -
± © - )! ± ® ) ®
® ) )
 ± ± ©
±©

| |

} } - - } { %

- 2 11 5 6 24 22,2
±
- 3 10 10 6 29 26,94
±©
- 3 4 8 2 17 15,79

- 1 4 2 0 7 6,5%

-
- 1 2 1 4 3,7%

- 3 9 9 6 27 25,09,
±
12 11.1% 39 36.1% 36 33.3% 27 19.59, 108 100%
2 6.2% 12 37.5% 11 34.4% 7 21.99, 32 100%

-
{
25,0%
- ------ -
//^ {
.
(2! *
4 / 22,2%
-
^^^
6,5% 0 -
'
'i '}
26 9%
- 0'

15,7%

® ± © )
 ® © ® ®± -
± ( ® J ® ) ® ®
:5 ± ® ± ®±V ± ® (
® 8 © ® ® ® -
± ) i © ± ± ® ) C C
C©
®± 3 1)
2! 4 , .
% ± ® ($ ± ( ± ±
± %) . $. )
,!% ± C
CC© -
®± © - t ± ( ,+
$
214 !% ± ± ± ± -
© ± ± ®
± ± ©
)
C
C ©U ± ® ± ±
± ± ± ±} ® - ,, $ 1
/)2!% ®/
$.)0!%) ® © ® ®
© - ± ) ±
± ± ( ( ®® -
® ® ® ® ± ® ) CO ©
± © ® ± © ±
± 5,0$ 33 !% , 1$ 4
/),!% ( ® ® )
( ± ( ® ® ( ©
®± ® 0 4/ ! $,4
% ± ® ) ± ® ±
® ® ± ®± 0!) ± ±-
® ® -32)
0!$ ). %)
( ± ®® (
± ® ( ± © ® ® ®
± ®± ® ±© -
© ) ® ®
© ® ± ®
$± ± ® ® ®±
32
)0!%) ± SIRS ©
® ® ) ® ® ± ±-
± ( ± ( ±©
( ± ± SAPS, ®©
± ± ± ® ± -
± ®® SIRS-2 ±
® ® ® )
 ,
++2

409?
9
8

0
< C© C
CC© © C
O©

).) ± © ± )

[ ]
± ® {-
® © ere
±© © ± © )
£)) ± )) ± $,444%T2U ±
± © ® ,,
)! 2
+/ ± -
± © ) . /$ .4
),!% ± ± ©
± $ ± - ® ±
% ± ± ( 0 .$ 1
+),
!%
± ± ± ® ± ©
± ®®± ± $ ±
± ± ®%) ± ±-
© ( © ± -
( ® ± ® ®
© ± , )
± ±® )
± ± ±-
± ©( ± ±
( - (© ())
 ± ® ) ± ® ©
± ®-
± ®
± ( -
( ± -
( ® ± © ± )
® © © ±-
© ®± ® © ®
± ) ± ®-
® ® © ± ) ®
® T
2U5
"
± ±
± ® ( ± ± (
± ® ( -
± ± © -
± ) ± ® ® -
®® ± ®
)
©( ® ® ± ± ®
®± ± ± ± ± )
®± ® ± ® -
$® ® © ± %( © ©
-
® ± - ± ± ®) ±
®® ® ± ±
®± ® -
® ± - ±
®± ®® ®
± ) ®
± ® -
( ® ± -
± ® ® -
± ® ± ( ® )
( ± ± ±( -
(
± ® -
) ®± ® ® ®-
® ) ® ®-
± ( ® ± © -
) ±® © -
 ± 5 ±
NM ©® $± % ~9 -
®(TNFcc, IL-2, IL-6, IL-S )
%~9 ® ±®~>
± ± ®( ®-
© ± © ® ®( ® )
± ( ® -
® ± -® ® -
® ( ± ± ©
± (
® ± (± ( ®-
± ± CD4+ ®±
CD4+/CD8+. © ® ( (
)£ ® ® -
) ± ± ®
± © ( ( (
® ( -
± ( ± ® ± ®
CD4+, ®± CD8+ ® ® -
CD4+/CD8+ ± © -
© )
-
" -
( ±® ±® -
± ( ® ±
£ ) 80% £ ® ® -
® ©® - ) ±®
± ® ®
( ± ® ( ®-
± ® ( ® ± ) ±-
® ®(
( ± ®
® ) ( -® ( ® -
® ®® ± )
® ©± $f coli) -
© © 5 ± (±© ® ± -
) ( ±® ±
 ± ® ® ® ( ±®
±® -
® ± £ ± ±© )
± -
± ®± ® ± ©
± (
® ± ® )£ ®±-
® ± -
® © ± f coli. ® ®®
® ( ®± ® ® )
® ± © ®-
® © ±© ® ± -
) ©® ±± © ®® ( ®-
( ® ©±
®® $ - ± % ( ± -
- ± © T
2U)
® ± ± (
± ( ® ® ± ©
( ® -
)£ ® ± ±-
( ® ® ( -
® ± ( -
± ® ®( ( ®-
©®( ® ® -
±®) ®± -
( ® ± ©
± © )
" -
± ± ± -
© ® ® © ® -
± ± ± ) ,- ± ®-
± 3
+! ® ± ± ® ®
± ®$® ® ® ±%)£
± ® ®± ± ± ( -
± ®® ©
± ( -
® ®
± ® ± ®
)
® ± -
( ( ® ®
)
 "
± © -
± (© ± © ( -
®± ©± ± -
© ® ± ® ± ® -
® ®) ± ® ® ± ® ±-
® ® ® ® ± ± © -
± © ® ( ® ® -
± ) ± ( ± © ®-
® ® ® ® ±± ± ®
± © ® )£ ± ®
± ± ® T
2U)
± ±
± ( (® (
± © ±® ®
± ± ®(
(® © ® )
( ± ( ®
® ± © ( ® -
± ( ± © ® (
± ± ®( -
(® © ® ) ± -
± ® ® © ®$ -
%( ® ± ± -
±® ) © ® ± -
® ±® ®± ± ® ±-
© ®) ± © -
© ® ® $ © )%
( -
± ® ± ± ®® ± -
®( ))
£ ± -
® ©
± ± ± ( (
± ©
± ± ± ® ® -
£ ® ®) ®-
± ® ± ± ® ±© ±®-
®± © ®
 - ±
)
( ± ± ( ±
® (® ± -
± ± ± ® ©
© ) ± ® (
£( (® -
( ® ± ® ® -
® ® ± © -
( ± © ( ® ±
® ± © T
2U)

[ ]
±© © ®
± -
± { { -
) ± ±
± ( © ® ®
±
®
± ® ±)
±© ± ® - ± ® -
© ® © ) -
±© ± ® ® ± ± © -
® © ) ±
± ± ®
± ® ± ® ( -. ®
) ( (® ® ® -
± ® ® ® )
± - ± ®
± ( ® -
±© © ± ® ®( -
® .+
-4+ )
± © ® -
© ® ® -
® ® ± ± ® )
® ± ® ® ©
® ®
± ®
-
® ® ® ± ©
 £ ± ® ±
( ®® ± -
) © ®(® ® ©
®(® ± ® ± ® (
® ®( ® ) ©( ®
± ±® ® ® -
® ± (® ® ®( ) ±-
©± ( -. ® ® ( ® ± © -
± ® ± $ ® ± % -
±© ± ® ® ®± ® ® ® ±
® ® ± T/1U)
b } ( ®
®© ±©
$ ± ( ( ))% ®
® © ) © ® ®± ( ±
® ® Pseudomonas spp.;
± (® ® Proteus spp.-, ±® - ±
$Bacteroides spp., Fusiformis spp., Clostrid-
ium spp. Peptostreptococcus spp.).
b % } no d %-
© ) ( -
± ( ® -
® © )
p {
® ± ® © ( ± -
± ± ® ± ± ® )
± }{ ® ®
± © ®) (
± ® ® ± ± ( ®
± ± ± ® ®-
± © ®
® © ± ® ®(
) - ® ( ± -
® (© ± ® ± -
±® ± ® ® ) ± ®-
± ± -
®± ± ® ± ® ) -
229
 ± ± ± ± ± ®
-
± ® ®
( ® ® -
± ®
± ®/ )
b © ±±® -
® ® ® © ) -
®
± ±© ± ® ( ®±
±- ± ± ® -
® ± © ®
( © ±© -
± ® )
® ±© © ±-
± ® ( ® ®
) ± © ® ®±
± ± ® ® ±©-
± ± © ± -
± ± ®0
+! ± ® )
± © ®
± ® ±© © © ) ® ± -
© ® ( Staphylococcus aureus, Klebsiella
pneumoniae, Pseudomonas aeruginosa, © ( ± ® -
© ± ± © ± )
® ± © ®( ®±
© ® $Staphylococcus
epidermidis, © ©± © ® ± ( -
%( ± ® ®
± ± © ± ) ® ®
± ® © ± $ ( Bactec/Alert
system) ®± ® © ®® -
1-3 ® $ / ®%( ®±
24-/ 3 ® ± ® ±)
± ® ® ±© © -
± © ± ± ®±)
,) ® ± ± ®
®) ± ± ± ±
( ( ® ( ±
/ ( ± © ® ®)
 ®
( ® ±
®
® )
2 ®± ® (®
®± .
+ ) ± ®
±
®( ® ® ® ®±
± ® ± ( ± ±-
® ®
± ® ® ± ® ± ) ® ®
± ® ®® ± )
3. ® ± ± ® -
® ) ® ® )
® ± ®
±
± - ® ) ± -
© ± ® ± ® ±© ±-
® ®( ± ®
± ) ± ® ® ±-
© ( ± ® -
® ® ® ± -
± 0 ( ( ® ® (®± -
) ®® ± © © ®±
± 3+!( © ,++!)
4. ± ± ®± ± ®
± ® © ® ± (
± ± ( ® - ±®
± ( © ® ± ®± ) ® (
± © © ® ± ®
® ± © ® ® ± -
® ® ) ® ( ®
± ® ® ® -
± ± ® )
©( ® ± ±
®± ( ® ± © ± ©
± ® ® -
± ® ©
± ® ±
)
0
) ® ® - ± ®
± ± ) ® ®
® ® ® ,
® ®
2
+! ) ® ® ± -
± ) ± ®
)± ,+ ± ®)
® ® ±© -
± ® ® ® ± 0+
! ±
± ( )) ®
± ±© -
T+(.
0U)
 ] ]

r
} }
} % -
{
( ®
-
± ® ±® © © )
± © $®± ® (© ( -
% ® ® (©±® ±©
© ® ® ® ± © - © ®
®± -© - ± ± )
± ® ® ±
± ( ® ± 5
± ± ± /,! ®, 4+4©) / +
! ®
,
43+())( ± 2+± T21U)
® ±
± ± ®( © ( ®
®( ® ± ® ®-
® ) ± ± ± ©
® ±( ® ®® © ® ± 5 -
% f coli.
± ± { } -
3 ± © ±
± © ± ) (
[ ± ®© ± ±
± ®± ±
± ® ® )
- © ± '® ® ±© -
© © ® © -
- ' ® ) ® ± -
- - ®( -
± ® ) © ® ± ± ±
® ® ± (
® ® ® (® ± ®
± ® ±© ® ( -
233
± ± ® © ± ± -
® (® ± ® ± -
T
,12
U)
± ® - ®
-
± ®
( ®± ± ± © -
± ® )
( - (®± ± ) -
± ± ± ® ®( ®
± © - ®
) ± |© © ® }
® ® ®± -
© ±® ) ± © - © (
® © ® (
± )
|| | | ' ±
© © )/5

© ± ± ©
® ± ®

V ± £
® ±
©± ± ±
)± ®±

V
®± ®

© ±
©

)/)
- © © $ )
(,4
3,%
)
 ® ± ® ±( (® -
± ( ® ± © )£ -
®± ± ® © - ® © ® -
® ©
IL-1, ® ® ( ± -
® ® -
-TNF ' -TNF { -
" } -
Beutler s} -
-TNF - ) / kD ( -
c { TNF- e
- TNF - TNF-aJ.
± ® ±( ± (
® © © ( -
© ±) ± ± -
® ± © ® ± -
) ©( ± ® ® ± (
© ± ®
® © ) ±© ± -
® ®± ®® ® )
± ± © ±
± TNF-a ± -
± ) ± ® ® ± ( TNF-a ± ®± -
± in vitro. TNF-a -
± ® ®± © -
± ± ® ± ® ® -
± ® © )
® ® © -3
® ® ®
® ± ® ®) ± ±
TNF-a ®( ®®-
± ± E.coli ®® ± ± ± -
± ® TNF-a. £ ®±± ® ® -
© ± © ) ± -
± ± ® ®± ( ®® ® ±
® IL-1 IL-6, ® ± © (© -
± ® ® ± ) -
 ® TNF-a ±© ®©® ) TNF-a
® ® ® -
®
( ®± © ( © ± (± (
( ± ( ® ®
( ± ® ® ©
® ® ® ®
® ®) ± ± (± ± ©
®® © TNF-a, ©
) ® ® ® ®
±© ® ±© ( (
T
,43U)
± TNF- ( ±-
® ± ®± ® ® ®
( ± ± ± © -
± ± © ® TNF-a
) ± ± ±
( ® ± TNF-
® ® ± ± ®
*± TNF-a. ±-
TNF- ®( ± ® ® ± ® -
© ® (sTNFR-I sTNFR-II), -
® ® ± ± ® ® ® -
±( ± TNF-a.
® ( ® ® -
®
± ± ± ( ®
± ® ( ® ± ® © -
® ) ± ± ± ®® ±
±® ± ± ± ®± ± -
) © ± ® ± ±-
± ) © ± ± ©
± ± - ® ® ± ) ® ±
© ®± ± ( ± ® © ± -
±® ® { ' -
{ [ ® ± ®± ©®
© ® ±T ,43U)
® - ± -
® $ (
236
 © ± ± ® ®-
® ®
%) ± ®
± ®© © © )
] ] [
} ± ® ®±
± ( ± ± (
± ®,
40,©
)Waisbren T
21U ®± ( -
® -
® ± © ± ± ® (
® ® © ± ® ± (
® ± ® ® ® © -
)
®± ± © © ( (
±© ( ± ± -
( ± ± ®± ® ± ) -
® ® © © -
® ± ®-
®
± © © ± © ® ® (
± ® ± ©
® © ±)
± ® © ® © © © -
± © ) © -
® ©( ±
± (® ® (
® ( ® ©( ± © ) ±
© ± ± © ® ±-
6
} %

{
r % % -
3 ( ( ®
± -
% ( ® ®
® ( ® ± -
® $
£ % - )
£ ®
± ± ® ©
 © ® ( © -
) ± ® ® ±- ±± -
® ® ® ® ®
.s* V
- ) ® ® ®
± ©±®
-
© ® ® ) -
® © ® -
± ® ( ± ±-
© © ®)
± ± © ±®
-
±® ® ± ± (
- ) ® ©
©± ® -
® ® ® ® ®(® -
| ± }
)
± © ± -
® ± ®
5
® ® © $
© .
4 -
/+u%6
$ , .
+ 0
-,+ * ) % ® ± 6
± © ± ®© ® ± % 6
( ±© ( ± 6
® ± ± © ( ± ±
®6
®6
® ( 6
±© )
® © ®± ® (
© ® |
® © ±± } (
±©± ® ±) ± (
( ®
± ± -
®± ® ®± © -
) ± ± ( ± ®
± ® ( ® ® ® © -
)
± © © ©
© ®± © ( ±-
( ( ® ( -
238
 ± ® ®® ( ©± ±
± ©( ® ®® |
®
}
)
( .+ 0
-.! ± (® -
© - ± ( ®®
) ® ® ® ± (® (
® ® ® ± © ( ±© ®
5 E.coli, Aerobacter - Klebsiella, Proteus, Pseu-
domonas, Salmonella. ( ® ® Proteus, -
±®±® ± ® ± ± )
± ± ± /
+± ( ± -
± © postabortum ± postpartum, ± ® -
® © ® ( ®± © ®©
® ® ® ) -
±© ®
© ) ± © ®-
± ±® ) ± ± ± ® -
© © ( ± -
® ± ± ±® ± )

| | | |
± ± ©
[76]:
*
'$ ± © %
)
® ) - 5
( ®
± ±© )
® ( ©
± -
)
+' ±®±® ®
±
® ± © ±) ±© -
® ( ® - ± ( - ® 2+ ©
) )
$ ( ± © ®± ®
® ,
%) © - © -
± ± ±© )
+' ( (
®® ( ®- -
± ) ± ® ®
± -
) ± ± ® - -
± )£ ±© ( ©
±® (© ± ® -
±)
.
) © ±
-
( ® ± $ -
( ( %
)
© ® ® ± ± ®
)
£ - } © )
'£ ( ± 6
® ®± ® ® $-
® ± %) ®
± ± (
± ± ( ± -
® )
®± ± © ©
© 6 (® ®
© ± ± ® ± ® -
( 5} } %
( © ® }%
} }
± © ( ® ®± ®-
® © ) ® ±
®®( ± ( (
±© +
)0 ±*©* ®± ® -
) ® © ( ® ±-
± ®© ®± -
®® -
) ( (± ( ± ± (
©±© ® -
©® ® © ± )
®
± ±-
( ± ® ±-
® ® ( ± -
)
© © ®
±
® 5
' ® ±5 ' $± ® -
% ± - ® ± $± ±
® % ± ® ® ®
± ® ±(
$' ± -) - ± ± ® 6
' ± $ (® (® (
® ( ± % ( ± ±
- ® ®
$ ( ( %( -
± © )
± ± ®± ©-
± ® ± $
® (
Bacteroides), ± ±
® ® $ -
± %
) ® ±
$- ± '% ± ® $
± ± (
® % ® ®-
® ( ® -
± )

| | | | |
e } -
© ®± ± © ®±
© ® ) ± ® ® ®
© ®± © ± -
( ± ®± ©
) ±
± ±® )
® ® -
± ® ( ® ® -
T,
0,U5
®
± ± ® ®±© ±± $ %6
® $ %6
®± ®$ %
)
® ® ® ®
±
)..)
 ± ..
± © ® ®
______________ T
,0,U
___________________________
| | |
w
w®
w
w®
w ±
w ±
w®
± w
w®
®® ® ±
® ( ® )
® ( ®±
± ® ) ± ©( ±
± ± ® ©-
( ® ® )
± ® ®© -
± ± -
© ® )£ ± -
® © ) ±
± © ± ® -
® © )
( ® ® ±
© ® ® © -
® © ( - ®
© © ® ± T
21U5
{ } $ ® ±-
© © © %
( ®± © (® -
® ± ( ±© ± (
± ® )
{ } % -
® ( ± ® ± -
± ®
| | | | |
 ± ± ® ±
®6
/ ® 6
± ± ® 6
®± 6
/ ® 6
/ ± ®6
© ® ± $ %6
± ± ±)
) ± ©
® 5
- ® © ® ± ® ± -
© ± ± $ ©
±® (
- ± %6
®± ® ® ± ± ®
$ (
.- %6
®± ® ± ± ± 6
®± ® ® ±± ® ± $ -
-® ®%
®± )$
postabortum ® ± © %)
© © © ±-
5
± ®6
6
6
® ®
± ® ±-
6
$ ® ± © %6
®± ( ± ( ± ± -
®)
± (© ® ± ± ±-
± ± -
± ( ® ±
± ± )
 ] ] -

©
±® ± ®
± ) ® -
© ±©
® ± ( ®±( ®± ®
® ® © ( ±
± © )
© ®
± ® © ( © -
® ® ®
± ± ) ± ® ±© ±
± ®© ± ( © ± -
® ® ± ® $
| ±
® ® } % ( ( ( ® ®© -
®±© ±
± )
SIRS ( ( ± ® ( ®
( ©( ® ® ®
± ® ±© -
® ® ® © ± © ®-
) ® © ® ®
± ocmvoe } $ % ±
- $ %
)
o } - ® ± -
® ±© ( ® ±© -
( © ±© ± ) ±
±© ± -
-
± ©± ± -
$,44/%®± / 5
,% ±(
2) ® ± © © © (
3) ® ± ± ® ±© 7,3 ©
)) ±
® ± ® © ® ±® -
(/ % 02 : Fi02 7 . ++$ © 02 :
Fi02< 200) [215].
© / ± -
® - $ %
)
® ( ±
244
 ±© $
|®± ±© } %
6 ± ® ± © ® ±-
± © ® ± ) -
± ® 0+!T,0,U
)
® ®± ® ,
412 ©)
( ©
Ashbaugh et al. ± , ± ±
( ( © (
± ±©
© © © )
± ± ®
- - ± -
- ® )£
-
$ %
( )) ( ®
)
® $ ® ( ©±
© % ( ® ® ±© (® ® -
SIRS $ ® %
)
Garber et al. T,1U® ,441© ) ± ± 3 . -
± ® ( ® ) - ± ® ®
± ® ® ± ± 5SIRS- ( -
( ± ® ( ® ( - )
® SIRS.
® ± Ashbaugh et al. ©
± ® (® ® ±-
( ® , 44/ © )
- ® ©± ± $ ±)
34) [217].
® ® ) (
( ®, 44
/© ) ±
©± ± ± ± ±® ± ®-
® ® ± ® )
( © ± ©
± ® ± © ® (
± ( . 2 /*,++ ) ± )
 ± ./
© ______________________
± ± ± ®

Petty, 1971 ± ( ® ) -
Ashbaugh ) ( - ® ±
± ® ®
± )
© ) ®
± -
±© )

© ©
© )
± (
(
© © (
±©
© ± ®

Murray 1988 ® ± ± ± ±
± - / ®
) © -
et al.
® ± ± - )
±© ) ±
± ® ±©- ±© ) ± ® ± ±-
) ± © -
±© © - ± ® © © ±©
-
- © - )
) ±® )

Bernard et 1994 ±) ± - ± -
al. ® - ± ® ® ) ®-
± - ± - ± ± -
© © © ) ± ® - ® ) © -
®± ± - ±) ±©
® - )
® ±© -
± ± -
7,3 ))
± ® ±-
±® )
®
© ®±®
)
02: Fi02 < 200.
 1982 ©
) et ±± 3 ± ® ®
5,% *.3
!*( % ±-
© © *
.+!*
(.% ±© ©(/ % ® -
*/!*
(0% ® ±
± (1
% ± (2 % (3% ± ± ©
[215].
® ±© ® ®-
® ±
).0
5
± .0

|| - ie -
- - |
- | | |
| | - | | |
|
3
® $ © ©± ± ( ( - ±© ©
± ±- ® - ± ® ±( ( -
% $ % ± ( -
±- ® - ®
® - © - ® -
± ( ©
-

©
©±
® 5® -
± -
©
± - ±
© ©®
® -
± - ± (±© ±
- ®
± ± ® -
® ± ±- ® -
© *© -±
± -
© ®
5
-
NO2, CI2, SO2, NH3

-
® :
 [] ] '
- ( ®±(® ®
© ± ± ) ©( ®-
® ±© ± ( (
© ( ® © ® ® ®
(® -
± ±© ±® (
©© ® ± $® ( ±® % -
± ±© ® © ) ± ® ©
© ©© ®
( ® ±© )
± ® ® ©
® ± ( ®± ± ®
±© ± ) © ±® ±
® ® ® ® ® ( -
® ± 6 ©( ±
± ® ±© T/ (2.(,0, U
) ®-
® ±® - ©±® ±-
( ± ±© ( ® ( ® ± (
±±© ( © ± ) (® -
® ± ® ( ®
± ± ±
® ® © ) ® -
± (® ± ® ( ® ± -
(® ® ± ®
( -
©± ® ± - ® ® -
± ) ® ±)
£ ±® ©± ,++
! ± $ )0 %
.
( ® ©
± ( © ± ± © ( ± ® -
± ) ± (
© ± ±® ( ® -
±® ± ±± ) -
®
( )) ® -
® ± $ ©± ( (± %( -
± ®± ® (
± ® - ® ® (® -
® ±© ® ±® ® )
 ± ± ®® ®± ®
±® ± ±
± ® ® ®
±© [24].

©
±©

®
±

) 0) ( ±®
±® | ® ±© } $
1981).

± ® ± ± © ® -
® ± ® ®
± ± ® ±-
(®± ®
(
) ® -
±© ® ±
± ) ± ® ± -
$ ± ® © % ®
[215].
 ± ± ± $ % ®± -
® ± ± ® ®-
© © ® (® ® -
©± (® ± ± ± ± ) SIRS
±® ( ® ® ® ( ®
) ( ®± ±
± ± ) ® ( (
TNF-a, ® ± - ± ® ± ( ® -
® ) - ® ± -
5 S- $ © % R- $ %
)
± ® -
± ) / ± -
± ± 5 - ® ® ( CD-14,
,,- -/( ± MD-2. ±
®± ®
NF&B. ± ® ® IL-1, TNF-a,
® ( - - ± © ( ) ®
( ® H v< ® ± ARDS ± -
± ® ) ® ARDS NF/cB ® ®
±® ± ©® (® ® ® ©(
© ® ± ± ( ± ® ( ± ®)
® © ± ( NFAB
© ± ± ± ± ( -
II [218].
± ® NFAB ± ®
± ® ) ± ®± ±
®( ± ® ®® ± ® ©
ARDS, ®± TNF- ®( ± ( (
± - ± ( T,3U) © -
® ® NFAB ± ±
® ± ± ® ® ±© (
® ±© -
± ® ® ® ± ± ® ) -
® ® (® (© ® ± ® © -
5 ± ®( ± ±(
T+ 1
U.
 ® ® . 5, - ® (
± ® ® ± ±-
± (® ® ± ( ±
±
| } ±© 6 - ± ® ( -
± ± ®( ±
® ± 6. - ( -
± ±© )£ ®
± /
-/3 ®( ± ® - 2 (
- ± 2 )£ ® | -
} ( - | } T, 3( +U
)
® ±© ® ®-
® ±® ± ±± ±
( ± ® ± ( © ® ) -
® ±® ± ± ± (
©( ± ®
±© $ © © ® ® ±®-
± ( %
(
® ©± ® (® ± ±-
® ± ® ) ±© ±©
( ® ( -
± (® ® © ® ± -
® ®( ±© ± ©
© ,
++! ± T/U $ )1
2
%)
® ®©± $ ©± -
© II}% ±© (CJI), ± ± ® ±
±© ( - ( -
±© ± ® ( ® ®± ® ®
) ® rl ®± ® -
) ±©( ±© -
® ® ± - ± ®- © ±®
± ( ®® © ± ©
± ±© ® ±® ± © ® ©± -
® $ % )
® ±© ±
± ± ±© ®( ® ®
 ± ® © ± ±® ± ( -
® ©® ±© - CCJI [2].

® ®
dh

))
,
d' ± !

®
ipkJ _ ©
( 8
J11
, ±
w
$4-V ®© I
dv

±
<
© )
%
) 1) ® ± - ©
$ Schwartz S.I. ®)
(,4
44%
)

) 2) © $ )
%
$ ) % ® ±© ) 5 - ® ±
(H- $ Schwartz S.I. ®)
(,4
44%
)

. 5
* ® CJI, ) ) ® ±
® ± $± % ±
± ® ( ® © ± -
-® 6
* © ( ± ± © ± ± ( -
± (± ± (® ® ® ( -
± ( ± 6 ® ± ©
® ±® ± ® ± ± ( ± -
±® ± ± 6
' ± CCJ1 ®± ®
±® ± -© ( -
± CJ1, ±® ± ©-
) ±© ±
± -© ± ± ± TU )
±© ±® ®± ±® ± ®
®( ® © -
® ® ® ± ) -
± ±® ± ©± ( ®-
5 - ± ± ±-
© ± ® © (® -
®± ® ±® ± ) ± ®±-
® ± © ±© ( ® ® ®
± ± ®± $ ® ±-
® ± ® ±® ± ®± %)
©± ± © ±© ©
) ® - ± -
® © ± ® ® ( ± ® -
© ±© ± -
5 ® ©
®± ) ®± ® -
±( ®
± ± * . ± ©
±© ( ® ± (® (® © -
±© ® © ± ( © ±© -
®± ± ©)
® © ±-
® © ( ® ±® © ( -
 ® ® ® ± ® -
± ( |
® ® } CJ1 ±® ±
(
® ® ± ± TU)
® ® ® ® ±© ©
® ) ± ±-
CJ1 ® © ±-
± ) ® ® ® ®-
± ® ± (
® ± ® ® ± ) -
© ® ® ® ±-
®( ( TU)
±® ® © ®
± ® -
® ± 5 ±± ±® ± )
© ± ® ±© $ ( %
® ) ® © ©±®
® ±® ± (® ® ( ±-
® ± ( ±® ± ® ©± -
® ) ± (
®± ( ®® © ® ± ®
® $® -© © ( -
® ± © ®
± )%
) (
®±( ± ®
) ® ®±
± ±© ( ® ® )
® 3 ( -
±® ± ± ® ± ) (®
® ® -
±® ± 5 © ® ±
± ® ® ® ( ®
®± ©© ) © -
® © ±
© ® ± ± ( © © ± ) -
® ®
± ± ®
±© ® ±®
®® © © © ± ©
)
 © ® ±© -
± © ® ± ®( ±® ±-
® ) ® ± ±© -
±
± ®
± - 12 )) ±
±© ± © ±
-
±± ® ± ® ( ®
®± ® ±® ± ® ( ©
±®
® ® © ± ® )
± ± ® © ±
( ( ± ® ®
-
± ©
±® ® © -
± ± ±© ® © (®
± ® ± [24, 151].
© ®
± ®
± 5
± .1
© © -

® ± ® ® ± ± ® ±

Montgomery 1985 22 ® - 1
3! -
ARDS- ® ® ARDS-
( /2- ARDS- .0! ®
®± ® ± © 6
© ARDS- ,
1! -
±-
±© 6 ±-
® - ®± ®
®® ©
Russel 1990 /
+ ® ARDS- ® $ - ®
± (( - ARDS- -
© ±®©± ± ±
± ® ±
( 6 ± -
® +
3 ®
®
®± ®
® © -
± © -
±®© ±
Suchyta 1992 ,0 ® ARDS- ARDS- /
+! ±-
( © ± ±®
±
( - ± -
© ) MODS,
® ®± -
®± ®
± ± © oi
ARDS-

Clark 1995 ,
,2 ® ARDS- ±
±© (. ®± ®
( ±- ±±© 3 ®
© - 1 - ±® ±
® ® ± -
± ®± ± ±
®
© ®
Donnelly 1996 3 ARDS-
( ±- ± ( - ®® ± ±
© - 4 -± ,( 3
( ,+( ® ®
® ® © -1 ® -
® ± ± ®
± ®± ® -

ARDS-
Headley 1997 .
/ ARDS- ± ® - ±
( ±© ®
± 4 ©± - ARDS- ( ±© (
(TNF, ® ®® ARDS,
® ± ®
- ))
-, /
(1(
3% ±- ± ®± -
ARDS ±® - ±® )
± ±
® ®± ®
® ±
®)

Milberg 1995 4
,3 ® ARDS- ® ± ± - ® -
ARDS- ®
® ® -© ®
±© ® 1+ ±
® ©
±® ±© -
® ®
±© ) -
± ® ,4
4. ©
)
® ± .1!)
Abel 1998 ® ARDS- ,4
4+- ,
,
44. $
, % ±
® ,4
4.- 11! ./!)
41: 1990-1993
,
442 $ % ® ©
78: 1993-1997 ® - APACHE-II PaOi/FiO,
( ±© - © ®± -
± ® ®
±©
±®

Zilberberg 1998 ,
+2 ± ® ± ± - ©
® ±® ( ± ± ©
±© ® -® ( ± ®
±® ( ± ® 1
0( ©
±© ® - ± ( -
( ±© ( ( ( ±-
® ® ®-
±© © - ®

Hudson 1995 1
40 ® - ±
( - ARDS- ±
®± 1!( © -
,4!6
ARDS- ( ® ®
® ( ARDS - 01! ®
ARDS- ,.! ARDS: ® © -
®± ±
ARDS - 1 4! ®
49% ARDS

[
±© - ±
( ± ® -
5,%® ± ± © -
( ©± ± (® 700
)) Fi02 $ ± ® ® %
9+
(06 % ® ® ± ±© (
® ®± © ±© ( ® ®± -
© ® ( | ® ©} ( ® ©
± ± ® )
±-
® ± ± ®®) ± ±
®® ± ± ± -
 ( ±® ±® ® -
© ± ± © T
/.U) ± ®
® © ® ®± -
® ® ) ® -
® ®
± ± ± ) -
® © ® ± ® - ®
® ® ( ± (®
± ± ± ± ± T/. U
) ±-
± ® ® -
® ® © ® 5 ®± ®±
± © ® © (
± ( ± ± ( -
® ® ± ± )
± ± ® ± ± ±
(® ± ® (T/
.U) ® -
® ® © ® ±®±
± ± ± -
± ® - ® ( ®
® ± ± - ® )
± ± ®± ® © -
® ± © ± ±® ® -© -
- ± ( ® ® ® ® ) -
® ±® ±
- ± ± © ( (
± ±© © ®± ® ± ©
® ± ( ® ® -
± ( ® ® ± ± ® ) ©( ©
® ® ®± ± ® ® ©
® © © ® ±® ±
© © ( ® ± ® ® ®
® © ® ± ±-
(® ± © ± ± T/.
U)
( ® ® -
® ®± ± ® © ® ±® ±
T, (
/.(,.3U) ® ® © ® ±® ± (
®- ® ( ® ® ( ±®±-
 ® © ± ® ±® ±
±® © ) -® ( ® -
® © ®
±© ( ® ®± © -
T,
U) - ( ® CJ1
±®±® ±© ® ® ± -
© T,.3
U( ® © ±
® ) - ® ( ® ® © -
® ±® ± ® ®± © ±©
± ( ® -
±© © ® ±® ±-
±± T,(0 U
)
® ( ± ®-
® ±© (® ®® ( ®
©
±® ® ®± ®©) ® ± -
±® ®± ± ® ± -
® ® © ) 2 ± (
® © (
© © © ± T (0 (3(,0,U
)
± ± ®
)) ±© ®)$ ,
431 %T,.
U® ® ®
± ± © ± ®
© ( ®± ± © ±© -
)
$C% ± ( © ±-
© ± ) ±
( © +2 ( ±
© ® ± ) © © -
± ±© © ® ± ±© )
© ©± -
© ® ( ± ® ± (
±® ± ±± ® ± -
® )
CC ±® ( ®±
( ± © ® ±© ( ± ±-
± ( ± )
 $ * ± ®± %
( ±©
-
( 02) ® ® © ±® ±
®
± ± + ! © ® ) -
± ) © ±© ® ®± -
® ® ±© ± ) ®
© ( ± ® ®-
® ± ±© ±® -
± © ® ®)
± C C
C | ® } 5
±® ® ( © ± ©(
® ( ® ± (
® © ± ± ) -
± ± ( © ±-
© ±© ) ® ±
® ) ±© ±
© ± ( ( ± ®± (
© ± ± © )
±© ®± 0
! ± ®± ( -
± ± © ±® ± ( -
± ® ® ®
± ± 1 +! ±-
© ) ® ±
) © ± ±
± ® ©® ) ± ® ± -
)
CO ® ± ) -
( ± ® ± ) -
( © ® ©® )
© ±© ® ®± © © ±©
± ) ± ® ©
)
±© ±
± ± ® ( ® ±® ±
)
)) © ®)$ ,
443% ®± ± © ±-
© ®±© ,+ ® ± -
 ± ® ) ® ® ± (
± © - [15].
± C © ±© -
± ® ® ® ±± ±© )
® ± ®± ( -
± ( ± ± ±
(® ® ) ± ® ® ®
®± ( ® ( ®® -
) ± ( ® ® (
® ( ®± ( ± ® -
- ®± © © ) £ ±
® ® ± ®
± ±-
© ® ® ®( ± ® ® )
±® ± ® ® ±© (
® ±© ± ± ® ( ® -
± © ±© ( ® ±® ± -
± ( ± ® ( © -
± ±© )
© ® ±® ® ® ®-
± ( ± C
C )
®
± ® ( © ± ®
,- / ± ® ) C
C ® ± -
) ± ± ©® ±
® ® ± ©® ( -
® ( ± ±© © ( -
±© ) ©® ®
® $ ± % ±± ® -
©® ( ±® ® -
©± ( ®± ® ± | }
±© ©(© ) -
®± ® ± (® ± ® -
)
± © ® ±® -
® ± ± CC
C ( ®±± ®
±© ) ® ® ± ± (© -
± ® -. ± ® ) CC
C
± ® ®
261
® ±© ( ±®
± ® (
T
,0U
)
© ± ±© -
± ®± ±® ±-
® ( ® )O
± ±© ± -
± © ± ® ) ( (
± ±® ±© ( -
® ® -
® ( ±© ©-
) © ± -
®± ® ± ± ® ( ±® ( -
© ± ® ±© ±-
± ®® ® ® © © -
© ± ®± ± / +!T/(,0,U
)
© ® ± ©
® © ±© ) -
± ± © ± ©
© © ±© ®± -
±® ( ®±(±© ) ± © -
± ±© ® (
o er } { % } -
} % } } }
} } }
*,
%28, 151].
© ®± © ± ( ±(
± © © ± ©-
±© ® $± ± ±-
© %)
±). 2 ® ® ± © ±-
© © © ±©
 ± .2
± ±© ± © T
,0,
U

- [ |
| | -

© ±© - ±
±
® ± ±
±
® ® ±
® ±©
- ®
±©
®
± ± - ±
± - ®±
® ® ±© © ®±
±± $ %
® - >0,7 <0,5
$
*± %
± ( ® ( ± - -
© ( ® -
± © ( -

||3 ® ® Kerley $ ,4..% T

// U ±® ® ± © ±-
© .-0 © ± ± ® - © ± ©±
® ± ± ±© ) ± © ± ±
®± +(0 . ,-2 £ ± ±© -
±±± , ® ®± -± ) ±-
-± ±© ® ® ± ( ®(
± , ± ±® ±)Kerley -
±©±( © ± ± ®
± ® ±©
© ® ®± ®®
± ±© © ® ) ± ± ± -
± ±© ® ® ®® © ®® ±
( © ) ® © ± ±-
± ® ± ( ±®) ±© ± ® ®-
± ® ( © ±© ± ± -
® ® ± ± ® ± -
® ± ± ±® ± )
 ± ± - ±
± ® ±© )
© ± ±-
® ® ± (± % -
® ±© ( ±® ± ® ) ± (®
® © ±© ® © -
© ±© ®± )
± ( ® ©-
© ® ( ( ®±(
® ® ± ©-
± )
± ® ®
± © ±©-
® ,
+-,/ ) ©
± ® ®
± 2
0! ®
( (
± © ± ±)
0
! ± ± -
± ± T,
0U)

]] ]
±® ± ± © ®
± 5
1) ) ® ± ± -
$ ( ® %
) © ± -
® ® ® -
± )
2) ® ( ± ± ± $ ±
© %
)
3) ± ± ® )
4) ® )
±
± 5
,
% ± ® ± ±© (
± © ± ± ® ±-
±© $ % ± (± ® ±
 ® ® © ± ± ± -
© )
2) ± ® ® ® ±© -
® ( ®© 6 ©
® ® ± )
3) ( ® ® ± ®-
( ± © ( ®± -
©± ©± © (
®(± ± ± )
4) ® ® ± ± -
® ±© ( ® ( ±
© ± ±
±±-
T/U ) ±
r CBJ1. ± -
© $ ® ©% ± ± © ®± $ % ±-
± © ®± ® ® $ %( -
± ± ) ± -
®±® ± ®± + 2
± ® ® ® (Fi02) +
)0 )
-+1® -
® ,++! ± ( ® ±
® ® ± © ® ) ® -
® © -
® ® ® (
® ® ®
®® © T/ U) ±
® ± ( -
® ® ± (® ± -
( ®±(® ) ± ±-
± ®
±± ± $ %
) ®
± ® ® © ( ± ± -
± $1 ± *© % © ( -
® 2)0
-2).
+) ® ®± ® ±
) Fi02 ± ® , )
+( -
± ± ®
+2)
t1+ )) (© Fi02= , )
+ -
 ® © ( ± ® ® ® -
± ® ± T/(
,0,
U)
® ±© (
( ± ± ( -
® ® ± © ± ( ©
® ± ± © ®-
± ©± ± ) ® ®
± ® © ®
± ±
© ) ®
± ® $± %
)
( ± ± -
( ® ® ( © ©
) ± ® -
® © ® ® )
±© ± ) ± ©(®
± ® ± ) © -
® - © ± © © ± )
± ® ® ® -
® ± )
± ( ®® $ % -
± T3
(,0
,U)

± ±©
® ( ®± -
± ±© ( ±® ± ®
© ® ® ± 5,
% ± -
® ±© $ (® ®
± ( ± ±
® ® ± ® ®6
% ± ® ® ±© ® ®
±© ±© ® $ (
® ± ( ± ±© ®%) ±-
® ± ®± ± -
± ( ± ±
± ( -
® ( ± -
® ( ( )
± ®( -
| |
| ® ± ±
® - ± ® )
± ( ±® ±©
®± ® -
® ± ± ® ±© ± ± -
) ® ® (®
® ± ® -
® ® ® )
®
± ± ( ± ® © ®(® -
± ® ± © © ©
± -
© ) ± © -
© ± ® ®® ± -
) ® ® ± ( ±
®® ± ± ( ± ±± © -
® ® ) ©( ®± ® ® -
± ®( ® ± ® (® (® -
® ±© ) -® ± ±
±© ® ® -
©
± ® ±© ) -
± ( ® ± ® ®-
( ) ± -
± ® ® ® © ± (
( -® ( ± - ® ©
® ® T/( 3 (,0 ,U
) ±
± ® ±
© ± ®
( ±© ( ± ±
$ ( ( © )
%T/ U
)
± ®© ®
±© ( ® ® ± © -
® ®
± ± ©±
- ± ±®© ± ) ± ©± ±
-
± ® 0+-,++ © *© ® ®
± © ± ®(
( ± ±© ® ( ® (
) ± ± )
 ± ® ± ± ®
® ± ) ± ± -
® ± - ± ®
± ® ± Exosurf (GSK)
® ± ± ± ± ©
© T,U) © ± ® ± -
± ®
® © © © Survanta
(Abbott Laborat.) ® © Curosurf (Dey Laborat.).
® ± ± © ±
± ® ® T ( . U) © (Exo-
surf ± ® ® -
® ( ± ® ± (
±® ± © ) ®® -
± ± ( ® -
® © ® ±
47! .0!( ± ® ® ± ± ® -
±© ®® ® ® © )
( ± ®( ± -
® ® CC ( © ©-
± ± ± ®± ) ® ( -
( ®± ® ® ± ® -
± ± ( ® ( -
( ® ) ( ±-
± ± $© - % ±-
± $ % ® ® ± -
( ± ® ®)
® ® ® ±® ± $ ±© % ( ±-
± ( ©
±®© ± ©± ± (®
® ± ® © -
± T/ U)
H+ $ ©± % ± ± © ±
® ± ® ± © ® ± (
± ± ±T/(3 (
151].
)) ® $+++% ( ® ® © -
± ) ® - ± ® -
 © © CJ1 ® ±® -© )
± ± (
± ±
® ( (© ® ± ®® -
® ® ± -
© ® ±© - ® © ® ® ±© -
© ® ®(®± ® © -
® ± ±© © ± ) -
± ® © ©
CJT ® ± ® ± ® © CJ1 [43].
® ± ( © ± © ©± ±
$
,44
/%(± T,0(,2U
5
1. ® ® +2( ±
2.
2. ® O2(
F £2( © Fi02 > 0.65.
3. © ® ±® ± ®
) ± ® ®
± (
® © )£ © -
® )
4. ± © |± ®
±
® }(IPP) < 30-/
+ 20.
5. ± ± ® ± ®-
± ® ® © ± ± )
6. ± ® ® * ±© )
± ® ± ® ±
)

| | |
®± -
± © ± - ± © ® ® ±©
( © ®± ± (± -
® ±© (® ®® ( ® ± -
© )
± ± ® ± ±
®(®± ®
) ± -
 ± ® ± ±) ( -
± ± $
® ® % ( ± -
® $© ±© ©±-
( ± © © ±© -
± 6©
±
%
( ± ® ® ± )
® ® ® ( -
® ±© ±
± ® )
± ® © ±©
± ®
± ± ± )
® ±© ±± ® ± ®-
®
± ±± © © © ®± -
± ® ® ® ) ®
± ±© ± -
®
± $® ± ± ® ±©
±± ®
% ± ® © ® (
± ±®© ± (
$± ± - ®± % ± ® ® -
± )
© © ® ± -
± © © ±© ( ±
® $ % -
® ® ± ® ® ± ®
$®± ® %
)£ ® © ©
±© ) ® ±©
± )£
® ± ( ±
( ( ( -
( ± ± ± ® -
± ) © ±® ( - ® ± ±©
( ® ® ®( ©
® ± ( T/(,
0,U) ® ®® -
® ± ©
±© ± ) -
® - ®± ±© © ® ®
® ± ±© ) ®
± ±© ©
 ® ± ± ± ® - -
© ® $± ®© ± %) ±
±© © ( ± © ®( -
® ± © ) ± ( -
®
± ±© ( (
® ® ® ± }
( ®
-
T
,0,
U)
± ® © ® © ® -
± ® ±© ± ®
©
± ® ±± ±® ± (
( ® ® (
©
± ( ) © ©-
© ® ( ® © ® -
© ® ® ( ± ® ©© ® -
® ® ±© ( ® ±
± )
© ± ©
± -
© ®$ ± )
%( ®-
± ( ± ® ± ( ® ®-
® ® ®
C
C ( ® ± ± ) (
± ( ® ©
± ® -
® ±© ® (
± ± )
® ± ® ©± r
$ ( ®± ® ± ( ± -
±© ® ) ±© © © ®
-
± ± ( ® -
© ( ©± ( -
© ® ± ± ) r® +)
+0 © *©- -
® ±© ®
± ±-
±© ® ±
) ± ± ® ® ± ®(
© ±© ®
®± ® (
,, , ® ® ± -
 ) +© ± ® ± (
± © © ± ® )
® © ®± ®± ±-
® ®± ©
±® ® -
± © © ( ©
® ) ©( ( -
( ® ±© -
® ®( © © ± ( ® © ®± )
± ® ± (± ® © ®± ®±
± ( ® ) -
® ® ® ® -
© ®
± ± ® ® -
± ) ± ®
± )

| |
- ©±® ± ® ®
©
±® ® ® © ) ®
± ± ±© - -
® ± ) ± -
± VO2 ± ® -
± D02. ® ± ® -
± ± © + 2( ®
© ® ( ± ® V02. © -
2 2
D02 8 0+ ± *$ - % V02 8 , ,+ ± *$ - ), - ±-
± ±
® ± ®± ± ) ±
D02 V02 ± ® ± ) ± -
± ± ± -
© ± © ± ® ® ®
[24, 151].
® © - ©± -
± - ® ® ®
) ± ® ±
© ± - ®± ® © ® ±©-
( ®® ( ® ±
 ( ± ± ( ± ©
±© ® ± © ® ) -
® © $® %
( © -
) ± ±
( ± ® ® ®-
© ® © © ± ) ( -
( ± © ± ®± ® ±
( ©®© ® ) ©
®© ± ®
± ( ®± © ± ®
± )£ (
± ± ® ±
® ® )
± -
© © ± ± © -
® ± ©
® © ± ± © ®
± ® -
± ± ± ® ®
,
5(, 5
,(5 , ® ± ± © ®±-
,)/
2 $,
0+ ® )) %T/.
U)
±
© 6 ® ®± -
®
± ®(® ±
± ©
± ±© © ± ® ®
© ) -
® - ® © © -
± ® ® ± ±© )
® © ®± ® -
© ( ± ( ± ± ® ± -
® © ( ± ± -
® © ±® )
® ( ® ± ® ©
® $ % ( © © ± $ %
± ® ± (Sa02). ®
® ( © ®
® ® ®® 6 © 0-15
©
*©* ) © ®® ®
273
 ® - ± ,
+ © *©
* ( ® ±
® ® ±© ® ® ) ±-
© ® ± ®( -
± © ± © ®± ® -
±© © $ ± ®± %T/(3 (,
0 ,
U)
d ® ± -
© ©± ® ,++©*±
( ® ® -
±® ® ± © )
® ®® ® ® ® -
®± ® ® ±© ( ±® ±
® ® ±® ® ®
) ± ©(
± (®® (® ± -
® ® ® (
)
n % Sa02,
®±( ® ® 4+!) ± ± © -
© ® ± ± -
® © ® ® ®
(Fi02) ± ® $ ® 1+
!%) ± -
( Sa02, +
2 ± © ±
®) Sa02, ® 4
+!( ± -
® ± ) ±
Fi02 ® 1+!( ± -
® ± T/(3(,
0,U)
 ]

| || |
2+- © ) ®± ± ®
® ® ® ® ± -
(® ± ® ± ±© )
© ± ®± ® © ±
±© ) 3 +-4+ © ® ± ± ®
® © ® (® ± ®
± © ( ® ± -
± ® ® © ±
®
)
® ± ® ± -
® ±© ( ± ± ®, *
. ±-
® © ± -
±)£ ® ± ©
± ® ± -
) ®±
± ± ® ± ( ± -
®
± © ®
) ® ( ®
± ± ©® ( ® ± © ±
® ®±
± ( ± ± ® ± -
)
® ( ® ( ( -
®® ®± 3+! ± )
( ± ® ®± -
± ± (® ± ± ±-
± ) ±
® 0-,2! © ± ® ( ® ± -
® (© ± ® ® -
± © ( ® )
) ± $,44
3%(® ± © -
® ± ®© - ± ®®
 (
0 ±) ± ( ® ± ± -
® ® ®± ± ± (
© .+ +
-/!) , 44 © ®
® ± ®± /
(0± ) ± ± ® )
4 +
! ± ® ± ®
±-
(® , +!- © (® ) ® ± ( -
( ± ± ± ± -
± ® ® ± ±
® ± ® © © ® ± ± -
±© ©® )
± ® ® © ®
® ( /0
! ± ( ® ( -
® ) ±® ® (® ® -
± ± ) 1
+! ® ± ±± -
± ) 10! ©
± - © $
/1!%( $3 !%( ± -
$1 !%( * ± $,!% )
© ® )

| |
® ± -
± ±-
® $ %T 3U) - © -
± ± ®
± ,
0 3
-,!( ®
© .++ )± ® ®© ) ® ®-
± ± ) ± ± ± -
© ®® ± ±
± ± , /!( ® ± ®± +
-0+
!®
® ® © ±® ( ® ± ®-
± ) ®..-2+! ± ®± ±
® ® ) ± -
® ® ( ® ± ® © ± ±® (
®®± ± ® -
± ± © ® ) ± ©( ± -
± ± © ± © ± ® ( -
± ® ( ®®
/
3 ± ± © ± ) ± $-
( ± © ©% ®
©® © [8].
± ® ± -
® $ % © © ±) ± -
± ®® ® ®0 -10
( ® © ± ) -
± ® ®± 0! -
® ® ± ± ® ± ® -
± ) ± ® -
± ± ® © ®© ± ®-
EPIC (European Prevalence of Infection in Intensive Care,
4)+
/)4), 2 ® (, /,2 (4 010 ®%5/ 1
(4!
® ± ®± ® )
® ® ± © ± ®
® +(
0-+(2!(® ± ®± ( -
( ,0 /+!) ±
© ®® ®0 2-1.
! ± ®T 3
U)
® ± ® -
®( ® ( ±© © ±
( ± ©( ± © )
± ® (® ®-
(® © ± ± ±
[ $ % )
± ® ± ® ® ± ®
® ± ( © ® ± ± / 3 ( ©
2 ) ® (
± ± ® ® ( ®®
® ± (® ® (® ,-
± ® ± © (
® ® )
± © ® ± ® -
| | | -
| ' ± ± -
± © ® ±© © 5
,
%® $
® (® ( %
6% ® -
( ± ± ©$ -
277
 ± ( ± -
± © ®( (
± ©%6 . % © 6 /
% ±6
0
% ± © ± ©)
® / ® ©-
( 0 - ( ± (- © )
£ © ® ±© © ®
± ® ® 5 ± ,*
0® © -
(/ *
0- © )
® ® ±© ® ± 5
,
% ©
± ± 6 % ©± -
® ± ± © ® 6. % ® ±-
± 6/ % © ® -
60 %© © ® ± ®-
©® 61 % ± ± - ©
$ % 62% ® ±® ± ± )
® ®± ( ®
± ± © ®
± ± ® ± -
± © ± © -
± © 5® ® ® ( © ±-
± ( ®± ±
® ± 2- ±
® ± ± )
® ® ±
® © ©± ® ± )
®$ ( %
®± ± ± ® )
( /0-2+! ®
± ® ) ® ® ©
©± ® ( ®-
)
± ®( ® -
© ©± 5, % 6 % -
± 6.% © ± © © 6
/
% ©
± 60 % ± ± © ±®©
± $® ± ® - ±® ( -
 %
61 % © ± 62% ± -
± 63
% ± ± © -
©69) ± )
± ± ® © © ± -
±® - © ( ®
± ®±-
) ®± -
© © ( ®( © ( -
± © ±© ®®
± -
®) ± ® ±
) ( ±
® 20
! ± ±-
( 0+ ! ® ) ± -
±© ± ± ® ± (
± ( ( ® © ±(
±© © ® ± -
)
± ® ®®
®± ± ® )
®/-0 ® ( ®
(
® ©® ) ± ± ®
(Torres A. et al., ,44% ( ® ® ® ±®
© ± © ©
® 0+-4 +! ± ) ® ®
± ± ± )
® ®± ± -
® 5
± ± $ ®
(
©- ± ®( ®© © )) %
( ® -
± ± -
®® ± 6
®® ® ® -
® ±© 5 -
± ± ( ®
±® ± ©® ( -
 ( ® ± ± ±
± © ± 6
® ± ± -
±®© ± ( ©± - -
©± ± © ± )
® ® ± 5
u cap
® 1+± 6
® ±® ±© ( 6
© 6
± ± ± 6
( 6
® ®
6
® 2 ± ® *± ®
6
± ± ® ® 6
6
6
6
© ± ± ©±® ± ©6
u { % -

® 1+± 6
® ±±APACHE II;
® ©±® 6
6
6
© ± 6
± 6
© © ± © ® © -
± ± 6
® ± 6
±® 6
® 2 ± ®T /
U)
' ± ± ® 90% ® ± ®
®
± $ ± ) . 3
%)
280
 ± .3
±i ± ® ®®
$ ± )) ®)
(,444% [8]
| EPIC, 1992 [86] J. A. Ramirez, 1994 R.J. Estes,
[72] G.U. Meduri, 1995 [41]
Ps.aeruginosa 29,8 24,8 9,0
Enterobacter spp. 7,9 11,8
Klebsiella spp. 8,0 7,0 14,0
E.coli 6,8 7,2 14,0
Serratia spp. 4,0
Proteus spp. 11,0
Citrobacter spp.
Acinetobacter spp. 9,9
H. influenzae 17,0
St.aureus 31,7 26,6 26,0
Streptococci spp. 4,4 31,0
a { 35,0
d { 14,0
® ® ® ± ®-
± ) ®± ® ±
® ± ± ® ± ® )
® ± ® ® ® ± ±
© ± ± Streptococcus pneumoniae, ±
- ± ( ± ( ± ( ± ±±) ±-
± ±© ) ® * . ± ®® -
± ®
± © ± )
± ± © Ps. aeruginosa, Aciueto-
bacter spp., © ® $ Flavobacterium
spp., Aeromonas spp., Stenotrophomonas maltophilia), Enterobacter
spp., MRSA.
± ® )) ± ®)$ ,444%T 3U( ±(
® ® ® Ps. aeruginosa et spp.
(41%), Citrobacter freundii (12%), S. aureus (11%), Proteus spp.
(11%), Enterobacter spp. (9%), Klebsiella spp., Staphylococci spp.
(7%), E. coli $/!% )± ±© ® -
± ® ® ® ±
[ [np" % ®
 (® ) ± ® ( ) ) ®® -
® ® / © ± ( ±©
S. pneumoniae, Moraxella catarrhalis, Haemophilus influ-
enzae. ® © ® ®
aeruginosa, S. aureus, Klebsiella spp., Acinetobacter spp. ®-
/-0 ® ® Pneumococcus, n influenzae,
Moraxella catarrhalis, S. aureus. ±
® ± - ®
Ps. aeruginosa, Enterobacter spp., Acinetobacter spp., Serratia
marcescens, Kl. pneumoniae, E. coli, ±® ±©
St.aureus [8].
± ® ® ® (® ® ( - ±-
± 6 ® ®
® ± ®± H.influenzae, ® -
- ± ) ± (
± ( ® ±© ±
Ps. aeruginosa, Acinetobacter spp., Enterobacter spp. ®-
®± ± (
® © ± )
± ± ® ® 20
-4+! (
± ® ® ± ± )
± ®± 0 1
-87% [225].
± ± ® ® ® ± ±®
® ® ® ± $ ® -
% ± ®±® ± ®® ±-
©( ® ± ± ± ©® ® ® ±
±© ) © $£% ®±
± ± ( ® ±-
± © ±© ©) ® ®± -
£ ® ± ( ( ( ± -
© ± ±( © © ®-
( $ 0 -4% ® ® -
® (® £) ± ( -
±( ± ® ®± ® ± -
® ® © ( ® ® ± © ±© -
± ® © ± )
 ®® © © -
± ® ® Ps. aeruginosa. ® ( ® ®
Ps. aeruginosa, ®® ®( ®-
( ± ± ± (
± ®2 +
! ± ® ®-
± ± )
£ ±© ± Enterobacteriaceae
® ® ± ± ( ± ® -
± ) ® -
© ±® ( ±© ® (® -
± © ) , 0-/+! ± ®
± ± ® ±
) ( - ® ®-
± ± ( ± ®
±© © ®± ® -
® ) ± ± ® ±-
® ± ( ® ± -
® T3U)
± ® ( ® ® ± ±± (
±( ® ±± ® -
( ± ®© ( ± ® ( ±
| ® } ( ± ®± ® ® ± ®-
±© ® ® ( ® ( ±)
® ® ( -
± ± ) ® © ® ±-
± © ® ±© £ © ± ®-
± )
± ± ® ®, /! ± ®
® ± © Candida. ® ± ®
© © ® ± ® (
(® ® ( ± -
± ® ® ) ® -
®® ( )
± ©± ± ( ± ® ® ®
(® ± ® ± -© ( -
© ± ®( ± ± ®
® © ®
)£ ®±
283
 ® ( © ®
± © -
$ ( ± ± ±
® ± %
)
© ®- ® ± ®
® © ± ® -
)£ ®
± ± ® -
® © ®(® ± ®
± ± ( ± ® ( ® -
© ± ®)
| ®
± -
± ® ± ±
± ) ± -
$
± (© (± ± -
®© ( ®
± ® ±
± ® © © %® ± ®
±®-
® © ± ® ® ) -
± © ® ®-
± ®® ® )
± ® ( ± ®
± ® ®± ® © ±® © -
± ( ®± SIRS © ± (
® ( © ® ® ±© ((
( ± © T
3U)
© ±© ± ® © ± -
® © ±-
® ±© ) ® ( ± ±©-
®± © ±© ± ®± -
± ® ® ® .+-0+!)
®® ± © © ± ® ±-
± ± ® ±© ( -
)
± ± ® ® ©
® ±± ( ±© ©
± )
)) ± ®)$
,444%T
3U( ® -
 ± ±
± ± ± $ ±
).4
%)
± .4
® © ® ± CPIS
____________ $ ± )) ®)
(,4
44%T
3U___________ ] ____
* | | |

s %r 36,5-38,4 0
38,5-39,0 1
7.1(
+ ± 9.4(
+ 2
%
)((
() 4-1J 0
11-17 1
> 17 2
b +/- 0
+ 1
++ 2
% Pv02/FiC>7 >300 0
300-226 1
225-151 2
<150 3
i } } }- ® 0
" 1
© (±®
- 2

| |3 © ® - 1 ±±® ±
± ® ®±©
S.Violan ®)$
,44
3%( ± ®± " -
} } c ATI:
,% ± 9.3
(0u 6%© 6
3
3) ± $
9, ®, % ± ± $7/
+++®, 3);
4) ® ( © ± $9/ % -
± © © © ± )
± © © 5,% ±® ©
± -± ± ® ®
±® ± ( 6
% ® ± ® ® ± ±® ± -
6.
% ® ±© © ± 6/
%±
± ® ± ® ® ® -
± © ® )
®±
®.+
!( ®. 1! ± ® ± ® ®
© ® ) ± ± ®
© © © ± ® -
© ( ± ®
± ± ® © -
±© ) ± -
-{ } -
} np 2 ®
± © ® ±
± ± ( ± ±
® ±®(
® ± ® ± ± -
±© © ± ® )
± © ±© ©
± ±© )
± ( ®® ± -
±© © 0+
-1+!6 ±© -
®± ± © ®
-
6 ®± ±©
± 6 ©
4
± ± ,+ *± ® ± ± ±© -
± ± ® ® T
3U)
± ® ± ®
± ±© ± ® -
± ®( ® ± -
- ±® )£ ± -
± ® $ ± , + +
!% ® ® ± (
( ® ± ±
® ± ± ) ±
± ® ® ± -
± ± ® ©-
6
®$9,+ *± %( ® ®-
± )± ® ® ± ® -
 ® ± ± ±-
± © ±© © ± ® -
, $ )£ © ± ±
± ± % ®
± ± -
© ®) ± 0 ± ±
± ®1 ± ± ®± $ % ® (
® ©± ©
± ±© © ± ® ) ®( ®
® © ±® ± © © ®
® ± ® ±
( ®± ± ® ± ± ± ± ©
± ® ) £± ® ®± ( ® -
± ± ( ® ± ±© -
( ® ± ® -
® ) ® ± © ±
±® $ ± 0® ± ± ®± %
® ±© © -
® ±© ( ®± ® ®
© T3U
)
± ® ® ( ±
±© ± ® ( ± -
± ± ( ®±
® ± -
± ( © ± ® -
± ( ± ® ± -
± ± ® © -
± )
® © ® ± ( ± ® -
±© ® ±
± ) -
( ±( ± -
® ± ±
± $ ( %
( ©
± ±© © ® ® -
w
7 iero ± ± ©
± ® ± ) ±
 ± ± ± ® ±©
± ® ± © |-
} ) -
± ) ± ® -
±© ± ®± ®
3
± - ± ,
+ *±
± ± ® © )
± ® ®± -
4
±® ± ±® $ %) ± , + *±
± ® ± © -
®) ®± 4!( ®® ± -
42
!) ± ± © ©
) ®± ® ± © ± -
± ± ®( ®
® © ± ± ® ) ±-
( ± ± -
±© © ± ®5 ©
± ± ± $ .+-/+!%(
± ± ± ± T3U)
± ± ± ± ® ®-
± ± ±©
®( ± ± (
± © ® ®
± ( ® ® ± -
( ± ( ® ©
?
± ©® $ ,+
±%± ± ±)
± ± ± © ±
0+
! ± ® ±®
±© $ ± ® ® %( ±
± ® ©® ® )
® ® © -
± ® ( © ©
( ) ± ® ® ±
® ( ©( -
® ® © ) ®
 ® ® ± ± ® -
± ± ±
± $)) % ±-
) -
© ®
± © ±
± ±® ± ®± 5
®® ± 1+
-100%;
± ® ± ® $»,/%
+± ±© © ® 6
3
± ± ® ± ± © $
,+ -105
*± ±% 6
- ± 2 ! ± ( ©
$ ® - ®® ± 31!( -
4+!% 6
4
± , + *± - ® $
2
+!% )
® ( ®® ± -
( ® -
( ® ,++! 3)!(
1
/)2! 4.
) 0! ® ® ) ( ± ®
± -
® ( ( -
® ( ± ± © ±
: ® ± ( ® ±
® ±© ) © -
± ® ± ± ±-
© © ± ®
) ± ® ® ® ® ( (
® ® ® ©
(± ± ® ® ® T
3U)
| || | -
| ' ® ± -
± 5
± © ® ®±
± © )
 © ® ®-
± ± ± ® ®-
± ± © ®® ± -
± ® )£
± ± © ® -
± ±® ®$ -
± %
)
® © © ±( ®±(
®® ®
)
® ± ®
2 ®± ± ®
± ,
,!( ® -
1
+!) ± ( ® -
®± ® ( ® ®
± ± © ± T
3U)
±© © © ± ±
T
3,5
® ± ± ®
® .-/ 6
APACHE C C ± + ± ±® ® / -2 (SAPS ±
18);
± © (MODS
J.C. Marshall) ± , 3 ± ±®® /-2 ) 6
© /Fi © ,0+® /-1 6
© © 6
Pseudomonas aeruginosa ± Acinetobacter;
6
± ® ± )
©± American Thoracic Society (1995),

® ± 5 3
%
} { 3 -
np ± ± ® ±
.© ± 5
[ *
3% ± © ® 6
 % ® ( ®® ®± -
® ® 6
®
% ± ® ® (
5% ± ( 6
% ® ( ®® ®± -
® ® )
[ ,3% ± ® ± ±
® ± ® ± )
® © ± ± -
® ± 5, % ® -
± ± ±© ® 6
% ® ± -
( ® ® ± ±-
6.% ( ±
- ±© © ©)
® ±
® ©
± ± -
± $ ± ± ±® ± %®
± ) ® M4SA $ (
( ± ® ± . ( ( ®-
( - ©® ® % ®± ® ) -
± ± ® ± ® © ± -
( ®± ±
) ® ®
- ± ) ± ± © ®-
® ±$ %
±® ®)
© ® ®
® ± ) ®-
± ® ± ® -
-± ®
( ± ® ®) -
©± ® ±
± ± ® ± ® ± -

®$ ©
± ® ®
± ® ± ( ±® ® -
® ± ( -
 ® ® © ± %
) ± ©
± ® -
© ± ® ± ®-
® © ®® ) ±
±© ® ® ® ( ®
® 6± ® ® ®
( ± )
±© ± (
® ® ±© ± -
© ®( ± ± -
) ± ± (® ®
Acinetobacter spp., ( ©± (
± 6 Flavobacterium spp. - ® ( Aeromonas
spp. - ± ( Stenotrophomonas maltophilia - -
$ ±%) ± © ®± ®
± ® Acinetobacter spp.
© ® -
®± ± ®
±® ± ± ® ± -
33 .0!)£ ® ± ® -
± ± ® ± 5
® ® ® $3 2
!% -
$23-3+!% 6 ® (
® ® Ps. aeruginosa, ® © ®
$1+! ®, +!% 6 ± -
± ® 1+!)
± ® ® ® ® (® -
± ± ± $ )3 )%)
+ +,© ± ± (
±® ± 5
1. ® ± ® -
® ± ®
® ± $ ®± ® ® © -
®% ® ® ±® -
± ± )
2. ® ( ® ± ®
± © ® ± ® ®
© )
 ®±
®

1}

© - ±
S. pneumoniae
)influenzae S. aureus (MRSA)
Polymicrobial oropharynx Candida spp.
S. aureus (MSSA)

1}

(CMV, EBV) Pseudomonas spp. (ESBL)

P. carinii S. aureus (MRSA)
(Aspergillus) © ±
Polymicrobial oropharynx Acinetobacter spp.
± - Candida spp.

)3
)± ± ® )
MSSA - ±± - ® ® ± S. aureus; MRSA - -
±
± - aureus; CMV - ©±® 6EBV - ®
£ - 6ESBL - -± © ®

.
) © ®
± ®± 5
- ± ® $
® ( ( -
%
6
- ± ® $ ® -
(± ± © ± ( %
4. ®® ±© ® -
± ® ±© -
® ® ± ) ± ©
© ± MRSA, Pseudomonas Acinetobac-
tor.
5. (® ® Pseudomonas( ® -
® ± )
6. ®± ® ±
± ± )
± ± ® ± -
® ©
® (® ± ® ±
© © © ® ( © ®
) ± ± ®
$ ± % ± ± ±© ©
± ® )
± ± ©
Pseudomonas, S. aureus, Acinetobacter, ±
® ± ± ® -
®± ) ± ±-
± ±© © ± ® ( ± -
®
± ± ©
± ® ( ±
± )
® (® ® S. aureus, )) ± ®
±© ©) © ® ® ±
® * ± ±± *
) ± ® / +! ® © -
± ± ) Paterson $+ +
,% ±© ±
± ® $ ± )
/+ %)
± © ® -
© ± ( ± ±©
$ ( ± ))%)
 ± /+
± ® (Paterson, 2001)

| | | |
|
Enterobacter, ( ± ± III
Citrobacter, Serratia, ±
Morganella.
E coli, Klebsiella, ± III
± ( -
-±
©
Acinetobacter spp. ( ± - ® ±
) ® ®
±
Pseudomonas - ® ±
aeruginosa ± ' ©
± ® ®
±
Stenotrophomonas Trimethoprim / sulfomethoxazol ©
± (
maltophila (
± )
± ± (® ® Pseudomonas,
±( ® ® ± -
© ± $
MultiDrugResistant Ps. aeruginosa) ®± -
± ® $± ± %)
± ® ® ±® ± ®® ±
© ± ® ±) ® ® ± Mul-
tiDrugResistant Ps. aeruginosa ±
( ± ± ± -
±© © ± ® )
® ± ® ±-
© © ± ) ± ± ± ± ±-
± ® ® ® (®
± ® ® J-
0 © © ©
± ± ® Ps. aeruginosa.
± ± ®( ±
 ± ( ± ® ®
® ± )
± © ± .
© T
3U5
®± ± © © ® (
± ® ©
± ± 6
®± ® ( ®± -
® - ±© © 6
® ® ± -
± ± ± ® -
® )
r re " -
} % ± )) Soutenbeek ®©)
$
,43/%T ,23U
( ® ® ±
©± (® ±® ±
) ®± ® ± )
± ® ® ± ( ± ® -
± ± ± ® -
( ©± ® ± ® ±-
± ± ± -
± © )£ ® (® ( © © ±-
© ®( -
± ± ©
± ( -
® ( ±±±
) ®
± 5 ®± ±-
® ®± -
± ® ± ©
± ± ) ± ® ©
® ± ± ± ± -
® T0 U)
( ® ±
± ® ®± 5
® ± ®6
± ® ± ± 6
 ® ±
© (
4 ± ®
6
4 © ± ® ± 6
4 ©
± 6
4 ©± ± © 6
/© ± © $ -
®® %
6
4 ® ± ©( ® ( ® -
6
± ± ® - ®
± ± ± ® ±© ±-
± ( $ ®®± .
+ + © -
-/
± ® © ® % ® ® © .-5-
® © ( ± ® -
± ® ® ±
± ) -
® ®± © -
© ®
© ® © ©)
± ± ( -
± © 5 +2 0
+ ( -
© ± © ( ©
±© ( ® © ± ±-
± ® ± ®± -
± ® - © (
± (© ± $ ® ± ±©-
( ± - ® %)
± ± ( ± ®
± ) ± ® ± ±-
© ±© ± ® -
-©© © ® ± ( ©© ±
® ® ( ± ± ®
® ® ±© © © ®
± )
 ]]-
]
® ® - ® -
$ % © ± ) ± ±® ±-
® ® $ © ®( -
© ©( ± % ( ®
® ® ( ®
® ± ® ® ± ®( ± © ( -
± © ( ® © ± ( ± )
15- 0
! ± ® ® ®
)
© ®® ® 0 ±) ± -
± , /0 ±) ®
± ± ®. ! ± ®
-0 ± ® ®
+(
0! ) ,
+! ± (© ± ®
± 2 ®® © ( ®® ±-
( ± ® ± ®± ® )
± ® ® ± )
/ ,)
± ± ± (®±
( ® ± (® ®± ©±® -
© - ± ± © )
± ®/ +- © ±© ± ± -
± (® ® © - ± ± ± (
® ®± © - ± ( ±± 3
+-
© ® ) ± ,0- +± ®-
| ±© } ± ® ® -
± ) (© - ± ±
® ® ® © ± ) -
( ± ± $ 2+!% ± © ±® -
(® ±
± © ± ®) ± -
® ± ® ± ® ( ® -
© ± © ( ±± -
± ± ± (® -
- )
 ± /,
± - ® T/
U

____________________________________________________
C
) ® ± ® ( ±
± ( ® ©( ± ± ± ± -
±© ± ® )
t )£ ( ± ( $
± . ®
%
® ± -© © ±-
6 ± ± ( ± ± ±-
© ± ® $ - ± © -
®%)______________________________________________________________
___________________________________________________
1. ® © ± ± ©( © ±
±© ® ® ± ©© -
) ± ± ® ± ® ±-
© ± ® © ® © ± -
)
2. ± ® ±© ± ® ® ® ± ,+-
® ® -
® © ± )
3. ® © ± ® ® ±
© © © ( ® ® ± -
( © © ±) ________________
______________________________________________
1. ® ± ® © ±t ® ® ± © ©
© ± © ) ± ±©-
® ® ± ©© (
® ± © ± )
2. ® © ± ( ® ®® S.aureus ± Can-
dida. ± ±© ® ® ± ©-
© ( ® ± © ± )
3. ® © ± ( ® ®® ± ©-
( $ ©± - © ® -
± ( Bacillus, Corynebacterium, Malasssezia furfur), ± © -
± $70++
*± %)± ±© ® ® ± -
© ( ® ± © ± ) ____________

® ® ® ±© ( -
± © ®± ® ®
) ®
 ®
± ± ±
± ) ±
© ® ®± -
± / ) © ±-
5 ® ® ± (
± . ( ®
( ± © ± © ±
± T0U
)
® ® ± / ±
® ± 5
1. ± ± ± ® ®
® ® )
2. ® ± ® -
® © ± ® )
3. © ® ( © ® -
® ( ± ©® ®
)
4. ® ® ®( ® ±
® ® © © ))
T0 U
)
± ± ® ® ( ® ± ® ±-
® ® ®± ® ® ©-
® ® ®
® ±-
) ± ® ® -
® © -
) © ( ® -
( © ® ) ©-
® ® -
± ® ® (
© ± )
® ® ®-
(® ® ( ± ®± ±-
) ® ®
± ± ±)
© ® ®
± ± © ®
( ( ®
)) ® (® ® ® ®
Enterococus, Klebsiella, E.coli, } { ®
 ® ± ± ( ± ±
( ± © © )
® ± ® ® -
± ± ± $ ± 50%),
S.epidermidis ® ® © ± ® (
® (® ® -
© ) ± ® ± ® ±
®( ® © ± ©-
( ±± - ± -
± ± ( ® - )
- ( -
± ©
Candida, Psendomonas.
® ± ± ® -
± ( ±© ± ® ®
( ± ®® ®
®
*® © / -2 )
± ( - ®
± © ± © ) -
® ® ±© -
± ® ® ) ± ± ± -
® ) -
( ® © ± ± ± © (
± ± )
± 3
+! ± ® ® ® © -
± ± ± © ± ® ®
®
® ®® ,
+- , ) ®-
® ) ® ®-
±
± ©± )
± ± ® -
± ®± ®
® ±
®® ) ± ±
± ± ® ® ± ± -
- - ® ( ± ± ®
- ) ® ± /3 -
®
)
® ® -
®± ± ® ± ® )
 ± ® ®
± ( © ® ®
® ( © ( © ± ® -
® )
± ® ®
$± © - %
( © ®
$ %
0+-80% [225].
± ± ± ± ®
± ± ± ® ® -
® ®
( ( ( ®-
( ± ±)

] [] [

± © ± ®
±-
© ± %) $ ® ® ±
30-/+ ! ® ± ± 3
+!
© ± ± ± ) -
® ®, -.! ± ® (± ±
® ± ,.!) (® ® ®±-
± © ± )/
-/)0
[225].
® © ± $ %®
( ® 0-
,+! ® ) ± 5 ( -
± ® ( ( ±© ±© (
( ( ± (
( )
© ® ± . ® 5
( ± ® ® ® © -
© ®© ( ©
) ± © -
®© ± ) ±

1
®
 © ± -
) ® ± | } -
± $ ® ®© ( ( -
± ® ± ( %
® ± ( ®-
© ® ® ) ±
®± © 5 E.coli, Klebsiella,
Enterobacter, Proteus, Pseudomonas, Enterococcus, Candida [225].
© ± ®® )
5
± ® ± 9, + ± (9 , ++ *± ( ± -
± ® ( ® ± © -
)
± ± ®± ± (
® ®® © ± -
©) ® ® ±
© ± ©
±© © ± ® ) ®
± ±
©± ±© © ± ® ®
7-,+ ) ® ±® ® -
± ( ® - 1 ± ± ) -
® - ®± ® ) ® -
® ® ® ®)£ ® ® -
®© ® ± © )
± ® ± ® ± ®©
± ® ®) ± ®
± ( ® ± ± ® ®
) ± ® ® ® -
± ± ® T0 U)

[ ]
® ( ® ® Candida, ®
© ® ( ± ±
®
± ± ®± -
± ) ± ± ® /!
 ± ± ®
® ± © )
( ± ± ® ( ®-
® © Candida:
© ± ( ± © ® (
®
± ,
3 T0 U
) © ® ®
©± ®± 5 ®
®
( ± (® ® ®( -
± ©® (© ± ( ( ±
® ± ®( ± © ® ( -
± ± ®T 0 U
)
Candida ® ® ®
® ® ±® ) ± ® ® -
® © ± ± ±
Candida. ± ©± ®
© ®® ± ®
® ±) ± ® © ®± -
© ® )C.albicans ® ± -
© ( ® C.krusei, C.parapsilosis,
C.guilliermondi, C.lusitaniae, C.glabrata.
® © ® )
± - © ®
± ± © ± ± © ±© -
© ® ® ) © ® -
± 5 ± ± © ± ± ±
± ©© ® © ®( Candida
± ( ± ) © ©
®® ® ® ) ± © -
± ( ®-
©± ®± ®® ± -
) ® ® Candida ± ©® -
± 5 ± ® ® ± ® ©®(
± ® ® )
®± ® ± ± -
) ( - ( ± -
± ± ® ) -
 | | ± ± © ® -
± ± ) ± ® ± ± ±
®± /
++ ©
* ) ® ®± © ®
$ ®® ± ±-
±% ®± 1++-3++© )
± © ® ± ®
± ®
( ® )
± ± ® Candida ® ® ± -
® ) ± ®
® ± ± ± -
±( ( ® ± ( ± ® -
®
± ®
( ralbicans C.kriisei.

] ]
± ® ± (
® ( ± ± ± ® ±
®
) ± ® © ® ®
- (® -
Clostridium difficile ® -
® ± ) ® ±© ®
± ( ± ( ±
± $ 0 - 0!% ) ©
® ® ® ± ® )
Clostridium difficile ® ® , ! © -
± ® ± ) ± ® ± (
© ± ± ® ® ± ®-
± )
£ ® ® ® 5
$ % $ %( ±®±-
® ± ±® (® ® ® ±-
± ® ® ® ®
± © ) ±® ® ±©
( ± ( ® ± ® ® -
© ± ( ± © ( © ± ( -
± )
0-2 ± ®
®± ± ± ± ±(
305
 © ® ± , ®
(
± ) ® ±
®® ) ± ± ® ± ± (
±® ® ( ®® T0 U)
±® / ® ± ± ® ±-
© Clostridium difficile. ©
® ® ± ± ± ® ± ® ®)
- *± ± ®± © -
± ® ( ® ® ±
® $ © ± © -
± %( ® ® ® )
® © ®-
) ± ® ± ± ®
) ® ®±
± 0 + +
-0+ ©per as 4 ) * ) ± ® ®±
± © $ ,0 © per os 4 ) * , + )%)
® ®® ® ®± -
± © ® ® ±
) ± per os ± -
® ® ± © ® ® ( ®-
® ( ± ® )
± ± ± -
±© ® ® Clostridium difficile.
\ ± ® ®± ® ( -
+
- 0! ® ® ±® ) ® -
®± ® ± ®
± ) ± ± $® ± %
± ± ®
± ± T
,12U)
± ± ® © ± -
± ±( ®( -
± ® ® ( ± ®
® ® ± ® ± ) -
®± ® ± ± ®
® ®
® T0 U)
 - [ ] ] ]
]
^ ]
' ± ± © © ® -
® ® © © ±-
© ± ± ± $© (
© ( )% -
© ® © ( ±
® ± )
' ± ± ®© ® (
( ® ( © ( (
± ® -
± ± © © ±®
± -
± ( © ( ±®-
)
( ±© ±-
® ( © ® ± ® © ±
© ± ( ®± -
® ±© © ( ± -
® ( ± ®
© ® ± ® ±
© ®
± ± )
| ®± -
© ( ( -
- © © ® ±® -
® ± ©
$ ±
)/%
)
-
-

± ± - ±
® © ) -
® © ® ®
± ± ® ® -
± ± ) ® -
 ± ®
± ®® ± ± -
) -
" -
" -

± /
© ± ±
® ® T
,+U

| | | || | | -
|
± ©
±
- ± ± $ -
± ® % ± -

± ±-
® ± © ®
- ©
± ®
$ %

± ± -

± ®
©
±
± -
®

± { -
± ± ® ®-
® ©
±® ©)
© ± ®
± ± ± ±
® $ %
T
,23
(, 3/
( 1
( 2 U
) - ®
± ±® - © © ± ® ®
©± ( ®
± ± -
© ± ®® ® )
$± %
® $± (
± % ®
± ® -
( (® ± ® © ®
(
± ® ® )o -
re 2 ,% 6
2% 6.
% ± ± 6/% © ± -
± 6 0 % ©6 1
% 6
2% ± ± ® )
±)/
. ®± ±© T2U
)

± /.
± ® ± - ©

1- | 2- |

± ± ±
± ±
± ±
± ± ®± 5 -
® ±© ± ± © ±-
®
6 -
± - ± ® ( © © © -
± © 6 ± ± -
6 ® ± ± -
® ( ® © ®
[178, 227].
± (
± ® ± ± ® ± ±-
± © ± ( ± ® ± ±
± ± ® © [226].
± ±® ® ± -
®
± ±© -
± ® ± ® ®-
± ± ± ± -
) ± © ±® © ®
 © ± ± ( -
± ®
± ® )
® ® ±© ® -
± ± © ± (
± ± ® ± )
£ ® ® ® -
© 5 ± ( ®
( -
© ) ® ±© ( ± -
( ± ± -
(© ± © ( ± -
±® ± ® ® ± )
± ® ± ( ® ±
® ± - ® ® -
® ® $ (© ± ( %
® ± )
© ( ®
± -
± ± ± (
®± 5, % ® © ®
© 6 % ± ± - ©
® 6.% ± )
± ± ©5 -
± © 6- © ± ®©
$-. ©*©® %6- ± ± ± -
± ®
® ©± ® ± $+
-/+ ±, +
! -
® ± ©
± ® %6- ® -
© $
/+! ± ® ± %(
® ± ± -
)
 [ ]

± ® -
© ( -
® © ® )
± © ®± -
± ± ±© ( ®®
± ® ±®
®) ± ®± 3
+-
© ®
( © ® ® ® ± ± -
( ® ± © ®
® ±©-
T
13U
) ,
420©
) )) ±
( ® ® ± ( -
± © ®
)
±©± ® 5 © - ® (
( ± ® ± © T3U
)
® ± } ±-
®± Eiseman ®)®,4
22© )T 4 U ® ®± -
± )
± ® ® ± ±© ( -
( ( ) ± ± ®± ®
±© © 5 ©± ( -
± ( ( ± ± ) ® ® -
®± 5, % -
6 % ±© 6
.
% 6/ %
60% ®6 1
%
)

3| | 6
® ±© ® ® ±
®± © ® ) ± -
± ® ± ± (© ± -
® ® ±± ® ®
 ± ® ( © ®
± ®© ±-
® ) ± ® ® -
± ±© ®± -
© ARDS. ± ® ± ± ±
( ) ± ® ± -
® ± ± ® ±© ( ® -
( ( ( ± ©±® ©) ©
® ± ® ( -
± )
® © ® ®
-
® $ IL- ( IL-6) ®±
® ) ® $ ®
))
%( ©± ± ) ®©
®
± ± ® ±©
( ® ± ©±©
± ®
± )
± ® ® ± ®
± ® ® NO. -
±© ® ( ± -
® © ® -
© ® ) ± ± ± © -
® ® ®
®
± ( -
© ® ±
© ®± © ± © © )
® ® ±© ® -
®
± © ( ®
© ®
( | ®® } ± -
® | } ®-
± © ± ©
® ) © ( ( -
± ® ±©-
© ( ±
± ® -
± )
®
± ®
© ® ®
 ® ± ® ® -
± ± | } ( ® ® ± -
® )
© ± ® ± ® ® ± ( ® -
® ® ®± ® ® ® TNF-a.
® ® TNF-a ± -
±® ± ± ) ® IL-1 ± ®-
® © ± -
) ® IL-6 ® ®
)IL-10 ® ± © -
* © ® ± ± ®
)
± ® IL-10 ± ®± ® -
± ± )
® ± ± ®
± ® ) ± ® - ±
®® ± ± © ± ±-
) ( ±
TNF-a, IL-6 ± ® © ® ® -
± ( ® ®)
( ±
± ® ©( ( ( ©
® ® ± ( ± (
® ® ® ± ( © ® SIRS ±
® ® © ®)

| || ||| | -

© (® -
( ± 5 ©± © SIRS
±© © ± ® ® ±-
±( ©± -
® ) Goris ®)T.
+U ±-
±( ± 0+
! ± ± -
© ) ± ® (
SIRS ®® ©± ® © ® ± ±-
®( ®± ® ±
-
 ) (
® ® ® ®( ®±-
- ® ) ®
( ± ± ( ®
±
± ± ± © ± © ® ± ± © ®
® ± -
© ® ® )
® ® ± ®
® ± 5 ®( no-reperfusion -
® ®± ® ±± ® -
± ± ® ±-
( ® 6 ®
± - © ± ® ® ± ®± -
® ® ® ±®( PAF, ® ®
± ) ± ® ±± -
± $
capillary leak), ± ®
®± ® ® )
± ± ® -
® ± ± ±-
®± ± ® ± ®) ± ®
® ± ® ± ® ± ®
± ± ) ± ®±
± ® ± ®
± ©± ) ± ® -
,1 ± ® ± ± ® -
± ± ± ®
® ± © ) ± ( ± -
® ± ® ( ±( -
® ± , + ) ±
© ( ± ± ± ® ( ® -
± ± T. ,
U)
± ® ® -
® ® ± ± ± © ®
± ± (ELAM), ® ® © ± ® ±
± ) ±±± © ® ± ± -1 (ICAM-
1) - © ® ± ± ( ® ® ®
® ® ®) ICAM-1 ® ± -
314
 ± ± ± ® ® ±
± ) ±
± ® /0
® ICAM-1 ± ® ± ®
® ±( ® ® ±( ® (
( ± ± ) ±©
® ± ± ) ( -
- ® ICAM-1 ® ± ®
± © (® ( ® © ® -
± ± ® T.U) ±
± © ® ®
® ® )
± © ( ± © ±
© ±
± ®$ ± ±%
) in vivo ±
± © ± T. . U
)
( ± -
® ® ®± ®± © -
C ®® ± ± ® ( ®® ®
) ®® ± ± ©
± ® - ( -
± ® ® ) ® -
- ® ® ±® ® ®
± ® ±) -
® ® ® -
± )
® ± ± © ® ± © ) ± -
± ®± © ± ± ±
© ± ® ± ± © ® T. /U
)

| -
|
| | |
| |
| " '£ ± -
®
± ® ® ©
± ± 2+
!) ± ® ®
 ± © © ( ± ± -
± ( ® ± ± .0
!( -
® © ®- 0 0!) -
± © ®± ± ® ® -
3 0! T 0+U) ± © ®
± ® ®( ± ® -
± } "pace-maker" pon
} [50].
1, 43+© )D.E. Fry ®) ± ± ®
® ® © ± ®
(
® ® ± ®5 ±© ( (
® ± - © )
W.A. Knaus ®)® , 43,© )T ,/ .
U ± ± -
± APACHE, ®, 43
0© )
± ± ® ® APACHE II
T,/U ( ® ® APACHE III [235]. Marshall J.C.
®) $ , 4
40% ± ± Multiple Organ Dysfunction Score
(MODS). ® © -
± $ ± ) //%
)
± ± ® © (
(± ±© ( © (± -
® ® © )
( ± -
® © ± ® ; I N M -system failure in-
sujfuciency- I
M[ } %
®© ® ± ® )£ ® ®-
± ® ( © -
© ± ( ®±®
© ( © © | -
± }( ® ®© © ± ©-
) ± ( ± ® -
® ) © ( ±
± © $ % )
 ± //
© ( ® ±®
$
® ± ± © %

APACHE I, II, - ±©
III ± (Acute Physiology and Chronic Health
Evaluation)
SAPS - ±© -
± (Simplified Acute Physiology Score)
MPS - npoi ® ± ± © (Mortality
1 'robability Score)
CARE - ± ± (Clinical
Assessment, Research scoring system)
PODS - © ® ® ± ± © -
(Probability of death score)
MOFc - ® ©
(Multiple Organ Failure score)
MODS - ® © (Multi-
ple Organ Dysfunction Score)
HPI - © ± © (Hospital Prog-
nostic Index
TISS - © ® ® -
± ®(Therapeutic Intervention Scoring System)
PNI - © (Prognostic Nutritional
Index)
PRISM - © ® ®
± ± © (Pediatric Risk of Mortality)

® ® ( ©
®± ± ® ®
® ± ® ± ® ± ® -
± ± ®
) ® ( ± ® -
® ©-± © ±-
± ±© ( ® ±
± © ±© ) ± -
© ®± ® © ±© ©
± © ± ± | ±
±® }
( -
® © ±( ± ±
© ©
( ± © )

[ [
]
© ± © ®( ±
/ © ® ±
± © ®T
,43
U5
r -
> 70/
7/4 ) )± ± 71
+
))6
> ± ® *± ±± 6
> ® 72
(/ +
2 7/
4 ))6
l}
> 70 -, ± 9/ 4 -1;
> + 90+ ))6
> AaD02 9.
0+ ))(AaD02=713 Fi02 - +-
+%
6
> / © ®
±© $ ® ® ® 2
%6
p
> ± 91 ©
!$ ,
+)1 ±*
±%
> ® ® /)® ± ©
p
> 7/24±* ± 7, 0
4± *
36
> 9,+
+© !$92
)23 ±* ±
%6
> ® ® 9. (
0©!$
9.,
+
±*±%
6

> 7,+++
*±
> 7 ++++
*±
> 7+ !
 ± ± © 71$
® ® ®
-
%
® ± ± © -
± ® ( ® ±© -
®
± ± ) © ± -
© ± ± ± ®
±-
® ± ©( ± -
©( ± ( ® ®
® ± ® ±
±© ® ® ) ®
- ± ±
± ±© ( ©
®± ®
® ±® $ ® -
%® ± ( ± ±
® ( ®- ®
± © )
))$,4±
43%T
13U( ± ©
© ± ®
© © ± ®
±® ±
$
® ± ® ® ± ® %
( -
® ± ® $©
± ( ®± ± -
®
± ® © © % -
± ( © ± -±
± © ± © © ± -
) /- ® © ®
®± ± ®
© ® ®± ± )
± ± ))$
,44
3%( ® (
®± ± ± ©
± © © T
13U
)

| |
,w ®
±® ± 5
 ® ® ± ® -
± 6
± 1 +
-,+
+ * ( 6
9,++ ))6
£ - ® ± ® 6 -
® ® )
2. ® 5
± / +-1+ ± ,+
+-,+ * ± ®
® 6
)3 + +
-,+ ))6
± ± ® -
6
£ - ) © ST
± 6 ± ±
)
3. ®
± /+± ± ,+ * 6
± ® -
6
± ® 6
± ± $ % ® ®®
±© ± © 6
± ®® ® * ± -
±© © 6
± © ±© 6
© ST £ 9 , ) £ -
©® 6
® 2 ±± © )
4. ± 5
® *± ± © ±
® £ 6
© $ 71 + ) )%
( -
6
 ± ±( ±
® © ± ® ± ® © ±
±± ± 6
® ® -±© -
)

| |
1. | | 3
© ± 6
± ® -
± $ ±© ®
±®-
.
+)%
)
2. | | 3
® ± 3+ ) )$ ®
± ®-
± ® % ©
± -
© ®
6
±-
5 ± $ % ®®
( -
( * ( ® -
$ % ± -
± $ % (
*± ±© )
3. ® 5
® ® 1 + +
-3 )) -
© ® $± % ± ®6
® ± 5
( ® ± )
4. ± 5
71+ )) ® ®
)
® ® -±© -
)

| |
1- ®
±® ± 5
 ® $ ± % ± -
© ®© ® ®® ± )
2. ® 5
® ± © ®© ® ® $+ 2, pv02,
pa-v02, +
2, pa-vC02, Sa02, Sv02, Sa-v02) ® ±
± © © (
) ) ± (® ± ©± +2 ®
± ( ® ®
$ (© ( ( © -
± ( %
)
3. ® 5
® )) ± $, 43
4%T/ U5
- ± 0± *©6
- ®, ± . 06
- , 0± *© ( ® ©®
,+± *© 6
- ±© - © ± $ ± % -
+(.± * 6
- ± ®± ± , (
/ * $
±- %
6
- ± . ©* 6
- * ± + (
1 6
- ±® ± ± + ! © ®
$ %6
- ±® (0 6
- ± ®± ± + (
/ 6
- ® 2(6
- 02 1+ )) ® ± -
3+ )) ©± ,++!+ 2;
- +2900 )) 6
- ±® ± - ± ± +2 ©±
02 ® ,+ ) (- ± / 0
+ )) 6
- 2*± 27+0 )
4. ± 5
+2 70 + ) )± +2(9 0+ ) ) -
+ ± )
 | ||
1. | | 3
± 6
± ± ( - ± -
$ ± %® ± 6
*±AT ® ,
(+-1,3.
2. | | 3
®± ® $± %
6
± 0+ +
-, + ±* ±(± , -0 ±*
±6
*± + )0-1.0.
3. ® 5
®± ® ± . ®, 6
± ,++ -.++ ±*±$ ® ®
± %6 ® ± ± + ±*
±®
, 6
± 90 ±* $-± %
6
®± ± © -
® ©© © © )
4. ± 5
± ± . +
+ ±*±$ ® ®
± %( ® ± ± 0 + ±*
±®
, 6
± 9, + ±* $-± %
6
( ® (® ® © -
® ±© © )
|
1- ®
±® ± 5
± © $ ®©( ©% (
± ± ®
( ® ( ®( ± ®
± ± ® ® ± )
) ® 5
 ± ± ±
® ± ± ® -
± ±5
- 0++± * 6
- ® ± , 0 ±* ±6
- ± +(. ±* ±6
- ' ± / (
0 ±* ±
)
3. ® 5
++-0++ ± * ± ±
$± 0++-, +
++© * % 6
® , 0-.+ ±*±6
+(.-+(
3 ±* ±6
'/(
0-1(
0 ±*±)
4. ± 5
7 + + ±* ± ± $
±-
0++-,+++© * % 6
® ± . + ±* ±6
® ± 0 ±* ±®, 6
± + (
3 ±* ±6
'91(0 ±* ±6
± ® ,+
,+ ®
± ® ± ®± ® -
®6
© )

| ||
1. ®
±® ± 5
® ± ± ® ±-
© © ® ± ± 6
± ± ©
± ® ® ±
)
2. ® 5
± ± - © $
± % ± ±
± ® 6
 ± ± -
± ( ® -
®
6
± ® ( -
( ®
± ± )
3. ® 5
± © ± ± © ±
± ± - ® © ±
©®© 6
± ® © ± ® © -
© 6
± ® © ± © -
© ® ± 0++±
* )
4. ± 5
± ± © © © © ± ®© -
® ® ± ± ± -
6
± $ %
6
± ® © © ® -
± ± 0++ ±
* ± ® © -
© ® )
| | ^
1. ®
±® ± 5
® -± ±® ( ®( -
© ®
± ± ® )
2. ® 5
± ± / ® ® -
± ± 6
1- ± © ±
® ® ± © ®( ± -
6
 ± ® ® ± -
© ® ± ® ®
± - ® -
)
3. ® 5
± ± ® ± / ® ± (
±®
± ® - ± ± -
6
± ± © ± ± ,
+++
±
* 6
± © ±
® ®
± - ® $-
®± ± %
6
± © ± ® ± ± © ±®
± *± ® ± ±
®)
4. ± 5
± ® ®± 6
± © ® 6
± ® © ± © ® 6
1- ± © ±
® ® ± © ®
6
± ± ® © ®± -
® ± 6
± ± ± © ® ± -
± © ®
6
± ±© ® (
±© ® ±© )

| |
1. ®
±® ± 5
± ± (®
© ® ® ® 6
© ± )
2. ® 5
 ® 4
+ ) )$ ® ±
-
% ©
± © ®6
±
± © ±® ± -
©( ± © )
3. ® 5
® ® 3+ ) ) ® $
®±® ± % ©
®6
±± © ±® ± -
©( ± © )
4. ± 5
3
+ )) ® ®
6
® ± -
6
± )

| | | |
$ ® ±
± ± ± ©$ GCRS)
± ± (ICRS).
1. ®
±® ± 5
± ( ® ( ±
±-
( 6
ICRS = 19-21;
GCRS = 14-15
2. ® 5
®( ± ®
±
±- ( 6
ICRS = 12-18;
GCRS = 11-13.
3. ® 5
® ± ±
±- -
( (
± ± ©6
ICRS =3-11;
 GCRS = 8-10.
/
) ± 5
® ± ± ±©
® 6
II-III;
ICRS = 0-3;
GCRS <8.
| || |
®
±® ± ± -
± ® ±© © -
© ®± ® ® ® ± -
± ©) ®
± -
$ %
( ®
± ® ® ® ® © ©-
® ) ®-
± ± •)•) ± - ± $,
4/,%T 1
( 1 (/4U
)
± ®
± +(
. ,(
0 ± )) -
® ® ® -
±® ( ®± ± © © (
± ± © ± ®( ®±-
± ± $ ®® ©
® ± % ± ± ® -
® $± ®© ± © -
± - ©± %
) ® ®
±
® ® © © ® ±® -
±( -
) ± ® ± / -
5 ±© ( ± ( ± ± )
± ±-
© )) ± $
,443%T 13U ±©
± © ( ® ±5
1. | | 3 0,5 +) ' )
2. | | 3 (
, 2(
+ ± )
)
6 ± ©© -® ± ± © ±® ±
 ±
± © © ± ® -
± )
3. | | | 3 2
(, ,(0
±)) ± © © -® ± ± © ±®
(
© © ± ± ) -
® © -
5 ± ±
® © ©( ± ±-
®± © ±® $ -
± © ( © -
±±%( ©© )
4. | | || | ®
-
±® ± ,( , ±)) ± +(
0
±))( ± ± $ -
© ©%( © $ ® ± -
± ® © ©%(
- $ % ± ±
ae 3+ ) )(
±±)

| | | (PACK)
± ±
PACK ® ® -
® © ® © ® ® ( ®
± © -
© )
1. | | | | ± ±-
®
± PACK ( ± -
± ® ® ±
|
|| + +
-0! © ±© )
2. | | 3© - ± © ©-
± - ± © ± ©±-
± ± © ®© ©
± ® ± + +
-0! © ( -
±© © ± ®± )
3. | | | 3 ± ± ©
®© © ± 0
+!
± ± ±© © ®± )
4. | | 3 © ®
9
+(0©*± ( ± ® ® 1+
n,+ *
± ±
± © ± © © +! ) ±-
©± © ® )
± + ++ ® ® ±
- © )) ± $,44
3% T 1
3U ®±(
® ± (
©® . ± © ( ® ±-
± ®4 1 3
-4! ± ± ®
± © ± ( ®± © ± ®
- ( )
® ± -
® ( ®± ( ± -
( ( ±
© ±© ± ( -
®± ± ± ± ./
! ®, 44.-,440©©) !®
,441©)
± ®® , +
-± ± ©
± -
± ± , 0++ ± ± ® -
± ( ® © ©-
® ( ® )) ®)$ ,443%T 01
U ± -
± ( © ± ® ± ®-
® ® © ® ®( -
® ( ®© ± -
© ® )
® ±© ± ® ©
± -
||
| || ± ® ®® ± -
® ±© ± )
( ± ® -
® ® © -
) ® ®
± ( © ® -
 ( ± (± -
- ® ® © -
± ® ± ® ) -
® ± © -
®
± ( ®±( ± ®
± ± )
® ± (
© ® ® © ± ® © (
®® © ( © ®
±
±® ± ±© ± ® -
® © ± ± © ® (®
® ® ± © ® -
|© ® } © ® © -
® )
± ± © ±® ± -
® ( ® ( ® -
® } % -
® ® ©
± © © ) ©
± ( © ± ± ® -
® © ± ± ©( ± ®
( ® ± -
) ©( © ±
± ( ± -
© ( ® ® © ±®
-
± 5
1) © ( ® ± ( ®©
® ® ® ® 6
2) ® ® ©
® © ® © ® © ®
© ± 6
3) ® © ± © ®©
® ± © ± ® ( -
± © ± ® ®
± )
 || | | | -
| |
)) ® ®)$
,44
3%T01U ±©
® © ± ± ® ±-
®® © ® ( ® -
± ® ( -
± ± 1 ±
$ ±)
/0%
5
± /0
± -± ©

® $)) ® ®)
(,443%T
01U
| || ||
[ -9-13 '
| '
| || | | '
| [- 5-1 '
- *
| || |
| | [ 4.
II-III
| || | | |
| | - |
3 | | |
| | |
| | " |

VAPE
| | | " 5*
. (-

| | | |
| | |
p02/Fi02 5+
.) ' '
| |
| |
.
p02/Fi02 = 100-+) ' '
| ||
| | 50 +
))
p02/Fi02 = 75-* ' '
|| | |
| | |
FeNa - 0,5-* "+) *- ) (
| % |
 | | " | 5+)
) (
FeNa 5* " +) 4* (
| CVVH, CAVH, CVVDH
| | " |
|
50) (
|
|| " [[ [
| " /
) (
[| |
| [ | "
4*.(
| | " /)
|
| | ||
[| |
| | |
^| - | |
|
| | |
| | |
| ^
|
| | |
|| | ^
[|
p -. FeNa - ( CVVH -
® -® © ± ( CAVH - ® ±
± (CVVDH - © ±

± ® ± ®® ©-
® T
01U
5

| | - |
1) | - ® -
± ± © -
( © ±© ± © ©± -
± ± ® ®
± ©
( © © ®±-
( ± ®©®) ± ® -
( ®±( ± ®
±
®± ± )
2) | -
® ± © ( -
± ® ± ® -
®- ( ( -
± ± ) ± ± ©
± ® ± (VAPE), -
± ® ± ( ± )
3) - | | ®±
® ® ± -
( ®
± ± ±
±± ® -
® )

|
1) ±© ± ( © -
± $ ( ®® ® ®-
% ® ® ± ±-
© © © )
$ ( ± ®
± © (
± ±
®
± ( ± ±® ) )
% -
)
2) ® | ®
±© ®
± ± ± © -
( ® ±® © -
±© ( -
®± )
3) ± | | ± -
± 2 ( © ® ( ±
( ± ® ® - ® (®± -
© +
2 ® ® ( -
® ® ±
± ±© © © ) ±
® ® ® ±© © ® ®
© ± ±© ( -
± ® -® © ±
 (CVVH), ±
± ±© © © )

|
1) | ® $ ® )) ®)
(,443
%
T
01U ± ( © -
® ®
® ( -
( ® -
® ± ± $©
- ©
± ±
®± ®
(FeNa). ® ® ® ± ±
®
± © ©
-
± )
2) | ±
± ® ± ( ± ®-
± ® ® ± ++
±* ±$ ® | ©} %( ®
® ® ±-
® |® }® ) -
© ® ® ( ®
-
± ± (®± ® ©
® CVVH ± ® -
± © ± (CAVH) ± © ±
(CVVDH).
3) | | - ±© -
± (© ± ± -
® ± £ - © -
± ( © © © © ±© ©±®-
© ©( ® ® ± . . ±*±)
£ ± -± ®
±
± ± ± ®± © -
©© ± )
 ||
1) ± ± -
± © ® ± ±
) ± ®
± ±
© ®® ® © ® -
)
2) ± ± ® ®
± ® ± -
®
± | -
) ® ®
-
±
®$® ® %® -
® ± ± ® ® -
± )
3) ®© © © *±
± ± ±
® | | ±
± -
© )

| - |
1) © ® ®
± -
© ® ± -±
± ± ) ± ±
± ®± ® ®
± -
± ± ®
(
± ))
2) ± ± ± -
± ®® © ± ® ± ®
| ± )
± ®
± ± -
± )
3) £ ©( ± - ® ( ± -
® © © ( ®
±
| | ) ® -
® ± ® ±-
® ® ® )
336
 ]] [] ]
]] [ ] 6
( ® ® ±-
® ® ® ± ± (
® ± ®® ®±® ® ® )
(® ± ± ®± ® ± ©
©( ® ( ®± ® -
®( ® ®® ® ( ± ® ® -
® ± ® ± © ® ® ) -
® ® } -
[ ± ® -
® ± ± ® ± ±
± : ± ( ® ± ® -
} [ ± ± ± ± ®)
± ® ( ( ®
® ® ® ) -
± ® ± ® ® )
© ® (
® ®± -
© ± © ± ± )
(® ±7 ®± ±
± ±© ( ® ®
±)/0 ±)/1)
± ±± ® ©
G.Regel ®)T. 2
U( ® ® ± ± $± -
± ± % ± ® ® ± 5,42-,43,©©)
1982-,44,©©) ® ± ±
± ± © ± ) ± ® ®
® ®
$
43 !%( ® ®4 ,! ± ® ( ±® ± -
± ® 21! ± )
± ( ® ± ± ) -
© ± ± ®
® ©±® ) ± ® ± ® ® ©±®
® ® ±( ± ® ± -
± ) ± ± ( ®± ± ©
 ® ) ± ± )
± ± ® 5
± ± ± .
2! !(
® ± ,0)
/! 3)!) ©( |± ± }
® ± ,
.)3
! ,3)
1!) ( ± ±
± ® ® ® ± ® $
® -
%
( ®® ± (
(± ± )

± /1
± ® © -
± (® © ± -
± ± T.1
U

| ® } ® ±
* ± ® ± ® ± ( ®±
± ® © ®
± ±® $
± % ® $
®
%
± ( ® ( ± $ -
(± ® ©
%
± ± ® ±
± ® ± -
±
± ± ± ± ± -
® ® ±
± ± ®± ± ±
® ± ± ® -
± ®
± ® © ± ®
± ® ®
( ® ± 6 ® ©
© ± ± ® ®
® ± ± ±
± ± © ®
®± ® ® ± ® ® *± ® -
® ± ( ± ( ± ® ± ®
 ± /2
± ( ( -® (± ± ± ±
T.1U

£ ± $ ± ( (©
± (
©-3- ± ( © %
± ® ® ± ± (pHi) ± ®-
®
©± NO
± ® ® ® D02 V02 ±-

± ® © *
© ± ® ®
±
±
± ®
£ ± ©
± © ©
± ® © ® ±
± ® © ® ± ® (
® ± ( ±
±
± 5 © ± ± ®
(
(prone-posititon% ± ® ± ( -
©
± ± ® ±
± ® ± ®© ± ± ® -
®

± ® ± ® ® ±

| | | || | |
-
|
| | | |
| -
'
 ]] ] ]

± -± ±®
® ±© ± ® ®
® ® ± ) ±
®
± ± ( © ( -
®
± ®® ) -
± ® ( ±
± )
® ® ®
± ± -
( ® ®± ® -
® )
± $ ©
© ©% $ - -
( ( ( -
)
%) ± -
± ® ( ± ®
± © ) ± -
± ± 5 ® ® -
© © ( © ®
® ® ± ±
(® ± ® (
±© ®$ )4 %
5
® ® -
± ± © ® ®± ® ± -
6
® ± ®± ±±±
± ® ± ©( ® ©-
± © 6
®
± © ® ± -
® $ %( ©$ ©%
±©)
® ± ® ® ®
®± -® ® © ± ©( -
 © (® ® © ) ± -
® ± © )

R _ R^
R ' C' Cv02.
2 2 K
(l) _
+ R _

_ R
1
--------- f
:]
_ R
1 [
_ [
_ -
R

K K 6 _ K K R R _K
R R _ - R^
K[ R R R R
^

\
, R
[ [
R _ [ ] - [
R -
6 R
R K_ R K -
[
K K
: ,
_ ]
|
[]
K -
R R R
R R R [
6
- [ R - R K_ R
_
K_ R
K ^-
-
R
-
R
6 R K
[
, 6 R [
6 K K
R _ K - 6 R _ K ^
^ [ R R R ______ R K _________
R K [

* R K_ R R

* [ ^ [

C K
] - 1 [[
_
*
_
[ - C K
K R K [[
_

,2
i ^ _
6 ^
R R
_
[ [ R
[ R
[

)4) ±
© ± ® ± ± © $ )
)
1995).
 ° •
© ± -
5 3 % { -
} } 3 }-

|| | | | 3 © ®
( © ± -
) ® ( ® ®
±-
) ® ® ® © ©
® ± ® ± ± )
| 3 ± -
® ±© © ® ©-
) ± ® ®±-
® ( ®± -
± ± © ®
)
| | 3 ®± | ® ®
}- ± ®
± ±® ® ® ) ± -
® ® (
® ± ® ® ®± )
± ± ( ± © -
± ® ®® ®
0
3 © ® -
(® ® ± © ± ® ± -
± (® ® ± ® © ( -
± ) ® -
® ± -
® )
| -
© © ±
® ( ® ± ® ±±
) ® ®
± ® © )
± -
® © © ® ® © ±-
© ± ® ( ® © Buskind R. ®)
$++%
342
T.
3U ± ± ± ®± ± -
) ® ® ( ®© -
® ± ± ®® ± ) -
± ± ± © ( ± ® -
± ® © (® ± -
± ® ± ± ) ± ® 3
± ® ± © - ..
).! ® -
± - 0.)
3!6 ( ± ® ± © ±
± © © ) ®
± ± ( ® ® ±
® ® ® © ± -
© )
| || ±
± ©
) © © -
- ± © © $ ® © ± -
©%( ®
± © -
) ))
)) $
,44+%T/0U
( © 3+! ±
5
© ± ± ,+
± ®, © ( ± ®( ®
® ) © { -
} } }
} { © -
± ( ® ± ( ®
® ® ® © ® © ±
©® ( ® ® ± -
)
o } } }
} } %
}
c } { -
% % -
-
 ® ® -
± ® ® ®
±© ± ± )
± ® ® ® © -
± © © © ± -
©® ® ) ± ®
± © ®
© ± ±®
± ± ±-
± © ® © © © ) ± ©
® © -
-± ± ± ± -
© ) ® ©®
± ® ®
± © © -
© ( © ® -
T
/0U)
± © ® © (® ( -
® ® ® © $
±© ( ( )%) -
± ©® ® ± ±-
® ® ± T/U) ± ± ®© -
® ®® © ( -
® ( ( © 6 (® ® -
± - ® ( ± © ±© 6® ®
- ® (±© ©® ± 6® ®
± - ± © © - ® ® ( ( -
)) ±® © © ±
® ± ® ) ± -
® © ± ± (
® ± ® ®© ® ± ® -
©± ©( ® ±±± -
±© ® © © © ± ( -
±© ® ® ®
© ( | ± ± } ±-
± © ®( ±
© ® ® ±) ® ® © -
± ± ® © - ® ® -
© ( © ©® ± ) ©
® ® -
 © ® ± ± © ±
© © ) © ±© ±
® © © ± ± ± © ± )
® ©® ® ©
®
± ®
© ) ± ©
± ® ® ®
( ©
± ® ± ® 6 -
®± ± ±
± ®± ± ± ) -
® ± ± ®
±-
± ® ( © ±© -
® ± ® 5 ®
® ( ±® ± (| }
± ( - ©
± ©© ±© ©(
± (® ± © ) ® © ®
© - ± ( ( (
± © -
)
© © ® ®-
©®(®® -
® ®± ± ± -
± ±® ± ® -
® ± ± )
© ± ©®
® ± ® ) ± ± ®
± ± ® ± ± © -
5 ©® © -® ± ± © ± -
± ® ® ® ® (® ® -
®© - -
© ©± )
± ® © ± ® ± ±-
± ® ± -
± ± © © -
± $
® ® % ®) £ ( -
®± ® ( ® © -® ± ± © -
345
 ± © ® - ( -
®® ± ± ( © ±® ) -
± ® ±( © ± ® ®-
® ® ± $
® +-
3
+ % ® ± ® -
® ± ( ± -
± ± ) ® ® ( ± -
± $ ® ®% ® ®
®© ± ® ± ± © ± (©
±® ( ® ® ® -
®) © ©
® ® ®© ®± ® © ® -
± ( ± ± ( ®
® ® ©® )£ ®
® ( ± ± ®
± -
® - ® ® ±
[62].
± ©® ® © -
® ± ± ±
® © © © ± ® © ©
± ) ± ® ( © -
®± ®±® ± ± ± -
© ® -
© © ) ± ( -
© ® ± ® -
© ® ® ® -
( © ® IN II [ T3(/0U
) -
® © ± ©® ©
T
1U 5
®
± ( ± ± ©
® © ± 6
± ®± ( ® ©
±®© $ -
} { * " ± ®© ®
% }
"%
/ ® ± ® ± -
( 6 -
®® 6
4 ± ® -
© © ® © -
©®© )
a } } -
} { } - -

{ } } } { -
{ } } -
} } } { -
{ %
}

© ± © © ± -
®
± ± ± ® 5
1) ± ® ± ® ±® © ±-
® ( ®± -
± ® ± ® -
®® © © )
2) ® © ® ±-
)
3) ® ± ©
© © ® ± ® -
( ± ®
® ®) ± ± ± -
± ® ( © ±-
)
4) © © © © ® ® ®-
± 5
± ®® ® ±® ® © ®
± ® ® - ±
| } 6
 ± ® ©
© ± $
® ® % ®6
® ©
± $ © %
)
0
% ® ± ± ©
±® ® ± ±
± ±® ± ± ®
-
- ®± )
± ® © ® -
± ( ® ® ± ®
® ® ® 2 +
-, ® 1-,
® ® ) ® -
© © © ®© -
® ± ® ® -
± ) )) )) $,44+%T/ 0U ® (
± ® ±® ± | ©} -
® ® ± 3
-10- ± )
( ®± ±®-
)
± ± ® ® ® © -
® © ( )) ®)$ , 44
0%T 1U® ± ®
± ± ) ®± ( -
® © ± .
-
1 ® © ® ± ± © -
± ) ® ®-
® ® © ® ® ± (® ®
© ± © ®© ± ) ±
® ( ® © ± ® ® -
®
® ® ©
® ® ®) ( © (
± ®
® ,1-,3 ( ± © ® -
± ) ±© ±
© ®) ®±
± .-0 ± .
® © ® -
® ©± ©® )
© ® ( -
® ® ( - ± ±-
® ®± ( ® ± ®±® ±-
± (® ® ® -
® ± © ± ©® ) ® ® -
© ± ©® © ®± ® ®-
© © ± -
®) ® ®
$ ±( ( ± ( ± %( ± ± ®
$ ( ± % ± ® $ (
( %® ± © ± -
® ( ® © ± ®
± $
/-2 % ® © | -
}) © ®® ± ± ®
© © ± ® -
,
1-,3 ( ® ® ±®
) ® ± ® -
®5 ( ®® ± ± ( © -
±® ( ®± ®, )
0-
± ©®( ®± ® ±-
® ± ± ®± ± )
® ©± ® ± ©-
© © © ® ±®
® © ) ± ® ®
® ( ± ± © - © ®
® ± ± ( ±-
± ® ± ® -
® ® © )
± ( ± ® ±®
© ® ®± ) -
)) ®) $,440%T 1U ( ® ®
± ® ® ± ± -
© © © ± ±® © -
± ®)£ ® ® ± -
® ©® ®®( ®
®® ± .-/ ) -
© ® © ± ® ® -
 ® © ( ± ± ®®
) ±
® ± ® © -
( ± ± .
-,+ (
®
$ ® ® ± ± ® % ±
± ® $ .
-6- % ±
® $ 2-10- % ®) -
± ± )
® © © © ± ©® ±-
® I II -
®© ± ± ± )

[ ] ] ]] ]
]
® ® ± -
± $ ±
)/3
%)

|| |
1) )
2) ± )
3) ± )
4) )
© ®± ± © ® -
± 5
1) ± )
2) ± ± ® ± )
3) © )
® ±
® -
± ± )
® ± 5
1) ± ±® )
2) ® ± ±® )
3) $ ® %
)
4) ± ® ( © ® ± )
 ± ®

*
'| | '
A. | ||'
± -
' |
® ® '
® © © ) 0! -
B. | | | '
± )
+
' | ' A. | | -
± $ % ± - '
®± ® 1. ± - -
® © © ) ± 4+!
± ) 2.
3. ±®
' | | |
1.
2. ± ± ®-
±
B. | |
1. ± ® ®
2. ± ©

,
' | | ' A. | | -
( ® ® ±- | '
'
[ | '
(
® ® © B. | -
( ± - | '
) ,+! ± )
± ± ± ± )
© ® ± ± © ® ± -
®® ® ( ±
± ± ®
± -
®
( ® ® -
± © ®
± ) ± ®
/ 1-2 ( ®
± ® )
®± 5
w ± ®
± ± ©
)
2. ±® ©
± )
3. -
)
4. £® © ± © ±©
-
± T/+
U)
® ® ® ±®
± ( ± ± ® ± ( -
± ± ( ® ± -
± ±) ®
± ± ) ± ( ©
( ®
± ± ©( © -
© ± ( ± -
± ± )

] ] ]
® ®± ® -
± ) ± © ± ±-
± ( ( ® -
± ®
± ± ± ) ® -
± ± ± (® ®
© ± © ± ± © -
(
© )
± ±
± ±© © © ± -
± ® ±© © ± ® ( )) )
± ± ± ® ±© © ± ®-
± ± -
® ® ± ± ®-
® ± )
1) p { -
® ± ( © ® © ±
® $ ± ( ( ©%
 ± ®± ± ± ® $ ± ® -
± ®%
)
2) y {
± ®
± © ±-
± ® ±© ± ® )
5 ± ± ± ® ®-
± ± © ©6 -
© 6 ± .
3) n {
® ± -
± ®® ± ± -
)

| | |
1) | | | '
- © (± ( ©-
± ® © ± -
$ .+! ± ± %
)
2) ||| | | | || | -
| '
3) ±©-
± ± ® ® ± ( ®
© ® ® ± © )
4) ® ® ±
®5
'®® ± ® ±( -
®$® ® -
(® ( -
® © %6
) ± ® $ -
±
± ( ± ( ± ( ©
± -
( ±
( )
%( -
$± ( ± ( ± ± (
± ±
% ) ± © -
)
353
 ' ® ± -
)
5) | | ' ±
© ± ) -
® ®± ± ® ( ®
( ® ± )
6) ' ± ® ® -( -
-( © ®
( ® ± -
))
7) || ' © -
±® ® ® ®
®
® ± ®® -
± ® ® © -
$® ( ® ±® ± ( ®
))
%)
8) ' © - -
±® ± ± ®-
± ®)
9) || | ± ± ±-
± ® ±© ± ® ) -
± ± ( -
® )
10) | | -
| | ± ® ± )
± ®® ± © ±
®
( ± ® ©
® )
© ± -
® ® ± ® ®
5&
±© ® ± ® ® ±-
± ® © ©6
® ± ® ±
±© © ©6
±® ® ® -® ± ± -
± 6
 ( ± ± © -
± APACHE II.
± ( ®
® ® -
® ( © ® (
® ± ® ±
± ®® ± ) ± ± ® ©
© ® ± ©
± ± -
® ® -
© ®) ± ± ±©
® ® ± ± ± -
® ) ± ©
© ( ± ®
940
! ± ® ) ® ® ± ® © -
± © ± ± ©
© ± © ± ± ®)
± ±© ± )
± ® ±
®® ± ± ®
± ) ® ± ® ® ± -
± © ± ( -
-® ± ± $ ±)/4%
)
± /4
± ± ±© ® ® ± ±

® © ©
| |
|| | |

| | " | - Streptococcus pneumoniae

| Enterobacteriaceae (Klebsiella spp.,
E.coli)
Staphylococcus aureus
| | " | - Pseudomonas aeruginosa
Staphylococcus aureus
Enterobacteriaceae
Acinetobacter spp.
Enterobacteriaceae
Bacteroides spp.
Enterococcus spp.
Streptococcus spp.
 | Staphylococcus aureus
Streptococcus spp.
Enterobacteriaceae

Enterobacteriaceae (E.coli, Klebsiella

spp., Enterobacter spp., Proteus spp.)
Enterococcus spp.

Streptococcus spp.
Staphylococcus spp.
(Peptostreptococcus spp.)
| | Streptococcus pneumoniae
Haemophilus influenzae
| || Staphylococcus epidermidis
Staphylococcus aureus;
| |- Enterococcus spp., Candida spp

®± ± ± ± (
( ± ®
® © -
±®± ®± ® ± © ® ®-
© ® ( Enterococcus faecium,
Stenotrophomonas maltophilia, Fiavobacterium spp. ±
± ±© ±© ®± ± (
® ® © $ Candida spp.). ± ®
± ±
± ± ± ± © ( ±-
® ® ® $
® ± ± -
± % ) ± ® ± ® ± -
( ® © ± -
C
CC ± $ ( % ± -
± ) ± ® ®©
± $
±® ± ( ± %
( ± -
± ® ® ®© ± ± )
± ® ± ® C C ±
± ±
± ® $ ±-
± *±®± ( ±± *± %® -
©± ) ® ® ® ±
® ( ± ±® ± ± -
® ± $ ± )0+%)
 ± 0+
± ®±
^ ___________________ _____ ® © ______________________ ______ i
| |
- | *- | | |

| | - | %(
- |- (
+/-
( %(
-
| %(
- | -
%(
- | -
| %(
- | -
| %(
- | -

%(
- | -

| - || %(
- | - ||
APACHE 4*
. | | ||
| | ( | %(
- | -

%(
- | -

| - || || %(
- |
APACHE >15 | || | | (
( "
* %(
- | -

$
,% ® MRS ±
® ± ± ± ±
)

$ ±
)0, 0% ® -
© ± ® © -
( ® T
,24
U)
51.
£ © ± ®
| | | - | | | | | -
|
^u u || su n influenzae; S. Pneumoniae: ) p | u p
p u y ru u N. Meningitidis; S. Aureus u |
ppvu u 0
g- p p| yp
s - p p|p 1
 u
0 u || s- S. aureus; S. Pneumoniae; //. ) p | g- p p| y
u p u y ru - Influenzae; N. Meningitidis; p r | p
u ppvu u Enterobacteriacae s |g- p p|p 4 +
p| s t67

0| uu| |u uu|
p| s t6

d ) p | up -
+-s u p| -
s t6

u
0 u || s- a { } - 2. | uu| |u uu |
u p u y - a { p| s t 0

u ppvu u 3. g- p p| y p -
s g- p p|p- 4 +
p| s t
6

Candida 4. p | p u p|
t
p| p| s -
t6 p -
rs rp up
r pu r ru s r
r pu r u s
p

dp |p uS. aureus ) fu y ry
r'
rp u pu
4 su p|
0p | s
u p|
u S. pneumoniae mu p | u p
H. influemae u | rp | -
N. meningitidis
duy u 1-(('
| Enterobacteriacae; ) | uu
| |u uu|
Pse/idomonas p| s t6 rp | -

0 r p | |u t
p-
S. aureus; S. epidermidis;
p u p| -
Sir. viridans; Corynebacterium
p
JK
0 g- p p| y p -
s g- p p|p 4 +
p| s t6

h t | u s p 1. fu y ry
u pu
5 u
t
p|
0 rp | t
p| -

Streptococci
2. fu y ry
u pu
5

0 up )-s -
u

S. aureus
 ± 0
£ ______________
± ±©
® ±
h pu y S. aureus 1. p |
- || u S. epiderinidis 2. fu y ry
- u pu
5
® 3. mu p )-s u
-

0| uu | |u uu|
0g- p p| yp -
s g- p p|p 4
duy u S. aureus ) | uu| |u uu|
S. epiderinidis p| s tr
6 p |
Enterobacteriacae: 0 up - p p p|
f urt| pt t - p - pr p r p -
u| sp | p p rp-
|
0 r p | p-
p u p|
hu u u h pu y S. aureus; ) mu p )-s +-s
u - || u S. epidermidis u r
p | p| -
ru u Enterobacteriacae s t
puu p u y 0| uu | |u uu|
Pseudonwnas spp.
t
p u u | p u p|
p
0 r p | p-
p| s t6

duy u S. aureus ) p | up -
S. epiderinidis p p p| p -
pr p r p p p| s -
Enterobacteriacae
t
6
Pseudomonas spp.
0rp | | uu |
|u uu| p| s t 6

0u p +-s u-
2 p rp -
|
hu u y h pu y S. epidermidis ) p | up
| u || u 3-s u |u uu|
S. aureus
| uu | p| s t6
Candida spp.
0 u y ry
u pu5 p| s -
t
f rs r p up -
r pu p vu s -
r
gp | u u t| p-
pu s up p
 duy u ivu 1. | uu| |u uu
|
1-(('
| Pseudomonas p| s t r
6 p |
Enterobacteriacae 2. f up - p psp|
p - pr p rp -
Corynebacterium
p p r
p-
JK
|
Aspergillus Rhizopua
0 r p | p-
p u p|
hu u y f u tr Streptococci 1. | uu| |u uu|
| u p p u- p| s t6

ru |p s pp p y p - 2. f up - p p p|
Bacteroides
s
pp |p s p - pr p r p -
Enterobacteriacae
pp p
p| s t6

0rp | p
p| s t
6

gp | u u t| p-
pu s up p
i | pru- S. aureus ) fu y ry
s p Aspergillus Rhizopus u pu" 5 up
| | 3-s u rp |
H. influemae p| s t6

hu s2 a rp | p u p|
A up +-s u
p| s t6

f rs r p up -
r pur ru s r
| 3*- ®© 6 - ± ® )
1
® ±± 5 ±± ( ± ±± ( -
±± )
2
± ± ± © ®
® 5 ,-© ± 5 -
± 6 -© ± 5 ( ( ( ±
6 .-
© ± 5 ( ( ( ( -
)
3
± 5 ± ( ± (±® ± )
4
$-± ® © -± 5
±± - ±®± ® ± ( ±± - ± ( ±
-
± - )
5
±± ( ® ® ±± 5 ±± ( -
±± ( ±± )
6
©± 5© ( ( ( ± )

® ® © ± ©
± ± ® ± ® ® ±-
® ± ( ® ®
 ± © ± ® ©-
®
) ® ® -
$ © -
± ( ±
® % ±± ± -
®( $Klebsiella spp., E.coli) - -
® -± © $ ® -
® ± ® ©
-
± ® ± ® %
( © ± ( ®
© ± ( © - -
±± ) ® ± ( -
± ± ±©
± © ® ± $ -
( %( ( ± ±
® -
® ® ± ®© -
± ) ±-
® ®± ( -
® -± $ *± ( -
±± * % ± ® ® )
± ® ® ±
± ± ± © ® -
± ± ± ( ©±
®$± ±( %)
© ® ( ± ©
® ( ® ± -
±® ) ± ( ±
( ± ® ± ± ®-
® ± © © ) ±
± ±© ±-
® (
± © ± ±
± ± ®±
± )
± ® -
± ± ± © ( ± -
® ± (
 © ® -
± ® ® ® -
®,
-© $ ± % ± ® ®)
® ,
-© - ± (
( ® -
± ( ®± ± ® ®
± © ) ®±
( ® ® -
® ® ® ®± ±
® )
± ® ± ®
( ® ±© -
®± ( ® ® ± -
$ ( ( ® ®-
% ±
®,
-© )
® -
® ± ® ±© ®
® (® ® ± ® -
)
© ±
® ± ® -
± ± (© ± ± ® ©© -
± ® $ ± )
0.%)
® ± ®
± ± ® -
± ® © ® -
( ® ± © ® -
© © ® © -
)
± © © © $ ©% (® ±©
© ± ± ( ± -
®± ® ± ± )
 ± 0.
± ®±
_________ ______________ ® © _______________________________
± - ® 1-s ± ® ®
-
® ©
©
u p | ' pr pp | ' psp|+/-
p
+/- p| s t p| s t
mu p | |u t
p- bur p |u tp-

c p
mu p |u -
e p |u t
p
tp
fu p |u tp
i p ' pr pp
mu | |u tp
o puu|

d |p p mu u | '
- |u t
p- | uu|
APACHE <15, bur p |u t
p-
u fed mu up ' p p|
cu uu|
mu p t| |u tp
m p |u -
tp

d |p p | uu| mu u | |u t
p
APACHE >15 u uu|
c mu up ' p p| '
-
p| p
' fed
m p |u -
tp '
- p| p
d |p p bur p | uu|
ur| ru mu p | cu uu|
eg i mu p e p
fu p
mu u |
o puu|
bus u d |p p mu u | | uu|
ur
| r mu p t| p| p cu uu|
eg i APACHE mu up ' p p| '
-
1)- u fed p| p
m p '
- p| p-

d |p p | uu| mu u | '
- p| p
ur
| r cu uu|
eg i APACHE
2)- ' fed)
 HI ru - | ' pr pp | uu|
pvu vp bur p '- - cu uu|
t vp tp| |u t
p-
mu u | t
p|
up p-
|u t
p
|
mu p |'u p
t
p| |u t
p-

m p ' p
t
p| |u -
t
p

bur p |u t
p-

a vp |s- hrruu u
| | uu| mu p |'u p
u p u
y cu uu| tp| |u t
p-
mu u | |u t
p
tp| mu up ' p p|
m p ' p
t
p| |u -
t
p

du - | uu| mu u | t
p|
u u cu uu| mu p |'u p
tp|

| ' pr pp ^

dp u - f ut v t p u u |ut p uu t
p-
u p u
- y s u y u ut pr u r |v | r
y r py | p p u
| u | -
s e r p p p u p y up u t-
|p p p r p pu p y
up
)) u y e p bur p
mu s
sp |c vp
mu p m p
d |p - bur p | uu|
y e p cu uu|
m p mu u |

f u u
- mu p | | ' pr pp
| mu p | uu|
bur p
cu uu|
mu u |
mdh u u mu p | fu p
u r | mu p l p| u
u u
pr| uup
r p

d |p - cu u | fu p
u u mu u | l p| u
(1)
apuu- p | e p s
u p|
p - b u t mu p s
u p|
rp y
g p| p-
- | p
k tur
p p -
p - | p
$
,% ® MRS ± ± -
® ± ± ± ±
6± ± ± ® ® ±©
-
)

| | | ' ®-
± ® ± ® © © ±©
© © ( ®± ® ®
®® ± ( -
® ® ± $ ±)0
/%)
± 0/

© r ® ,-© ± ® ®
± ± ©
Staphylococcus aureus en e p | ' pr pp
mu p a tp|
b |
mu |
Staphylococcus aureus OP, p | g p| - | p
Staphylococcus b u t p
epidermidis k tur
p p -
| p p
Streptococcus viridans | p |
u u | uu|
cu uu|
mu p |
mu p
Streptococcus pneumoniae mu p | |
mu p u u
| uu|
bur p
cu uu|
c p
mu u |
Enterococcus faecalis | s
u p| p | '
-su p|
u u s
u- b u t
p|
Enterococcus faecium b u t p | s
u p|
±
E. coli, P. mirabilis, | ' pr pp | uu|
mu p | cu uu|
mu p k
mu u |
K.pneumoniae | uu| | p
cu uu| mu up ' p p|
mu u | mu p |
mu p
m p
Enterobacter spp., Citro- mu u | | p
bacterspp., P.vulgaris, Ser- mu p | | uu|
ratia spp. mu p cu uu|
m p
Acinetobacter spp. | uu| | ' p p|
cu uu| mu p t| p| p
mu up ' p p| m p p| p
P.aeruginosa cu uu| | uu|
mu p t| '- p| p f |
mu u | '
- p| p mu up ' p p| '
-
p| p
m p '
- p| p
Burkholderia cepacia cu uu| mu p t|
m p mu up
a- | p

Stenotrophomonas a | p i p ' pr pp
maltophilia ^
Candida spp. k p | u
- ±± ®® ± 6 - ±
±-
)

® ® ±© ® -
± ± ± ± -
 ± ) ± ® ±-
®© ± ®
® i ±± ± ®
( -
©± - © ® ± ®)
± (® ® © ±± ®® ±
S.aureus, ® ®± ±± ( -
± ®± , © )
® ± ±
± ® ± © -
± ( ©± © ® ± ®$ -
®® ± ±± % -
± ®
± ® ± ±-
± ) ± ® ®± -
( ® ® -
® ®® ± ±± -
± ® $ 3
+ 0
-4!% ( ± ® ®
© ® ®
® ) ® ±
®± ± ± -
± $ ®® ± %
) -
( ®® ± -
±± ± ®( ® ± ® -
± ( ± © -
© ) (® ® -
©± © ® ± ( ±
® ± ( ® ±
± © ± ®± ±-
)
® ® ® ® ® -
± ± ® ± C
CC -
± ( ® ® ®
S.pneumonicie, ®® ± ± -
±± ) ± © ©
pneumoniae, ® ± C
CC ± ( -
± ® ± ®-
® ± CO ± $ % (
)
 © ± ® ±© ® -
± © ±
(Enterobacteriaceae)) ± ± ® ®-
± ® ( -
® ( ® ®
® ± © ® ®± ± )
® Klebsiella
pneumoniae $ E.coli% -± ® ±
-± © $ %( © ±
± ± ( ± I-III ±
CO ± ) ± ® ®± -
® ± ® -
± ® ©± ® ® ± ®-
® ) ± -
(® ® © Klebsiella spp., ® ® ± -
® ± )
© ® © -
± ®± ± © -
-± ± (© ±
± ± ± I-III ± ) -
± Enterobacter spp.,
Citrobacter freunclii, Serratia marcescens, P.vulgaris, P.rettgeri. c
© ® ®-
)
± ± ® ® -
± ( ® ® ©
© - Acinetobacter spp., Pseudomonas spp.
®
± ® ± ®
® ® ® ) ± -
® ± ® ± Acinetobacter spp. ® -
± *± ) ® ® ±-
© © ±
± © ( © -±
± ® )
 ® ® -
®
± ® -
) ® -
© ® ®® ± P.aeruginosa $
2+-
4+!% ® ± ® ) ± ® -
® ®® ± P.aeruginosa ® -
± © ® -
( ± ® ® ® ± ®-
®( ± - ® ® ®
1-© ) ® ® ±
® ® ± -. © P.aeruginosa
( ± ( © - -
± )
® ± ±
±® ® ® ± ± $
0+! ® % )
± ( ® ® © ®©
© ® ® ® - -
± ± )
® ± ®
± ® ± )00)
±
)00

® ® ®±
| I-III | | |

± © -. )
* )
©.-/ )
* )
©C )
* )
,(
0©. )
* )
| III-IV | |

© )
* )
©. )
* )
2-.©. )
* )
||

+(
0©/ )® ) ± ,©. )
* )
WW +(
0©/ )® ± ,©. )
* )
£ ,©, )
* )
 - -

±
± *±®± ,(©.-/ )
* )
±± * ,(
0©3-/ )
* )
*± /© )
* )

0©
*©® &
,0 ©
*©® &

® ± 500-,+++ ©, )
* )
± /++ ©, )
* )
± /++ © )
* )
± /++ © )
* )
± 400-1++ © )
* )
|

,© )
* )
± 1++ © )
* )
300-/0+ © )
* )
® ± 0++ ©/ )
* )
& ®
® ® ± -.®
® )

p {
± ®
± ® ® ®
® -
± ®
) ± ® ± ® -
± © ± ± © ®
® ®
)
{ { -
± ® ± ©
± ® ± ) -
± ± - ± ® (
-± ® ©
±
® ® -
± ® ± ± ® ®-
) ® ± ®
 ® ± (
® ® © Enterobcicteriaceae P.aeruginosa.
p { -
± ® -
± ± ®-
® ® ) ® ® -
© ® ± ( ± -
± -
® ± ) ® -
® ± ® ±
) ® -
± © -
®± ± 5
± ±6
± ± ® ® 6
® ® ® ± ± 6
± ± - © 6
± ± ®± ®® ® ± -
±6
± © ± )
± © ± -
$
± ± ± % ®± ± -
± ± ± ) ± -
® ± $ ± ® ®
± . 2(4u% ® ®
® ®± ±
± © ® ± ± ® © ® ± -
® ± ± )
9
© ± $4-, ,+* ±% -
® ®© ® ±® © ® ± -
)
± ©
± ± ± $ © ( -
( ± ® % ® ± 0 , + )
± ± ± ± ± - ®-
® ± ± ( ± -
® ® ) ® ± -
371
® ± ± © ® ©- ± © ±-
® ® ± ±©
® 3 ,
0 ® ± ® -
( ± ® ±®
± ± ± ±T/+
U)
® © ± -± © ®
® ± ® 0
-2 ( -
® ± ± © ± ® $ (
)
% ± ® ® ± ± ± © ©
± ± )
± ± ±
± ± ± )
± (± ± ® © -
( ® ® ®
( ± ® ± ( ± ®
® ® ± ®® )£ -
( ® ©( ± ( -
(® © © ) ©( -
(® ® S.aureus, ±
± ± ± - 2-. ±)
± -
± ® -
® © ® ± -
± ± )
± ± -
) ± ® ± ±
® ± )
% }
{
p } -
{ - {-
% -
}
 | | |
® ®
± {
ar" }
}
} { ' { }
-
} pon" ® ±-
± ± ® ® ± -
± © ® -
® ® ± ± ®± ®
-
± ® ± ® ± ±©-
± ± ±© ) -
® ± ® ® ®
® ± T4
U)
© © © ±® ( © -
± ®
© ( ± ± -
±® $)) ± ®)
(,4
43%T
4U5
1) © ( ®-
® ®± ® ±© © -
)
2) ± ( ±®
-
± ( ®±( ± ®® -
®)
3) - ® © 5
® ± ± ( -
±© ± (® ©
© ( ± ± ± -
)
® ± - ©
± ± ± ® ± ±
©® ) ® ®
± 5
± ( ®( ± -
) ± ± ®
± ® -
©( ® ± ± 6 ± -
® 6 © -
 © ± 6 ® © ®
± © 6 ®± -
© © $ ±
®%
6 ± ±
± 6® ± ± )
® ± ± ±
© ® ± (® ± -
± ©®( ± )
® ± ± ©
® ® ±
© ± ( ® ± ±
© © ± ( ± ® ±-
( ® © © ± )
± ® ©
±( ® © © -
) ( ®
®
± ® ± ±
®© ® ®) ±
- ®
± ( ±
® ± ± ® © ©
® ) ( ±-
( © -
( ® ®± ® ± ) ±
± ® ® ®
± ± ± 3+± ®
-
± +! $3+! ® ©
%
) © ± ®® ( ® -
®± ® ± ±
+
!( )) ® ± ,
+) -
® ± ± -
- ®± ® ± ® ©
± 34!( © ± -
® ± .+!T4U
)
± ®
®± ® ± ± ®) ( -
)) ± ®)
$,443
%(± 5
1) ® ® ± 6
2) ®® ©
© ®6
3) ® ®
®
)
® © -
± ®( -
± ± ±© ® -
®( ±©
± ® ( ® ® ± ± ±-
) ± ± © -
® ± ® ± ® -
- ® ± )
± -
® ± ® ©
± ( -
± ± )
±± ® ( ± ®
( ®
(
± ® ©± ® ®
± 5 ± ± -
±± ®- 4 )!( ± ® -3-© ±-
- 3)
1!( - / )
2!( - ,,)
3!( -
©
± ®.-© ± - 13.4% [9].
® ®± -
© © ± ® ± -
® ©® ( ( ± ® -
± )£ ± ®( ®- ® (
® ® ± ©
( (®-® (®± ® ®® ©
) ®± ( -
± ®® ± -
® ± ( ® ± -
® ® © )
© ® -
®® © )£ ±®-
± 5, % ®± ®® ®
® ® 6 %
®
± ( ® © ( -
 | ±± }
( ±
6. % ± ® $± %6
/
% © © © ® (
® © 60
% ® |±® } ±
® $ ( ± ® ± ( ©©
± %
)
® ±
® ) ®
®± ® (
( ®± ® ± ® ( -
±© ± ®± )£ (
® ± ®± ±
® ®® ± )
£ -± ® ± ® ® ±-
± ®
® ® (
® /+
! ± ©
)
® ® ©© ® ± ©-
® ± ® ®
± © © ©®
( ® ± -
) ® ®( ©-
± ®
( ® ±
± ® ( ± ®
± )£ | ®-
} ®® ± -
® ® ± -
± ® © -® ± ± ©®)
( © ® -
® ®( © ± ( ±
) ± (® ± ®
± ® ® ©-
T4U
)
± ± -
± ® ± ® ±
± ( © (
® ) ® -
± ®
± 5
| ± ®± ® ® ± -
±© ±© © 6
±© ©
6
± ® 6
' ©®
® ® ± ®
-
®
6
' © 6
$
® ± ± % ± -
© )
± ®
± -
®
± ± ±© ( ®
± © ©
± ±©-
( -
®)
± ® ( ©
± ® ± ® ± ® ± ± $
3-/ ±% ± ( -
( ( -3 -
®( )) ® -( © ®)
± ®
® ± ®( ®
± -± ® ± ± -
© /
-0 ® ± -
®
± ®© ®(
® © ± ® ±-
® ©® $ ± ® ( -
± ( © © ( ® -
± ± %
) ®
( ±
±± ( ®± ® ±)01)
® ® ® -
®
± ±© ( ±-
© ± ±© ) ®
® ± ®
± ® ± )02)
 ± ±±

| |

±
± * ©
± ' ±
± .-© ± ' ±
± /-© ± ' ±
©
± ' ± .
-© ± '
$ ( ±
* ©
± '® ' ±
± %
©
± ' ±
± *±®± ' -
±
± ' ±

± 0
2
± ± © T
4U

[ | | [ | | |
|
Esherichia coli £ Bacteroides fragilis
Klebsiella spp. Staphylococcus spp. Bacteroides spp.
Proteus spp. Streptococcus spp. Fusobactcrium spp.
Enterobacter spp. Clostridium spp.
Morganella morganii Peptococcus spp.
© Peptostreptococcus
spp.
Pseudomonas spp. Lactobacillus spp.
± ± ©
± © -
± © ®5 -
± - .
+!( - ,2!( ± ±± - ,
/!( ®
-
-,
.!( -,
+! )
T4U)
| ± } ± © ±
®
± ©± $
.-± -
) ± -
® ® ®± ( -
± -© ± - ± ±)
 ® ® ® ± ±
( ®
( 1
-,+ (
® ® ®
± ® 3! ± ±
± ®,,! ± ®
) ®,(2 ®
± © ± ®
± © ± ® -
± ®
) ± ® ®
©
± © ± -
.-© ± ( ® ( T4U
)
± .-© ± -
© ® ® ® ©
± ® ± ± ± ®
)£ (
)£ ® ® ®
± ® © ± ± ©-
± ( ± ± ® -
® ( ± ® ® -
®) ± ®. -© ± -
) ± ± ± ±® ® -
$ ± 3 % ( ®± ® ® ® ©,
* ( ® ® ±
± )
® ± © /0!(
® © ® ± ± -
± ® ( )
± ® ± ±© -
® ± ± ± ® -
±
± - ±± © T.-± - -
T
4U)
± ± ±
( © ® ± ®±
) (
® ® ±
® © ± ( © -
± ( ±
® ± -
± ± ® ) -
 ± © ®
© ® ® - )
© ® ( ®± ®
±© ® ±
( ( ± ® -
© © ( ®±
± )
± ® ( ® ® -
±± ® ± ) ®-
± ± ± ±
± ® )
± ®© ± /
-© -
± - ®± ) ®
® © ± ± © © ±-
® ± ® © ® ® -
( ± ® -
$ ± ± ± %
) ® -
® ® ± © ® ®
± ( ® ® © (
® ± ©± )

| | | |
± ©
®
± )
® ± ± ®
® ® ± ( ®
® (
± © -
)£ ±®
± (©±® ( ± -
® ® ® ® ±-
® - )
® ®± -
±® (± ( ± ± ± ) ± -
© $±% ® ® ©
± ® © ± ®
± ®
± ± )
 ± 1 +! (® ± ©® -
± ± ( ® ± © ± ©-
( +-30% - © ± ± ,+-15% - -
) ± ®± ± -
© ® ± ± ± ®, *
. ± ® ) ®
( ® Candida sp., ® ,+-
,
0! ± ( ® ± ± © -
)£ ® ® ± ± -
® ± .
£ -
± ± ® ±( ©
© ® ± ± ± )
± ®
± ± $
± © % -
) ± -
± ± ® ± ±
® 2 ® *
. ® -
( ± ,+! ± ® ) ®
(
± ( © ± ± ®
± ® ± ± ± -
)
±
® ® ± ± ) ±-
± ® ± -
± ± ± ± 5
1) ® ® ® ± -
6
2) ® ± ± ( -
± ® ± ®
( ®
± 6
3) ® ± ± -
® ± 6
4) ® ® © -
± ± )
± ( ± ©
®
± © ± ± © )
 ( ± ± ± ®
± -
© ®± © )
® ® ® -
± ®± (
®± ± ®(© ® ( (
®
)£ ±© © -
©® © © ±
± ® ± ®
.
® ®® ± -
± ® ® © -
) ® ( ®
( © ± (
® ® ( ® ® ± ( -
® ® ) ® ® -
® ®
± ®
)
®
± ( ® ®
) ± ® T30
( ,+ U ± -
® ®
± ± ( ®
)£ ©® ® ± ©
® ± ±-
± ) ®
® ± © ©-
®( ® ® ®$ ® ( -
( )) ® ( ® -
® %) ± ± ± -
® ® T,3
2U5
± 0
3

£ ® ®
$ Buchler ®)(
,44
3%

| |
* ± 0.98 ±± 0.72
± 0.87 ± ±
± 0.71
± 0.86 0.22
0.78 ± 0.21
0.75
 ® ( ® ® -
( ± © -
| ® } ®,
0! ±
® ®, +! ± © ®
( )) ± ±
®
) ± ( -
± ± ®© ®
®
± ± ± )
© ® ® ®
± (® ® ® ( ®
-
± ®
( ± ®
$ % ± ± -
)
® ± ® © $® -
® . % ± ± © $ . ±% -
© ® ± ©
T
,1U) ® 0
++ © ® ( -
± ± ® ® ©
$ .+! ,!%) ±© ± ±-
( © ®±± 0+
! ± )
( ± ±
± ± ± © (± ± -
® -
© ± -
® )
.1
! ± ± $± 0
+! ± %
- ± © ® ®
) ® ± ® ®
(® © ± ® ® ©-
±± )
±
± ± ®• )Takeda et al. $
,441
%T,3+
U ± -
± ® © ±-
± $ 2!% ® ± ®®
$
0++ © )
* %) ® ® (® ± ®
®-
± ® ® ( -
©( © ± ( ±
 ) $)) -
®)(+
++%®
® ® ® ®± ± -
® ®± ©® ±
± ® -
± ®
® )
® ± ®
( ±
± ® ® ± ( © ®
± ( ± ®
±
( ± ± ± ± ± -
) ©
± ® © ± © ® (
± ® ® (
® $ ± % ± ©
® $
® ± %
)
± ®± ®© ® )
± © ® ± © ®± -
± ®. ± ) ®®
( ®
± ± ±$ /++ ©® %)
® ® ® ± © -
± ±
± ®± © ® ® ± ® +
++© )

$ - ± +
(0©. ® *
,/
*
( ,
(+©. ® *
,/ *
%)
± 0
++ © -. ® )
© ® ± $± ± /
++ ©® %
)
+
(, ©. ® $
0 +
-, %
)
- ±® $
.-/±
* %
©
- ± )
© ®
± ± ®
± ( ®
® ® ® ±
± ) ± ± -
± © ®
® ,% ( ± ( -
6% ± ( ± ( )
 ± ±® ®
± ® ) -
® ©
± ® ± ( ± © ( (
® ® ± ® ± ± ( ® ® -
)
± ±©
® ) ± -
± ± ± ( ( ( ®
®
)
± ®± ± -
©® $
( ® %
( ) ± ±-
± © ± ®
±© © )
± - ± ® ±
± ± © © © © ® ®
±© ® ®
±® ± - © ( ®± ® ± ®
± © ©)
± ± (
}} { } -
2 } % -
{ } } -
}

R ] ] ]
T V ]T]R] ]T]
® ® ® ± ± ®-
± ® © ) ± -
± ± (
± ® -
± ± © T/
,U)
± ( © ± ® -
® © ® © ® ( ©
 ® ±® - © © )
±® ® © ®
®
± ® $ ©± (
( ( ±( © ® % ±
± $ ± ®%T
.U)
© ® ®® ® ± -
( © ® ± ®-
± ®± ( ®
© ©
) ® ® ® ® -
© ( ( ®
® )
± ® ® ± ©
) ± ® -
± ® ( ® ®±
® ± ±( ® ± © ±
® ( ± ®
$± ® ( ± % ) -
± ® -
© © ® ± ®( © ® -
® ± ® © )
± ® ® ® ± -
± © { -
$ % ) ® ®
± ® 5
1) ± ± ® :
2) ± ± ® :
3) © ®
® ®
:
4) ± ® :
5) ® ± ± ± :
® -
± ± ®( (
®© ±®± ® -
® ® © ) ® -
± ® © T/,U± 5
, ± ®± ± -
 )
2 ±© ± :
e [- ± ® ± ±
± *±®-
± )
n [- ± ® ± ± )
3 ± ®
® ® ® ®
)
4 ® ± ± ± ® ± ®-
®)
5 ± ± ® ®
® -
)
6 ± ± ± -
® )
® ( ± ®
± ©± -
± ) ± ® © ® -
® ® ± ® ) ® ( -
© ® ® ®
± ® ± ®® ±
© ) ®® -
® ® ®
® ± ± )
®®
®
( ® ®± -
® © ®) ± ± ± ®-
® ± ± ®
( ®± © © )
®± © ± ® ®
(
®© [ ® -
® ±) ± ®
®
± ,!(
± © ® ± © ±)
± ® ± ± ®-
® © © ® ± ®(
± ± ®
± ± -
± ® ± ) ±
 © ± ® ± ± ®
® © ® ± ®)
±
® ± ± ® -
®) ± ± ® -
± ± © ) -
® ± ®
® ®± ± )
I ® ® ± ® © ± -
© ® ® -
5 ® ± ( ® ±-
( ( ± - © -
® 6® ± ® ®± ±
± ® ± ( ± ® ±-
© © )
) © ® ± ® ± ®®
® ® ( ®± 5
® 1+± ( ® ±-
± ( ® ± ( ± -
± 6 ®( ® ± -
© ± ® ± ® ±-
)
3 ± ® ± ± -
)
4 © ®
)
5 )
6 ® (
®)
7 )
g ® ® )
4 ©
± ± ®
© )
) )
II ± ± ±©® -
±®)
, ®
± ® ± -
)
® ® ®
® $
± ( ± %) ®
®-
® ® ® -
)
14 ® ( ® ± ± -
®± ® © ( ® -
*± ® )
15 ® ± ® )
® | } -
( ® ± ±®) -
© ® ± ± ® ±-
( ® ©© ± ®
© ± ® ± ± (
® ± ( ®
( ± ®-
± T/U
) ( ® ©
® ± ® ® ® ® ® -
± )
± ±©
± ± | } C ®
± NNIS ® ®±
± ± ® T/
.U)
© ± ® ®
± ( © ± -
± ® -
± © ® ®
® )£ ®± © ® -
®± © ( © -
® ® ± © ±) ® -
®
( ,- ± ± (
± ® ( ® ± -
± ® )
 ( ® ( ®
® ®
( ®
®
© $ )
.+%
)

,14/369
15/441

3< !
i 1/41 I
I 1/47
i
t/81 i
2/180
i
i 5/699
1 5/1009
1

i
m !=

!
s-3 - 2 - 1 0 1 2 3 4 a5
( (
)
.+)® ®® ® ® -
± ± -
T/
,U)

± ® ® ® ±
®
® ® ® ® ® ®
® © ) ® -
®
® ® ( , (
± ) ® ± -
© ± ± ® -
®® ®© )
± ± ± ® -
± ± ®® ® ®-
± ( ® 1- © ±® ® )p
} { -
{ )
* ® ®-
± ± ® ±
® ®± ® (
± ± ± )
 © ± -
± ®
( ® ± © ± ® -
© ® ± )£ ± ± ± ®
® ®± ® ± ®
± ± ® ® ± ® ® ® (
± ± ® ± ± © ± ®
® )
©( ± ® ± (
® ®
® -
± ± ® ) ± ®
© $ ( ® -
© ® ( ± ± ±© © % -
® ® ± ®
(® ® ®
± © ( -
T//U
)
© ® ®
± ® ®
© ® ± )
© ( ±® ® ±® -
± ( ± ® ± ® -
® ® ® -
® )
® ± ® ®
±
)04)
± 0
4
± ( ® ®

T
,12
U
| | | | | |
| S.aureus, 1. - ,)
0©®
*® 3
S.epidermidis, ®
© - -
±
2. ± - 1- ©®
*® 3
®
±
 .) - ,0 ©*© ®
*® ,
+
©
*© , ®

- S.aureus, ± - ,©®
*® 3
5 S.epidermidis, ®
- © - -
±
®
- ,0 ©
*©®
*®
5 S.aureus, 1. ± - ,©®
*®
± ®® ( S.epidermidis
±
-
- ,0 ©
*©®
*®
© S.aureus, 1. ± - ,©®
*®
S.epidermidis
±
- ,0 ©*©®
*®
±® 5 - ± ± - ©® *
® 3
®®
± ( ®
± ©
± - S.aureus, -
±
± - 1++ © ®
*® -
3 ®

± 5 ± - ± - ©®
*® 3
±© ® ( S.aureus, -®
( © ±
-
± - ++ ©®
*®
± - 1++ ©®
*®
± 5 ©± ± - ©®
*® 3
® ± ± ± (© - - ®
- ± ( ) ±
® ® - S. aureus
' ± - 2.5
( ±
©
*©'1++ ©®
*®
± ± £ - ± ' -
® - - , © . *
® colon
± rectum ±
± ' ± - 1- ©
®
*®'0++ ©®
*®

£ ± - ,) ± ' ± - 1- ©
®*
®'0++ ©®
*®
±
 ) ' ±- 2.5
©*©'0++ ©®
*®
® £ ± - 1. ± - ,©®
*® ± -
( ®
( ±
2. ±- ,0+ ©®
*® ± -
©
®
£ ± - 1. ± - ,©®
*®
(
±
(
2. ± - ++ ©®
*®
©
± - £ ± - 1. ± ' ±- ©
® ®* ®'0++ ©®
*®
±
2. ' ± - 2.5
© *©'1++ ©®
*®
| 3 ® ± ,
++ © ± ®
©
) ± ± ®
® ® 5
± / ( / (® ,
)
(± 1 ( ± 3 ) ± (
® ®® ) ±
® ± ±
± © ± ± ± ( ± ® ©
± ± )

®
± ©( ± ®
® ± ® ®
±
© ( ® ® ±
±© $Bacteroides spp.). ±© ±
± ± ( (
± ( ± ± ® ±
( ± ±
( ® ® Bacteroides spp., (
$
,- ©® ® ® %
) ± -
® ®± ± ©
±
± ® $ ( ±± *±®± ,)- )/ ©
® ® ® ( ® ® ® ® ® -
®± ®/ -0 %
)
 ± ± ±© ( -
® ± ®± ±
± © ± C ± $
,- ©® ® ®
( ® ®
® ® ® -
®± ® . -/ % ) ± ® ®
± © ± ±-
± © ±® ® ) ® ±
± ©
± ± ( ® -
( ® ±
±
S.aureus, ± ® ® )
± ® ® ® ± ± ±
® ± ® ®± ® -
- ± ®
) ± ® -
± ± ® (
® ® © ± ± (
®T/,
U)
± ® ® ® © ±
® ) -
© © -
± ® ± ® ( ± -
( ® ® ± ®
® ± )
± ® ± -
± ® ± ±
®±
5
1. ® ± ± -
( ± ± ± ©
® )
2. ± ®
( ±
± ®
® ® -
)
( ®±( ® ® ± -
( © ±® ± ± ±
© 5
1. ® ± ® $± -
± ± %
6
2. ± ® 6
 ® ± ® ±
±® ± ± 6
± ® ® ( ®
©® )
 ] ] SURVIVING SEPSIS CAMPAIGN
]] ]

± ± ®
++ ©) ± © ® © Surviving Sepsis Campaign $ -
± SSC) ,
, © -
® ® ± ±
0
! ® ± 0± )
± ® ± ± ® ® ++/© ) ®
T.2
,U)

]
± ± -
® ) ± ®
® ® ® ±© ± ©
±-
© ( T/
,U)
| |
A. ® ( ® ± ® ,
-©
®
B. ® ± ® ,-© ®
C. ® ± ± ® -© ®
D. ® ® ± ® .
-©
®
E. ® /-© ± 0-© ®
| |
1. ± ® ± ® ±-
6 ± - ± ± $± % ± -
- ± $ % © )
2. ± ® ± ® -
± 6 -® ± - ± ±
$± % ± - ± $ % © )
3. ® ( ± ± ® )
4. ® ± ® ( ± ® -
± ® )
5. ± ®® ± ± ® ( ®-
)
±© ± © ± ® ®®
+ +, ± ( ® ± -
± ± -
) ± ± ± ®± ® ©-
± ±( ® (® -
( )
± © ® ® - ®
± ± ® ± ® ±-
± )
® © ± ® ±©± + +, ± (
® Medline
,+±( ± | } ® ©
) ® ± ± ® ±® 5
( ± ( ( (
)
± ® ® ©
(Surviving Sepsis Campaign, ± SSC) ± ® ++. ©-
® (© ± ®
± ± -
( ± ± ± ) -
± ± ® ( ± ® ± ®
( ± ± ® ® ® ® -
±© ( ®± -
± ± ® ® ± ®
( |± }
( ® ± ®( ±
± ( ± ® ® ±® ±-
) ± ± ± ®
© ® ® ± )
® ± ± 3 -.+ ±® ± -
( ± © ®± ±
± (® ± ± ® ± ® ®
® ±© )
 ± ± ® ( ±
© ± (® ± ® -
® $ ( ( ± ® ® -
® ± % ± ® ± ® (
® ± ® ®± ± ± (
± ± ± ® ©± ± -
$) ® % ®± ® ± ® )
± ± © ® ® (
± ® ) ± ® $
HI), ± © ®® -
( ® ± ® ®)
© ± ©± ® ± ± ®
$ ± ®, ± % ( ©
± ± ® -
±©)
± ± | ± ®
}(
© ± ± © -
® ®© ± ) ± ® ±
©
± ®± ® )
± ®± ® |± ©}
± ± ® ®® )
® ® ± ® ± ®
± ++.© ) ± ±
© ® -
++.© )
| ± } ® ±
± ® ( ± ® (
© ) ± ( ±-
® ® ± ®-
|® ©} ® ) ± ®® ±
) ± ©( -
®± ± ® ® $ © A,B,C,D
%
( ± ® ± ± ± ® ( -
® ± ® ± ±®-
) ( ± ±© (
©
± ± ±© © ± -
© ( ± ®± ® ® -
 ® ( ± ®± ± ® ® -
± ® ( ® ± ® ±
® ( ( ® ®
± ± ± ±-
® ® ) © ( ± -
® ± ® )
± ® ® -
) ± ® © D ± ) -
© ± ® ± -
± ® ± ®
± ®
( ± ©
± ± ©
® )
© ®( ± ( -
± ± ® ± ®
( ® -
)
± ® © (
)

'] ] '
,
) ± ± ® ® -
© $
© ± ± %
± ( ± © ® ( -
± ® ± © ± ® ) ® -
± ® ® © -
® © ) ® 1 ® -
( ® ± © ± ® ® © -
± ®± ® ± ( -
±± 5
w 53
-, ) ) ) 6
w ± ®± 910 ) ))
6
-1
w 9+
)0± *©* ;
w ± ® $® ± ® %±
® ± 92
+!)

) ± ®± ±
± ± ± ®
® ® ( ± ( - ® ±-
® ) ® ( ®
± ® -
® ® 1 ®± ( ± ± ± ©
® ± 3 ) ® -
± ± ® ±
± ® ®( -
± ®®± ) ©
( -
± -
± ) ® ± -
± ( ®
±
± ® ) ®
( ( -
® ± ® ± $,-15
)® - )) %
( ± ® ® ®± ® ©
®
± ) ® ® ±-
®± © ®± )
® © © ( -
®
®± ± ± ± ®
)
) ± ® ® 1 ®± ±
± 2
+! ± -
± ® ± ® ® ®-
® © * ® 3 -, ) ))* ©
-
( ± ® ® -
® ± © 9. +! *±
$ ( + © *©
* % )

±( ± ® ® ± ®-
( ®± ® ± ® ® © -
± 9 2
+!) £ ± © ± ® ±
( ® ® -
®( ) ± ®± ® ®-
® )

' [ '
,
) ± ®© ±
± ® ® ± )±
 ±© © ®
( ±
® ® © ± 5
( © - ®
*® ®
(
®± ±( /
3 ®
) ± © ( -
( 5 ( ©® ( ( -
± ± © ±( ± ± -
©±
± )
D.
± ± © ± T/1U) ±(
,© ± ± ® © -
® © © ) ± © ±
® © ®± ® ©
± © ± ® ®®(® -
©( © ® ® ± 9 (
®± ® ) ± ©( ± ± (® ± -
( ± ± ± ± © $)) -
± ( %
( ® ® (
® ( ®± -
T/
2U) ®(® ± ®( -
® T/3U)
) © ± ® ± ® ± -
( ± ±©
© -® ±) © ±© ± ®
± ® ® ±
® ± ( ( © ± -
± ± ® ® ® © -
± ® ± ® ± )
® ± ® ± ± ©( (
® ± )
D.
© ± ® © ® ® © -
( ± ® ± ± © ®-
± ® ± ± © -
) ( ®± © ®
± ( ® ®
 ) ® ®
± ® ©
® ± ( ® ± )

' ] '
1. ® ± ® -
®© ± ®
± ±
±® ® ® ± )

® ® ® ± |© © -
® } ®
± ®± -
± ± ± )
( ± ®
® ® ®
±
® ±© © ®
± ± © ® © ) ± ® ±-
± ± ® © ®-
± ® © -
® - ®± © ± ®± ® ©(
® ±
®
® ) ± ± ® ± ( -
± ± ± (® ® ( ©
© ®® )±
2. ® ± ®
± ®± ± ± ®
( -
® ®® © ® $ ± © ®%
® ±© ) -
® ± ® ® ® ® ® ®
© ®
( ± ±-
)
D.
£ ® ® ® ®
®5 ± $
®±
® %
( ® © ±® ( ± © (
® ® © ®® -
 ® ± )
® ± ® © ©
± ( ± -
( ® ® ®® © (
® ± ) ®
( ± ± -
± ±© ®± T/ 4)
250, 251, 252].
© ± ® ®
(® -
( ® © ® (® ± ©-
± ® © ® ( ®
( ® ± ± -
© ®
( ® ® ± © -® ± © ® -
® ) ± © © ± ® -
® ®
®± ® © ± ± ® -
© ® ± ± )
± ± ± © -
© ) ( ® -
-
® ± - ±
) ± ±
® ( ® ( © -
® ® -
T0.(0/(0 0(01U)
.) ® /
3-
2 )® ® ® ±© ±
) ®± ± ® -
® © ® ( ® ®
® ( ± ± -
©) ± © -® ±
± ® ( ® ± -
® ( )± ± ±
403
 ± 2
-,+ ® ± ± ± -
)

A. ± ® -
® ± ® ® -
)

B, ± ® ® ± ®
® ® -
± ± ) ©
® ® ± ®-
® )

± ® ® ±
© ® ± ±
® ©( ® -
© ± ® © ( -
Candida ± ® ®(Clostridium difficile ± ® -
- Enterococcus faecium. (
± ® © ± -
± ± -
® ® ± ® -
®
)
4. ± ®
± ( ® ± -
±®± (
± ± ®
± ( -
® ® © ® ©
© © )

± ± ® ( ® ± ®
± ® ± © © ± -
© ® ) ( ± ( ±
± ® ± -
404
 ± © ± -
± ® )

D. )
,
) ± ± -
± ® ± © ( © ±-
® ® 5 ® ± © ©
© ( ( ± ® -
± ± ® ±
± © © $ ±
)1+
%)
± 1
+
± © T
.2,J

| |
® ±
£ ±®

± ( ± ©

± | ®} ®
®
± ® ±
® ® -
® ®
± | ±} © ® ® -
±
± ©© ±-

± -

± ± ®± ± ± -
± ± ®( ±©®( -
 ©® ( ± ±©® © ±©® ( ± ®± © -
® © ± ® -
± ® )
2. ± ® ± ® ± ±
® ± © ® ± ®) ®-
® ® ± ® © ± -
± ( ® ( ® ( ® ©-
®6® (® ± ® ± ® ®-
± ± ©) ± -
® ± ® ® T0
2U)

3. ® ®
± © ( ®
± © -
± © © ©
±( ® ( ± -
( ± © ± (® -
± ® ± ®
± ± ® ±-
® © ® )

± ® ® ® ® -
( ©
®
± ©
±® ± ® ®
± -
® ® ± )
± ® ± ± ± ®
® $
© ® %) ®® ® ± ®
® ± ® ©
T0
3U)
4. ± ® ® ®± ± -
± ± © ( -
± ± ( ± ® ©© ® -
© )

( ® ®
± -
 ± ® ® ± ®)
± ( © ®± ® -
( ® -
± ) ( ± ±
± ± © ® ©
( ± ± ® -
± ± ® ± ®(
± ± ± ® ©
[259].

]' ] '
®® ®
® $,
-2).
1. ® ® ±
±± ± ±± ®
) ©
® ( ® ± ® © ® ©
© ( ® )

± ® ® -
± ® ® ®
( - ± ± ± ® (
® ® ±± ±± ®
© ( ± ® ±
® ±
± ±
± 6 ® ® (®-
( ± T1+
(
261, 262].
± ±
± ® ©
± ( ±± ® (® ®± ® © ± -
±± ± ± ©
± ( ±
± ( ® ± )
2. ® ® © ® ©-
®± ® 0
++-,+
++ ± ±
± ®
±. ++ +
-0+± ±± ®® .+ 6 ®
®
® ® ® $®± %
± $ ® © % ©-
)

} [ ± ±
®± ® ® ± ® © -
± )| c } [- ( ± ± ® -
± © ® ® ± © (®
© ± ® ®® -
) ® © ( ± ©
®® ± ©
± ®
±© ) ® ©
® ± ® ) ±
® ± ±
±
± $
capillary leak) ± ® ® ®-
|} } ® ® -
± ) ® ® ©
® ®® -
' ® ® ± -
± )

F. ]
,
) ± ® ® ®
® ® ® ± ®
± -
© ®
( ± ® ) -
® ® ± ± -
© © ( ® ® ®-
( © © ®± -
® )
5&

± ± ®
± -
± © ® (® ©± ® ® © ± -
 © ± ®
± ® ®± ) ( -
® ® ± -
± © © ®
±
® © ® ) ±
± © ®± ®
± ±
( ( ± ®)
® - ± ©-
© ± ® ) -
± ® ± ± © ®-
®( -
® ®® ® ® -
± T1.(1 /
U)
) ± ± $ ± ®®
± %-® ®© ® -
± © )
D.
® ® ± ® -
®© ® ± © ± © (
± ® ± ® ± -
® ± ± $ -
± (® ± ® ®
© ± % ± $ ©
%) ± - © (
®© ® ® ) ®± ®
± ®± ® (® ®
®± © ) ± ®±-
® ± ®± ® (
±
®± © ® -
) ± ® ®-
© ® ± © ) ±
® ± ± ( ® ® © -
® )
 ± ± ± ±
( ±® ®
® © ® )
3. ± ® ® ± ±
± ± ± -
)

± ® ± ® - ±(
® ® ® ± ±
± ® ± ® ® ©
± $ ® ® © (
± ( (® ® ®±
% ® ± ® © $® ®
© ± ® ± ® ± ( ± ±-
© ± ® ( ± ± © ± -
® ± %) ( -
® ® ± ± ±
± T1
0(266]
4. ( ®® ® ®
( -
® ± $ ± -
® ®± %
)

® ± © ®
±-
± ® (® ®
± ® ± © ® ± -
± ± © ®
± )
±( ® ®
( ®-
© ® © ± ( ))
® ± ± -
T1
.U) ® ± © ®
± ± ( ®±( ® -
± ) ® ® ±
® ± © (®± ®
 ® )
0
) ± ® ® ® -
® ® -
®
® ® ®® ± )
± ± ® ± ® ( ® ® -
® ( ® ® ® -
± ± ) ± ®
® ± © ± ® ® +)
+,-
0. 04 * ) ± © )

® ± ® ±
®( © ® -
( ± ® ® ) -
® ± ± (® -
® ® © -
© ® ® ® © ®
© -® ± © ® ) ± ± ® -
± ® ± ® ± ® -
® ( ± 7- )
0± & &
2
( ± ± ® ®
) ± ® ® ( -
® ® ® ©
( ±
± © ® ± ® ®® ,
-2
T1 2U
)£ ®± ±
® ( )) © ® ® ±
® ) © ® ) ® -
9+(
+/ * ® ( ® -
© ® ® T13
(
269, 270].

G. ] '
1. ® ® ( -
® ® ± ( ± ® -
± © ± ® ) -
± ®
± © ® )

- ®© ± ® -
® ® ®
± ±
±®© ± $± ± ® -
® % ® ±-
®± ) ® ® (
®© ® ±
± ( ± ± ® ® ) -
± ± ® -
® ( ( ± ) ©
® ® © ± ± ©
®± ( © ® (® $ -
± % $ %( © ±
± ® ± ± © ® ©
± © ® ± ©® )
) © ®± © ± -
±® ± ©| ± ©} ® )

® ® ± -
± ® ( ®± ® ± ®
± ( ± ± ± ®
± ®± ± ® ®
© ± ® T2
,( 2U
) ©
± ± ® ®-
® ± ® © ( -
® ® )

' ] '
,
) ± ( ( -
® ® ± ( ®
± ® © ± © ®± ( -
® ® ®
® ®$©
+
200-.+©
* ® 2 ( (
± ± .
-/ %
)

± ® ±-
± ® ( ® ® ±
© ( ± ±
® ® ±-
® $ ± -
® ® ± 74 © *± ± ± ®® -
%T2 .U) ® ± ± -
® ± ± ® ± -
± T2 /
( 2 0U
) ® -
± ® ® ± ± ± ©
$ ± ± ®
± 74 + ) ))( -
± ® ® ®%( ® ± ®
± ® $ ± 94 + ) )) ± -
® ®%
)
) ± ® -
± ®
® 0+ © ± ® ® ± -
® ± ± $®± ®
± .+
-1+ ± ® ® ± 94
©
*± % ) ± -
± ± ® -
± ± ®)

± ® ±( ®± ®
± 94 ©*± ± - ± 0+ © ®-
®
± ± (® ® ± © T2 1
U) -
± ± ® ±( | ®} -
® ± ± ® ® ®(
± ± ) © (± -
 ± ® ± ± ±
- T2
.U) -
± ® © ®
5 © ® ±( © ± ± -
( ® ® ± ± ± (
®± ® ± ± ±
® T22(23(24U) ® -
( ± ©
® - ± ( )) (® ±
© ( ®
± ® ®
±)
®
) ® -
® ± ®® ± © © )

® ± ± ® ± ® ® ®5
®± ± ± ± -
±®
± ± ± ( ® ± ) ® -
® ± ± ® ± ®± ±
± ± ®
± ± ± T2
.( 2
0U
® ± ® ± ± ®®
© ® 1
[274].
c. ®
®® ± )
.
± ® ± © -
±© | } ± ©
®T3+U
)
d. ®± ®
± $
0+© ± /* )%
)

± ® ± ±
± $
0+©
%T2
.U) ))
© ®
414
 ± ® ( ® ®
± ® ± )
2. ®9 .+
+ ©© ®
± ± ® ± ± ± ±
© )

± ® ® ®
± ® ® - ± ®
( ± ± (
± ± ± ± © (
®® ± ±
® ± ® T3,
( 3( 3 .(3/
U) ©
© ® ± ± -
® ® © ( © )
3. ® ( ±
± ± ) ( ® ± -
± ® ± ± ±-
® ®( ± ±®± -
®® ± ©
)

® ± ® ( ® (
® ± -
® © ( ± ±
( ® ®
± ±© ®
)

<
'] ] ]]
] "
,
) ® -
(APACHE II 9 0
( ® ( -
(® ® ARDS %
( ± -
® ( ® ® ± ±-
® ( ® ® ±-
415
 ± ) ± ® -
® ® ± 5
± 1
,
® T
.2,
U

® ® ®
- ® $
® ). )
%© © -
- ±
- ® $
® ) )
%
" - ± ± ±-
- © ® ± ®6 ±
± ® ©±®
- ® ® ®-
(© ©
± ± ©

± ® -
±

® ® ® -
®9.
+++
+

± ± ± -
©± ® ©± ® ® ®-
± ) ± ±
® ©± ( © ©-
± ®® ± ± ® ® ( ± -
® ± ± -
± ® T3/
U( ± ® ® -
®® ® © ®)

J. )
,
) ± ± © -
® ® ±® ( -
( ± ® ±± -
416
 $) ® %
(
® ± ® ± ® 72
+
©
*±± ® © ©± 2
+ +©
-4 *
±)

( ± ® © © ± ±
® ± ± ± ®± -
( ® ® ± ® Critical Care
(Transfusion Requirements in Critical Care) ±© (
® © © ± 2+ +©
-4 *
± ® ± ± ® -
®® ) © 2+© *± ®-
®± ) ® -
®± ® ® ± (
® ± ± T30( 3 1 ( 32U
) | -
©
} ® ®± .+
!-© © -
® ± ®
® ® 1 ®± © )
2. £ ® ® ® ©
± ( ® ± (
± ® ( © ® -
© ± ( -
(® ® ® ®)

± ( ± ®-
®
( ±
± ® ± ® ±
® ®
®± ± T33(3
4U) ® -
± © ®-
® © )
3. ± ® ® ± ± -
± ® ® ®
± ± ® ® ® ® ± ® -
)
 ( ± ± ® ±
® ± ® ± -
±® ± ®( -
± © ® ±
©± ( © ® ©±
® $®± ®© ® ( ± ©
± ®© ® %
( ± ® © ®
± © ± ® ® T4
+(
291, 292].
4. ± ± ± -
© ® )

C
CC ± © ± ® -
® ± ® ± ® ±
± -
± ± ® ® 3
) ± ± ®
® ® © © -
T4
.U)
5. ± ±
3 9
( © ± ® 70 +
++* ®
± $
0, + *±
%(
® ® ® ) -
® ( © ± ® ®±
3
5000-.+
+++
* n
(3-0,+u*
±% ® ± -
® ) ± © ± ® ®
3
® 90 ++
++* (> 50x10%).

( ®
( -
± ± ± ± (
± ) ®
±© ( ®
(
418
 ® ± ® ±© T4
+(4U
)

' ]
]^ ] ][ " ( (ARDS).
1. * ± © ® ®® ®
® ± ± ®± ® ®
$ %
) ± ± ® ® ® -
® | ©} $
1 ±*© ±%
± 7.+ )
® ))

± ,+± ® ± ± -
® ± ® ±
® © ®± ® ± -
® T4 /( 40
( 4 1( 42U
)£ ± ® ± -
± ± ( ©
± ± ±-
®± ® ± (® ±
± © T43( 44(.++U
) ± ± -
® © ± ( ® ©
®
± ( ± 4!- -
®
(® ± ® 1 ± *© ±© ©
® $ ® , ± *©% ± 7. + ) ® ))
[300].
2. $© ® ©®
( ® © % -
* ( ± -
® ® ®± ± )

® ® © ±©-
± ® ( ®± ® ± ( ®±
( ± © ®
± © ® )
© ® ©
® ® ± ® ± -
® ± ® ± T
.+,(.
+U) -
 ( ± ® ± ± ® ( ± -
± ± ® © ® ±-
© ®± ® ± ( ± ± -
± ®± ( ® ± ® © -
± ® ± ± T
.++U
) ± ®
© © ® ® -
± ® ® -
® ®± ) ® -
± ±
® © )
3. ± ®± ± ® ±
©( ±± ±© © ® ® ) -
® ( ® -
± ® FiCb, ± -
® © - ® ® )
® ± ± ©
©
± ±® © ± ±©-
$± ® ± (
® ®± ±© % )

® * ±® ±
± ®© T
.+.
(.+/
(.+
0U)£ ®± -
® +2( © ® ± -
± (± )
4. ± ® ± -
© ± ± ± * (
± ® ® © ± ) -
± ® ± ( ± © ± ± ®
±-
±© ± ® )

± ± ± ± ± ®-
±( ± ® ® * ©-
© ± ± ± ® ± -
 © T.
+1(. +2(. +
3(. +4(.,+U
) ± -
± ® ( ® © ± ±-
® 2 * ( ± ± ® ® -
® * ( (post hoc ± ©®-
± ® ± ± ©
Pa02/Fi02 T.+
4U) ± ± ±
® ® ® ©
± ( ®± ± -
± ± ® ®
( ±©
± -
)
5. ± ® ( ± -
® ±± ± ©±® ® ( -
©± /0u
( ® ® ® ± -
® ® $ %
)

±± ± ±
T. ,
,U) ® ± © ± ± ® -
(© ® ® ®© -
) ®® ® ±± ± ± -
® ( ® ® )
6. ± ± ± ®®
± ±
± ® ) -
® ( © ± ®
±® ± -
5
% © ® ®
%© ± $ ® -
®%
6
®% ® ® ± ®
6
©% ® ± © ® ± ® ±
® 6
% ® FiC>2
421
 ± ± ±)
± ( ± -
® ± ) -
®± ®
±
® ( ± ± © -
® © ®
± ® ± ® 0 )® ) )
± - )

® ± ® ±( ®
© ± ± T.
,( .,.
(
.
,/U
) ( ® ± ® ± ©
± ® ® ® * (
±© ( ® * ± -
± © ± ®
)
® ± ® ®
® © )

L. ] [] ] ]
] ]'
1. ± ± ± ® ( ± ±
) ®
® ® ®
± )

2. ± ® ® ± -
® ® (±
®
® ± ± ©
± ±
) ® ± ® ®
®
± ®
® ± -
± ©( © ( ( -
® ®
)
 o{ ) *
" ® ( ±
± ± ( ( ® ®
± © ® ± T
.,0U
) ®
® ®® ±
± ©(
® ® T
.,1
U) ± ® -
±® ®® ® ® ® ±
± ± ( ® ± ± © ± -
± ® T.,
2U)
.) ± ± ® ©
± ®$ ® ® -
% - ± ± ± ±
®® ± ) ± -
± ® ± ( ® ® (
± ± ® ± ® $± % ®
® (
± ® ® /- -
± ©± ± )

± ± ± ± ±
± ± ® ± ® -
± ® © ± ± © ® T.
,3(.,4
(
.+
(.,
(. (.. (./
(.0 U
) ± ± © ±
® ± ©
±
± T
.1(.2U)

' [ ] '
,) ± ® ± ® ±
w ® ©
± ® ®
7,0+ ©! $73 ( ±*±%
) ± ® ® ± -
± ©
± ± ®± ±
©± ) ©
± ®
± ± ( ©
©± ± ® ® ± ©
±
 +
30-1 ) ± ± ® / )

± ± ® ( ®
± © ®( ±
± ± ® ® ( © ± ®± -
® ® ®® ± ± ®-
©± 3+
-,,
+ © ! $ /
)/ )
-1, *
±%)£ © ®®
©
± ± ±±± ®® ± ) ®
©
± ± ®± (® ± ®® - -
± ) ± ± ± © © ± ) ±-
© ( ± ® -
± ) ® ± ± -
® ±( ± ± ± ©
® © ± /(
/ (
-1, ±*±
( ±
©
± ® 3 (
. ±*± ± ± ( ®
-
± ® )£ ® (® -
( © © ± ) -® ( ± ®
©± ® ® ± ± ® ® ®-
© ® ® ± T.3U) ®
©
± ® ± ± ± -
± ®± ® ± )
) ± ± © ± © ±
± ®± ± ± -
± ® ± © )

± © (© © ± -
±© ®® ©± .
± $± ©
± © © ± -
% © ®
® 0
! ±, +
! ( ±-
± ( ± ± © $
± ©%T
..+U
)
 >' ] ] ] ]'
,
) ® © ± (
® © ± ® © ±
®®± ) ® © ± ®
±-
± ±© ® © ± © -
± ®
)

± ® ® ®®±
± ± ±-
± ®T
..,
(. .U) -
© ± ± © -
± ) ® -
± ® ± ± ® ® ® -
® © ± ®± ® -
± )

' ] '
,
) $ ± ± ©
± ®® % ± ± © -
± - 92
),0 )
® ®
® ©
®® ± ( ® ®
± ± ( ± )

® ± -
®± ® © -
) ® ± ® ( ® ® -
® ® ® NaCl ® ® ± -
® 92
),.
-2)
,0( ± -
® © ± ® ®-
T.
..(../U)
 ' [ [ ] [
"
[ '
,
) ± - ± ±
± ± ® ©
© (± ®® ± ± © ®) ±
®( ® © $-
( ( ± ©± (
® ® ( ® ± % (
$± ® ® ® ±® -
®% ± ® ±
$± © ® ( ® -
%
) ® ®
$ ( ± ® %
( -
±© )

± ± ® ± ® ±
® ± ( ± ®-
( ® ± ®
(®± ± ± ± ® T
..0(
.
.1(..
2U)£ ± © ± ® -
® ± )

Q. ] '
,
) ± ± ±
± ® ®
) © 2 ® ±
® ( ± ®± ® )
© ®± ® ® -
© 2 ® ))
( ± -
® ® ) ® ® -
± ± ®± ®®± ®
® © 2 ®)

± ® ± ±-
426
 ± ® ® ± ( ± -
® ( ® ± ® ®
® (®± ± ± ± ® -
T.
.3(..4(.
/+(.
/,U)£ ® ® ± -
± ) -
® ( ( ± ® ®
± $ ©± ( ( © %
(
® ® ± -
)

R. ^] ] ]
] ] '
,
) ± ( ®± ®-
± ± ± ( ±
) ( -
± ± ± ©(
® ± ©)

® ± ©(
® © -
( ± ® -
± ® ) ® -
( ± ± ® ( ®-
®® ± ® ® ± ©)
® ± ± (
®® (® ( © ®± ® -
© ±® ( © ±© -
® )

S. ] ] ] '
± -
( ± ® ± -
© ® T.
/U) ±
® ±© ( ±® ± ) -
 ± ( ± ® ± ± ± -
© ( ® )
± ®
± ® ® ® ®±-
® ® W 6 ® ± ± ) American
Heart Association ± ± © ®-
± © T
./.U
) ®
± ± ® ± ®® ( -
±± ® ± ±± ®
± ± ® ® -
T
.//U) ± ® ( -
± ± ® ® ®± ± ® ±±
±± $ ( ± ( - ©
± NaCl + )
4 !% ± ©T .//U
)
® ±( ± ( ® -
® ± ± ®© ± ( ± ®
- © ) ± ± ( ® -
± ± ± ® ®± ±± ± ® (
±± ® ®±®± ± ± ® ®-
± ) ± ®© ±
+ © *© 0-,+ ( ® ®
± ± © ® ( ( (
± ±
± ® ® )
± ± ®± ( ® ± ©
® ® ®± -
) ± ® ± ( ®±
± ± ® ) ( ±
® ± © ( ® ± ® -
±± ) ®-
© ©± ( ± ®
)
± ±
/+-1+ ±*©( © ®
[345, 346, 347].
3. $± ± ® ± ± ®
%
) ± -
± ± ® ® -
®
± (® ®
®
± ( ± -
® ®
-
± ) ® ® (® ± -
( © ®
® ( ± -
± ®
± ® ± ) ®
± ®
© ( ) -
® ® ® ± ± -
) -
® ® ®
® ± ± ± T
./2U
)
± ® )
± ® ® ± ® (
© ± ® -
®
± ( ®-
T./2
(
.
/3U
) ® ± ±® -
® $ ©
± % ± ® -
® ® ® ± ± -
® ® -
®
± ) ® -
± ± ® ®
± ± ( ©±
± ± ® ±-
© T./
4U) ± ( © -
® ® © © © ®-
® © © © ®± (
®© ± ® ® ± (
± ® ± ® © ® -
T.0
+).0,
). 0U
) ® ©
± © ± ® ( ±± $
® 0
 1 ®
* % ± ± ±® -
® T
.0.
U)
4. ® ±
®
± 5 ± ±
± ® ( )
( ±-
± ( ± ( ±
, ±*©
* ( ± ( -
± ® ® ( ±
± ® ± 2 +!) © ®-
± ± ± © © ®-
± © ( (
® ±® ( -
± -® ± ®± ±
± ( ® ±
© ©
± ) ® ©
) ® ( ®±-
± ± ) ± ±
±© ( ® ± ®
-
± ± . ). 1)+±* *2 -
± ± ® ®± $ -
± ®
± * %)
5.
, © (
T
.0/
U)
6. © ± ©
± ® ±
® ®± ® ) © -
®± ± © -
T
.00(.
01U
( ( ® ©® -
®± ® ±® ±©
© ®) ® -
± ( ® ± -
± © ®
± ,
3 ©! $
/41 ±*±
%) -
© ± ® ± ®
 ) ®± ® ± 74
©
! $/ 3 ±*±% ± - ± -
® © ® ) ® -
® ± ± ® ± ®±
| ® }© $
® 0 ® ® -
% ± ©) ± ±
® ® T.02(.
03U) ® ® -
,- ©*© $ ® ± © ©
® % 0+ ©*© ± -
© ± ( ®® ® ® ®
- )

© ® ±© ® . © )£
® ± ©( ® ± -
$ (± ®® %
± ± ( ® ± ) ± -
- ± ± ® ( ® ± ®-
( ± ± -
® )£ ± ® ± ®± ® -
( ± ± ± -
©± (® ® T
.04(. 1+
U) ®
± ® ± ® ® ± )
8. - -
® ± ± ® ®
®± ® -
± ® ± ) -
® ± ± ® ± ± -
® ±® ® -
9
± ± ±® ,0
++*± $,)
0, + ±%
( -
± ± ® 2 © ± - ©± -
± ± T .
1,(.1U)
9. ± ±
® ± ® ) ±
± ® ( (®-
 ± ( ± 0
! ) -
± ® © ± ± -
® )
10. ± ® ( ± -
± ® ® ( -
® ± ) ± ® ±( ± ® © -
± ® ± (
® ± T .
1.(.1/
U) ® ± ( ©±
®± ± ± © -
± ® ) © ±
® ®( ± (
® 2 ± ( ® )
± ± ® © -
± ± ±
± ± ±© © (
® ± ± -
® ® ® ± )
12. ( © ® ® -
®
® ( ® ©-
© ± )£ ( ® ©± /-
1 © *©* ± ®® ,+! ©
± ® NaCl +
(/0
!) -
® ± ® ( ± ©© ©± -
© ± ± ® ± ) ®
© ©± ( ± ± ± -
± © ± )
13. ® ® ±©-
± ®± ± (
® -± ® ± -
® ® )
14. ® ± ® (
± ±
® ® © © ± ® ±
® ± 9,
+© !$,
++©*±
%)
15. ± ±- (
± ® ® ©± ± ®
®
± © ® ± ± -
© ) (® ± -
® ± ± ± ® -
± © ® ± ®
) -
± ± ± ® ± ± © © -
® © ©± ± ± T
.10
U)
16.
£ ± ®± -(
) ® ± © ± -
© ( ® ( -
®± 3+! ® 0+
! ) -
± ® ( ± , ® © ®
£ 63 , ® ® ±(1 ® -
± ± ® ® ,© $ / -
® /± % ± ) £ ±-
± ( ± ± -
± T.
11(.1
2(.13U
)

] ]
] '
± ® ± -
± ( ± ®
®
± ®© )
± Surviving Sepsis Campaign (SSC) -
± ® ® ± ® ® ±
® ± ±® (© ± ®-
® ® ±® © -
)
( ® ±
( ± © ®
±
® ± - ® -
 ± ®± ± )
( ® -
( ± ± © -
®® ) ®± -
± © ®® © ± ®
± )SSC ±
( ± ± ® ( ®-
® )
 ] ]
] ] ]] ]

± © ±-
© © ® ± ± © ® ±
®± ® ® ® ©
± ± ) -
®± ®© - ©( ± -
® | ©} ®± © -
© ± ® ± ® ±© T.2(.14U
)
± ® ± -
± ± ± ® ±
® ® ® ± ± -
± ® -± ® © ® ®
± ) ±® -
± ± ± A-IgM- ± $ -, % ®-
± ® © ® ©
T.2U) ® ±® 4+- © ® ®± ±®
®
± ( ±© © ® ©-
® ± ± ®
SIRS- ( ®© ±
® ® ® - (TNF, IL-I, 1(3 )
% -
®® ± ± (IL-4, ,+(,,(, . )
% ®)£ -
®±± R. Bone $ ,4 41%T ,++U®®
(compensatory antiinflammotory
response syndrome - CARS)
SIRS CARS ± -
± ± ® ©® ® 5
®± ® SlRS- ® ® ® -
± $ %6 © -
$ ± ± % 6 6
®± ® CARS ® (
® ® © *± ® ®® ± -
6
 ± ® SIRS CARS - © -
$
®® ® %)
( ® -
® ± ± ® ±© ±-
© ( ± ± ® -
® ± ± ® ®, ®±
± ± ± © ) ©( © ± -
± ( SIRS ® ± ± -
( ± ® -
© ®© T.2U
)
( ®± ®
( ( ®±(
± © ±© ± © ® -
® ® - ®® ± ± -
®) ± ,++
® ( © -
±© © © ) ) ± ®
± ® ± ® ± ± ®
±®© ® ® ® ( ® -
) ® ©-
± ± ® ®( ± ®-
©© T.2
(3,U
)
± ± -
® ®© ,440© ) ® ±±-
© ® ( ± © ±± ©
±® ( ± © ( ±©
® ® ®
-
© ® ® T
23U
)
® ® ± ± ® (
± ± © ±-
) ( ® ® ( ®±
± ( ( ± -
±® ( ± ®® ) ± ®
± ± ± ® ( ±-
± © ±
( ± ± ( ± -
± ± ± ± % -1,
% © ® -
± ® 5 ® ± ± -
( ± ® ± ± ) ± ±-
± ( | © ±} ± -
T
.2+
U)
® -
®
± ) ± ± ® ± -
® ± ) ± ®±
}- drotrecogin-alfa), ®-
® ±® - $ - ®-
® ® ® ± -
± ± ± 6 ® ® -
± ® ± ( ©± (
± ± ± ® ®® ± ± (
± ® ® %
) PROWESS
c -r -
" ± ®
drotrecogin-alfa ® 41 ® ) ± ® ,14 + ±
® ® ± ® ® ± ± ± 1),! ®
± ,4)
/!® ± )
( ± ±
® ©± ± ix ® ® ® ±)
| | ' ± ± (
±±± ± SIRS, © -
± ® ± ± ±(
®± ®® ± ± ±-
® ± ) ® ®
± (® ± ® -
®± ± ±® ) ©( -
® ®( ® ± ±-
± ±( ® ® ))$ -
® % ®±± } [% -
± ® ® ®
® ® © )
®± ® ®© ± © (® -
 ( ± ± -
® ® ©± © ® -
® ® ® )
± ±
© ± ® ) -
® ± ® © ± © ±
) ± ± ® ± ®-
® ± - ±±± ®
( ©± -
® | }
( ± ® ® ±
± ± ® ) ± ©(®
± ® © © ± ® ©
± ® ® ©
±® ± )
± ® ® © ± ±
©± ( ©± ® ® ( -
© © ( ± ± ±
± © ® [ © ® -
®± ® - ®® ± ±-
®®® ± ± © ± ©
© ) ± ® ± ® -
± © ©± ® ®( ® ® -
© ® ± )
± ± ± ® ®
± - © ® -
± ( -
© ± ® © ® ± ±
© ± ® T,41 U)
 ] ]

± © ± (
® ± ® ® ±-
±© ® © -
± ® ± -
®
) ± ( ±®± ( ± -
± © ®-
)
± ® ± ®-
® ( ± ( ©
± © ©
) © ( ® ® ±© ®
± ± ® ® ® -
®$ ( ( ( ± ( -
± ± )%
( © ± -
± ( ± ± ( -
® ) ® ± ®
® ® © © ® $
| ©
±}% © ® ±© (
± ® ® ® ®
± -
)
( © ® ©
± ( ® ± ±
± ®
(
| © ±}
( ® ® ( -
® ® ± ©-
)
® ® ® ®
± © )
© ©( ® ®-
± ® © ( ® -
® ® ®( ® ±
± ( © © ®
± -
± ® ± © ± © -
± © ® ± © -
 ) © ± ® ±(® ( -
± ( ® -® (
© ± ( ±® ± © -
® ©± ® © ±® )
© © ®±± ± ±
® ® ® ( ± )
( ( © ± -
± ( ± ±
±© ( ± ±
±© -
® ® ® ®® ® )
 °

1. ± ® )) ( )) ( ± )) )* *)5( -
)(, 43 .)(,3 )
2. )) ( ® )) ( ® )) ±© )- ®5
®( 1981,- ,1+)
3. © ±® )) ® ) ( )) ©-
® ± ± ± ®
±® ® © ® ) *
* ±© - 1991 -N. 1
- 0 0-58.
4. ))£ © ± ® ©±
© )II ( ±® i ® ) - 1997.
- »,) () . 4-53.
5. ± )) ( ® ® )) ( )) ± ® ± -
© ® © ® ± © ®
® ® )* * ± ) ) ±) - 1981. - ) 4) ( H, )
(
)
0 1
+-562.
6. )) ± © ±
® ± ± ®
)* * © ) - 1972. -
»4) () 3/-87.
7. ± £)) ( ± )) ± 5 -
© )** ©) - 1999. - », +)( )/-28.
8. ± )) ( ±© )) ( ± ® ))
( ± ))(
± ® )) ( ± )) ± ® ® ±-
® )* * ±© ±© ) - 1999.
-». )() .3 -46.
9. ± )) ( ±© ))( ± ))( ± ® )) ( -
® )) © ± ±-
© )* * ±© ±© )- 1998. - »/ )- ) ,1-
19.
10. ± )) ( ±© )) ( )) ( ± ))( -
± ® )) ± ® ® )
** ±© ±© ) - 1997. - ». )()/-8.
11. ± ® )) ( )) ( ® )) ± ± ± -
© © © )* * ±) ) ± )-
1983. - )4 1)(H, +)
() 2+ -73.
12. ± ® )) ( ® )) ( ® )) ± ±© ® -
® © - -
®)* * ±© ) - 1986. - )1)(H0 )
() 20-79.
13. ±© )) ( © ® )) ( )) ) ± -
± © ±© ±±±
 - )
** ±© ±© )
- 1986.- »,
)-
)
..-37
14. ® ® £)) ® ± © -
© )
*
*± )- 1999. - »,)() /,-43.
15. © )) ( ± )) ( )) © ±©
© © - )* * ) xip. - 1998. -
»,,) ( )2-28.
16. )) ( ® )) ( )) ©
® ± ± © ® ® ± ± -± ® -
© ) * * ©) - 2000. - », )() /2 -53
17. ))( )) ( ® )) ( ®± ))( -
±® )) ±© © -
±® © ± © ± © ) * *) -
) )| ± ® © ( ® ±© -
© ® }( ) ) )) © ±) ® ©(
,4
40() 1/-65.
18. )) ± ±© ±± ©±© 5 - 5
( ,44 4 )- 1+/)
19. )) ( ± ® )) ® ± ±
± ® )* * OC C
C © -
©® ) )( ,440) - )/2
4-480.
20. )) ( ± ® )) © $
± % )** © . - 2000. - ».) () //-46.
21. © ± ) ) ( )) ( ® ® ) )
±© ± )- ±5 -
) ( ,4 4 0)-2/)
22. )) ( ±® )) ( ± ))( ® )) © -
© - ® ± ± -
)** ±© ±© ) - 1997. - ».)( )1-30.
23. ®© )) ( ± ® )) ® © © -
) *
* ©) - 1999. - »,+ )
() 1-20.
24. ± )) ± )- $ ® ® ± ® -
%) - )5 (,43 4)-0, )
25. ± )) *
*£ -
)- ® 5 -® ( ,4 4 1)- )) -/33 )
26. ± - ± •) •) ± ©
)** ±) - 1941. - »,)() .
,-33.
27. ± )) ( ® )) ( ® )) £ © -
± )- 5 (, 44(0 1)
28. )
( ) ± © )* *) ( )
(, 4
43)(
2,
1 )
29. A.M., )) © ® ©
± ± ® )*
* ) )
- 1995.- ), 0/) ».) () 4-12.
30. A.JL, £)) ( © ±) )£ ± -
® ® ® ) - ©(| -
± ± } (,4 41( -..+)
31. )) ) ±© )* * -
© ) - 1999. - ».) () 31-88.
32. )) £ ±
© © ± ©) * * ±©
±© ) - 1999. - » )() /0-48.
33. )) ± ± ± ®)
** ) ±)- 1997. - ». )
() 22-83.
34. )) 5 © ± 5 ®-
) ) ) ) ) - )( ,431) -/2 )
35. )) © ® ® ± )* * © )-
2000. - » ) () 0/-59.
36. )) ( ® )) ± )
** ©) - 1995. - N1. - ) 1-65.
37. ® )) ( ® )) ± ® ®±
© ® )* * ±© -
±© ) - 1999. - ». )- )0/-59.
38. )) ( )) ( ± ® )) -
± © )** ) 5 (
1998,- , 2+)
39. ® )) ® ± )* *± -
)- 1999. - », )() 3-10.
40. © )) ( ® )) ( ® )) ( ® P.M. ®-
® ± ± -
)* * ) ±) - 1999. - ».) ( ) 1,-
67.
41. )) ( ))( © ® ))( )) -
± ± ® ® ® ®,
® © - ± )* * xipypriw. - 1995. -
» ) () ,,-12.
42. ® ) - ©) * * )
(
± )-, 42 2)(0+ )
43. ® )) ±
© ® ±© ) *
*± ) ) - 2000. - »4)( )4-31.
44. )) © ±© © )- )
( -
)-, 412)
( . . ) )
45. ® 5 ® ® ± ® ) * ) )
)) () ) )**) 5 )
( ,44+)- 04 )
46. ® ))
( ±® ))
( ® ® )) ® -
© ± © © )**© )- 1999.
-», +)() 13-15
47. ® )) )- )
(| }
)(
,44/)( .1+)
48. ®± ® B.C., ® )) ( © ® )) )- ) 5 -
(,43. )- / +)
49. ®± ® B.C., ± )) ( ±© ))( ± ® )) (
® )) ( ® )) ® ± ±
) * * ±© ±© ) -
1999. - »1 )( )3-33
50. )) ( )) ( ® )) ( ® )) ( -
®± )) ± )- ® ©5 -
±(+ +) - 1)
51. ® A.M., ® )) ( ® )) Xnpypi -
± ) ±© ) * * © ) - 1999. -
», +)() /-8.
52. ® )) ( I.C., )) ( © ),) ©
- 0 ,® © ® ® **
)- 1999. - »0 $
,. %)
() 10-70.
53. )( ± ) )* *)(| }
)(
,441)( /++)
54. )) 5® ± )
**± © ) - 1999. - » ) () /-9.
55. )) ( ± ))( ® )) ± -
(® ® © ± ) ± ®
) ** ±© ±© ) - 1999. - ». )
()/1-54
56. ® )) ( A.JL, ± )) ± ® ±-
© ® ® ® )
** ±© ±© ) - 1998. - » ) ( ) -25.
57. ® )) ±© ® ± -, ±® )
** ±© ) - 1998. - ». )
() 4-17.
58. ±® ) ± ® ©± ®)** | -
})- 1988. - H,) ( ).-38.
59. ±® ® ) ) ( ® )) ( ®±® )) ( -
± ± © - ± ® © )
- 5 (, 432( ,04)
60. )) ( ® )) ( ± ±® )) ( ± )•) -
± ~ ® ± ± -
® ® ± )* * ±© ) - 1991. -
»,) () //-47. -
61. ® )( ® )) ( ± ® )) ** -
- 1992 - ) . 2(» - / +-44.
62. © ± © ) * ) )
)) *
*) 5
(| ®} )- , 440 )(.3/)
63. 5 ±© ( © ( © ( ® )
* ± ® JI.A., JI.B., ® )) ( )JI.B.
*
*) ( © - (+ +/)-, 1 +)
64. ± )) ( )) ± ©±© ) -
5 - ©(,4 4/) - . 3)
65. ® P.M., © )) ( ® )) ( ® )) ( ± -
® )) ( © )) ±
± ®© ± ©± )
*
* ±© ) - 1994. - » ) ( .47-50.
66. ® P.M., © )) ± ©
± © ) **± ) ) - 1996. - »3)() 2-13.
67. ± )) ( )) ±
© ± ® ± ®± -
® ® )** © ) - 1999. - » ) () 2 .-76.
68. ± )) ± © ®
± © )
*
* ±© ±© ) - 1998. - » ) ( )0-30.
69. ® )) ( ± )) ( ± )) ( ± ® )) ( © ))
± ®± ±
± ± ©
)** ) ) - 1998. - »/ )
() /1)
70. ± ® )) ( ® )) ( ± )) -
© ± )- 5 ) (,44 +) - 2,)
71. ± ® )) ( ± ® )) ( ± )) ( ® ))
© ± ± )- ±5 ® ( , 4
42)-
01+)
72. )) ± ±© ) * * ) (| ± ±-
})(,443)( 0
14 )
73. ))( )) ( ± ® )) ( ± ® ))
© ® ± ± © ® )
*
* ±© ±© ) - 1998. - »/ )() 1+-64.
74. ®± )) ± ± ® -
± © -® ± ± -
© ) *
*± )xip. - 1998. - », , )(),0-16.
75. ®± )) ® ® -
5® © ) ) ) ) ) - ) (+ +) - +)
76. )
( ± ) ( )( )) ( ) )
* ) ) 5
( )
( ,4 3 ,)(0, 1)
77. Ahmed N.A., Yee J., Ginnnws ) (Giannias ) (Kapadia ) (Christou N.V.
Expression of human neutrophil L-selectin during the systemic inflamma-
 tory response syndrome is partly mediated by tumor factor alpha. //Arch.
Surg. - 1996. - Vol. 131(1)., P.31-36.
78. American College of Chest Physicians, National Institute of Allergy and
Infection Disease, and National Heart, Lung, and Blood Institute Workshop
//Chest. - 1997. - Vol.111., P.744-753.
79. Amir S., van Ree J.M. Beneficial effect of gamma-endorphine type peptides
in anaphylactic shock. //Brain Res. - 1985. - Vol.329 (1-2)., P.329-333.
80. Amura C.R, Silverstein R., Morrison D.C. Mechanisms involved in the
pathogenesis of sepsis are not necessarily reflected by in vitro cell activa-
tion studies. // Infection & Immunity. - 1998. - Vol.66 (11)., P.5372-5378.
81. AoeT., , •) ( Kon S., Imai M., AonoM., MizuguchiT., SaitoT., Ni-
shinoT. Heat shock protein 70 messenger RNA reflects the severity of
ischemia/hypoxia-reperfusion injury in the perfused rat liver. //Crit Care
Med. - 1997. -Vol. 25(2)., P. 324-329.
82. ;i iZ fjG A e [hc>) (=X hie B) (KX odfe[ D )(Akc YXk[D )
(<f _
kfe =)
High serum procalcitonin concentrations in patients with sepsis and infec-
tion. //Lancet. - 1993. -Of c)./,$33/ /%J) 0,0-518.
83. Balk R. Patophysiology of Septic Shock. //9th European Congress of An-
aesthesiology, Jerusalem., 1994., P.140-145.
84. Banks P.A., Gerzof S.G., Chong F.K., Worthington M.G., Doos W.G., Sul-
livan J.G., Johnson W.C. Bacteriologic status of necrotic tissue in necrotiz-
ing pancreatitis. //Pancreas. - 1990. - Ofc
)0$.%J) ..+-333.
85. Bassi C., Pederzoli P., Vesentini S. et al. Behavior of antibiotics during hu-
man necrotizing pancreatitis. //Antimicrobial Agents. Chemother. - 1994. -
Vol.38., P.830-836.
86. Bathe O.F., Rudston-Brown ) (Chow A.W., Phang P.T. Gut is not a source
of cytokines in a porcine model of endotoxicosis. //Surgery. - 1996. -
Vol. 120(3)., P. 522-533.
87. Baue A.E., Durham R., Faist E. Systemic inflammatory response syndrome
(SIRS), multiple organ dysfunction syndrome (MODS), multiple organ fail-
ure (MOF): are we winning the battle ? //Shock. - 1998. - Of c
)c
+$% J)
24-
89.
88. Bauer M. The physiopathology of sepsis. Current concepts. //Anaesthesist.
- 1996. - Vol.45(4)., P.312-322.
89. Beger H.G., Buchler M., Bittner R. Necrosectomy, postoperative local lav-
age in necrotizing pancreatitis. //WorldJ.Surg. - 1985. - Vol.9., P.972-979.
90. Belk R. Patophysiology of Septic Shock. //9th European Congress of An-
aesthesiology, Jerusalem., 1994., P.140-145.
91. Bengmark S. Gut and the Immune System. Enteral Nutrition. //In:
A.E.Baue, E.Faisl, D.E.Fry., eds. Multiply organ failure: pathophysiology,
prevention, and therapy. New York: Springer-Verlag, 2000, pp 420-437.
92. Berger M.L., Reynolds R.C., Hagler H.K. et al. Anoxic hepatocyte injury:
role of reversible changes in elemental content and distribution.
//Hepatology. - 1989. - Vol.9.. P.219.
93. Bertram G.Katzung. Basic & Clinical Pharmacology. 6th ed. - Prentice Hall
International Inc., 1995., 1249 p.
94. Blackwell T.S., Christmann J.W. Sepsis and cytokines: current status.
//Br.J.Anaesth. - 1996. - Vol.77(l)., P.l 10-117.
95. Bone R.C., Balk R.A. American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference: Definitions for sepsis and
organ failure and guidelines for the use of innovative therapies in sepsis.
//Crit.Care Med. - 1992. - Of c)+ $
1%J) 31/-874.
96. Bone R.C. Gram-negative Sepsis - a dilemma of Modern Medicine.
//Clin.Microbiol.Rev. - 1994. - Vol.6 (1)., P.57-68..
97. Bone R.C. Sepsis and Septic Shock. // 9th European Congress of Anaesthe-
siology, Jerusalem., 1994. - P. 125-139.
98. Bone R.C. Sepsis Current Perspectives in Pathophysiology and Therapy
//Eds. K.Reinhart et al. - Berlin, Heidelberg, 1994. - P. 16-22.
99. Bone R.C. Immunologic dissonance: a continuing evolution in our under-
standing of the systemic inflammatory response syndrome (SIRS) and the
multiple organ dysfunction syndrome (MODS) //Ann.Intern.Med. - 1996. -
Vol.125., N8. - P.680-687, 690-691.
100. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. // Crit Care Med. -
1996. - Vol.24(7)., P.l 125-1128.
101. Bone R.C. The sepsis syndrome. Definition and general approach to man-
agement. // Clin Chest Med. - 1996. - Vol.17 (2)., P.175-181.
102. Bolton C.F. Neuromuscular complications of sepsis. // Intensive Care
Med. - 1993. - Vol.19. - Suppl. 2., P.558-563.
103. Bolton C.F., Young G.B., Zocholden D.W. Neurolog:cal complications of
sepsis. //Ann.Neurol. - 1993. - Of c
).. $c
%J) 4/-100
104. Bosscha K., Hulstaert P.F., Hennipman A., Visser M.R., Gooszen H.G.,
van Vroonhoven T.J., v.d.Werken C. Fulminant acute pancreatitis and in-
fected necrosis: "results of open management of the abdomen and
planned" reoperations. //J.Am.CoIl.Surg. - 1998. - Vol. 187(3)., P.255-
262.
105. Bossink A.W., Groeneveld J., Hack C.T., Thijs L.G. Prediction of mortal-
ity in febrile medical patients: How useful are systemic inflammatory re-
sponse syndrome and sepsis criteria? //Chest. - 1998. - Vol.113(6).,
P. 1533-1541.
106. Bower R.H. Feeding of patients in sepsis. //New Horiz. - 1993. -
Vol.1(2)., P.348-352.
107. Bradley EL. A clinically based classification system for acute pancreati-
tis. //Arch.Surg. - 1993. - Vol. 128(5), P.586-590.
108. <kZ _ch G)( GX c]h j_ eh J) ( hi i B) (C iedX ee K OX eb ?) ( Ahdd
H., Schlegel P., Friess ) (Beger H.G. Human pancreatic tissue concentra-
tion of bactericidal antibiotics. //Gastroenterology. - 1992. - Vol. 103(6).,
P. 1902-1908.
109. Bulkley G.B., Oshima A.. Bailey R.W.. Pathophysiology of hepatic
ischemia in cardiogenic shock. //Am. J. Surg. - 1986. - Vol.151.. P.87.
110. Chretion M, Seidah N.G Precursor polyproteins in endocrine and neuro-
endocrine systems. //Jnt.J. Peptide Protein Res. - 1984. - Vol.23., P.335-
341.
111. Christmann J.W., Lancaster L.H., Blackwell T.S. Nuclear factor kappa B:
a pivotal role in the systemic inflammatory response syndrome and new
target for therapy. //Intensive Care Med. - 1998. - Ofc )/$ c
c% J),,.,-
1138.
112. Cohen J. Pathological Processes in Gram-negative Sepsis. //Proceed, of
satell.symposium of 7th European Congress of Clin.Microbiol. and
Inf.Diseas., 1995., P.4-7.
113. Cuztis M.T., LeferA.M. Protective actions of naloxone in hemorrhagic
shock. //Amer.J.Physiol. - 1980. - Of c
). 4 $.%J) ,/, 1-1421.
114. Cynober L. Is there a need of use of arginin and ornitin for support of gut
function? // Gut. - 1994. - Vol.35., Suppl.l.: - P.542-545.
115. Dafny N., Ziehnski M., Reyes-Varguez C. Alteration of morphine with-
drawal to naloxone by interferon. //Neuropeptides. - 1983. - Vol.3., N6. -
P.453-463.
116. Davies M.G., Hagen P.O. Systemic inflammatory response syndrome.
//Br.J.Surg. - 1997. - Of c)3/$2%J) 4+ -935.
117. Deitch E.A. Tumor necrosis factor as the proximal mediator of sepsis~or
this too will pass. //Crit Care Med. - 1995 - Vol.23(9)., P. 1457-1458.
118. Dinarello C.A. Interleukin-1 and its biologically related cytokines. //Adv
Immunol. - 1989. - Vol.44., P.153-205.
119. Dirksen R, Otten M.N., Wood G.J. Naloxone in shock //Lancet. - 1980. -
Iv 20/27., P. 1360-1361.
120. Drewelow ) (EfZ _ E) (Ij j
f= h Xeb ;) (K j _ce^ ;) E)Jeetration of
ceftazidime into human pancreas. //Infection. - 1993 - Of C),$/% J) 4-
234.
121. >k eZX e =) (>k^ XccB D f_
eijfe J) jX c)=_d Z Xc^eh Xjfe f] ej hZ
oxide in the mouth from the enterosalivary circulation of dietary nitrines.
//Nat.Med. - 1995. - Vol.1., F.546-551.
122. Dykhuizen R.S., FraserA., Mc KenzieH. et al. Helicobacter pylori is
killed by nitrite under acidic conditions. //Gut. - 1998. - Vol.42., P.334-
337.
123. Evans ) (=X h
ge jh ;) (Eh k[h dX e B =f _e D )?l[eZ f] eZ hXi[
nitric oxide production in patients with the sepsis syndrome. //Circ.Shock.
- 1993. - Of c)/,$% ) 2 2-81.
124. Faden A.J. Endogenous opiods: physiologic and pathophysiologic sec-
tion. //.T.Amer.Ostheopathol. Ass. - 1984. -Vol.84(1), Suppl., P.129-134.
125. FaistE., Markewit A., Maier R. et al //Sepsis Current Perspectives in
Pathophysiology and Therapy /Eds K.Reinhart et al. - Berlin, Heidelberg,
1994. - P.443-448.
126. Fein A.M., Bernard G.R., Criner G.J., Fletcher E.C., Good J.T.,
Knaus W.A., LevyH., Matuschak G.M., ShaniesH.M., Taylor R.W.,
Rodell T.C. Treatment of severe systemic inflammatory response syn-
drome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127).
Results of a randomized, double-blind, placebo-controlled trial. //JAMA -
1997 - Vol 277(6)., P.482-487.
127, Fernandes C., Pritchard R., Morris A., Benn R. In vitro evaluation of
cefpirome: an Australasian study of isolates from intensive care unit and
hematology/oncology patients. The Cefpirome Study Group.
//Diagn.Microbiol. Infect. Dis. - 1998. - Vol.31(3)., P.493-495.
128
Froelich CJ, Bankhurst AD The effect of Beta-endorphin on natural cyto-
toxicity and antibody dependent cellular cytotoxicity. //Life Sci. - 1984. -
129. Vol.35(2)., P.261-265.
Froon A.H., Bemelmans M.H., Greve J.W., van der Linden C.J., Buur-
man W.A. Increased plasma concentrations of soluble tumor necrosis fac-
tor receptors in sepsis syndrome: correlation with plasma creatinine val-
130. ues. //Crit Care Med. - 1994. - Of c)$ 0%J) 3+ .-809.
kai _dXL ;b XmXN. Neutrophil-mediated tissue injury and its modu-
131. lation. //Intensive Care Med. - 1995. - Vol.21(3)., P.277-285.
Goldstein A, Lowney L.A., Pal B.K. Stereospecific and nonspecific inter-
actions of the morphine congener levorphonol in subcellular fractions of
132. mouse. //Brain. - Proc.not.Acad.Sci, 1971, Vol.68., P.1742-1747.
Goris R.J. MODS/SIRS: result of an overwhelming inflammatory re-
133. sponse ? //World J.Surg. - 1996. - Of c)+ $/%J) /, 3-421.
Gourley G.R, Chesney P.J., Davis J.P. et al. Acute cholestasis in patients
134. with toxic-shock syndrome. //Gastroenterology. - 1981. - Vol.81., P.928.
Grau G.E., Maennel D.N. TNF inhibition and sepsis ~ sounding a cau-
135, tionary note. //Nature Med. -1997. - Vol. 3(11)., P.l 193-1195.
Hasselgren P.O. Prevention and treatment of ischemia of the liver. //Surg.
136. Gynecol. Obstet. 1987. - Vol.164., P.187.
Henderson A., Hayes P. Acetylcystein as antioxidant in patients with
grave sepsis: potentially new use of old medecine. //Ann.Pharmacother. -
137,
1994. - Of c
)3 $4%J) 1086-1088.
Hickman P.E, Potter J.M. Mortality associated with ischaemic hepatitis.
138,
//Aust. NZ J. Med. - 1990. - Vol.20., P.32.
Hills B.A. The role of lung surfactant // Brit. J. Anaesth.- 1990. - Vol. 65,
N1. - P. 13-29.
139. Hung J., Lew W.Y. Temporal sequence of endotoxin-induced systolic and
diastolic myocardial depression in rabbits. //Amer.J.Physiol. - 1993. -
Vol.265.(3 Pt2): ) 3,
+-819.
140. Jones G.R. Assessment criteria in identifying the sick sepsis patient.
//J.Infect. - 1998. - Vol.37(Suppl. 1)., P.24-29.
141. E ] jB Bfgc dXe ;c )
(S_ f k P) jX c
)Lgii e Nelh ijo Bfi
gjXcf]
Utrecht: clinical observations. //Arch.Int.Med. - 1993. - Vol.153(19)..
)/ ,-2247.
142. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II
score: a severity of disease classification. //Crit.Care Med. - 1985. -
Vol.13., P.818-829.
143. Knaus W.A., Zimmerman J.E., Wagner D.P. et al. APACHE score - acute
physiology and chronic health evaluation: a physiologically based classi-
fication system. //Crit.Care Med. -1981. - Vol.9., P.591-597.
144. Lechleuthner A., Troidl H , Lefering R. Duration of antibiotic treatment
in surgical infections of the abdomen. Minimal antibiotic therapy: tech-
nology assessment instead of clinical trials. //Eur J Surg Suppl. - 1996;
Vol.576., P.36-38.
145. Lefkowitch J.H. Bile ductular cholestasis: an ominous histopathologic
sign related to sepsis and 'cholangitis tenta. //Hum. Pathol. - 1982. -
Vol.13., P. 19.
146. FY flZ F) (JX kcG JfoX eib I) (>h kZ
bh G LX dh
X S)
(Efe^ iYh-
ger H., Pitlik S.D. Monotherapy versus beta-lactam-aminoglycoside com-
bination treatment for gram-negative bacteremia: a prospective, observa-
tional study. //Antimicrob.Agents Chemother. - 1997. - Of c)
/,$0%
P.l 127-1133.
147. Ling G.S.E., Spiegel K., Nishimura S.L, Padternak G.W. Dissociation of
morphine's analgesic and respiratory depressant actions. //Europ.J.Pharm.
- 1983. - Vol.86(3-4), P.487-488.
148. Ma T.T., Ischiropoulos H., Brass C.A. Endotoxin-stimulated nitric oxide
production increases injury and reduces rat liver chemiluminescence dur-
ing reperfusion. //Gastroenterology. - 1995. - Vol.108., P.463.
149. Mainous M.R., Block E.F., Deitch E.A. Nutritional enteral support: how
and why ? //New Horiz. - 1994. - Vol.2(2)., P. 193-201.
150. Mammen E.F. Perspectives for the future. //Intensive Care Med. - 1993. -
Vol.19., Suppl 1: S.29-34.
151. Marino P. The ICU book. //Philadelphia., Williams&Wilkins. - 1997, 972
P-
152. Marshall J.C., Cook D.J., Christou N.V., Bernard G.R., Sprung C.L., Sib-
bald W.J. Multiple organ dysfunction score: a reliable descriptor of a
complex clinical outcome. //Crit.Care Med. - 1995. - Vol.23(10).,
P.1638-1652.
153. Mc Cain ) (Lamster I., Bozzone J., Grbic J.T. Beta-endorphin modulates
human immune activity via non-opiate receptor mechanisms. //Life Sci. -
1982.- Vol.31(15)., P.1619-1624
154. Mc Knight G.M., Smith L.M., Drummond R.S. Chemical synthesis of
nitric oxide in the stomach from dietary intake in human. //Gut. - 1997. -
Vol.40., P.211-214.
155. GficoK) B) (PX e^P MX b[XB) jX c)?] ]Z jf] e [ fjfnef eYc X
Z[
transport in rat liver: a potential model for sepsis-associated cholestasis.
//Am. J. Physiol. - Vol.271., P. 137.
156. Munster A.M., Smith-Meek M., Dickerson C., Winchurch R.A. Translo-
cation: occasional phenomenon or real pathology ? //Ann.Surg. - 1993. -
Vol.218(3)., P.321-326.
157. Naef M., von Overbeck J., Seiler C., Baer H.U. Candida infection in sur-
gery ///Chirurg. - 1994. - Vol.65(9)., P.785-790.
158.
Namias N., Harvill S., Ball S.. McKenney M.G., Salomone J.P., Slee-
man D., Civetta J.M. Empiric therapy of sepsis in the surgical intensive
care unit with broad-spectrum antibiotics for 72 hours does not lead to the
emergence of resistant bacteria. //J. Trauma. - 1998. - Vol.45(5)., P.887-
159. 91.
Offenbartl K., Bengmark S. Intraabdominal infections and gut origin sep-
160. sis. //World J.Surg. - 1990. - Vol. 14(2)., P.191-195.
Olson G.A., Olson R.D., Kastin A.J. Endogenous opiates. //Peptides. -
161. 1984. - Vol.5(5)., P.975-992.
Paye F., Frileux P., Lehman P., Ollivier J-M., Vaillant J C., MD; Pare R.
Reoperation for Severe Pancreatitis. //Arch.Surg. - 1999. - Vol.134.,
162. P.316-320.
Pederzoli P., Bassi C., Vesentini S. et al. A randomized multicentric clini-
cal study of antibiotic prophylaxis of septic complications of acute ne-
163. crotizing pancreatitis. //Surg.Gynec.Obst. - 1993. - Vol.176. - P.480-483.
Pert C.B., Snyder S.H. Opiate-receptor; demonstration in nervous tissue.
//Science. - 1973. - Vol.179., N4077, P.1011-1014.
164.
Pierard D., Emmerechts K., Lauwers S. Comparative in-vitro activity of
cefpirome against isolates from intensive care and haematology/oncology
units. //J.antimicrob.Chemother. - 1998. - Vol.41(4)., P.443-450.
165.
Plank L.D., Connolly A.B., Hill G.L. Sequential changes in the metabolic
response in severely septic patients during the first 23 days after the onset
of peritonitis. // Ann.Surg. - 1998. - Ofc) 3$%J) ,/1-158.
166.
Pollock A.V. Duration of antibiotic treatment in surgical infections of the
abdomen. At what point is infection cured but inflammation persists?
//Eur.J.Surg. Suppl. -1996 - Suppl.576., P.13-15.
167.
Principles of Surgery. 7th ed. /ed.-in-ch. Seymour I. Schwartz., McGraw-
Hill, Inc., 1999, 2162 p.
168. Quale J.M, Mandel L.J., BergasaN.V. et al. Clinical significance and
pathogenesis of hyperbilirubinemia associated with staphylococcus
aureus septicemia. //Am. J. Med. - 1988. - Vol.85., P.615.
169. Refsum S.E., Rowlands B.J., Boston V.E. Pentoxillin improves intracellu-
lar balance of electrolites in sepsis. //J.Pediatr.Surg. - 1994. - Of c
)1
P.801-804.
170. Reis Miranda R., Landrehr D. Recent Advances in Critical Care Medicine
//Ed. Ledingham J.McA. - Edinburgh. - 1998. - P.109-118.
171. Ridings P.C., Windsor A.C., Sugerman H.J., Kennedy E., Sholley M.M.,
Blocher C.R., Fisher B.J., Fowler A.A. Pentoxifillin effects in experimen-
tal sepsis. //Arch.Surg. - 1994. - Vol.l29(l 1)., P.l 144-1152.
172. Rubanyi G.M., Botelho L.H. Endothelins. //FASEB J. - 1991.. Vol.5
(12)., P.2713-2720.
173. Ruth J, Doerr A., Eiden L. Enkephalin inhibits norepinephrine-induced
contraction of rat aorta. //Europ.J.Pharm., 1984. - Vol.105., N1-2., P.189-
191.
174. Schweigerer L, Teschemacher H., Bhakdi S., LederleM. Interaction of
human Beta-endorphin with binding sites on the terminal SC5B-9 com-
plex of human complement. //J.Biol.chem. - 1983. - Vol.258(20).,
P. 12287-12292.
175. Sikuler E, Guetta V, Keynan A et al. Abnormalities in bilirubin and liver
enzyme levels in adult patients with bacteremia. //Arch. Intern. Med. -
1989.-Vol.149., P.2246.
176. Simms H.H., D'Amico R. Polymorphonuclear leukocyte dysregulation
during the systemic inflammatory response syndrome. // Blood - 1994 -
Vol 83(5), P.1398-1407.
177. Sole Violan, Sanchez-Ramirez C., MujicaA.P., Cendrero J.C., Fernan-
dez J.A., de Castro F.R. Impact of nosocomial pneumonia on the outcome
of mechanically-ventilated patients. //Crit Care. - 1998. - Vol.2(l), P. 19-
23.
178. Stoutenbeek C.P., van Saene H.K., Miranda D.R., Zandstra D.F. The ef-
fect of selective decontamination of the digestive tract on colonisation
and infection rate in multiple trauma patients. //Intensive Care Med. -
1984. - Vol. 10(4)., P. 185-192.
179. Susla G.M., MasurH., Cunnion R.E., Suffredini A.F., Ognibene F.P.,
Hoffman W.D., Shelhamer J.H. Critical care drug thepary. //2-nd Ed. Wil-
liams & Wilkins, 1997,436 p.
180. Takeda K., Matsuna S., Sunamura M.. et al. Continuous regional arterial
infusion of protease inhibitor and antibiotic in acute necrotizing pancreati-
tis. //Amer.J.Surg. -1996. - Vol.171., P.334-338.
181. Terregino C.A., Lubkin C.L., Thom S.R. Impaired neutrophil adherence
as an early marker of systemic inflammatoiy response syndrome and se-
vere sepsis. //Ann.Emerg.Med. - 1997. - Of c)4 $
.%J400-403.
182. Tsukahara Y., Morisaki ) (Bf hjX R) ( Mfhi k G MX eXb XG) ?nghi ife
of inducible nitric oxide synthase in circulating neutrophils of the sys-
temic inflammatory response syndrome and septic patients. // World
J.Surg. - 1998. - Vol.22(8)., P.771-777.
183. Van Leeuwen P.A., Boermeester M.A., Houdijk A.P. Clinical signifi-
cance of translocation //Gut. - 1994. - Vol.35(l Suppl)., P.528-534.
184. Van Saene H.K.F., Stoutenbeek C.P., Zandstra D.F. A possible explana-
tion for success of SGD. //In: Infection control by Selective Decontamina-
tion. /Eds H.K.F. Van Saene et al. - Berlin, 1989., P.193-196
185. Vincent J.L., Bihari D.J., Suter P.M., Bruining H.A., White J., Nicolas-
Chanoin M.H., Wolff M., Spencer R.C., Hemmer M. The prevalence of
nosocomial infection in intensive care units in Europe. Results of the
European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC
International Advisory Committee. //JAMA. - 1995. - Vol.274., N8. -
P.639-644.
186. OeZejD )F)(Gfhe f K MX b Xc
XD )(P c cXjj
iL > G e [f eZ X ;)
(<h ke-
ing H., Reinhart C.K., Suter P.M., Thijs L.G. The SOFA (Sepsis-related
Organ Failure Assessment) score to describe organ dysfunction/failure.
On behalf of the Working Group on Sepsis-Related Problems of the
European Society of Intensive Care Medicine. //Intensive Care Med. -
1996. - Vol.22., P.707-710.
187. N_ cP C iedX e e K) (<uchler M.W. Infections complicating pancreatitis:
diagnosing, treating, preventing. //New Horiz. - 1998. - Vol.6 (2 Suppl):,
P.72-79.
188. PX [ L <k ii
fm G BX ei Z_ ?) ?g[dfc f^ o f] i oijd Z e] c
X ddX -
tory response syndrome, infection and septic shock in surgical intensive
care patients. //Chirurg. - 1998. - Ofc)
1 4$1%J) 1/3-655.
189. Way L.W. Current Surgical Diagnosis and Treatment. 10th Edition.,
1994., 568 p.
190. WeisigerR.A. Oxygen radicals and ischemic tissue injury.
//Gastroenterology. - 1986. - Vol.90., P.494.
191. de Werra I., Jaccard C., Corradin S.B., Chiolero R., Yersin ) (AXcc
X jB
Assicot M., Bohuon C., Baumgartner J.D., Glauser M.P., Heumann D.
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and
procalcitonin concentrations: comparisons in patients with septic shock,
cardiogenic shock, and bacterial pneumonia. //Crit Care Med. - 1997. ~
Vol. 25(4)., P.607-613.
192. Whiting J.F., Green R.M., Rosenbluth A.B. et al. Tumor necrosis factor-
alpha decreases hepatocyte bile salt uptake and mediates endotoxin-
induced cholestasis. //Hepatology. - 1995. - Vol.22., P.1273.
193. Angus D.C., Linde-Zwirble W.T., LidickerJ.M. et al. Epidemiology of
severe sepsis in the United States: analysis of incidence, outcome, and as-
sociated costs of care. //Crit.Care Med.-2001.-29: 1303-1310.
194. Alberti ) (Brun-Buisson ) (Burchardi H. et al. Epidemiology of sepsis
and infection in ICU patients from an international multicentre cohort
study. // IntCare Med.-2002.-28: 108-121.
195. Fenton K.E., Parker M.M. Severe sepsis: recent advances in management
and the need to do more. // Advances in sepsis. - 2004.-3(3): 75-82.
de Bel E.E., Goris R.J.A.: Systemic inflammation after trauma, infection,
and cardiopulmonary bypass: is autodestruction a necessary evil? //In:
196. A.E.Baue, E.Faist, D.E.Fry., eds. Multiply organ failure: pathophysiol-
ogy, prevention, and therapy. New York: Springer-Verlag, 2000, pp 71-
81.
Moldawer L.L., Minter R.M., Rectenwald J.E.III. Emerging evidence of a
more complex role for proinflammatory and antiinflammatory cytokines
197. in the sepsis response. P. 145-154. in: Multiply organ failure: pathophysi-
ology, prevention, and therapy /ed. By A.E.Baue, E.Faist, D.E.Fry.
Springer-Verlag New York, 2000, 697 p.
Multiply organ failure: pathophysiology, prevention, and therapy /ed. By
A.E.Baue, E.Faist, D.E.Fry., Springer-Verlag New York, 2000,697 p.
198. Faist E., Wichmann M.W. Immunomodulation of cell-mediated re-
sponses: is it feasible. P.389-395. in: Multiply organ failure: pathophysi-
199. ology, prevention, and therapy, /ed. By A.E.Baue, E.Faist, D.E.Fry.,
Springer-Verlag New York, 2000,697 p.
Majno G., Joris I. Apoptosis. oncosis, and necrosis. An overview of cell
death.//Am J Pathol 1995,146:3-15.
200.
Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death.
//FASEB J. 1992,6:2450-2455.
201.
Kaufmann SH, Hengartner MO. Programmed cell death alive and well m
the new millennium. //Trends Cell Biol. 2001 ;11:526-534.
202.
Wang CY, Mayo MW, Kroneluk RG, et al. NF-kappa antiapoptosis:
induction of TRAF1 and TRAF2 and c-IAPl and C-IAP2 to suppress cas-
203.
pase-8 activation. //Science 1998;281:1680-1683.
Parsey MV, Kaneko D, Shenkar R, et al. Neutrophil apoptosis in the lung
204. after hemorrhage or endotoxemia: Apoptosis and migration are independ-
ent of IL-lbeta.//Clin Immunol. 1999;91:219-225;
Matute-Bello G. Liles WC, Radella F, et al Neutrophil apoptosis in the
205. acute respiratory distress syndrome. //Am.J.Respir.Crit.Care.Med.
1997;156:1969-1977.
Matute Bello G, Liles WC, Sternberg (et al. Soluble Fas ligand in-
duces epithelial cell apoptosis in humans with acute lung injury. Hi. Im-
206.
munol 1999;163:2217-2225.
Munster A.M. Gut: Clinical importance of bacterial traslocation, perme-
ability, and other factors. P.86-91. in: Multiply organ failure: pathophysi-
207.
ology, prevention, and therapy /ed. By A.E.Baue, E.Faist, D.E.Fry.,
Springer-Verlag New York, 2000, 697 p
208. >i X GB B h e[ fe >H) )Kk jXe KF) );Yi jfe L))FeX hi B;)C iZ_d Z
intestinal complications in patients with burns. //Surg.Gyn.Obstet.
1991;172:257-261
209. L ^cD B)(= h hX < =f cdX e ) (et al. Physiologic and metabolic cor-
relations in human sepsis. //Surg., 1979; 86:163-193;
210. Fry D.E. Systemic inflammatory response and multiply organ dysfunction
syndrome: biologic domino effect. P.23-29. in: Multiply organ failure:
pathophysiology, prevention, and therapy, /ed. By A.E.Baue, E.Faist,
D. E.Fry., Springer-Verlag New York, 2000,697 p
211. Fry D.E. Infection: cause or result of organ failure. // in: Multiply organ
failure: pathophysiology, prevention, and therapy, /ed. By A.E.Baue,
E. Faist, D.E.Fry., New York: Springer-Verlag, 2000, pp.598-603.
212. Dellinger R.P. Surgery for intra-abdominal sepsis. //In: White T.T., Harri-
son R.C., Debas H.T., Mulholland M., eds. Reoperative gastrointestinal
surgery. New York: Appleton, Century, Crofts, 1989. p.63-73.
213. Dellinger R.P. Approach to the patient with postoperative fever. //In:
Afh YX Z_ L <X hjcjjD )
(<c XZ bcfm N.. eds. Infectious diseases in medicine
and surgery. Philadelphia: W.B. Saunders, 1998. p.903-909.
214. WuL., Holbrooke., ZaborinaO. et al. Pseudomonas aeruginosa ex-
presses a lethal virulence determinant, the PA-I Lectin / Adhesin, in the
intestinal tract of a stressed host. The role of epithelia cell contact and
molecules of the quorum sensing signaling system. //Ann.Surg., 2003.-
V.238.-P.754-764.
215. Dellinger R.P. Lung. P.353-364. in: Multiply organ failure: pathophysiol-
ogy, prevention, and therapy, /ed. By A.E.Baue, E.Faist, D.E.Fry.,
Springer-Verlag New York, 2000, 697 p
216. GarberG.R., Herbert P.C., YelleJ.D., et al.: Adult-respiratory distress
syndrome: a systemic overview of incidence and risk factors. // Crit.Care
Med.-1996; 24: 687-695.
217. Bernard G.R., Artigas A., Brigham K.L., et.al.: The American-European
consensus conference on ARDS: definitions, mechanisms, relevant out-
comes, and clinical trial coordination. //Am.J.Respir.Crit.Med.-1994;
149:818-824
218. Balibrea J.L., Arias-Diaz J. Acute respiratory distress syndrome in the
septic surgical patient. //World J.Surg., 2003.-27:1275-1284
219. Wiedemann H.p., Tai D.Y. Adult respiratory distress syndrom (ARDS):
current management, future directions. //Cleve.Clin.J.Med.-1997; 64:
365-372.
220. Sachdeva R.C., Guntupalli K.K. Adult respiratory distress syndrom.
//Crit.Care.Med,-1997; 13: 503-521.
221. Borron R., Mcintosh JC., Korfhagen TR., et al. Surfactant-associated pro-
tein A inhibits LPS-induced cytokine and nitric oxide production in vivo.
//Am.J.Physiol.Lung Cell.Mol.Physiol.2000; 278:L840-L847.
222. Gregory ) (LjeYh ^ EJ) (Lg hX^^ K jX c)<fle i kh]
XZjX
ejj _h Xgo ] fh
patients with acute respiratory distress syndrom. //Am.J.Respir.Crit.Care
Med. 1997; 155:1309-1315;
223. Spragg R., Gilliard N., Richman P., et al. Acute effects of a single dose of
porcine surfactant therapy on patients with the adult respiratory distress
syndrom. // Chest. 1994; 105:195-202.
224. Hall J.B., Schmidt G.A., Wood l.D.H. Principles of critical care medicine.
225. 2nd ed., McGraw-Hill, 1998., 659 P
Quaid G., Solomkin J.S. Nosocomial infections in the ICU. P.309-321. in:
Multiply organ failure: pathophysiology, prevention, and therapy, /ed. By
226. A.E.Baue, E.Faist, D.E.Fry., Springer-Verlag New York, 2000, 697 p.
Cerra F.B., Maddaus M.A., Dunn D.I., et al. Selective gut decontamina-
tion reduces nosocomial infections and length of stay but not mortality or
organ failure in surgical intensive care unit patients.//Arch.Surg., 1992,
227. Vol.2:127-163.
Nathens A.B., Marshall J.C. Selective decontamination of the digestive
tract in surgical patients: a systematic review of the evidence.
228.
//Arch.Surg., 1999, Vol.6:134-170.
Baue A.E. Multiply, progressive or sequential system failure.
229. //Arch.Surg., 1975;110:79-81.
Eiseman )( Beart R., Norton L. Multiply organ failure.
230. //Surg.Gynec.Obstet., 1977; 144:323-326.
AfhiK) D
);) (j <fb _fhijMJ;(Hko jeZbD L jX c)Gk cjgcf h
^ Xe] Xc -
ure: generalized autodestructive inflammation? //Arch.Surg. - 1985. -
231.
Vol.120, P.l 109-1115.
Pearl JM., Laks H., Drinkwater DC., et al. Leukocyte depleted reperfu-
sion of transplanted human hearts prevents ultrastructural evidence of
232.
reperfusion injury. Hi. Surg.Res.. 1992, 52: 298-308.
G ohE <h fme G ) (SYX h A) ( jX c)ICAM-1 up regulation in distant
tissues after hepatic reperfusion: a clue to the mechanism of multiply or-
233.
gan failure. //J.Pediatr.Surg., 1998,33:350-353.
H c ie O) A) (MX e L) (<hZ bi;? <Xh [ GL) (JX hbi>;)B n je[$ _j Xi-
tarch solution) decreases multple organ injury and xanthine oxidase re-
234. lease after hepatoenteric ischemia reperfusion in rabbits. //Crit.Care Med.,
1997;25:1565-1574.3
Cryer G.H. Ischemia and reperfusion as a cause of multiply organ failure.
P. 108-113. in: Multiply organ failure: pathophysiology, prevention, and
235. therapy, /ed. By A.E.Baue, E.Faist, D.E.Fry., Springer-Verlag New York,
2000, 697 p.
Knaus W.A., Wagner D.P., Draper E.A., et al. APACHE III prognostic
system: risk prediction of hospital mortality for critically ill hospitalized
adults. //Chest.-1991.-Vol.100., P.1619-1636.
236. Baue A.E. Are we making progress in preventing and treating MOF.
P.656-661. in: Multiply organ failure: pathophysiology, prevention, and
therapy, /ed. By A.E.Baue, E.Faist, D.E.Fry., Springer-Verlag New York,
+ ++(142)
237. K ^cA) (FfYe _f]]hJ) (Ah fjp G jX c)MhX jde jhi kc
ji f]g Xjej i
with multiply trauma: an analysis of 3406 cases treated between 1972 and
1991 at a German level I trauma center. //J.Trauma., 1995; 38: 70-78.
238. Buskind R., Koukline V., tjtrobin U. et al. Plasmapheresis in severe sep-
sis and septic shock: A prospective, randomized, controlled trial.
// Int.Care Med. - 2002.-28: 1434-1439.
239. ® ® ± © (* * ) )) ®± ®) (
®5| }(+ +( /32)
240. Chastre )et al. Nosocomial pneumonia: 8th and 15th cours of treatment.
//JAMA, 2003; 290:2588-98.
241. ±± )) ± ® ®
© ) *
* - ++ ,( )( ».) - ) /-7.
242. Piatt R., Zaleznik D.F., Hopkins )) (et al. Perioperative antibiotic pro-
phylaxis for herniorrhaphy and breast surgery. N Engl J Med 1990;
322:152-60.
243. Page C.P., Bohnen J.M.A., Fletcher J.R., McManus A.T., Solomkin J.S.,
Wittman D.H. Antimicrobial prophylaxis for surgical wounds: Guidelines
for clinical care. Arch Surg 1993; 128:79-88.
244. Dellinger R.P., Gross P.A., Barrett T.L., et al. Quality standard for antim-
icrobial prophylaxis in surgical procedures. // Clin.Infect.Dis., 1994;
18:422-7.
245. Sackett DL: Rules of evidence and clinical recommendations on the use
246 of antithrombotic agents. //Chest, 1989; 95:2S-4S.
Weinstein MP, Reller LP, Murphy JR, et al: The clinical significance of
positive blood cultures: A comprehensive analysis of 500 episodes of bac-
teremia and fungemia in adults. I. Laboratory and epidemiologic observa-
247. tions. Rev Infect Dis 1983; 5:35-53
Blot F., Schmidt E., Nitenberg G, et al: Earlier positivity of central ve-
nous versus peripheral blood cultures is highly predictive of catheter-
248. related sepsis. J din Microbiol 1998; 36:105-109.
Mermel LA, Maki DG: Detection of bacteremia in adults: Consequences
of culturing an inadequate volume of blood. Ann Intern Med 1993;
249. 119:270-272
250. McCabe WR, Jackson GG: Gram negative bacteremia. Arch Intern Med
1962; 110:92-100
KregerBE, Craven DE, McCabe WR: Gram negative bacteremia. IV.
Reevaluation of clinical features and treatment in 612 patients. Am J Med
1980; 68:344-355
251. Leibovici L, Shraga I, Drucker M, et al: The benefit of appropriate em-
pirical antibiotic treatment in patients with bloodstream in-fection. J In-
tern Med 1998; 244:379-386
252. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate an-
timicrobial treatment of bloodstream infections on patient outcomes in the
ICU setting. Chest 2000; 118:146-155
253. Hatala R, Dinh T, Cook DJ: Once-daily ami-noglycoside dosing in im-
munocompetent adults: A meta-analysis. Ann Intern Med 1996; 124:717-
725
254. Ali MZ, Goetz MB: A meta-analysis of the relative efficacy and toxicity
of single daily dosing versus multiple daily dosing of ami-noglycosides.
Clin Infect Dis 1997; 24:796-809
255. Amsden GW, Ballow CH, Bertino JS: Pharmacokinetics and Pharmaco-
dynamcis of Anti-infective Agents. In: Principles and Practice of Infec-
tious Diseases. Fifth Edition. Mandell GL, Bennett JE, Dolin R (Eds).
Philadelphia, Churchill Livingstone, 2000, pp 253-261
256. Hyatt JM, McKinnon PS, Zimmer GS, et al: The importance of pharma-
cokinetic/phar-macodynamic surrogate markers to outcomes. Focus on
antibacterial agents. Clin Pharmacokinet 1995; 28:143-160
257. Bufalari A, Giustozzi G, Moggi L: Postoperative intraabdominal ab-
scesses: Percutaneous versus surgical treatment. Acta Chir Beig 1996;
96:197-200
258. Moss RL, Musemeche CA, Kosloske AM: Necrotizing fascitis in chil-
dren: Prompt recognition and aggressive therapy improve survival.
//Arch.Surg 1996; 31:1142-1146
259 Centers for Disease Control and Prevention: Guidelines for the Prevention
of Intravascular Catheier-Related Infections. MMWR 2002; 51:1-29;
O'Grady NP, Alexander M, Dellinger R.P., et al: Guidelines for the pre-
vention of intra-vascular catheter-related infections. Clin Infect Dis 2002;
35:1281-1307
260. Choi PTL, Yip G, Quinonez LG, et al: Crystalloids vs. colloids in fluid
resuscitation: A systematic review. Crit Care Med 1999; 27:200-210
261. Cook D, Guyatt G: Colloid use for fluid resuscitation: Evidence and spin.
Ann Intern Med 2001; 135:205-208
262. Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid
solutions in critically ill patients: A systematic review of randomized tri-
als. BMJ 1998; 316:961-964
263. Hollenberg SM, Ahrens TS, Astiz ME, et al: Practice parameters for
hemodynamic support of sepsis in adult patients. Crit Care Med 1999;
27:639-660
264. LeDoux D, Astiz ME, Caipati CM, et al: Effects of perfusion pressure on
tissue per-fusion in septic shock. Crit Care Med 2000; 28:2729-2732
265. Bellomo R, Chapman M, Finfer S. et al: Low-dose dopamine in patients
with early renal dysfunction: A placeho-controlled randomised trial. Aus-
tralian and New Zealand Intensive Care Society (ANZICS) Clinical Trials
Group. Lancet 2000; 356:2139-2143
266. KellumJ, Decker J: Use of dopamine in acute renal failure: A meta-
analysis. CritCare Med 2001; 29:1526-1531
267. Sharshar T, Blarichard A, Paillard M, et al: Circulating vasopressin levels
in septic shock. Crit Care Med 2003; 31:1752-1758
268. Holmes CL, Patel BM, Russell JA, et al: Physiology of vasopressin rele-
vant to management of septic shock. Chest 2001; 120: 989-1002
26^ Malay MB, Ashton RC. Landry DW, et al: Low-dose vasopressin in the
treatment of vasodilatory septic shock. J Trauma 1999:47:699-705
270. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on
hemodynamics and renal function in severe septic shock: A case series.
Intensive Care Med 2001; 27:1416-1421
271. Gattinoni L, Brazzi L, Pelosi P, et al: A trial of goal-oriented hemody-
namic therapy in critically ill patients. N Engi J Med 1995; 333:1025-
1032
272. Hayes MA, Timmins AC, Yau EHS, et al: Elevation of systemic oxygen
delivery in the treatment of critically ill patients. N Engi J Med 1994;
330:1717-1722
273. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low
doses of hydro-cortisone and fludrocortisone on mortality in patients with
septic shock. JAMA 2002; 288:862-871
274. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse
hyperdynamic septic shock: A prospective, randomized, double-blind,
single-center study. Crit Care Med 1999; 27:723-732.
275. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock
with supra-physiologic doses of hydrocortisone. Crit Care Med 1998;
26:645-650
276. Annane D, Sebille V, Troche G, et al: A 3-level prognostic classification
in septic shock based on Cortisol levels and Cortisol response to cortico-
tropin. JAMA 2000; 283: 1038-1045
277. Annane D, Cavaillon JM: Corticosteroids in sepsis: From bench to bed-
side? Shock 2003; 20:197-207
278. Marik PE, Zaioga GP: Adrenal insufficiency during septic shock. Crit
Care Med 2003; 31:141-145
279. Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill pa-
tients. N Engi J Medm3\ 348:727-734
280. Keh D, Boehnke T, Weber-Carstens S, et al: Immunologic and hemody-
namic effects of "low-dose" hydrocortisone in septic shock: A double-
blind, randomized, placebo-controlled, crossover study. Am J Respir Crit
Care Med 2003; 167:512-520
281. Bone RC. Fisher CJ, Clemmer TP: A controlled clinical trial of high-dose
methyl-frednisolone in the treatment of severe sepsis and septic shock. N
Engi J Med 1987; 317:653-658
282. Cronin L, Cook DJ, Carlet J, et al: Corticosteroid treatment for sepsis: A
critical appraisal and meta-analysis of the literature. Crit Care Med 1995;
23:1430-1439
283. The Veterans Administration Systemic Sepsis Cooperative Study Group:
Effect on high-dose glucocorticoid therapy on mortality in patients with
clinical signs of sepsis. N Engi J Med 1987; 317:659-665
284. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recom-
binant human activated protein for severe sepsis. N Engi J Med2m;
344:699-709
285. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized,
conttrolled clinical trial of transfusion in critical'care. N Engl J Med 1999;
340:409-417
286. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen de-
livery in patients with sepsis. JAMA 1993; 269:3024-3029
Lorente J A, Landfn L, De Pablo R, et al: Effects of blood transfusion on
287. oxygen transport variables in severe sepsis. Crit Care Med 1993; 21:1312-
1318
Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant
288. human erythro-poietin in the critically ill patient: A randomized double-
blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350
Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human
289. erythropoietin in critically ill patients. JAMA 2002; 288:2827-2835
290. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and
platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administra-
tion Practice Guidelines Development Task Force of the College of
American Pathologists. JAMA 1994; 271:777-781
291. Guidelines for red blood cell and plasma transfusion for adults and chil-
dren. Report of the Working Group. CMAJ 1997; 156(Suppl):Sl-S24
292. Practice guidelines for blood component therapy. A report by the Ameri-
can Society of Anaesthesiologists Task Force on Blood Component Ther-
apy. Anesthesiology 1996; 84:732-747
293. Warren BL, Eid A, Singer ( et al: High-dose antithrombin III in severe
294. sepsis. A randomized controlled trial. JAMA 2001; 286:1869-1878
AmatoMB, Barbas CS, Medeiros DM, et al: Effect of a protective-
ventilation strategy on mortality in the acute respiratory distress syn-
295. drome. N Engi J Med 1998; 338:347-354
Stewart (Meade MO, Cook DJ, et al: Evaluation of a ventilation strat-
egy to prevent barotrauma in patients at high risk for acute respiratory
distress syndrome. Pressure- and Volume-Limited Ventilation Strategy
Group. N Engi J Med 1998; 338: 355-361
296. Brochard L, Roudat-Thoraval F, Roupie E, et al: Tidal volume reduction
for prevention of ventilator-induced lung injury in acute respiratory dis-
tress syndrome. The Multicenter Trial Group on Tidal Volume reduction
in ARDS. Am J Respir Grit Care Med 1998; 158:1831-1838
297. Brower RG, Shanholtz CB. Fessler HE, et al: Prospective, randomized,
controlled clinical trial comparing traditional versus reduced tidal volume
ventilation in acute respiratory distress syndrome patients. Crit Care Med
1999; 27:1492-1498
298. Brower RG, Fessler HE: Mechanical ventilation in acute lung injury and
acute respiratory distress syndrome. Clin Chest Med 2000; 21:491-510
299. Eichacker PQ, Gerstenberger EP, Banks SM, et al: Meta-analysis of acute
lung injury and acute respiratory distress syndrome trials testing low tidal
volumes. Am J Respir Crit Care Med 2002; 166:1510-1514
300. Ventilation with lower tidal volumes as compared with traditional tidal
volumes for acute lung injury and the acute respiratory distress syndrome.
The Acute Respiratory Distress Syndrome Network. N Engi J Med 2000;
342:1301-1308
301. Hickling KG, Walsh J, Henderson S, et al: Low mortality rate in adult
respiratory distress syndrome using low-volume, pressure-limited ventila-
tion with permissive hy-percapnia: A prospective study. Crit Care Med
1994;22:1568-1578
302. Bidani A, Tzouanakis AE, Cardenas VJ, et al: Permissive hypercapnia in
acute respiratory failure. JAMA 272:957-962
303. Marini JJ, Ravenscraft SA: Mean airway pressure: Physiologic determi-
nants and clinical importance~Part I: Physiologic determinants and
measurements. Crit Care Med 1992; 20:1461-1472
304. Gattinoni L, Marcolin R, Caspani ML, et al: Constant mean airway pres-
sure with different patterns of positive pressure breathing during the adult
respiratory distress syndrome. Bull Eur Physiopathol Respir 1985;21:275-
279
305. Pesenti A, Marcolin R, Prato P, et al: Mean airway pressure vs. positive
end-expiratory pressure during mechanical ventilation. Crit Care Med
1985; 13:34-37
306. Stocker R, Neff T, Stein S, et al: Prone positioning and low-volume pres-
sure-limited ventilation improve survival in patients with severe ARDS
Chest 1997; 111:1008-1017
307. Lamm WJ, Graham MM, Albert RK: Mechanism by which prone posi-
tion improves oxygenation in acute lung injury. Am J Respir Crit Care
Med 1994; 150:184-193
308. Jolliet P, Bulpa P, Chevrolet JC: Effects of the prone position on gas ex-
change and hemodynamics in severe acute respiratory distress syndrome.
Crit Care Med 1998; 26:1977-1985
309. Gattinoni L, Tognoni G, Pesenti A, et al: Effect of prone positioning on
the survival of patients with acute respiratory failure. N Engi J Med 2001;
345:568-573
310. Chatte G, Sab JM. Dubois JM, et al: Prone position in mechanically venti-
lated patients with severe acute respiratory failure. Am J Respir Crit Care
Med 1997; 155:473-478
311. DrakulovicM, Torres A, Bauer T, et al: Supine body position as a risk
factor for nos-ocomial pneumonia in mechanically ventilated patients: A
randomised trial. Lancet 1999; 354:1851-1858
312. Esteban A, Alia I. Tobin MJ, et al: Effect of spontaneous breathing trial
duration on outcome of attempts to discontinue mechanical ventilation.
Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med
1999; 159:512-518
313. ElyEW, Baker AM, Dunagan DP, et al: Effect on the duration of me-
chanical ventilation of identifying patients capable of breathing spontane-
ously. N Engi J Med 1996; 335:1864-1869
314. Esteban A, Alia I, Gordo F, et al: Extubation outcome after spontaneous
breathing trials with T tube or pressure support ventilation. The Spanish
Lung Failure Collaborative Group. Am J Respir Crit Care Med
1997;156:459-465
315. Kollef MH, Levy NT, Ahrens TS, et al: The use of continuous IV seda-
tion is associated with prolongation of mechanical ventilation. Chest
1998; 114:541-548
316. Kress JP, Pohlman AS, O'Connor MF, et al.Daily interruption of sedative
infusions in critically ill patients undergoing mechanical ventilation. 7v
Engi J Med 2000; 342:1471-1477
317. Brook AD, Ahrens TS, Schaiff R, et al: Effect of a nursing-implemented
sedation protocol on the duration of mechanical ventilation. Crit Care
Med 1999; 27:2609-2615
318. GiostraE, Magistris MR, Pizzolato G, et al: Neuromuscular disorder in
intensive care unit patients treated witn pancuronium bromide. Occur-
rence in a cluster group of seven patients and two sporadic cases, with
electrophysiologic and histologic examination. Chest 1994; 106:210-220
319. Rossiter A, Souney PF, McGowan S, et al: Pancuronium-induced pro-
longed neuro-muscular blockade. Crit Care Med 1991;19:1583-1587
320. Partridge BL, Abrams JH, Bazemore C, et al: Prolonged neuromuscular
blockade after long-term infusion of vecuronium bromide in the intensive
care unit. Crit Care Med 1990; 18:1177-1179
321. Vanderheyden A, Reynolds HN, Gerold KB, et al: Prolonged paralysis
after long-term vecuronium infusion. Crit Care Med 1992; 20:304-307
322. Meyer (Prielipp RC, Grossman JE, et al: Prolonged weakness after
infusion of atra-curium in two intensive care unit patients. Anesth Analg
1994; 78:772-774
323. Manthous CA, Chatila W: Prolonged weakness after withdrawal of atra-
curium. Am J Respir Crit Care Med 1994; 150:1441-1443
324. Prielipp RC, Coursin DB, Scuderi PE, et al: Comparison of the infusion
requirements and recovery profiles of vecuronium and cisatracurium
51W89 in intensive care unit patients. Anesth Analg 1995; 81:3-12
325. Brandom BW. Yellon FF, Lloyd ME, et al: Recovery from doxacurium
infusion administered to produce immobility for more than four days in
pediatric patients in the intensive care unit. Anesth Analg 1997; 84:307-
314.
326. Rudis MI, Sikora CA. Angus E. et al: A prospective, randomized, con-
trolled evaluation of peripheral nerve stimulation versus standard clinical
dosing of neuromuscular blocking agents in critically ill patients. Crit
Care Med 1997; 25:25575-25583
327. Frankel H, Jeng J, Tilly E, et al: The impact of implementation of neuro-
muscular blockade monitoring standards in 3 surgical intensive care unit.
m Am Surg 1996; 62:503-506
329. Rvmey SS, Zek\e\d ( ( eV Gtacose, tovteol ° me-irtetoty m
critically ill patients. JAMA 2003; 2041-2047
Van den Berghe G, Wouters PJ, Bouillon R, et al: Outcome benefit of
330. intensive insulin therapy in the critically ill: Insulin dose versus glycemic
control. Crit Care Med 2003; 31:359-366
Klein S, Kinney J, Jeejeebhoy K, et al: Nutrition support in clinical prac-
tice: Review of published data and recommendations for future research
directions. A summary of a conference sponsored by the National Insti-
tutes of Health, American Society for Parenteral and Enteral Nutrition,
331 and American Society for Clinical Nutrition. Am J Clin Nutr 1997;
66:683-706
Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical trial of
332. continuous versus inte-mittent dialysis for acute renal failure. Kidney Int
2001;60:1154-1163
Kellum J, Angus DC, Johnson JP, et al: Continuous versus intermittent
333. renal replacement therapy: A meta-analysis. Intensive Care Med 2002;
28:29-37
Cooper DJ, Walley KR, Wiggs BR, et al: Bicarbonate does not improve
334. hemodynamics in critically ill patients who have lactic acidosis: A pro-
spective, controlled clinical study. Ann Intern Med 1990; 112:492-498
Mathieu D, Neviere R, Billard V, et al: Effects of bicarbonate therapy on
335. hemodynamics and tissue oxygenation in patients with lactic acidosis: A
336. prospective, controlled clinical study. Crit Care Med 1991;19:1352-1356
Cade JF: High risk of the critically ill for venous thromboembolism. Crit
Care Med 1982; 10:448-450
Belch JJ, Lowe GD, Ward AG, et al: Prevention of deep vein thrombosis
in medical patients by low-dose heparin. Scoff Med J 1981; 26:115-117
337. Samama MM, Cohen AT, Darmon JY, et al:A comparison of enoxaparin
with p/acebo for the prevention of venous thromboembolism in acutely ill
medical patients. Prophylaxis in Medical Patients with Enoxaparin Study
Group. N Engi J Med 1999; 341:793-800
338. Borrero E, Bank S, Margolis I, et al: Comparison of antacid and sucralfate
in the prevention of gastrointestinal bleeding in patients who are critically
ill. Am J Med 1985;79:62-64
339. Bresalier RS, Grendell JH, Cello JP, et al: Sucralfate versus titrated ant-
acid for the prevention of acute stress-related gastrointestinal hemorrhage
in critically ill patients. Am J Med 1987; 83:110-116
340. Cook D, Guyatt G, Marshall J, et al: A comparison of sucralfate and
ranitidine for the prevention of upper gastrointestinal bleeding in patients
requiring mechanical ventilation. Canadian Critical Care Trials Group. N
Engi J Med 1998; 338:791-797
341. Stothert JC, Simonowitz DA, Dellinger RP, et al: Randomized prospec-
tive evaluation of cimetidine and antacid control of gastric pH in the criti-
cally ill. Ann Surg 1980; 192:169-174
342. Pollard AJ, Britto J, Nadel S, et al: Emergency management of meningo-
coccal disease. Arch Dis Child 1999; 80:290-296
343. Kanter RK, Zimmerman JJ, Strauss RH, et al: Pediatric emergency intra-
venous access. Evaluation of a protocol. Am J Dis Child 1986; 140:132-
134
344. Ngo NT, Cao XT, Kneen R, et al: Acute management of dengue shock
syndrome: A randomized double-blind comparison of 4 intravenous fluid
regimens in the first hour. Clin Infect Dis 2001; 32:204-213
345. Carcillo JA, Davis AL, Zaritsky A: Role of early fluid resuscitation in
pediatric septic shock. JAMA 1991; 266:1242-1243/
346. Powell KR, Sugarman LI, Eskenazi AE, et al: Normalization of plasma
arginine vaso-pressin concentrations when children with meningitis are
given maintenance plus replacement fluid therapy. J Pediatr
1991;117:515-522.
347. Ceneviva G, Paschall JA, Maffei F, et al: Hemodynamic support in fluid-
refractory pediatric septic shock. Pediatrics 1998; 102:el9
348. Keeley SR, Bohn DJ: The use of inotropic and afterload-reducing agents
in neonates, din Perinatol 1988; 15:467-489
349. Roberts JD Jr, Fineman JR, Morin FC III, et al: Inhaled nitric oxide and
persistent pulmonary hypertension of the new born. Inhaled Nitric Oxide
Study Group. N Engi J Med W7; 336:605-610
350. Barton (Garcia J, Kouatii A, et al: Hemodynamic effects of i. v. milri-
none lactate in pediatric patients with septic shock. A prospective, dou-
ble-blinded, randomized, placebo-controlled, interventional study. Chest
1996; 109:1302-1312
351. Lindsay A, Barton P, Lawless S, et al: Pharmacokinetics and pharmaco-
dynamics of milrinone lactate in pediatric patients with septic shock. J
Pediatr 1998;132:329-334
352. Irazuzta JE, Pretzlaff RK, Rowin ME: Amrinone in pediatric refractory
septic shock: \n open-label pharmacodynamic study. Pediatr Crit Care
Med 2001; 2:24-28
353. Lauterbach R, Pawlik D, Kowalczyk D, et al: Effect of the immunomodu-
lating agent, pentoxifylline, in the treatment of sepsis in prematurely de-
livered infants: A placebo-controlled, double-blind trial. Crit Care Med
1999; 27:807-814
354. Carcillo JA, Fields Al, American College of Critical Care Medicine Task
Force Committee Members: Clinical practice parameters for hemody-
namic support of pediatric and neonatal patients in septic shock. Crit Care
Med 2002; 30:1365-1378
355. De Kleijn ED, Joosten KF, Van Rijn B, et al: Low serum Cortisol in com-
bination with high adrenocorticotrophic hormone concentrations is asso-
ciated with poor outcome in children with severe meningococcal disease.
Pediatr Infect Dis J 2002; 21:330-336
356. Riordan FA, Thomson AP, Ratcliffe JM, et al: Admission Cortisol and
adrenocorticotrophic hormone levels in children with meningococcal dis-
ease: Evidence of adrenal insufficiency? Crit Care Med 1999; 27:2257-
2261
357. Min M, U T, Aye M, et al: Hydrocortisone in the management of dengue
shock syndrome. Southeast Asian J Trop Med Public Health 1975; 6:573-
579
358. Sumarmo N, Talogo W, Asrin A, et al: Failure of hydrocortisone to affect
outcome in dengue shock syndrome. Pediatrics 1982; 69:45-49
359. Hazelzet JA, de Kleijn ED, de Groot R: Endothelial protein activation
in meningococcal sepsis. N Engi J Med 2001; 345:1776-1777
360. de Kleijn ED, de Groot R, Hack CE, et al: Activation of protein follow-
ing infusion of protein concentrate in children with severe meningococ-
cal sepsis and purpura fulminans: A randomized, double-blinded, pla-
cebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839-1847
361. Bilgin K, Yaramis A, Haspolat K, et al: A randomized trial of granulo-
cyte-macroph-age colony-stimulating factor in neonates with sepsis and
neutropenia. Pediatrics 2001; 107:36-41
362. La Gamma EF, De Castro MH: What is the rationale for the use of granu-
locyte and granulocyte-macrophage colony-stimulating factors in the
neonatal intensive care unit? Acta Paediatr Suppi 2002; 91:109-116
363. Chaibou M, Tucci M, Dugas MA, et al: Clinically significant upper gas-
trointestinal bleeding acquired in a pediatric intensive care unit: A pro-
spective study. Pediatrics 1998; 102:933-938
364. Gauvin F, Dugas M, Chaibou M, et al: The impact of clinically significant
upper gastrointestinal bleeding in a pediatric intensive care unit. Pediatr
Crit Care Med 2001;2:294-298
365. Alejandria MM, Lansang MA, Dan? LF, et al: Intravenous immunoglobu-
lin for treating sepsis and septic shock. Cochrane Database Syst Rev
2002; (1):CD00I090
366. Meyer DM, Jessen ME: Results of extracor-poreal membrane oxygena-
tion in children with sepsis. The Extracorporeal LifeSupport Organiza-
tion. Ann Thorac Surg 1997; 63:756-761
367. Goldman AP, Kerr SJ, Butt W, et al: Extra-corporeal support for intracta-
ble cardiore-spiratory failure due to meningococcal disease. Lancet 1997;
349:466-469
368. Brochard L, Rauss A, Benito S, et al: Comparison of three methods of
gradual withdrawal from ventilatory support during weaning from me-
chanical ventilation. Am J Respir Crit Care Med 1994; 150:896-903
369. Van der Poll ) (de Waal Malefyt R., Coyle SM., et al. Antiinflammatory
cytokine responses during clinical sepsis and experimental endotoxemia:
sequential measurements of plasma soluble interleukins (IL)-l receptor
type II, IL-10, and IL-13. //J.Infect.Dis. 1997;175:118-122
370. Foster DM., Doig GS., Clinical trials for the evaluation of sepsis thera-
pies. /in Vincent J-L. Yearbook of intensive care and emergency medi-
cine. 1997. Berlin. Springer, 1997, 1997; 149-157.
371. >c ce^hK) J) (=X h
cjD )G) (GX ikhB jX c
)5Lk hlle^ Lgii =X
dgX^e
guidelines for management of severe sepsis and septic shock. // Crit Care
Med. - 2004. -Vol. 32(3), P.858-873.
 | |

± ®
] ] ± ® ®
] ] ± ®
±

] [ ]

± ® ±
± ®5 ))
5 ® ))
5 ® ))
® 5 ®
±® ))

| '
® 1 )
+/)
+0©) ,,)
+0)
+0©
)
1+n
3/4Jt. © ) )
± ® ) )± )2 (+) 3++ ) )» , 4 )
0++0+(©) ® ©
( ) ±± ©®( 3(
| ® © })
 s{ *( } ( (} %
/( }
V )
((}'
)(
ihKpyi.Q )
(( }o * ((}
')(
( ,
(r}
%*(
(

||* - |
| N | \ Pseudomonas aeruginosa).

, ® ± ± 0
+ ± ±© ®|, (}® ± 6
©)
0++© 2 0+| " © ®
® ± - ®% )±
© ± ),+± ± ®
| ± tOO © ® ( ®
± amvw ±© ) 0+± cairn ± ©± (
± ,++© (
® ® ( ® ©
± ® ±© ) ,+ + ® ©® ± V )
± } Z00 © ® ± ± ± &±±
®© ± ±© ) ± ±
| ® 5 $ ®© 5± ( )wci
© © © 6/ & ® ( ( ©± )
® ( ©}© ±6 ® V6 ± )
© ® , &6 , | r © (
±"® 5uxipHi , , 6 ( ©±® }
} &Saknonda:
, » ©
± ®
® ®& + © 7S0 ©

t
± ® + +© / ++ © ®,
e } {

p
2
t s ( ,, ".1*
0+0
KR
(
)()
, '*
1 u
E-mail
(,
,". 1
*0,
0 K